[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2015081203A1 - Bicyclic heterocycles as bet protein inhibitors - Google Patents

Bicyclic heterocycles as bet protein inhibitors Download PDF

Info

Publication number
WO2015081203A1
WO2015081203A1 PCT/US2014/067629 US2014067629W WO2015081203A1 WO 2015081203 A1 WO2015081203 A1 WO 2015081203A1 US 2014067629 W US2014067629 W US 2014067629W WO 2015081203 A1 WO2015081203 A1 WO 2015081203A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
dihydro
pyridin
pyrrolo
alkyl
Prior art date
Application number
PCT/US2014/067629
Other languages
French (fr)
Inventor
Brent Douty
Eddy W. Yue
Andrew P. Combs
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of WO2015081203A1 publication Critical patent/WO2015081203A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
  • the genomes of eukaryotic organisms are highly organized within the nucleus of the cell.
  • DNA is packaged into chromatin by wrapping around a core of histone proteins to form a nucleosome. These nucleosomes are further compacted by aggregation and folding to form a highly condensed chromatin structure. A range of different states of condensation are possible, and the tightness of this structure varies during the cell cycle, being most compact during the process of cell division.
  • Chromatin structure plays a critical role in regulating gene transcription by regulating protein access to the DNA.
  • the chromatin structure is controlled by a series of post translational modifications to histone proteins, mainly within the tails of histones H3 and H4 that extend beyond the core nucleosome structure.
  • Histone acetylation is typically associated with the activation of gene transcription, as the modification weakens the interaction between the DNA and the histone proteins, permitting greater access to DNA by the transcriptional machinery.
  • Specific proteins bind to acetylated lysine residues within histones to "read" the epigenetic code.
  • a highly conserved protein module called the bromodomain binds to acetylated lysine residues on histone and other proteins. There are more than 60 bromodomain-containing proteins in the human genome.
  • the BET (Bromodomain and Extra-Terminal) family of bromodomain containing proteins comprises 4 proteins (BRD2, BRD3, BRD4 and BRD-t) that share a conserved structural organization containing tandem N-terminal bromodomains capable of binding to acetylated lysine residues of histones and other proteins.
  • BRD2, BRD3 and BRD4 are ubiquitiously expressed while BRDt is restricted to germ cells.
  • BRD proteins play essential, but non-overlapping roles in regulating gene transcription and controlling cell growth.
  • BET proteins are associated with large protein complexes including Mediator, PAFc and super elongation complex that regulate many aspects of gene transcription.
  • BRD2 and BRD4 proteins have been shown to remain in complex with chromosomes during mitosis and are required to promote transcription of critical genes including cyclin D and c-Myc that initiate the cell cycle
  • BRD4 is essential for recruiting the protein translational elongation factor B complex to the promoters of inducible genes resulting in the phosphorylation of RNA polymerase II and stimulating productive gene transcription and elongation (Jang et al. Mol. Cell 2005 19:523-534).
  • a kinase activity of BRD4 may directly phosphorylate and activate RNA polymerase II (Devaiah et al. PNAS 2012
  • BRD2 and BRD3 are reported to associate with histones along actively transcribed genes and may be involved in facilitating transcriptional elongation (Leroy et al, Mol. Cell. 2008 30:51-60).
  • BET proteins have been shown to bind selectively to acetylated transcription factors including the RelA subunit of NF-kB and GATA1 thereby directly regulating the transcriptional activity of these proteins to control expression of genes involved in inflammation and hematopoietic differentiation (Huang et al, Mol. Cell. Biol. 2009 29: 1375- 1387; Lamonica Proc. Nat. Acad. Sci. 2011 108:E159-168).
  • NUT nuclear protein in testes
  • BRD3 or BRD4 BRD3 or BRD4 to form a novel fusion oncogene
  • BRD-NUT BRD-NUT
  • BRD2, BRD3 and BRD4 have been shown to impair the growth and viability of a wide range of hematological and solid tumor cells (Zuber et al, Nature 2011 478:524-528; Delmore et al, Cell 2011 146:904-917).
  • BET proteins regulate inflammatory responses to bacterial challenge
  • a BRD2 hypomorph mouse model showed dramatically lower levels of inflammatory cytokines and protection from obesity induced diabetes (Wang et al Biochem J. 2009 425:71-83; Belkina et al. J. Immunol 2013).
  • BET proteins make use of these BET proteins to tether their genomes to the host cell chromatin, as part of the process of viral replication or use BET proteins to facilitate viral gene transcription and repression (You et al, Cell 2004 117:349-60; Zhu et al, Cell Reports 2012 2:807-816).
  • the present invention provides, inter alia, a compound of Formula I:
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
  • the present invention also provides a method of inhibiting a BET protein comprising contacting a compound of Formula I, or a pharmaceutically acceptable salt thereof, with the BET protein.
  • the present invention also provides a method of treating cancer and other diseases comprising administering to a patient a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in therapy.
  • the present invention also provides use of a compound of Formula I, or a
  • the present invention provides, inter alia, a compound of Formula I
  • Ring B is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, Cs-cycloalkyl, C 6 - cycloalkyl, 5-membered heterocycloalkyl, or 6-membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 R B ;
  • L is absent, -(CR a R b ) P -, -(CR a R b ) n -0-(CR a R b ) m -, -(CR a R b ) n -S-(CR a R b ) m -,
  • Al is CR 3 or N;
  • A2 is CR 4 or N;
  • A3 is C or N
  • A4 is C or N
  • W is CR 5 or N
  • X is CR 6 or N
  • Y is CR 7 or N
  • Z is Ci-6 alkyl, C 6 -io aryl, C3-10 cycloalkyl, or 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 R z ;
  • R 1 is H or C 1-4 alkyl
  • R 2 is H, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, or C 6 -io aryl-Ci-6 alkyl;
  • R 3 and R 4 are each independently selected from H, halo, CN, NO2, Ci-6 alkyl, Ci-6 haloalkyl, C 1-6 hydroxyalkyl, Ci-6 aminoalkyl, Ci-6 alkylamino-Ci-6 alkyl, di-Ci-6-alkylamino-Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said Ci-6 alkylamino-Ci-6 alkyl, di-Ci-6-alkylamino- C1-6 alkyl, are each optionally substituted with 1 or 2 substituents independently selected from C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl;
  • R 5 is H, halo, Ci-6 alkyl, or Ci-6 haloalkyl
  • R 6 is H, Ci-6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)R bl , C(0)NR cl R dl , C(0)OR al , S(0)R bl , S(0)NR cl R dl , S(0) 2 R bl , or S(0) 2 NR cl R dl , wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)OR al , OC(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl ,
  • R 7 is H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , S(0)R b2 , S(0)NR c2 R d2 , S(0) 2 R b2 , or S(0) 2 NR c2 R d2 , wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, OR a2 , SR a2 , C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , OC(0)R b2 , OC(0)NR c2 R d2 , NR c2 R d2 , NR c2
  • each R B is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl CN, NO2, OR a3 , SR 33 , C(0)R b3 , C(0)NR c3 R d3 , C(0)OR a3 , OC(0)R b3 ,
  • NR c3 C( NR e3 )NR c3 R d3 , NR c3 R d3 , NR c3 C(0)R b3 , NR c3 C(0)OR a3 , NR c3 C(0)NR c3 R d3 ,
  • each R z is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl CN, NO2, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , C(0)OR a4 , OC(0)R b4 ,
  • each R a and R b is independently selected from H, halo, OH, methyl, and ethyl;
  • each R c and R d is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, and cyclopropyl;
  • each R al , R bl , R cl , R dl , R a2 , R b2 , R c2 , R d2 , R 33 , R b3 , R c3 , R d3 , R a4 , R b4 , R c4 , and R d4 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3- 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-6 alkyl, C3-10 cycloalky-Ci-6 alkyl, (5-10 membered heteroaryl)-Ci-6 alkyl, and (4-10 membered heterocycloalkyl)-Ci-6 alkyl, wherein said Ci-6 alkyl, C2
  • heterocycloalkyl)-Ci-6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents
  • Ci-4 alkyl independently selected from Ci-4 alkyl, C 1-4 haloalkyl, halo, CN, OR a5 , SR a5 , C(0)R b5 ,
  • R cl and R dl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6 -io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a5 , SR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , OC(0)NR c5 R d5 , NR c5 R d5 , NR c5 C(0)R b5 , NR c5 C(0)NR c5 R d5 ,
  • Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C 6 -io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR a5 , SR a5 , C(0)R b5 ,
  • R c3 and R d3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6 -io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a5 , SR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , OC(0)NR c5 R d5 , NR c5 R d5 , NR c5 C(0)R b5 , NR c5 C(0)NR c5 R d5 ,
  • R c4 and R d4 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6 -io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a5 , SR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , OC(0)NR c5 R d5 , NR c5 R d5 , NR c5 C(0)R b5 , NR c5 C(0)NR c5 R d5 ,
  • Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C 6 -io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR a5 , SR a5 , C(0)R b5 ,
  • each R el , R e2 , R e3 , and R e4 is independently selected from H, CM alkyl, CN, OR a5 , SR b5 , S(0) 2 R b5 , C(0)R b5 , S(0) 2 NR c5 R d5 , and C(0)NR c5 R d5 ;
  • each R a5 , R b5 , R c5 , and R d5 is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, C 2 -4 alkenyl, and C 2 -4 alkynyl, wherein said Ci-4 alkyl, C 2 -4 alkenyl, and C 2 -4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, C1-4 haloalkyl, and Ci-4 haloalkoxy;
  • each R e5 is independently selected from H, Ci-4 alkyl, and CN;
  • n 0, 1, or 2;
  • n 0, 1, or 2;
  • p 1, 2, 3, or 4;
  • the present invention further provides, inter alia, a compound of Formula I:
  • Ring B is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, Cs-cycloalkyl, Ce- cycloalkyl, 5-membered heterocycloalkyl, or 6-membered heterocycloalkyl, each optionally substituted by 1 , 2, 3, or 4 R B ;
  • L is absent, -(CR a R b ) P -, -(CR a R b ) n -0-(CR a R b ) m -, -(CR a R b ) n -S-(CR a R b ) m -, , -
  • Al is CR 3 or N
  • A2 is CR 4 or N
  • A3 is C or N
  • A4 is C or N
  • W is CR 5 or N
  • X is CR 6 or N
  • Y is CR 7 or N
  • Z is C6-io aryl, C3-10 cycloalkyl, or 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1 , 2, 3, 4, or 5 R z ;
  • R 1 is H or Ci- 4 alkyl
  • R 2 is Ci-4 alkyl, Ci-4 haloalkyl, or Ci-4 hydroxyalkyl
  • R 3 and R 4 are each independently selected from H, halo, CN, NO2, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
  • R 5 is H, halo, Ci-6 alkyl, or Ci-6 haloalkyl
  • R 6 is H, Ci-6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)R bl , C(0)NR cl R dl , C(0)OR al , S(0)R bl , S(0)NR cl R dl , S(0) 2 R bl , or S(0) 2 NR cl R dl , wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, OR al , SR al , C(0)R bl , C(0)NR cl R dl , C(0)OR al , OC(0)R bl , OC(0)NR cl R dl , NR cl R dl , NR cl C(0)R bl
  • R 7 is H, Ci-6 alkyl, Ci-e haloalkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , S(0)R b2 , S(0)NR c2 R d2 , S(0) 2 R b2 , or S(0) 2 NR c2 R d2 , wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, OR a2 , SR a2 , C(0)R b2 , C(0)NR c2 R d2 , C(0)OR a2 , OC(0)R b2 , OC(0)NR c2 R d2 , NR c2 R d2 , NR
  • each R B is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • NR c3 C( NR e3 )NR c3 R d3 , NR c3 R d3 , NR c3 C(0)R b3 , NR c3 C(0)OR a3 , NR c3 C(0)NR c3 R d3 ,
  • each R z is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl CN, NO2, OR a4 , SR a4 , C(0)R b4 , C(0)NR c4 R d4 , C(0)OR a4 , OC(0)R b4 ,
  • each R a and R b is independently selected from H, halo, OH, methyl, and ethyl;
  • each R c and R d is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, and cyclopropyl;
  • each R al , R bl , R cl , R dl , R a2 , R b2 , R c2 , R d2 , R 33 , R b3 , R c3 , R d3 , R a4 , R b4 , R c4 , and R d4 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C 6 -io aryl, C3- 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6 -io aryl-Ci-6 alkyl, C3-10 cycloalky-Ci-6 alkyl, (5-10 membered heteroaryl)-Ci-6 alkyl, and (4-10 membered heterocycloalkyl)-Ci-6 alkyl, wherein said Ci-6 alkyl, C2
  • heterocycloalkyl)-Ci-6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents
  • Ci-4 alkyl independently selected from Ci-4 alkyl, C 1-4 haloalkyl, halo, CN, OR a5 , SR a5 , C(0)R b5 ,
  • R cl and R dl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6 -io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a5 , SR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , OC(0)NR c5 R d5 , NR c5 R d5 , NR c5 C(0)R b5 , NR c5 C(0)NR c5 R d5 ,
  • Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C 6 -io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR a5 , SR a5 , C(0)R b5 ,
  • R c3 and R d3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6 -io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a5 , SR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , OC(0)NR c5 R d5 , NR c5 R d5 , NR c5 C(0)R b5 , NR c5 C(0)NR c5 R d5 ,
  • R c4 and R d4 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C 6 -io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, OR a5 , SR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , OC(0)NR c5 R d5 , NR c5 R d5 , NR c5 C(0)R b5 , NR c5 C(0)NR c5 R d5 ,
  • Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C 6 -io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR a5 , SR a5 , C(0)R b5 ,
  • each R el , R e2 , R e3 , and R e4 is independently selected from H, CM alkyl, CN, OR a5 , SR b5 , S(0) 2 R b5 , C(0)R b5 , S(0) 2 NR c5 R d5 , and C(0)NR c5 R d5 ;
  • each R a5 , R b5 , R c5 , and R d5 is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, C 2 -4 alkenyl, and C 2 -4 alkynyl, wherein said Ci-4 alkyl, C 2 -4 alkenyl, and C 2 -4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, C1-4 haloalkyl, and Ci-4 haloalkoxy;
  • each R e5 is independently selected from H, Ci-4 alkyl, and CN;
  • n 0, 1, or 2;
  • n 0, 1, or 2;
  • p 1, 2, 3, or 4;
  • any aforementioned heterocycloalkyl group including the heterocycloalkyl group of Ring B, is optionally substituted by 1 or 2 oxo groups.
  • A3 and A4 are C, then the symbol represents a double bond, and when one of A3 and A4 is N and the other is C, then the symbol represents a single bond.
  • R 1 is H.
  • R 2 is Ci-4 alkyl, Ci-4 cyanoalkyl, or C 6 -io aryl-Ci-6 alkyl.
  • R 2 is methyl, cyanomethyl, or benzyl.
  • R 2 is C1-4 alkyl.
  • R 2 is methyl
  • W is CR 5 .
  • X is CR 6 .
  • Y is CR 7 .
  • Y is N.
  • the bicyclic ring containing W, X, and Y is selected from:
  • L is -(CR a R b ) P -, -(CR a R b ) n -0-(CR a R b ) m -, -(CR a R b ) n -S-(CR a R b )
  • L is -(CR a R b ) n -0-(CR a R b ) m -.
  • L is -CH 2 -0-.
  • L is O.
  • Z is Ci-4 alkyl, C 6 -io aryl, C3-10 cycloalkyl, or 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 R z .
  • Z is C 6 -io aryl or C3-10 cycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 R z .
  • Z is phenyl optionally substituted by 1, 2, 3, 4, or 5 R z .
  • Z is
  • Z is Ci-4 alkyl. In some embodiments, Z is C3-7 cycloalkyl optionally substituted by 1, 2, 3, 4, or 5 R z . In some embodiments, Z is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 R z .
  • Z is 4-10 membered heterocycloalkyl optionally substituted by 1, 2, 3, 4, or 5 R z
  • Z is tetrahydropyranyl
  • Z is cyclopropyl
  • each R z is independently selected from F, CI, and Br.
  • Al is CR 3 .
  • A2 is CR 4 .
  • A2 is N.
  • A3 is C.
  • A4 is C.
  • A4 is N.
  • R 3 is H or Ci-6 alkyl.
  • R 3 is H or methyl.
  • R 3 is H.
  • R 4 is H, Ci-6 hydroxyalkyl, or Ci-6 alkylamino-Ci-6 alkyl, wherein said Ci-6 alkylamino-Ci-6 alkyl is optionally substituted with 1 or 2 substituents independently selected from C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl.
  • R 4 is H.
  • R 4 is 1 -hydroxy ethyl.
  • R 4 is Ci-6 alkylamino-Ci-6 alkyl substituted with 2-(morpholin-N- yl)ethyl, benzyl, or cyclopropylmethyl.
  • R 5 is H. In some embodiments, R 6 is H.
  • R 7 is H.
  • each R B is independently selected from Ci-6 alkyl, C 6 -io aryl, or NR c3 R d3 ; wherein said Ci-6 alkyl is optionally substituted with 1 , 2, or 3 substituents
  • phenyl, 4-7 membered heterocycloalkyl independently selected from phenyl, 4-7 membered heterocycloalkyl, CN, C(0)NR c3 R d3 , NR c3 R d3 , and NR c3 C(0)R b3 , and wherein said phenyl and 4-7 membered heterocycloalkyl are each optionally substituted by 1 , 2, or 3 substituents independently selected from Ci-6 alkyl, C(0)R b3 , and S(0) 2 R b3 .
  • each R B is Ci-6 alkyl optionally substituted with 1 , 2, or 3 substituents independently selected from phenyl, 4-7 membered heterocycloalkyl, CN,
  • each R B is Ci-6 alkyl.
  • Ring B is substituted by 1 or 2 oxo groups.
  • Ring B is substituted by 1 oxo group.
  • the compounds of the invention have Formula II:
  • the 5-membered ring formed by A3, A4, Bl , B2, and B3 is (1) 5-membered heteroaryl wherein Bl , B2, and B3 are each independently selected from CH, N, NH, O, and S, (2) Cs- cycloalkyl wherein Bl , B2, and B3 are each independently selected from CH, CH 2 , and C(O), or (3) 5-membered heterocycloalkyl wherein Bl, B2, and B3 are each independently selected from CH, CH 2 , C(O), N, NH, O, S, S(O), and S(0) 2 ; and
  • q 0, 1, 2 or 3.
  • the floating substituent -(R B )q depicted in Formula II and other formulae is meant to indicate that there can be q number of R B groups substituted on any of the Bl, B2, and B3 components of the A3, A4, Bl, B2, and B3 5-membered ring.
  • Bl is selected as CH
  • the hydrogen of the CH can be replaced by R B when it is substituted.
  • Bl, B2, and B3 are each independently selected from CH, C(O), N, O, and NH.
  • Bl, B2, and B3 are each independently selected from CH, C(O),
  • Bl is N, NH, CH, or O.
  • Bl is NH
  • B2 is N, C(O), C or CH.
  • B2 is N, C(O), or CH.
  • B3 is N, NH, or CH.
  • B3 is N or NH.
  • the compounds of the invention have Formula Ila:
  • the compounds of the invention have Formula Ila- 1 :
  • the compounds of the invention have Formula lib
  • the compounds of the invention have Formula lib- 1 , IIb-2, IIb-3, -4. or IIb-5:
  • R 8 , R 9 , and R 10 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a3 , SR 33 , C(0)R b3 , C(0)NR c3 R d3 , C(0)OR a3 , OC(0)R b3 ,
  • NR c3 C( NR e3 )NR c3 R d3 , NR c3 R d3 , NR c3 C(0)R b3 , NR c3 C(0)OR a3 , NR c3 C(0)NR c3 R d3 ,
  • r is 0, 1, 2, 3, 4, or 5.
  • r is 0, 1, 2, 3, 4, or 5;
  • R 8 , R 9 , and R 10 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a3 , SR 33 , C(0)R b3 , C(0)NR c3 R d3 , C(0)OR a3 , OC(0)R b3 ,
  • NR c3 C( NR e3 )NR c3 R d3 , NR c3 R d3 , NR c3 C(0)R b3 , NR c3 C(0)OR a3 , NR c3 C(0)NR c3 R d3 ,
  • the compounds of the invention have Formula lid, He, or Ilf:
  • R 8 , R 9 , and R 10 are each independently selected from H, Ci-6 alkyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said Ci-6 alkyl, C 6 -io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
  • heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-e alkyl, Ci-e haloalkyl, CN, NO2, OR 33 , SR a3 , C(0)R b3 , C(0)NR c3 R d3 , C(0)OR a3 , NR c3 R d3 , NR c3 C(0)R b3 , NR c3 C(0)NR c3 R d3 , NR c3 S(0)R b3 , NR c3 S(0) 2 R b3 ,
  • r is 0, 1, 2, or 3.
  • r is 0, 1, or 2.
  • the compounds of the invention have Formula Ilg:
  • the compounds of the invention have Formula III
  • the 6-membered ring formed by A3, A4, B4, B5, B6, and B7 is (1) phenyl, (2) 6- membered heteroaryl wherein B4, B5, B6, and B7 are each independently selected from CH and N, (3) C6-cycloalkyl wherein B4, B5, B6, and B7 are each independently selected from CH, CH 2 , and C(O), or (4) 6-membered heterocycloalkyl wherein B4, B5, B6, and B7 are each
  • s 0, 1, 2, 3, or 4.
  • the floating substituent -(R B )s depicted in Formula III and other formulae herein is meant to indicate that there can be s number of R B groups substituted on any of the B4, B5, B6, and B7 components of the A3, A4, B4, B5, B6, and B7 6-membered ring.
  • B4 is selected as CH
  • the hydrogen of the CH can be replaced by R B when it is substituted.
  • the 6-membered ring formed by A3, A4, B4, B5, B6, and B7 is 6- membered heterocycloalkyl wherein B4, B5, B6, and B7 are each independently selected from CH, CH 2 , C(O), N, NH, O, S, S(O), and S(0) 2 .
  • B4 is selected from O or N.
  • B5 is selected from C, CH, or CH 2 .
  • B7 is selected from N or NH.
  • the compounds of the invention have Formula Ilia:
  • the compounds of the invention have Formula Ilia- 1 , IIIa-2, or IIIa-3:
  • the bicyclic moiety containing Ring B has the formula:
  • the bicyclic moiety containing Ring B has the formula
  • the bicyclic moiety containing Ring B has the formula:
  • the bicyclic moiety containing Ring B has the formula:
  • the bichang moiety containing Ring B has the formula
  • the bi Ring B has the formula:
  • s 0, 1, 2, 3, or 4.
  • the bicyclic moiety containing Ring B has the formula:
  • s 0, 1, 2, 3, or 4.
  • the bicyclic moiety containing Ring B has the formula:
  • s 0, 1, 2, 3, or 4.
  • the bi Ring B has the formula:
  • s 0, 1, 2, 3, or 4.
  • the bicyclic moiety containing Ring B is selected from:
  • each of the above formulas can be optionally substituted by one or more R B on the 5- or 6- membered ring corresponding to Ring B by up to 5 substituents or up to the available substitutable valencies, whichever is less.
  • the bicyclic moiety containing Ring B is selected from: , and wherein each of the above formulas can be optionally substituted as valency allows by one or two R on the 5-membered ring corresponding to Ring B.
  • Al and A2 are each CH.
  • the phrase "optionally substituted” means unsubstituted or substituted.
  • substituted means that a hydrogen atom is removed and replaced by a monovalent non-hydrogen substituent or two hydrogen atoms are removed and replaced by a divalent substituent, like oxo. It is to be understood that substitution at a given atom is limited by valency.
  • Ci-j indicates a range which includes the endpoints, wherein i and j are integers and indicate the number of carbons. Examples include Ci- 4, Ci-6, and the like.
  • n-membered where n is an integer typically describes the number of ring- forming atoms in a moiety where the number of ring-forming atoms is n.
  • piperidinyl is an example of a 6-membered heterocycloalkyl ring
  • pyrazolyl is an example of a 5- membered heteroaryl ring
  • pyridyl is an example of a 6-membered heteroaryl ring
  • 1, 2, 3, 4- tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
  • Ci-j alkyl refers to a saturated hydrocarbon group that may be straight-chain or branched, having i to j carbons.
  • the alkyl group contains from 1 to 6 carbon atoms or from 1 to 4 carbon atoms, or from 1 to 3 carbon atoms.
  • alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, and t- butyl.
  • Ci-j alkoxy employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group has i to j carbons.
  • Example alkoxy groups include methoxy, ethoxy, and propoxy (e.g., n-propoxy and isopropoxy).
  • the alkyl group has 1 to 3 carbon atoms.
  • G-j alkenyl refers to an unsaturated hydrocarbon group having one or more double carbon-carbon bonds and having i to j carbons.
  • the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
  • Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.
  • G-j alkynyl refers to an unsaturated hydrocarbon group having one or more triple carbon-carbon bonds and having i to j carbons.
  • Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl, and the like.
  • the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
  • G-j alkylamino employed alone or in combination with other terms, refers to a group of formula -NH(alkyl), wherein the alkyl group has i to j carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • di-G-j-alkylamino employed alone or in combination with other terms, refers to a group of formula -N(alkyl) 2 , wherein each of the two alkyl groups has, independently, i to j carbon atoms. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.
  • G-j alkylthio employed alone or in combination with other terms, refers to a group of formula -S-alkyl, wherein the alkyl group has i to j carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • amino employed alone or in combination with other terms, refers to a group of formula -NH 2 .
  • aryl employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbon, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, anthracenyl, phenanthrenyl, and the like.
  • aryl is G-io aryl.
  • the aryl group is a naphthalene ring or phenyl ring.
  • the aryl group is phenyl.
  • carbonyl employed alone or in combination with other terms, refers to a -C(O)- group.
  • Cycloalkyl refers to a non-aromatic cyclic hydrocarbon moiety having i to j ring-forming carbon atoms, which may optionally contain one or more alkenylene groups as part of the ring structure.
  • Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems.
  • cycloalkyl moieties that have one or more aromatic rings fused (i.e.,, having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclopentene, cyclohexane, and the like.
  • One or more ring- forming carbon atoms of a cycloalkyl group can be oxidized to form carbonyl linkages.
  • cycloalkyl is C3-7 cycloalkyl.
  • Examplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, and the like.
  • Ci j haloalkoxy refers to a group of formula -O-haloalkyl having i to j carbon atoms.
  • An example haloalkoxy group is OCF3.
  • An additional example haloalkoxy group is OCHF2.
  • the haloalkoxy group is fluorinated only.
  • the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • halo refers to a halogen atom selected from F, CI, I or Br. In some embodiments, “halo” refers to a halogen atom selected from F, CI, or Br. In some embodiments, the halo substituent is F.
  • Ci j haloalkyl refers to an alkyl group having from one halogen atom to 2s+l halogen atoms which may be the same or different, where "s" is the number of carbon atoms in the alkyl group, wherein the alkyl group has i to j carbon atoms.
  • the haloalkyl group is fluorinated only.
  • the haloalkyl group is fluoromethyl, difluoromethyl, or
  • the haloalkyl group is trifluoromethyl.
  • the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • heteroaryl employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic heterocylic moiety, having one or more heteroatom ring members selected from nitrogen, sulfur and oxygen.
  • the heteroaryl group has 1, 2, 3, or 4 heteroatom ring members.
  • the heteroaryl group has 1, 2, or 3 heteroatom ring members.
  • the heteroaryl group has 1 or 2 heteroatom ring members.
  • the heteroaryl group has 1 heteroatom ring member.
  • the heteroaryl group is 5- to 10-membered.
  • heteroaryl groups include, but are not limited to, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, azolyl, oxazole, isoxazole, thiazole, isothiazole, imidazole, furan, thiophene, triazole, tetrazole, thiadiazole, quinoline, isoquinoline, indole, benzothiophene, benzofuran, benzisoxazole, imidazo[l, 2-b]thiazole, purine, triazine. and the like.
  • a 5-membered heteroaryl is a heteroaryl group having five ring-forming atoms comprising wherein one or more of the ring-forming atoms are independently selected from N, O, and S.
  • the 5-membered heteroaryl group has 1, 2, or 3 heteroatom ring members.
  • the 5-membered heteroaryl group has 1 or 2 heteroatom ring members.
  • the 5-membered heteroaryl group has 1 heteroatom ring member.
  • Example ring-forming members include CH, N, NH, O, and S.
  • Example five- membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1, 2, 3-triazolyl, tetrazolyl, 1, 2, 3-thiadiazolyl, 1, 2, 3-oxadiazolyl, 1, 2, 4-triazolyl, 1, 2, 4-thiadiazolyl, 1, 2, 4-oxadiazolyl, 1, 3, 4-triazolyl, 1, 3, 4-thiadiazolyl, and 1, 3, 4-oxadiazolyl.
  • a 6-membered heteroaryl is a heteroaryl group having six ring-forming atoms wherein one or more of the ring-forming atoms is N. In some embodiments, the 6-membered heteroaryl group has 1, 2, or 3 heteroatom ring members. In some embodiments, the 6-membered heteroaryl group has 1 or 2 heteroatom ring members. In some embodiments, the 6-membered heteroaryl group has 1 heteroatom ring member.
  • Example ring-forming members include CH and N.
  • Example six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl, and pyridazinyl.
  • heterocycloalkyl refers to non-aromatic heterocyclic ring system, which may optionally contain one or more unsaturations as part of the ring structure, and which has at least one heteroatom ring member independently selected from nitrogen, sulfur and oxygen.
  • the heterocycloalkyl group has 1, 2, 3, or 4 heteroatom ring members.
  • the heterocycloalkyl group has 1, 2, or 3 heteroatom ring members.
  • the heterocycloalkyl group has 1 or 2 heteroatom ring members.
  • the heterocycloalkyl group has 1 heteroatom ring member.When the heterocycloalkyl group contains more than one heteroatom, the heteroatoms may be the same or different.
  • Example ring-forming members include CH, CH 2 , C(O), N, NH, O, S, S(O), and S(0) 2 .
  • Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems, including spiro systems.
  • heterocycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the non-aromatic ring, for example, 1, 2, 3, 4-tetrahydro-quinoline, dihydrobenzofuran and the like.
  • aromatic rings fused (i.e., having a bond in common with) to the non-aromatic ring, for example, 1, 2, 3, 4-tetrahydro-quinoline, dihydrobenzofuran and the like.
  • heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, sulfmyl, or sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized.
  • heterocycloalkyl is 5- to 10-membered.
  • heterocycloalkyl groups include 1, 2, 3, 4-tetrahydro-quinoline, dihydrobenzofuran, azetidine, azepane, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, and pyran.
  • the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereoisomers, are intended unless otherwise indicated.
  • the compounds of the invention can be any of the possible stereoisomers.
  • the stereochemistry of the chiral center can be (R) or (S).
  • the stereochemistry of the chiral centers can each be independently (R) or (S) so the configuration of the chiral centers can be (R) and (R), (R) and (S); (S) and (R), or (S) and (S).
  • each of the three chiral centers can each be independently (R) or (S) so the configuration of the chiral centers can be (R), (R) and (R); (R), (R) and (S); (R), (S) and (R); (R), (S) and (S); (S), (R) and (R); (S), (R) and (S); (S), (S) and (R); or (S), (S) and (S).
  • An example method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt- forming organic acid.
  • Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as ⁇ -camphorsulfonic acid.
  • resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereoisomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1, 2- diaminocyclohexane, and the like.
  • Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
  • an optically active resolving agent e.g., dinitrobenzoylphenylglycine
  • Suitable elution solvent composition can be determined by one skilled in the art.
  • Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
  • Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
  • Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, amide - imidic acid pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1, 2, 4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole.
  • Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
  • Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • compound as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted.
  • Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified (e.g., in the case of purine rings, unless otherwise indicated, when the compound name or structure has the 9H tautomer, it is understood that the 7H tautomer is also encompassed).
  • All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., hydrates and solvates) or can be isolated.
  • the compounds of the invention, or salts thereof are substantially isolated.
  • substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
  • Partial separation can include, for example, a composition enriched in a compound of the invention.
  • Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • ambient temperature and “room temperature,” as used herein, are understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a
  • the present invention also includes pharmaceutically acceptable salts of the compounds described herein.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g. , methanol, ethanol, iso-propanol, or butanol) or acetonitrile (MeCN) are preferred.
  • non-aqueous media like ether, ethyl acetate, alcohols (e.g. , methanol, ethanol, iso-propanol, or butanol) or acetonitrile (MeCN) are preferred.
  • suitable salts are found in Remington 's Pharmaceutical Sciences, 17 th Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge et al., J. Pharm. Sci., 1977, 66(1), 1-19, and in Stahl et
  • Suitable solvents can be substantially non-reactive with the starting materials (reactants), the
  • reaction can be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular reaction step can be selected by the skilled artisan.
  • Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups.
  • the need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
  • the chemistry of protecting groups can be found, for example, in P. G. M. Wuts and T. W. Greene, Protective Groups in Organic Synthesis, 4 th Ed., Wiley & Sons, Inc., New York (2006), which is incorporated herein by reference in its entirety.
  • Protecting groups in the synthetic schemes are typically represented by "PG.”
  • Reactions can be monitored according to any suitable method known in the art.
  • product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy ⁇ e.g., J H or 13 C), infrared spectroscopy, spectrophotometry ⁇ e.g., UV- visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC).
  • HPLC high performance liquid chromatography
  • LCMS liquid chromatography-mass spectroscopy
  • TLC thin layer chromatography
  • Compounds can be purified by those skilled in the art by a variety of methods, including high performance liquid chromatography (HPLC) ⁇ "Preparative LC-MS Purification: Improved Compound Specific Method Optimization" Karl F. Blom, Brian Glass, Richard Sparks, Andrew P. Combs J. Combi. Chem. 2004, 6(6), 874-883, which is
  • M is a boronic acid, boronic ester or an appropriately substituted metal
  • Het-M is Het-B(OH) 2
  • heterocyclic halide (i) can be converted to a boronic acid or boronate ester (iv) under standard transmetalation conditions (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)).
  • a palladium(O) catalyst such as tetrakis(triphenylphosphine)palladium(0).
  • a palladium(O) catalyst such as tetrakis(triphenylphosphine)palladium(0)
  • base e.
  • a base e.g., triethylamine, NaH or Na 2 C0 3
  • heterocycle (i) can be arylated either under Evans' conditions with an aryl-boronic acid (e.g., Z-B(OR) 2 , in the presence of a palladium(O) catalyst) or Ullman conditions with an aryl halide (e.g., Z-Hal, in the presence of palladium(O)) to afford the heterocycle (ii).
  • aryl-boronic acid e.g., Z-B(OR) 2
  • Ullman conditions e.g., Z-Hal, in the presence of palladium(O)
  • Halogenation of heterocycle (ii) under standard conditions Br 2 , AcOH or N-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide
  • Formula I can be formed as shown in Scheme III.
  • Halogenation of heterocycle (i) under standard conditions e.g., Br 2 , AcOH or N-chlorosuccinamide, N-bromosuccinamide or N- iodosuccinamide
  • heterocycle (ii) can be arylated either under Evans' conditions with an aryl-boronic acid (e.g., Z-B(OR) 2 , in the presence of a palladium(O) catalyst) or Ullmann conditions with an aryl halide (e.g., Z-Hal, in the presence of copper) to afford the heterocycle (iii).
  • aryl-boronic acid e.g., Z-B(OR) 2
  • aryl halide e.g., Z-Hal, in the presence of copper
  • the heterocyclic fluoride (i) can be coupled to Het-M (ii), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)2, Het-B(OR) 2 , Het-Sn(Bu)4, or Zn- Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)), to give a compound of formula (iii).
  • M is a boronic acid, boronic ester or an appropriately substituted metal
  • Het-M is Het-B(OH
  • heterocyclic halide (i) can be converted to a boronic acid or boronate acid (iv) under standard transmetalation conditions (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)).
  • a palladium(O) catalyst such as tetrakis(triphenylphosphine)palladium(0).
  • a palladium(O) catalyst such as tetrakis(triphenylphosphine)palladium(0)
  • base e.g., bicarbonate or carbonate base
  • Negishi conditions e.g.,
  • Thiols, amines, and alcohols of formula H-L-Z can displace the fluoro group of compounds (iii) using standard conditions (e.g., CS2CO3/DMSO) to give thioethers, arylamines, and ethers of Formula I (vi) after deprotection of the nitrogen protecting group and optional alkylation with Hal-R 2 .
  • heterocycle Protection of the heterocyclic nitrogen atom with a protecting group such as, but not limited to, benzyl, tosyl, and (trimethylsilyl)ethoxy)methyl group can provide heterocycle (iii). Hydrolysis of the methoxy substituent with an acid such as, but not limited to, hydrochloric acid or hydrobromic acid to provides heterocycles (iv).
  • Compound (iv) can be alkylated (e.g., R 2 -Hal and a base (e.g., triethylamine, NaH or Na 2 C03) or under Mitsunobu conditions) to afford the heterocycle (v).
  • halide (v) to the boronate (vi) or boronic acid (vi) can be performed under standard conditions (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)).
  • a palladium(O) catalyst such as tetrakis(triphenylphosphine)palladium(0)
  • halide (v) to the boronate ester (vi) or boronic acid (vi) can be performed under standard conditions (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)).
  • a palladium(O) catalyst such as tetrakis(triphenylphosphine)palladium(0)
  • Synthesis of heterocyclic intermediates useful in the preparation of compounds of Formula I can be formed as shown in Scheme VII.
  • Conversion of iodo derivative (i) to heterocyclic acid (ii) can be performed by reacting with pyruvic acid in the presence of a palladium catalyst (e.g., palladium(II)acetate, and a base such as DBU).
  • a palladium catalyst e.g., palladium(II)acetate, and a base such as DBU.
  • Esterification of the acid (ii) can be performed by standard reaction conditions such as treatment with an alcohol under acidic condition. Protection of the nitrogen of the heterocycle (iii) can be performed under standard conditions to give N-protected heterocycle (iv).
  • Hydrolysis of the ester to the acid and formation of the amide (v) can be performed under standard peptide coupling conditions, (e.g., amine HNR in the presence of a coupling reagent, such as, ⁇ , ⁇ -carbonyldiimidazole (CDI) or ⁇ , ⁇ , ⁇ ', ⁇ ' -tetramethyluronium hexafluorophosphate (HATU)).
  • a coupling reagent such as, ⁇ , ⁇ -carbonyldiimidazole (CDI) or ⁇ , ⁇ , ⁇ ', ⁇ ' -tetramethyluronium hexafluorophosphate (HATU)
  • the conversion of halide (v) to the boronate ester (vi) or boronic acid (vi) can be performed under standard condition (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as
  • heterocyclic intermediates useful in the preparation of compounds of Formula I can be formed as shown in Scheme VIII.
  • Reaction of heterocycle (i) with an oxalate ester in the presence of a base (e.g., potassium ethoxide) and reduction followed by cyclization of the resulting ester (ii) upon heating and protection of the heterocyclic nitrogen can afford heterocycle (iii).
  • Cleavage of the methyl ether under acidic conditions can afford heterocycle (iv).
  • a base such as triethylamine, NaH or Na 2 C03 or under Mitsunobu conditions to afford the heterocycle (v).
  • the conversion of halide (v) to the boronate ester (vi) or boronic acid (vi) can be performed under standard condition (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)).
  • a suitable base e.g., NaH
  • Cyclization of (iii) to (iv) can be accomplished by isoamylnitrite.
  • Protection of the nitrogen of (iv) can be accomplished using standard conditions (e.g., tosylchloride and NaH) to give (v).
  • the conversion of halide (v) to the boronate ester (vi) or boronic acid (vi) can be performed under standard condition (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)).
  • Synthesis of compounds of Formula I can be formed as shown in Scheme X.
  • Conversion of bis-aniline to urea can occur under standard conditions (e.g., carbonyl diimidazole or triphosgene) to give (iv).
  • heterocyclic halide (iv) can be coupled to Het-M (v), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH) 2 , Het-B(OR) 2 , Het-
  • a suitable base e.g., NaH
  • Conversion of bis-aniline to urea can occur under standard conditions (e.g., carbonyl diimidazole or triphosgene) to give (iv).
  • the heterocyclic halide (iv) can be coupled to Het-M (v), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH) 2 , Het-B(OR) 2 , Het-Sn(Bu) 4 , or Zn- Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) to give compounds (vi). Deprotection of (vi) can give compounds of the invention (vii). heme XI
  • the aniline (i) can be coupled to Het-M (ii), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH) 2 , Het-B(OR) 2 , Het-Sn(Bu) 4 , or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as
  • R B -Hal CI, Br, I, or other leaving group, eg. Mel
  • a suitable base e.g., NaH
  • Removal of the trifluoroacetamide followed by reduction of the nitro under standard conditions e.g., hydrogenation with palladium, iron/AcOH, or zinc
  • the bis-aniline which can be converted to the urea under standard conditions (e.g., carbonyl diimidazole or triphosgene) to give (v).
  • deprotection of (v) can give compounds of the invention (vi).
  • benzimidazole (ii) can be coupled to Het-M (iii), where M is a boronic acid, boronate ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH) 2 , Het-B(OR) 2 , Het- Sn(Bu) 4 , or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium
  • R B -Hal CI, Br, I, or other leaving group, eg. Mel
  • a suitable base e.g., NaH
  • benzimidazole (vii) can be coupled to Het-M (iii), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH) 2 , Het-B(OR) 2 , Het-Sn(Bu) 4 , or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as
  • tetrakis(triphenylphosphine)palladium(0) and a base e.g., bicarbonate or carbonate base
  • a base e.g., bicarbonate or carbonate base
  • standard Negishi conditions e.g., in the presence of a palladium(O) catalyst, such as
  • the benzotriazole (ii) can be coupled to Het-M (iii), where M is a boronic acid, boronate ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH) 2 , Het-B(OR) 2 , Het-Sn(Bu , or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) to give compounds (iv).
  • a palladium(O) catalyst such as tetrakis(triphenylphosphine)palladium(0)
  • R B -Hal CI, Br, I, or other leaving group, eg. Mel
  • a suitable base e.g., NaH
  • the benzotriazole (vii) can be coupled to Het-M (iii), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH) 2 , Het-B(OR) 2 , Het-Sn(Bu) 4 , or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as
  • tetrakis(triphenylphosphine)palladium(0) and a base e.g., bicarbonate or carbonate base
  • a base e.g., bicarbonate or carbonate base
  • standard Negishi conditions e.g., in the presence of a palladium(O) catalyst, such as
  • Compounds of the invention are BET protein inhibitors and, thus, are useful in treating diseases and disorders associated with activity of BET proteins.
  • any of the compounds of the invention including any of the embodiments thereof, may be used.
  • the compounds of the invention can inhibit one or more of BET proteins BRD2, BRD3, BRD4, and BRD-t.
  • the BET protein is BRD2.
  • the BET protein is BRD3.
  • the BET protein is BRD4.
  • the BET protein is BRD-t.
  • the compounds of the invention selectively inhibit one or more BET proteins over another. "Selective" means that the compound binds to or inhibits a BET protein with greater affinity or potency, respectively, compared to a reference, such as another BET protein.
  • the compounds can be selective for BRD2 over BRD3, BRD4 and BRD-t, selective for BRD3 over BRD2, BRD4 and BRD-t, selective for BRD4 over BRD2, BRD3 and BRD-t, or selective for BRD-t over BRD2, BRD3 and BRD4.
  • the compounds inhibit two or more of the BET proteins, or all of the BET proteins.
  • selectivity can be at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500- fold or at least about 1000-fold.
  • the present invention is directed to a method of inhibiting BRD2 comprising contacting a compound of the invention with BRD2. In some embodiments, the present invention is directed to a method of inhibiting BRD3 comprising contacting a compound of the invention with BRD3. In some embodiments, the present invention is directed to a method of inhibiting BRD4 comprising contacting a compound of the invention with BRD4. In some embodiments, the present invention is directed to a method of inhibiting BRD-t comprising contacting a compound of the invention with BRD-t.
  • the compounds of the invention are therefore useful for treating BET protein mediated disorders.
  • BET-mediated refers to any disease or condition in which one or more of the BET proteins, such as BRD2, BRD3, BRD4 and/or BRD-t, or a mutant thereof, plays a role, or where the disease or condition is associated with expression or activity of one or more of the BET proteins.
  • the compounds of the invention can therefore be used to treat or lessen the severity of diseases and conditions where BET proteins, such as BRD2, BRD3, BRD4, and/or BRD-t, or a mutant thereof, are known to play a role.
  • Diseases and conditions treatable using the compounds of the invention include, but are not limited to, cancer and other proliferative disorders, autoimmune disease, chronic
  • inflammatory diseases can be treated by administering to an individual (e.g., a patient) in need of the treatment a therapeutically effective amount or dose of a compound of the invention, or any of the embodiments thereof, or a pharmaceutical composition thereof.
  • the present disclosure also provides a compound of the invention, or any of the embodiments thereof, or a pharmaceutical composition thereof, for use in treating a BET-mediated disease or disorder. Also provided is the use of a compound of the invention, or any of the embodiments thereof, or a pharmaceutical composition thereof, in the manufacture of a medicament for treating a BET-mediated disease or disorder.
  • the cancers can include, but are not limited to, adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia,
  • AIDS-related lymphoma alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B- cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papillom
  • craniopharyngioma cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fetus in fetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gyn
  • hemangiopericytoma hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediast
  • the cancer can be adenocarcinoma, adult T-cell leukemia/lymphoma, bladder cancer, blastoma, bone cancer, breast cancer, brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colorectal cancer, esophageal cancer,
  • gastrointestinal cancer glioblastoma multiforme, glioma, gallbladder cancer, gastric cancer, head and neck cancer
  • Hodgkin's lymphoma non-Hodgkin's lymphoma
  • intestinal cancer kidney cancer
  • laryngeal cancer leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, ocular cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, stomach cancer, T-cell lymphoma, testicular cancer, thyroid cancer, throat cancer, urogenital cancer, urothelial carcinoma, uterine cancer, vaginal cancer, or Wilms' tumor.
  • the diseases treatable using the compounds of the invention also include MYC dependent cancers wherein the cancer is associated with at least one of myc R A expression or MYC protein expression.
  • a patient can be identified for such treatment by determining myc RNA expression or MYC protein expression in the cancerous tissue or cells.
  • proliferative disorders that can be treated with compounds of the invention also include non-cancerous proliferative disorders.
  • proliferative disorders include, but are not limited to, benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, and juvenile polyposis syndrome.
  • the diseases and conditions that can be treated with the compounds of the invention also include chronic autoimmune and inflammatory conditions.
  • autoimmune and inflammatory conditions include acute, hyperacute or chronic rejection of transplanted organs, acute gout, acute inflammatory responses (such as acute respiratory distress syndrome and ischemia/reperfusion injury), Addison's disease, agammaglobulinemia, allergic rhinitis, allergy, alopecia, Alzheimer's disease, appendicitis, atherosclerosis, asthma,
  • osteoarthritis , juvenile arthritis, psoriatic arthritis, rheumatoid arthriti, satopic dermatitis, autoimmune alopecia, autoimmune hemolytic and thrombocytopenic states, autoimmune hypopituitarism, autoimmune polyglandular disease, Behcet's disease, bullous skin diseases, cholecystitis, chronic idiopathic thrombocytopenic purpura, chronic obstructive pulmonary disease (COPD), cirrhosis, degenerative joint disease, depression, dermatitis, dermatomyositis, eczema, enteritis, encephalitis, gastritis glomerulonephritis, giant cell arteritis, Goodpasture's syndrome, Guillain-Barre syndrome, gingivitis, Graves' disease, Hashimoto's thyroiditis, hepatitis, hypophysitis, inflammatory bowel disease (Crohn's disease and ulcerative colitis),
  • the diseases and conditions that can be treated with the compounds of the invention also include diseases and conditions which involve inflammatory responses to infections with bacteria, viruses, fungi, parasites or their toxins, such as sepsis, sepsis syndrome, septic shock, endotoxaemia, systemic inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome, toxic shock syndrome, acute lung injury, ARDS (adult respiratory distress syndrome), acute renal failure, fulminant hepatitis, burns, acute pancreatitis, post-surgical syndromes, sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis, malaria, SIRS associated with viral infections such as influenza, herpes zoster, herpes simplex and coronavirus.
  • diseases and conditions which involve inflammatory responses to infections with bacteria, viruses, fungi, parasites or their toxins such as sepsis, sepsis syndrome, septic shock, endotoxaemia, systemic inflammatory response syndrome (SIRS),
  • viral infections examples include Epstein-Barr virus, hepatitis B virus, hepatitis C virus, herpes virus, human immunodeficiency virus, human papilloma virus, adenovirus, poxvirus and other episome-based DNA viruses.
  • the compounds can therefore be used to treat disease and conditions such as herpes simplex infections and reactivations, cold sores, herpes zoster infections and reactivations, chickenpox, shingles, human papilloma virus, cervical neoplasia, adenovirus infections, including acute respiratory disease, and poxvirus infections such as cowpox and smallpox and African swine fever virus.
  • the compounds of the invention are indicated for the treatment of human papilloma virus infections of skin or cervical epithelia.
  • the diseases and conditions that can be treated with the compounds of the invention also include conditions that are associated with ischaemia-reperfusion injury. Examples of such conditions include, but are not limited to conditions such as myocardial infarction,
  • cerebrovascular ischaemia stroke
  • acute coronary syndromes renal reperfusion injury
  • organ transplantation organ transplantation
  • coronary artery bypass grafting cardio-pulmonary bypass procedures
  • pulmonary renal, hepatic, gastro-intestinal or peripheral limb embolism.
  • the compounds of the invention are also useful in the treatment of disorders of lipid metabolism via the regulation of APO-A1 such as hypercholesterolemia, atherosclerosis and Alzheimer's disease.
  • the compounds of the invention are also useful in the treatment of fibrotic conditions such as idiopathic pulmonary fibrosis, renal fibrosis, post-operative stricture, keloid formation, scleroderma and cardiac fibrosis.
  • the compounds of the invention can also be used to treat ophthamological indications such as dry eye.
  • the compounds of the invention can also be used to treat heart disease such as heart failure.
  • contacting refers to the bringing together of indicated moieties in an in vitro system or an in vivo system.
  • "contacting" a BET protein with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having a BET protein, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the BET protein.
  • the phrase "therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician.
  • treating refers to inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e.,, arresting further development of the pathology and/or symptomatology) or ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e.,, reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
  • preventing refers to preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.
  • the compounds of the invention can be used in combination treatments where the compound of the invention is administered in conjunction with other treatments such as the administration of one or more additional therapeutic agents.
  • the additional therapeutic agents are typically those which are normally used to treat the particular condition to be treated.
  • the additional therapeutic agents can include, e.g., chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, as well as Bcr-Abl, Flt-3, RAF, FAK, and JAK kinase inhibitors for treatment of BET protein-associated diseases, disorders or conditions.
  • the one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially.
  • the compounds of the invention can be used in combination with a therapeutic agent that targets an epigenetic regulator.
  • epigenetic regulators include the histone lysine methyltransferases, histone arginine methyl transferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases.
  • Histone deacetylase inhibitors include, e.g., vorinostat.
  • the compounds of the invention can be used in combination with chemotherapeutic agents, or other anti-proliferative agents.
  • the compounds of the invention can also be used in combination with medical therapy such as surgery or radiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes.
  • medical therapy such as surgery or radiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes.
  • chemotherapeutic agents include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxe
  • the compounds of the invention can be used in combination with ruxolitinib.
  • the compound of the invention can be administered in combination with a corticosteroid such as triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
  • a corticosteroid such as triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
  • an immune suppressant such as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol, Alcon), or cyclosporine (Restasis®).
  • the compound of the invention can be administered in combination with one or more additional agents selected from DehydrexTM (Holies Labs), Civamide (Opko), sodium hyaluronate (Vismed, Lantibio/TRB Chemedia), cyclosporine (ST-603, Sirion Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine, doxycycline (ALTY-0501, Alacrity), minocycline, iDestrinTM
  • NP50301 Nascent Pharmaceuticals
  • cyclosporine A Nova22007, Novagali
  • oxytetracycline Duramycin, MOLI1901, Lantibio
  • CF101 (2S, 3S, 4R, 5R)-3, 4-dihydroxy-5-[6-[(3- iodophenyl)methylamino]purin-9-yl]-N-methyl-oxolane-2-carbamyl, Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences), ARG103 (Agentis), RX- 10045 (synthetic resolvin analog, Resolvyx), DYN15 (Dyanmis Therapeutics), rivoglitazone (DE011, Daiichi Sanko), TB4 (RegeneRx), OPH-01 (Ophtalmis Monaco), PCS 101 (Pericor Science), REV 1-31 (Evolutec), Lacritin (Senju), rebamipid
  • the compound of the invention can be administered in any embodiments.
  • suitable medicaments include aminoglycosides such as amikacin, gentamycin, tobramycin, streptomycin, netilmycin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin; paramomycin;
  • rifampins colistimethate; bacitracin; vancomycin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; amphotericins; fluconazole; flucytosine; natamycin; miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen; ketorolac; suprofen;
  • agents one or more of which a provided compound may also be combined with include: a treatment for Alzheimer's Disease such as donepezil and rivastigmine; a treatment for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinirole, pramipexole, bromocriptine, pergolide, trihexyphenidyl, and amantadine; an agent for treating multiple sclerosis (MS) such as beta interferon (e.g., Avonex® and Rebif®), glatiramer acetate, and mitoxantrone; a treatment for asthma such as albuterol and montelukast; an agent for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; an anti-inflammatory agent such as a corticosteroid, such as dexamethasone or prednisone, a TNF blocker, IL-1 RA, azathi
  • immunodeficiency disorders such as gamma globulin.
  • compositions When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
  • Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral.
  • Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
  • Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
  • compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • compositions which contain, as the active ingredient, the compound of the invention or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers (excipients).
  • the composition is suitable for topical administration.
  • the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
  • the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
  • the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is
  • substantially insoluble it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
  • the compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types.
  • Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art, e.g., see International App. No. WO 2002/000196.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the active compound may be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the active ingredient of the present invention.
  • the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
  • Topical formulations can contain one or more conventional carriers. In some embodiments,
  • ointments can contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white vaseline, and the like.
  • Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol.
  • Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, for example, glycerol, hydroxyethyl cellulose, and the like.
  • topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2, or at least about 5 wt % of the compound of the invention.
  • the topical formulations can be suitably packaged in tubes of, for example, 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.
  • compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
  • compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
  • the pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
  • the therapeutic dosage of a compound of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
  • the proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
  • the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day.
  • the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • compositions of the invention can further include one or more additional ingredients
  • chemotherapeutic such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant, examples of which are listed hereinabove.
  • the compounds of the invention can be provided with or used in combination with a companion diagnostic.
  • a companion diagnostic refers to a diagnostic device useful for determining the safe and effective use of a therapeutic agent.
  • a companion diagnostic may be used to customize dosage of a therapeutic agent for a given subject, identify appropriate subpopulations for treatment, or identify populations who should not receive a particular treatment because of an increased risk of a serious side effect.
  • the companion diagnostic is used to monitor treatment response in a patient. In some embodiments, the companion diagnostic is used to identify a subject that is likely to benefit from a given compound or therapeutic agent. In some embodiments, the companion diagnostic is used to identify a subject having an increased risk of adverse side effects from administration of a therapeutic agent, compared to a reference standard. In some embodiments, the companion diagnostic is an in-vitro diagnostic or imaging tool selected from the list of FDA cleared or approved companion diagnostic devices. In some embodiments, the companion diagnostic is selected from the list of tests that have been cleared or approved by the Center for Devices and Radiological Health.
  • Another aspect of the present invention relates to labeled compounds of the invention (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating BET proteins in tissue samples, including human, and for identifying BET protein ligands by inhibition binding of a labeled compound.
  • the present invention includes BET protein assays that contain such labeled compounds.
  • the present invention further includes isotopically-labeled compounds of the invention.
  • An "isotopically” or “radio-labeled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
  • Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 3 H (also written as T for tritium), n C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 C1, 82 Br, 75 Br, 76 Br, 77 Br, 123 1, 124 1, 125 I and 131 I.
  • radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro BET protein labeling and competition assays, compounds that incorporate 3 H, 14 C, 82 Br, 125 1 , 131 I, or 35 S will generally be most useful. For radio-imaging applications U C, 18 F, 125 I, 123 I, 124 I, 131 I, 75 Br, 76 Br or 77 Br will generally be most useful.
  • a “radio-labeled " or “labeled compound” is a compound that has incorporated at least one radionuclide.
  • the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1, 35 S and 82 Br.
  • the compound incorporates 1, 2, or 3 deuterium atoms.
  • the present invention can further include synthetic methods for incorporating radio- isotopes into compounds of the invention. Synthetic methods for incorporating radio-isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of invention.
  • a newly synthesized or identified compound ⁇ i.e., test compound) which is labeled can be evaluated for its ability to bind a BET protein by monitoring its concentration variation when contacting with the BET protein, through tracking of the labeling.
  • a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a BET protein ⁇ i.e., standard
  • test compound Accordingly, the ability of a test compound to compete with the standard compound for binding to the BET protein directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
  • Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems.
  • the basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g. "Two- Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi.
  • Typical preparative reverse-phase high performance liquid chromatography (RP-HPLC) column conditions are as follows:
  • Step 3 4-[3,4-Diamino-2-(2,4-difluorophenoxy)phenyl] -6-methyl-l -[ (4-methylphenyl)sulfonylJ - 1, 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
  • Step 4 4-(2,4-Difluorophenoxy)-5-(6-methyl-7-oxo-6, 7-dihydro- lH-pyrrolo [2,3-c] pyridin-4-yl)- l,3-dihydro-2H-benzimidazol-2-one
  • the intermediate urea was dissolved in ethanol (1.0 mL), treated with 1.0 M sodium hydroxide in water (326 0.326 mmol), and heated at 60 °C overnight.
  • the reaction mixture was diluted with ethyl acetate and water.
  • the organic layer was separated and washed with brine, dried with sodium sulfate, filtered, and concentrated to give a crude residue.
  • This material was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of methanol/water containing 0.1%) trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (7.3 mg, 19%>) as a white solid.
  • the reaction mixture was concentrated to give the intermediate benzimidazole which was used immediately without further purification.
  • the intermediate benzimidazole was dissolved in ethanol (1.0 mL), treated with 1.0 M sodium hydroxide in water (300 ⁇ , 0.90 mmol), and heated at 60 °C overnight.
  • the reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of methanol/water containing 0.1% trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (6 mg, 26%) as a white solid.
  • Step 1 N-(3-(2,4-Difluorophenoxy)-4- ⁇ 6-methyl-l-[ (4-methylphenyl)sulfonyl]-7-oxo-6, 7- dihydro- lH-pyrrolo [2 ,3-c] pyridin-4-yl ⁇ -2-nitrophenyl)-2 2 ,2-trifluoroacetamide
  • the reaction mixture was diluted with ethyl acetate (200 mL), washed with water (3 x 50 mL) and brine, dried with magnesium sulfate, filtered, and concentrated to give the desired methylated amide that was used immediately without further purification.
  • the intermediate methyl trifluoroacetamide was dissolved in methanol (1.4 mL, 33.7 mmol) and water (0.27 mL), treated with potassium carbonate (83.4 mg, 0.604 mmol), and stirred at 60 °C for 3 h.
  • Step 3 4-[3-Amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
  • Step 4 4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-6-methyl- pyrrolo[2, 3-cJpyridin- 7 -one trifluoroacetate
  • This compound was synthesized according to the procedure of Example 2 using 4-[3- amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one instead of 4-[3,4-diamino- 2-(2,4-difluorophenoxy)phenyl]-6-methyl-l-[(4-methylphenyl)sulfonyl]-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one.
  • This compound was synthesized according to the procedure of Example 2 using 4-[3- amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one instead of 4-[3,4-diamino- 2-(2,4-difluorophenoxy)phenyl]-6-methyl-l-[(4-methylphenyl)sulfonyl]-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one and triethyl orthoacetate instead of ethyl orthoformate.
  • Step 1 4-(2,4-difluorophenoxy)-l-methyl-5- ⁇ 6-methyl-l-[(4-methylphenyl)sulfonylJ-7- dihydro- lH ⁇ yrrolo [2,3-c] pyridin-4-yl ⁇ - 1 ,3-dihydro-2H-benzimidazol-2-one
  • Analytical LCMS indicated the reaction was complete.
  • the reaction mixture was diluted with ethanol (3.0 mL), treated with 3.0 M sodium hydroxide in water (0.175 mL, 0.525 mmol), and stirred at RT overnight.
  • the reaction was quenched with acetic acid (0.044 mL, 0.780 mmol) and purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water containing 0.1% trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (14.5 mg, 64%).
  • Example 8 4- [4-(2,4-Difluorophenoxy)- 1H- 1 ,2,3-benzotriazol-5-yl] -6-methyl- 1 ,6-dihydro- 7H-pyr rolo [2,3-c] pyridin-7-one
  • Step 1 4-f4-(2,4-Difluorophenoxy)-lH-l,2,3-benzotriazol-5-ylJ-6-methyl-l-f(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H- rrolo[2, 3-cJpyridin- 7 -one
  • reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (13 mg, 56%).
  • This compound was synthesized according to the procedure of Example 8 using 4-[3- amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material.
  • the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with magnesium sulfate, filtered, and concentrated to give a mixture of the desired product along with the acetylated desired product.
  • This mixture was diluted with methanol (490 mL) and treated with 1.0 M sodium hydroxide in water (280 mL) and stirred at RT for 1 h.
  • the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with magnesium sulfate, filtered, and concentrated to give crude product. Purification by flash column chromatography (100% hexanes to 100% EtOAc) gave the desired product (8.4 g, 66%>).
  • the reaction mixture was diluted with ethyl acetate (100 mL) and saturated sodium bicarbonate solution (100 mL), filtered over Celite, and washed with ethyl acetate. The aqueous layer was separated and re- extracted with ethyl acetate (100 mL). The combined organic layers were washed with brine, dried with magnesium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (100% hexanes to 60% EtOAc/hexanes) gave the individual isomers of the desired product (major isomer: 5.23 g, 54%>; minor isomer: 1.28 g, 13%).
  • Step 6 4-Diamino-2-(2, 4-difluorophenoxy)phenyl]-6-methyl-2- ⁇ [ 2- ( trimethylsilyl)ethoxy] methyl ⁇ -2, 6-dihydro- 7H-pyrazolo[ 3, 4-cJpyridin- 7 -one
  • Step 7 4-f 4- ( 2, 4-Difluorophenoxy)-lH-l , 2, 3-benzotriazol-5-yl]-6-methyl-l, 6-dihydro- 7H- pyrazolo[3,4-c]pyridin-7-one
  • the organic layer was separated, washed with saturated sodium bicarbonate (2x) and brine, dried with magnesium sulfate, filtered, and concentrated to give the SEM- protected intermediate which was used without further purification.
  • the crude intermediate was diluted with methylene chloride (4.00 mL) and trifluoroacetic acid (4.00 mL) and stirred at 40 °C for 3 h.
  • the reaction mixture was concentrated, diluted with acetonitrile, adjusted to pH ⁇ 7 with 1 M NaOH, and purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (16 mg, 20%).
  • Step 3 4-[3,4-Diamino-2-(cyclopropylmethoxy)phenyl]-6-methyl-l-[ (4-methylphenyl)sulfonylJ- 1, 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
  • Step 4 4-(Cyclopropylmethoxy)-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin l,3-dihydro-2H-benzimidazol-2-one
  • This compound was synthesized according to the procedure of Example 1, Step 4, using 4-[3,4-diamino-2-(cyclopropylmethoxy)phenyl]-6-methyl-l-[(4-methylphenyl)sulfonyl]-l,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material.
  • This compound was synthesized according to the procedure of Example 2 using 4-[3,4- diamino-2-(cyclopropylmethoxy)phenyl]-6-methyl- 1 -[(4-methylphenyl)sulfonyl]- 1 ,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one as the starting material.
  • This compound was synthesized according to the procedure of Example 2 using 4- [3, 4- diamino-2-(cyclopropylmethoxy)phenyl]-6-methyl- 1 -[(4-methylphenyl)sulfonyl]- 1 ,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one as the starting material and triethyl orthoacetate instead of ethyl orthoformate.
  • reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (23 mg, 60%).
  • Step 1 4- [4-Amino-2-(2 ,4-difluorophenoxy)-3-nitrophenyl] -6-methyl- 1- ⁇ [2- ( trimethylsilyl)ethoxyJ methyl ⁇ - 1, 6-dihydro- 7H-pyrazolo[ 3, 4-c] pyridin- 7 -one
  • Step 2 4-Diamino-2-(2, 4-difluorophenoxy)phenyl]-6-methyl-l- ⁇ [ 2- ( trimethylsilyl)ethoxyJ methyl ⁇ - 1, 6-dihydro- 7H-pyrazolo[ 3, 4-c] pyridin- 7 -one
  • the organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the SEM-protected intermediate which was used without further purification.
  • the crude intermediate was diluted with methylene chloride (4.0 mL) and trifluoroacetic acid (4.0 mL) and stirred at 40 °C for 2 h.
  • the reaction mixture was concentrated, diluted with acetonitrile, adjusted to pH ⁇ 7 with 1 M NaOH, and purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (16 mg, 20%).
  • reaction mixture was treated with a solution of N-[3-(2,4-difluorophenoxy)-4-(6-methyl-7-oxo-l- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ - 6,7-dihydro-lH-pyrazolo[3,4-c]pyridin-4-yl)-2-nitrophenyl]-2,2,2-trifluoroacetamide (150 mg, 0.235 mmol) in THF and stirred overnight at RT. The reaction mixture was diluted with ethyl acetate and water.
  • This compound was synthesized according to the procedure of Example 14 using 4- ⁇ 3- amino-2-(2,4-difluorophenoxy)-4-[(2-morpholin-4-ylethyl)amino]phenyl ⁇ -6-methyl- 1 - ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material.
  • Example 18 4- [4-(2,4-Difluorophenoxy)- 1-methyl- lH-benzimidazol-5-yl] -6-methyl- 1 ,6- dihydr o-7H-pyrazolo [3 ,4-c] pyridin- -one.
  • Step 1 4-[2-(2, 4-Difluorophenoxy)-4-(methylamino)-3-nitrophenyl]-6-methyl-l- ⁇ [2- ( trimethylsilyl)ethoxy] methyl ⁇ - 1, 6-dihydro- 7H-pyrazolo[ 3, 4-c] pyridin- 7 -one
  • This compound was synthesized according to the procedure of Example 14 using 4-[3- amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl- 1 - ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material.
  • Example 20 4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-l,2,3-benzotriazol-5-yl]-6-methyl- l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one
  • Example 21 4-[4-(2,4-Difluorophenoxy)-l-methyl-2-oxo-2,3-dihydro-lH-benzimidazol-5- yl] -6-methyl- 1 ,6-dihydro-7H-pyrazolo 3,4-c] pyridin-7-one
  • Step 2 4-[4-Amino-2-(benzyloxy)-3-nitrophenyl]-6-methyl-l-[ (4-methylphenyl)sulfonylJ -1 ,6- dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
  • Step 4 4- [2-(Benzyloxy)-4-(methylamino)-3-nitrophenyl] -6-methyl- 1- [(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
  • Step 5 4-[3-Amino-2-(benzyloxy)-4-(methylamino)phenyl]-6-methyl-l-[ (4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
  • Step 6 4-(Benzyloxy)-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- l,3-dihydro-2H-benzimidazol-2-one
  • This compound was synthesized according to the procedure of Example 1, Step 4, using 4-[3-amino-2-(benzyloxy)-4-(methylamino)phenyl]-6-methyl- 1 -[(4-methylphenyl)sulfonyl]- 1 ,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material.
  • LCMS calculated for
  • Step 5 4-[ 3, 4-Diamino-2-(2, 4-dtfluorophenoxy)phenyl]-6-methyl-l- ⁇ [ 2- (trimethylsilyl)ethoxyJmethyl ⁇ -l,6-dih dro-7H-pyrrolo[2,3-cJpyridin-7-one
  • Step 7 Ethyl [4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-l- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ - 6, 7 -dihydro-lH-pyrrolo[2 ,3-c] pyridin-4-yl)- lH-benzimidazol- 1-yl] 'acetate and ethyl [7-(2,4- difluorophenoxy)-6-(6-methyl-7-oxo-l- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -6, 7-dihydro-lH- pyrrolo[2, 3-c]pyridin-4- l)-lH-benzimidazol-l-yl] acetate
  • Step 8 [4-(2,4-Difluorophenoxy)-5-(6-methyl-7-oxo-l- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -6, 7- dihydro-lH-pyrrolo[2,3-cJpyridin-4-yl)-lH-benzimidazol-l-ylJacetic acid and [7-(2,4- difluorophenoxy)-6-(6-methyl-7-oxo-l- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -6, 7-dihydro-lH- pyrrolo[2, 3-c]pyridin-4-yl)-lH-benzimidazol-l-yl] acetic acid
  • Step 9 4-f7-(2,4-Difluorophenoxy)-l-(2-morpholin-4-yl-2-oxoethyl)-lH-benzimidazol-6-ylJ-6- methyl-1 ,6-dihydro-7H-pyrrolo[2 ',3-cJpyridin- ' / 7 -one and 4-[4-(2,4-difluorophenoxy)-l-(2- morpholin-4-yl-2-oxoethyl)-lH-benzimidazol-5-yl]-6-methyl-l, 6-dihydro- 7H-pyrrolo[ 2, 3- cjpyridin- 7-one
  • reaction mixture was stirred for several minutes and treated with benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophosphate (34.3 mg, 0.0775 mmol) and the reasultant mixture was stirred at RT for 1 h, after which time the reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated to give the crude intermediate amide as a mixture of isomers which was used without further purification.
  • the crude mixture of intermediate amides was diluted with methylene chloride (2.00 mL) and trifluoroacetic acid (1.00 mL) and stirred at RT for 2 h, after which time the reaction mixture was concentrated in vacuo and the resultant residue was reconcentrated from toluene.
  • This crude residue was diluted with methanol (2.00 mL), treated with ethylenediamine (27.6 ⁇ , 0.413 mmol), and stirred at RT overnight.
  • the reaction mixture was concentrated in vacuo and purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of
  • the reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with water (3x) and brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude methylated amide which was used without further purification.
  • the crude intermediate methylated amide was dissolved in methanol (43.4 mL) and water (8.68 mL, 482 mmol), treated with potassium carbonate (2.65 g, 19.2 mmol), and the resultant mixture was stirred at 60 °C for 15 h, after which time the reaction mixture was concentrated to remove most of the methanol and the aqueous residue was extracted with ethyl acetate (2x).
  • the combined organic layers were diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with water (3x) and brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude methylated amide which
  • Step 3 4-[2-Methoxy-4-(methylamino)-3-nitrophenyl]-6-methyl-l-[ (4-methylphenyl)sulfonyl) '- 1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
  • reaction mixture was concentrated and purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired compound 6-Methyl-4-[l- (2-morpholin-4-ylethyl)-7-phenoxy-lH-benzimidazol-6-yl]-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one (Example 42) as peak 1 (6 mg, 12%) and the desired compound 6-methyl-4-[l- (2-morpholin-4-ylethyl)-4-phenoxy-lH-benzimidazol-5-yl]-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one (Example 43) as peak 2 (18 mg, 37%).
  • the flask containing 4-bromo-3-methoxy-N-methyl-2-nitroaniline was rinsed with ethanol (3.75 mL) and the solution was added to the reaction mixture.
  • the resultant reaction mixture was stirred at 60-65 °C for 2 h, after which time the reaction mixture was diluted with ethyl acetate (100 mL), treated with anhydrous magnesium sulfate, stirred for 10 min and then filtered through a pad of Celite. The filtrate was concentrated to dryness in vacuo and the resulting solid was used immediately without further purification.
  • Ci6Hi6BrN 2 0 2 (M+H) + : m/z 347.1, 349.1; found: 347.0, 349.0.
  • the reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated to give the crude intermediate urea which was used without further purification.
  • the intermediate urea was dissolved in methanol (1.0 mL), treated with 3.0 M sodium hydroxide in water (0.5 mL, 1.5 mmol), and heated at 60 °C for 3 h.
  • the reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water containing 0.1%) trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (40 mg, 47%).
  • 'H NMR 300 MHz, DMSO- ⁇ ) ⁇ 12.02 (br s, 1H), 7.38 - 7.28 (m, 2H), 7.28 - 7.15 (m, 5H),
  • Example 60 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo [2,3-c] pyridin-4-yl)-3-(2-mor holin-4-ylethyl)- 1 ,3-dihydro-2H-benzimidazol-2-one
  • Step 6 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-3-(2-morpholin-4-ylethyl)-l,3-dihydro-2H-benzimidazo
  • Example 65 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo [2,3-c] pyridin-4-yl)-3-(2-piperidin-4-ylethyl)- 1 ,3-dihydro-2H-benzimidazol-2-
  • Step 2 4-(Cyclobutylmethoxy)-l-methyl-5- ⁇ 6-methyl-l-[ (4-methylphenyl) sulfonyl] -7 -oxo-6, 7- dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl ⁇ -3-(2-piperidin-4-yletk ⁇
  • the reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude intermediate which was used without further purification.
  • the crude intermediate was dissolved in a mixture of methylene chloride (2.0 mL) and trifluoroacetic acid (1.0 mL) and the resultant solution was stirred at RT for 3 h, after which time the reaction mixture was purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1%
  • Step 3 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6, 7 -dihydro- lH-pyrrolo [2,3- c]pyridin-4-yl)-3-(2-piperidin-4-ylethyl)-l, 3-dihydro-2H-benzimidazol-2-one
  • reaction mixture was purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (1.1 mg, 7%).
  • LCMS calculated for C28H36N5O3 (M+H) + : m/z 490.3; found: 490.3.
  • Example 66 3-(2-(4-Acetylpiperazin-l-yl)ethyl)-4-(cyclobutylmethoxy)-l-methyl-5-(6- methyl- 7-oxo-6,7-dihydro-lH-pyrrolo [2,3-c] pyridin-4-yl)-lH-benzo [d] imidazol-2(3H)-one
  • Step 3 3-(2-(4-Acetylpiperazin-l-yl)ethyl)-4-(cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo- 6 -dihydro-lH-pyrrolo[2,3-c]pyridin-4- l)-lH-benzo[d]imidazol-2(3H)-one
  • This compound was synthesized according to the procedure of Example 44, Step 3, using 3 - [2-(4-acetylpiperazin- 1 -yl)ethyl] -5 -bromo-4-(cyclobutylmethoxy)- 1 -methyl- 1 ,3 -dihydro-2H- benzimidazol-2-one as the starting material.
  • Example 67 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl)-3- ⁇ 2-[4-(methylsulfonyl)piperazin-l-yl]ethyl ⁇ -l,3-dihyd] benzimidazol-2-one
  • Example 68 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl)-3-[2-(4-methylpiperazin-l-yl)ethyl]-l,3-dihydro-2H- benzimidazol-2-one
  • Step 2 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-3-[2-(4-methylpiperazin-l-yl)ethyl]-l,3-dihydro-2H-benzM
  • This compound was synthesized according to the procedure of Example 6, Step 2, using 5- ⁇ 6-methyl- 1 -[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl ⁇ - 1 - (2-morpholin-4-ylethyl)-4-phenoxy-l,3-dihydro-2H-benzimidazol-2-one trifluoroacetate as the starting material.
  • Example 70 l- ⁇ 2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]ethyl ⁇ -5-(6-methyl-7-oxo-6,7- dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-l,3-dihydro-2H-benzimidazol-2-one trifluoroacetate
  • Example 71 4-(2-(Benzylamino)-l- ⁇ 2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethyl ⁇ -4- phenoxy-lH-benzimidazol-5-yl)-6-methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one trifluoroacetate
  • Example 72 4-(2-[(Cyclopropylmethyl)amino]-l- ⁇ 2-[(2R,6S)-2,6-dimethylmorpholin-4- yl]ethyl ⁇ -4-phenoxy-lH-benzimidazol-5-yl)-6-methyl-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one trifluoroacetate
  • 3-Oxobutanoic acid ethyl ester (1.26 mL, 10.0 mmol) was added dropwise to a suspension of N-bromosuccinimide (1.78 g, 10.0 mmol) and /?-toluenesulfonic acid (10.0 mg, 0.0581 mmol) in methylene chloride (30.0 mL) at 0 °C, and the resultant reaction mixture was stirred at 0°C for 3 h, then warmed to RT and stirred at that temperature for 1 h. The reaction mixture was concentrated in vacuo and the resultant oily solid was treated with hexanes and the resultant suspension was filtered.
  • This compound was synthesized according to the procedure of Example 4, Step 1, using 4-bromo-3-(2,4-difluorophenoxy)-2-nitroaniline as the starting material.
  • Step 4. 8-(2,4-Difluorophenoxy)-7-(6-methyl-7-oxo-l- ⁇ f2-(trimethylsilyl)ethoxyJmethyl ⁇ -6, 7- dihydro-lH ⁇ yrazolo[3,4-cJpyridin-4- l)-3,4-dihydroquinoxalin-2(lH)-one
  • the reaction mixture was diluted with dichloromethane and filtered through a pad of Celite. The solids were washed with additional dichloromethane and the filtrate was concentrated in vacuo to yield a crude residue. The residue was dissolved in dichloromethane and the organic phase was washed with saturated sodium bicarbonate solution, dried with sodium sulfate, filtered, and concentrated oin vacuo to give the crude product.
  • Trifluoroacetic acid (0.40 mL, 5.19 mmol) was added dropwise at RT to a solution of 8- (2,4-difluorophenoxy)-7-(6-methyl-7-oxo- 1 - ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -6, 7-dihydro- 1 H- pyrazolo[3,4-c]pyridine-4-yl)-3,4-dihydroquinoxalin-2(lH)-one (10.5 mg, 0.0190 mmol, mixture of oxidized (quinoxalin) and reduced (dihydroquinoxalin) forms from previous step) in methylene chloride (0.40 mL), and the reaction mixture was stirred at RT for 1 h.
  • reaction mixture was purified via preparative LCMS (XBridge C 18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (4 mg, 50%).
  • Example 76 4-[4-(Cyclopropylmethoxy)-l-methyl-lH-indazol-5-yl]-6-methyl-l,6-dihydro- 7H-pyr rolo [2,3-c] pyridin-7-one
  • N,N- dimethylformamide (0.412 mL, 5.32 mmol) was added to the reaction mixture dropwise at -78 °C and the reaction mixture was stirred at -78 °C for 1 h.
  • Reaction mixture was quenched with saturated ammonium chloride, warmed to 20 °C, and diluted with ether and 1M aqueous solution of HC1. Layers were separated and the aqueous layer was and re-extracted with ether. The combined organic layers were washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give a crude residue.
  • reaction mixture was cooled to 0 °C, treated with more boron tribromide (0.0405 mL, 0.428 mmol), and stirred for 2 h.
  • the reaction mixture was then cooled to 0 °C and quenched carefully with saturated sodium bicarbonate (30 mL) and extracted with dichloromethane (2 x 30 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo to yield a crude mixture. This mixture was re-subjected to the initial reaction conditions.
  • the crude mixture was suspended in 1 ,2-dichloroethane (1.74 mL), cooled to 0 °C, treated with boron tribromide (0.0810 mL, 0.857 mmol), warmed to RT and stirred at RT for 2 h.
  • the reaction mixture was cooled to 0 °C and quenched carefully with saturated solution of sodium bicarbonate (30 mL) and extracted with dichloromethane (2 x 30 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo to give the crude product.
  • triphenylphosphine (0.102 g, 0.390 mmol), cooled to 0 °C, followed by dropwise addition of diisopropyl azodicarboxylate (0.0767 mL, 0.390 mmol). Reaction mixture was warmed to RT and stirred at RT for 16 h. The reaction mixture was poured into saturated sodium bicarbonate solution and extracted with ethyl acetate. Layers were separated and the organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo to give the crude product. Purification by flash column chromatography (100% hexanes to 100% CH2CI2) gave the desired product (72 mg, 78%>) as a yellow solid.
  • Step 7 4-[ 4-(Cyclopropylmethoxy)-l-methyl-lH-indazol-5-yl] -6-methyl-l , 6-dihydro- 7H- pyrrolo[2, 3-cJpyridin- 7 -one

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

Description

BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS
TECHNICAL FIELD
The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
BACKGROUND
The genomes of eukaryotic organisms are highly organized within the nucleus of the cell.
DNA is packaged into chromatin by wrapping around a core of histone proteins to form a nucleosome. These nucleosomes are further compacted by aggregation and folding to form a highly condensed chromatin structure. A range of different states of condensation are possible, and the tightness of this structure varies during the cell cycle, being most compact during the process of cell division. Chromatin structure plays a critical role in regulating gene transcription by regulating protein access to the DNA. The chromatin structure is controlled by a series of post translational modifications to histone proteins, mainly within the tails of histones H3 and H4 that extend beyond the core nucleosome structure. These reversible modifications include acetylation, methylation, phosphorylation, ubiquitination and SUMOylation. These epigenetic marks are written and erased by specific enzymes that modify specific residues within the histone tail, thereby forming an epigenetic code. Other nuclear proteins bind to these marks and effect outputs specified by this information through the regulation of chromatin structure and gene transcription. Increasing evidence links genetic changes to genes encoding epigenetic modifiers and regulators leading to aberrant histone marks in diseases such as neurodegenerative disorders, metabolic diseases, inflammation and cancer.
Histone acetylation is typically associated with the activation of gene transcription, as the modification weakens the interaction between the DNA and the histone proteins, permitting greater access to DNA by the transcriptional machinery. Specific proteins bind to acetylated lysine residues within histones to "read" the epigenetic code. A highly conserved protein module called the bromodomain binds to acetylated lysine residues on histone and other proteins. There are more than 60 bromodomain-containing proteins in the human genome. The BET (Bromodomain and Extra-Terminal) family of bromodomain containing proteins comprises 4 proteins (BRD2, BRD3, BRD4 and BRD-t) that share a conserved structural organization containing tandem N-terminal bromodomains capable of binding to acetylated lysine residues of histones and other proteins. BRD2, BRD3 and BRD4 are ubiquitiously expressed while BRDt is restricted to germ cells. BRD proteins play essential, but non-overlapping roles in regulating gene transcription and controlling cell growth. BET proteins are associated with large protein complexes including Mediator, PAFc and super elongation complex that regulate many aspects of gene transcription. BRD2 and BRD4 proteins have been shown to remain in complex with chromosomes during mitosis and are required to promote transcription of critical genes including cyclin D and c-Myc that initiate the cell cycle
(Mochizuki J Biol. Chem. 2008 283:9040-9048). BRD4 is essential for recruiting the protein translational elongation factor B complex to the promoters of inducible genes resulting in the phosphorylation of RNA polymerase II and stimulating productive gene transcription and elongation (Jang et al. Mol. Cell 2005 19:523-534). In some instances, a kinase activity of BRD4 may directly phosphorylate and activate RNA polymerase II (Devaiah et al. PNAS 2012
109:6927-6932). Cells lacking BRD4 show impaired progression through cell cycle. BRD2 and BRD3 are reported to associate with histones along actively transcribed genes and may be involved in facilitating transcriptional elongation (Leroy et al, Mol. Cell. 2008 30:51-60). In addition to acetylated histones, BET proteins have been shown to bind selectively to acetylated transcription factors including the RelA subunit of NF-kB and GATA1 thereby directly regulating the transcriptional activity of these proteins to control expression of genes involved in inflammation and hematopoietic differentiation (Huang et al, Mol. Cell. Biol. 2009 29: 1375- 1387; Lamonica Proc. Nat. Acad. Sci. 2011 108:E159-168).
A recurrent translocation involving NUT (nuclear protein in testes) with BRD3 or BRD4 to form a novel fusion oncogene, BRD-NUT, is found in a highly malignant form of epithelial neoplasia (French et al, Cancer Research 2003 63:304-307; French et al, Journal of Clinical Oncology 2004 22:4135-4139). Selective ablation of this oncogene restores normal cellular differentiation and reverses the tumorigenic phenotype (Filippakopoulos et al, Nature 2010 468: 1068-1073). Genetic knockdown of BRD2, BRD3 and BRD4 has been shown to impair the growth and viability of a wide range of hematological and solid tumor cells (Zuber et al, Nature 2011 478:524-528; Delmore et al, Cell 2011 146:904-917). Aside from a role in cancer, BET proteins regulate inflammatory responses to bacterial challenge, and a BRD2 hypomorph mouse model showed dramatically lower levels of inflammatory cytokines and protection from obesity induced diabetes (Wang et al Biochem J. 2009 425:71-83; Belkina et al. J. Immunol 2013). In addition, some viruses make use of these BET proteins to tether their genomes to the host cell chromatin, as part of the process of viral replication or use BET proteins to facilitate viral gene transcription and repression (You et al, Cell 2004 117:349-60; Zhu et al, Cell Reports 2012 2:807-816).
Accordingly, there is a need for compounds that modulate the activity of the BET family of proteins, including BRD2, BRD3, and BRD4, that can be used to treat BET protein-associated diseases such as cancer. The compounds of the invention help meet this need.
SUMMARY
The present invention provides, inter alia, a compound of Formula I:
Figure imgf000005_0001
I
or a pharmaceutically acceptable salt thereof; wherein the variables are as defined below.
The present invention also provides a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
The present invention also provides a method of inhibiting a BET protein comprising contacting a compound of Formula I, or a pharmaceutically acceptable salt thereof, with the BET protein. The present invention also provides a method of treating cancer and other diseases comprising administering to a patient a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
The present invention also provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in therapy.
The present invention also provides use of a compound of Formula I, or a
pharmaceutically acceptable salt thereof, in the preparation of a medicament for use in therapy.
DETAILED DESCRIPTION
The present invention provides, inter alia, a compound of Formula I
Figure imgf000006_0001
or a pharmaceutically acceptable salt thereof, wherein:
represents a single or double bond;
Ring B is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, Cs-cycloalkyl, C6- cycloalkyl, 5-membered heterocycloalkyl, or 6-membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 RB;
L is absent, -(CRaRb)P-, -(CRaRb)n-0-(CRaRb)m-, -(CRaRb)n-S-(CRaRb)m-,
Figure imgf000006_0002
b)n-NRc-(CRaRb)m-, -
Figure imgf000006_0003
-(CRaRb)n-NRcC(=0)NRd-(CRaRb)m-;
Al is CR3 or N; A2 is CR4 or N;
A3 is C or N;
A4 is C or N;
wherein when one of A3 and A4 is N, then the other of A3 and A4 is C;
W is CR5 or N;
X is CR6 or N;
Y is CR7 or N;
Z is Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, or 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 Rz;
R1 is H or C 1-4 alkyl;
R2 is H, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, or C6-io aryl-Ci-6 alkyl;
R3 and R4 are each independently selected from H, halo, CN, NO2, Ci-6 alkyl, Ci-6 haloalkyl, C 1-6 hydroxyalkyl, Ci-6 aminoalkyl, Ci-6 alkylamino-Ci-6 alkyl, di-Ci-6-alkylamino-Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said Ci-6 alkylamino-Ci-6 alkyl, di-Ci-6-alkylamino- C1-6 alkyl, are each optionally substituted with 1 or 2 substituents independently selected from C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl;
R5 is H, halo, Ci-6 alkyl, or Ci-6 haloalkyl;
R6 is H, Ci-6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)Rbl, C(0)NRclRdl, C(0)ORal, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, or S(0)2NRclRdl, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, ORal, SRal, C(0)Rbl, C(0)NRclRdl, C(0)ORal, OC(0)Rbl, OC(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)ORal,
NRclC(0)NRclRdl, C(=NRel)Rbl, C(=NRel)NRclRdl, NRclC(=NRel)NRclRdl, NRclS(0)Rbl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, and S(0)2NRclRdl;
R7 is H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, or S(0)2NRc2Rd2, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, OC(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)ORa2, NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2;
each RB is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, CN, NO2, ORa3, SR33, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3,
OC(0)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3, C(=NRe3)Rb3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3,
NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and
S(0)2NRc3Rd3, and wherein said phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each independently substituted by 1, 2, or 3 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and
S(0)2NRc3Rd3;
each Rz is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4,
OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, C(=NRe4)Rb4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4S(0)Rb4, NRc4S(0)2Rb4, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4,
NRc4S(0)Rb4, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2Rb4, and
S(0)2NRc4Rd4;
each Ra and Rb is independently selected from H, halo, OH, methyl, and ethyl;
each Rc and Rd is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, and cyclopropyl;
each Ral, Rbl, Rcl, Rdl, Ra2, Rb2, Rc2, Rd2, R33, Rb3, Rc3, Rd3, Ra4, Rb4, Rc4, and Rd4 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3- 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-6 alkyl, C3-10 cycloalky-Ci-6 alkyl, (5-10 membered heteroaryl)-Ci-6 alkyl, and (4-10 membered heterocycloalkyl)-Ci-6 alkyl, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-6 alkyl, C3- 10 cycloalky-Ci-6 alkyl, (5-10 membered heteroaryl)-Ci-6 alkyl, and (4-10 membered
heterocycloalkyl)-Ci-6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents
independently selected from Ci-4 alkyl, C 1-4 haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rcl and Rdl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5,
NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5; or any R and R together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rc4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5,
NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
each Rel, Re2, Re3, and Re4 is independently selected from H, CM alkyl, CN, ORa5, SRb5, S(0)2Rb5, C(0)Rb5, S(0)2NRc5Rd5, and C(0)NRc5Rd5;
each Ra5, Rb5, Rc5, and Rd5 is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein said Ci-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, C1-4 haloalkyl, and Ci-4 haloalkoxy;
each Re5 is independently selected from H, Ci-4 alkyl, and CN;
n is 0, 1, or 2;
m is 0, 1, or 2; and
p is 1, 2, 3, or 4;
wherein any aforementioned heterocycloalkyl group, including the heterocycloalkyl group of Ring B, is optionally substituted by 1 or 2 oxo groups. The present invention further provides, inter alia, a compound of Formula I:
Figure imgf000011_0001
or a pharmaceutically acceptable salt thereof; wherein
represents a single or double bond;
Ring B is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, Cs-cycloalkyl, Ce- cycloalkyl, 5-membered heterocycloalkyl, or 6-membered heterocycloalkyl, each optionally substituted by 1 , 2, 3, or 4 RB;
L is absent, -(CRaRb)P-, -(CRaRb)n-0-(CRaRb)m-, -(CRaRb)n-S-(CRaRb)m-, , -
Figure imgf000012_0001
-(CRaRb)n-NRcC(=0)NRd-(CRaRb)m-;
Al is CR3 or N;
A2 is CR4 or N;
A3 is C or N;
A4 is C or N;
wherein when one of A3 and A4 is N, then the other of A3 and A4 is C;
W is CR5 or N;
X is CR6 or N;
Y is CR7 or N;
Z is C6-io aryl, C3-10 cycloalkyl, or 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1 , 2, 3, 4, or 5 Rz;
R1 is H or Ci-4 alkyl;
R2 is Ci-4 alkyl, Ci-4 haloalkyl, or Ci-4 hydroxyalkyl;
R3 and R4 are each independently selected from H, halo, CN, NO2, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
R5 is H, halo, Ci-6 alkyl, or Ci-6 haloalkyl;
R6 is H, Ci-6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)Rbl, C(0)NRclRdl, C(0)ORal, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, or S(0)2NRclRdl, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1 , 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, ORal, SRal, C(0)Rbl, C(0)NRclRdl, C(0)ORal, OC(0)Rbl, OC(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)ORal, NRclC(0)NRclRdl, C(=NRel)Rbl, C(=NRel)NRclRdl, NRclC(=NRel)NRclRdl, NRclS(0)Rbl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, and S(0)2NRclRdl;
R7 is H, Ci-6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, or S(0)2NRc2Rd2, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, OC(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)ORa2,
NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2;
each RB is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, CN, NO2, ORa3, SR33, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3, C(=NRe3)Rb3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3,
NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3;
each Rz is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4,
OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, C(=NRe4)Rb4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4S(0)Rb4, NRc4S(0)2Rb4, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2Rb4, and S(0)2NRc4Rd4; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4,
NRc4S(0)Rb4, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2Rb4, and
S(0)2NRc4Rd4;
each Ra and Rb is independently selected from H, halo, OH, methyl, and ethyl;
each Rc and Rd is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, and cyclopropyl;
each Ral, Rbl, Rcl, Rdl, Ra2, Rb2, Rc2, Rd2, R33, Rb3, Rc3, Rd3, Ra4, Rb4, Rc4, and Rd4 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3- 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-6 alkyl, C3-10 cycloalky-Ci-6 alkyl, (5-10 membered heteroaryl)-Ci-6 alkyl, and (4-10 membered heterocycloalkyl)-Ci-6 alkyl, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-6 alkyl, C3- 10 cycloalky-Ci-6 alkyl, (5-10 membered heteroaryl)-Ci-6 alkyl, and (4-10 membered
heterocycloalkyl)-Ci-6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents
independently selected from Ci-4 alkyl, C 1-4 haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rcl and Rdl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5,
NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5; or any R and R together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rc4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5,
NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
each Rel, Re2, Re3, and Re4 is independently selected from H, CM alkyl, CN, ORa5, SRb5, S(0)2Rb5, C(0)Rb5, S(0)2NRc5Rd5, and C(0)NRc5Rd5;
each Ra5, Rb5, Rc5, and Rd5 is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein said Ci-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, C1-4 haloalkyl, and Ci-4 haloalkoxy;
each Re5 is independently selected from H, Ci-4 alkyl, and CN;
n is 0, 1, or 2;
m is 0, 1, or 2; and
p is 1, 2, 3, or 4;
wherein any aforementioned heterocycloalkyl group, including the heterocycloalkyl group of Ring B, is optionally substituted by 1 or 2 oxo groups. When both A3 and A4 are C, then the symbol represents a double bond, and when one of A3 and A4 is N and the other is C, then the symbol represents a single bond.
In some embodiments, R1 is H.
In some embodiments, R2 is Ci-4 alkyl, Ci-4 cyanoalkyl, or C6-io aryl-Ci-6 alkyl.
In some embodiments, R2 is methyl, cyanomethyl, or benzyl.
In some embodiments, R2 is C1-4 alkyl.
In some embodiments, R2 is methyl.
In some embodiments, W is CR5.
In some embodiments, X is CR6.
In some embodiments, Y is CR7.
In some embodiments, Y is N.
In some embodiments, the bicyclic ring containing W, X, and Y is selected from:
Figure imgf000017_0001
Figure imgf000017_0002
In some embodiments, L is -(CRaRb)P-, -(CRaRb)n-0-(CRaRb)m-, -(CRaRb)n-S-(CRaRb)
Figure imgf000017_0003
In some embodiments, L is -(CRaRb)n-0-(CRaRb)m-.
In some embodiments, L is -CH2-0-.
In some embodiments, L is O, S, or S(=0)2.
In some embodiments, L is O.
In some embodiments, Z is Ci-4 alkyl, C6-io aryl, C3-10 cycloalkyl, or 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 Rz.
In some embodiments, Z is C6-io aryl or C3-10 cycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 Rz.
In some embodiments, Z is phenyl optionally substituted by 1, 2, 3, 4, or 5 Rz.
In some embodiments, Z is
Figure imgf000017_0004
In some embodiments, Z is Ci-4 alkyl. In some embodiments, Z is C3-7 cycloalkyl optionally substituted by 1, 2, 3, 4, or 5 Rz. In some embodiments, Z is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 Rz.
In some embodiments, Z is 4-10 membered heterocycloalkyl optionally substituted by 1, 2, 3, 4, or 5 Rz
In some embodiments, Z is tetrahydropyranyl.
In some embodiments, Z is cyclopropyl.
In some embodiments, each Rz is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, C(=NRe4)Rb4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4S(0)Rb4, NRc4S(0)2Rb4, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2Rb4, and S(0)2NRc4Rd4.
In some embodiments, each Rz is independently selected from F, CI, and Br.
In some embodiments, Al is CR3.
In some embodiments, A2 is CR4.
In some embodiments, A2 is N.
In some embodiments, A3 is C.
In some embodiments, A4 is C.
In some embodiments, A4 is N.
In some embodiments, R3 is H or Ci-6 alkyl.
In some embodiments, R3 is H or methyl.
In some embodiments, R3 is H.
In some embodiments, R4 is H, Ci-6 hydroxyalkyl, or Ci-6 alkylamino-Ci-6 alkyl, wherein said Ci-6 alkylamino-Ci-6 alkyl is optionally substituted with 1 or 2 substituents independently selected from C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl.
In some embodiments, R4 is H.
In some embodiments, R4 is 1 -hydroxy ethyl.
In some embodiments, R4 is Ci-6 alkylamino-Ci-6 alkyl substituted with 2-(morpholin-N- yl)ethyl, benzyl, or cyclopropylmethyl.
In some embodiments, R5 is H. In some embodiments, R6 is H.
In some embodiments, R7 is H.
In some embodiments, each RB is independently selected from Ci-6 alkyl, C6-io aryl, or NRc3Rd3; wherein said Ci-6 alkyl is optionally substituted with 1 , 2, or 3 substituents
independently selected from phenyl, 4-7 membered heterocycloalkyl, CN, C(0)NRc3Rd3, NRc3Rd3, and NRc3C(0)Rb3, and wherein said phenyl and 4-7 membered heterocycloalkyl are each optionally substituted by 1 , 2, or 3 substituents independently selected from Ci-6 alkyl, C(0)Rb3, and S(0)2Rb3.
In some embodiments, each RB is Ci-6 alkyl optionally substituted with 1 , 2, or 3 substituents independently selected from phenyl, 4-7 membered heterocycloalkyl, CN,
C(0)NRc3Rd3, NRc3Rd3, and NRc3C(0)Rb3, and wherein said phenyl and 4-7 membered heterocycloalkyl are each optionally substituted by 1 , 2, or 3 substituents independently selected from Ci-6 alkyl, C(0)Rb3, and S(0)2Rb3.
In some embodiments, each RB is Ci-6 alkyl.
In some embodiments, Ring B is substituted by 1 or 2 oxo groups.
In some embodiments, Ring B is substituted by 1 oxo group.
In some embodiments, the compounds of the invention have Formula II:
Figure imgf000019_0001
II
wherein:
the 5-membered ring formed by A3, A4, Bl , B2, and B3 is (1) 5-membered heteroaryl wherein Bl , B2, and B3 are each independently selected from CH, N, NH, O, and S, (2) Cs- cycloalkyl wherein Bl , B2, and B3 are each independently selected from CH, CH2, and C(O), or (3) 5-membered heterocycloalkyl wherein Bl, B2, and B3 are each independently selected from CH, CH2, C(O), N, NH, O, S, S(O), and S(0)2; and
q is 0, 1, 2 or 3.
The floating substituent -(RB)q depicted in Formula II and other formulae is meant to indicate that there can be q number of RB groups substituted on any of the Bl, B2, and B3 components of the A3, A4, Bl, B2, and B3 5-membered ring. For example, when Bl is selected as CH, the hydrogen of the CH can be replaced by RB when it is substituted.
In some embodiments, Bl, B2, and B3 are each independently selected from CH, C(O), N, O, and NH.
In some embodiments, Bl, B2, and B3 are each independently selected from CH, C(O),
N, and NH.
In some embodiments, Bl is N, NH, CH, or O.
In some embodiments, Bl is NH.
In some embodiments, B2 is N, C(O), C or CH.
In some embodiments, B2 is N, C(O), or CH.
In some embodiments, B3 is N, NH, or CH.
In some embodiments, B3 is N or NH.
In some embodiments, the compounds of the invention have Formula Ila:
Figure imgf000020_0001
Ila.
In some embodiments, the compounds of the invention have Formula Ila- 1 :
Figure imgf000021_0001
In some embodiments, the compounds of the invention have Formula lib
Figure imgf000021_0002
lib.
In some embodiments, the compounds of the invention have Formula lib- 1 , IIb-2, IIb-3, -4. or IIb-5:
Figure imgf000022_0001
20
Figure imgf000023_0001
IIb-5
wherein:
R8, R9, and R10 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, ORa3, SR33, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3,
OC(0)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3, C(=NRe3)Rb3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3,
NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and
S(0)2NRc3Rd3, and wherein said phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each independently substituted by 1, 2, or 3 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3.
In some embodiment the compounds of the invention have Formula lie:
Figure imgf000024_0001
lie
wherein r is 0, 1, 2, 3, 4, or 5.
The floating substituent -(Rz)r depicted in the phenyl ring of Formula lie and in other formulae herein is meant to indicate that there can be r number of Rz groups substituted on the phenyl ring.
Figure imgf000024_0002
lid He
Figure imgf000025_0001
Ilf IIf-1
wherein:
r is 0, 1, 2, 3, 4, or 5; and
R8, R9, and R10 are each independently selected from H, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, ORa3, SR33, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3,
OC(0)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3, C(=NRe3)Rb3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3,
NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and
S(0)2NRc3Rd3, and wherein said phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each independently substituted by 1, 2, or 3 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3.
In some embodiments, the compounds of the invention have Formula lid, He, or Ilf:
Figure imgf000026_0001
Ilf
wherein:
r is 0, 1, 2, 3, 4, or 5; and R8, R9, and R10 are each independently selected from H, Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-e alkyl, Ci-e haloalkyl, CN, NO2, OR33, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3,
NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3.
In some embodiments, r is 0, 1, 2, or 3.
In some embodiments, r is 0, 1, or 2.
In some embodiments, the compounds of the invention have Formula Ilg:
Figure imgf000027_0001
In some embodiments, the compounds of the invention have Formula III
Figure imgf000028_0001
wherein:
the 6-membered ring formed by A3, A4, B4, B5, B6, and B7 is (1) phenyl, (2) 6- membered heteroaryl wherein B4, B5, B6, and B7 are each independently selected from CH and N, (3) C6-cycloalkyl wherein B4, B5, B6, and B7 are each independently selected from CH, CH2, and C(O), or (4) 6-membered heterocycloalkyl wherein B4, B5, B6, and B7 are each
independently selected from CH, CH2, C(O), N, NH, O, S, S(O), and S(0)2; and
s is 0, 1, 2, 3, or 4.
The floating substituent -(RB)s depicted in Formula III and other formulae herein is meant to indicate that there can be s number of RB groups substituted on any of the B4, B5, B6, and B7 components of the A3, A4, B4, B5, B6, and B7 6-membered ring. For example, when B4 is selected as CH, the hydrogen of the CH can be replaced by RB when it is substituted.
In some embodiments, the 6-membered ring formed by A3, A4, B4, B5, B6, and B7 is 6- membered heterocycloalkyl wherein B4, B5, B6, and B7 are each independently selected from CH, CH2, C(O), N, NH, O, S, S(O), and S(0)2.
In some embodiments, B4 is selected from O or N.
In some embodiments, B5 is selected from C, CH, or CH2.
In some embodiments, B6 is selected from CH or C(=0).
In some embodiments, B7 is selected from N or NH.
In some embodiments, the compounds of the invention have Formula Ilia:
Figure imgf000029_0001
In some embodiments, the compounds of the invention have Formula Ilia- 1 , IIIa-2, or IIIa-3:
Figure imgf000029_0002
In some embodiments, the bicyclic moiety containing Ring B has the formula:
Figure imgf000030_0001
wherein q is 0, 1, 2 or 3.
In some embodiments, the bicyclic moiety containing Ring B has the formula
Figure imgf000030_0002
wherein q is 0, 1, 2 or 3.
In some embodiments, the bicyclic moiety containing Ring B has the formula:
Figure imgf000030_0003
wherein q is 0, 1, 2 or 3.
In some embodiments, the bicyclic moiety containing Ring B has the formula:
Figure imgf000031_0001
wherein q is 0, 1, 2 or 3.
In some embodiments, the bic clic moiety containing Ring B has the formula
Figure imgf000031_0002
wherein q is 0, 1, 2 or 3.
In some embodiments, the bi Ring B has the formula:
Figure imgf000031_0003
wherein s is 0, 1, 2, 3, or 4.
In some embodiments, the bicyclic moiety containing Ring B has the formula:
Figure imgf000032_0001
wherein s is 0, 1, 2, 3, or 4.
In some embodiments, the bicyclic moiety containing Ring B has the formula:
Figure imgf000032_0002
wherein s is 0, 1, 2, 3, or 4.
In some embodiments, the bi Ring B has the formula:
Figure imgf000032_0003
vyv
wherein s is 0, 1, 2, 3, or 4.
In some embodiments, the bicyclic moiety containing Ring B is selected from:
Figure imgf000033_0001
Figure imgf000034_0001
wherein each of the above formulas can be optionally substituted by one or more RB on the 5- or 6- membered ring corresponding to Ring B by up to 5 substituents or up to the available substitutable valencies, whichever is less.
In some embodiments, the bicyclic moiety containing Ring B is selected from:
Figure imgf000035_0001
, and wherein each of the above formulas can be optionally substituted as valency allows by one or two R on the 5-membered ring corresponding to Ring B. In some embodiments, Al and A2 are each CH.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single
embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
As used herein, the phrase "optionally substituted" means unsubstituted or substituted. As used herein, the term "substituted" means that a hydrogen atom is removed and replaced by a monovalent non-hydrogen substituent or two hydrogen atoms are removed and replaced by a divalent substituent, like oxo. It is to be understood that substitution at a given atom is limited by valency. Throughout the definitions, the term "Ci-j" indicates a range which includes the endpoints, wherein i and j are integers and indicate the number of carbons. Examples include Ci- 4, Ci-6, and the like.
The term "n-membered" where n is an integer typically describes the number of ring- forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5- membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1, 2, 3, 4- tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
As used herein, the term "Ci-j alkyl," employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched, having i to j carbons. In some embodiments, the alkyl group contains from 1 to 6 carbon atoms or from 1 to 4 carbon atoms, or from 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, and t- butyl.
As used herein, the term "Ci-j alkoxy," employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group has i to j carbons. Example alkoxy groups include methoxy, ethoxy, and propoxy (e.g., n-propoxy and isopropoxy). In some embodiments, the alkyl group has 1 to 3 carbon atoms.
As used herein, "G-j alkenyl," employed alone or in combination with other terms, refers to an unsaturated hydrocarbon group having one or more double carbon-carbon bonds and having i to j carbons. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.
As used herein, "G-j alkynyl," employed alone or in combination with other terms, refers to an unsaturated hydrocarbon group having one or more triple carbon-carbon bonds and having i to j carbons. Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
As used herein, the term "G-j alkylamino," employed alone or in combination with other terms, refers to a group of formula -NH(alkyl), wherein the alkyl group has i to j carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "di-G-j-alkylamino," employed alone or in combination with other terms, refers to a group of formula -N(alkyl)2, wherein each of the two alkyl groups has, independently, i to j carbon atoms. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "G-j alkylthio," employed alone or in combination with other terms, refers to a group of formula -S-alkyl, wherein the alkyl group has i to j carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "amino," employed alone or in combination with other terms, refers to a group of formula -NH2.
As used herein, the term "oxo," employed alone or in combination with other terms, refers to a group of formula =0.
As used herein, the term "aryl," employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbon, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, anthracenyl, phenanthrenyl, and the like. In some embodiments, aryl is G-io aryl. In some embodiments, the aryl group is a naphthalene ring or phenyl ring. In some embodiments, the aryl group is phenyl. As used herein, the term "carbonyl", employed alone or in combination with other terms, refers to a -C(O)- group.
As used herein, the term "Ci-j cycloalkyl," employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon moiety having i to j ring-forming carbon atoms, which may optionally contain one or more alkenylene groups as part of the ring structure. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e.,, having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclopentene, cyclohexane, and the like. One or more ring- forming carbon atoms of a cycloalkyl group can be oxidized to form carbonyl linkages. In some embodiments, cycloalkyl is C3-7 cycloalkyl. Examplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, and the like.
As used herein, "Ci j haloalkoxy," employed alone or in combination with other terms, refers to a group of formula -O-haloalkyl having i to j carbon atoms. An example haloalkoxy group is OCF3. An additional example haloalkoxy group is OCHF2. In some embodiments, the haloalkoxy group is fluorinated only. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "halo," employed alone or in combination with other terms, refers to a halogen atom selected from F, CI, I or Br. In some embodiments, "halo" refers to a halogen atom selected from F, CI, or Br. In some embodiments, the halo substituent is F.
As used herein, the term "Ci j haloalkyl," employed alone or in combination with other terms, refers to an alkyl group having from one halogen atom to 2s+l halogen atoms which may be the same or different, where "s" is the number of carbon atoms in the alkyl group, wherein the alkyl group has i to j carbon atoms. In some embodiments, the haloalkyl group is fluorinated only. In some embodiments, the haloalkyl group is fluoromethyl, difluoromethyl, or
trifluoromethyl. In some embodiments, the haloalkyl group is trifluoromethyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "heteroaryl," employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic heterocylic moiety, having one or more heteroatom ring members selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group has 1, 2, 3, or 4 heteroatom ring members. In some embodiments, the heteroaryl group has 1, 2, or 3 heteroatom ring members. In some embodiments, the heteroaryl group has 1 or 2 heteroatom ring members. In some embodiments, the heteroaryl group has 1 heteroatom ring member. In some embodiments, the heteroaryl group is 5- to 10-membered. When the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different. The nitrogen atoms in the ring(s) of the heteroaryl group can be oxidized to form N-oxides. Example heteroaryl groups include, but are not limited to, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, azolyl, oxazole, isoxazole, thiazole, isothiazole, imidazole, furan, thiophene, triazole, tetrazole, thiadiazole, quinoline, isoquinoline, indole, benzothiophene, benzofuran, benzisoxazole, imidazo[l, 2-b]thiazole, purine, triazine. and the like.
A 5-membered heteroaryl is a heteroaryl group having five ring-forming atoms comprising wherein one or more of the ring-forming atoms are independently selected from N, O, and S. In some embodiments, the 5-membered heteroaryl group has 1, 2, or 3 heteroatom ring members. In some embodiments, the 5-membered heteroaryl group has 1 or 2 heteroatom ring members. In some embodiments, the 5-membered heteroaryl group has 1 heteroatom ring member. Example ring-forming members include CH, N, NH, O, and S. Example five- membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1, 2, 3-triazolyl, tetrazolyl, 1, 2, 3-thiadiazolyl, 1, 2, 3-oxadiazolyl, 1, 2, 4-triazolyl, 1, 2, 4-thiadiazolyl, 1, 2, 4-oxadiazolyl, 1, 3, 4-triazolyl, 1, 3, 4-thiadiazolyl, and 1, 3, 4-oxadiazolyl.
A 6-membered heteroaryl is a heteroaryl group having six ring-forming atoms wherein one or more of the ring-forming atoms is N. In some embodiments, the 6-membered heteroaryl group has 1, 2, or 3 heteroatom ring members. In some embodiments, the 6-membered heteroaryl group has 1 or 2 heteroatom ring members. In some embodiments, the 6-membered heteroaryl group has 1 heteroatom ring member. Example ring-forming members include CH and N. Example six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl, and pyridazinyl.
As used herein, the term "heterocycloalkyl," employed alone or in combination with other terms, refers to non-aromatic heterocyclic ring system, which may optionally contain one or more unsaturations as part of the ring structure, and which has at least one heteroatom ring member independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heterocycloalkyl group has 1, 2, 3, or 4 heteroatom ring members. In some embodiments, the heterocycloalkyl group has 1, 2, or 3 heteroatom ring members. In some embodiments, the heterocycloalkyl group has 1 or 2 heteroatom ring members. In some embodiments, the heterocycloalkyl group has 1 heteroatom ring member.When the heterocycloalkyl group contains more than one heteroatom, the heteroatoms may be the same or different. Example ring-forming members include CH, CH2, C(O), N, NH, O, S, S(O), and S(0)2. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems, including spiro systems. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the non-aromatic ring, for example, 1, 2, 3, 4-tetrahydro-quinoline, dihydrobenzofuran and the like. The carbon atoms or
heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, sulfmyl, or sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized. In some embodiments, heterocycloalkyl is 5- to 10-membered. Examples of heterocycloalkyl groups include 1, 2, 3, 4-tetrahydro-quinoline, dihydrobenzofuran, azetidine, azepane, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, and pyran.
The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereoisomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
When the compounds of the invention contain a chiral center, the compounds can be any of the possible stereoisomers. In compounds with a single chiral center, the stereochemistry of the chiral center can be (R) or (S). In compounds with two chiral centers, the stereochemistry of the chiral centers can each be independently (R) or (S) so the configuration of the chiral centers can be (R) and (R), (R) and (S); (S) and (R), or (S) and (S). In compounds with three chiral centers, the stereochemistry each of the three chiral centers can each be independently (R) or (S) so the configuration of the chiral centers can be (R), (R) and (R); (R), (R) and (S); (R), (S) and (R); (R), (S) and (S); (S), (R) and (R); (S), (R) and (S); (S), (S) and (R); or (S), (S) and (S).
Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt- forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as β-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereoisomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1, 2- diaminocyclohexane, and the like.
Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, amide - imidic acid pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1, 2, 4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers.
The term "compound" as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified (e.g., in the case of purine rings, unless otherwise indicated, when the compound name or structure has the 9H tautomer, it is understood that the 7H tautomer is also encompassed).
All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., hydrates and solvates) or can be isolated.
In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in a compound of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The expressions, "ambient temperature" and "room temperature," as used herein, are understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a
temperature from about 20 °C to about 30 °C.
The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g. , methanol, ethanol, iso-propanol, or butanol) or acetonitrile (MeCN) are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th Ed., (Mack Publishing Company, Easton, 1985), p. 1418, Berge et al., J. Pharm. Sci., 1977, 66(1), 1-19, and in Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (Wiley, 2002). In some embodiments, the compounds described herein include the N-oxide forms.
The following abbreviations may be used herein: AcOH (acetic acid); Ac20 (acetic anhydride); aq. (aqueous); atm. (atmosphere(s)); Boc (t-butoxycarbonyl); br (broad); Cbz (carboxybenzyl); calc. (calculated); d (doublet); dd (doublet of doublets); DCM
(dichloromethane); DIAD (N, N'-diisopropyl azidodicarboxylate); DIPEA (N, N- diisopropylethylamine); DMF (N, N-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); g (gram(s)); h (hour(s)); HATU (N, N, N', N'-tetramethyl-0-(7-azabenzotriazol-l-yl)uronium hexafluorophosphate); HC1 (hydrochloric acid); HPLC (high performance liquid
chromatography); Hz (hertz); J (coupling constant); LCMS (liquid chromatography - mass spectrometry); m (multiplet); M (molar); mCPBA (3-chloroperoxybenzoic acid); MgS04 (magnesium sulfate); MS (Mass spectrometry); Me (methyl); MeCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min. (minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N
(normal); NaHCCte (sodium bicarbonate); NaOH (sodium hydroxide); Na2S04 (sodium sulfate); NH4C1 (ammonium chloride); NH4OH (ammonium hydroxide); nM (nanomolar); NMR (nuclear magnetic resonance spectroscopy); OTf (trifluoromethanesulfonate); Pd (palladium); Ph
(phenyl); pM (picomolar); POCI3 (phosphoryl chloride); RP-HPLC (reverse phase high performance liquid chromatography); s (singlet); t (triplet or tertiary); TBS (tert- butyldimethylsilyl); tert (tertiary); tt (triplet of triplets); t-Bu (tert- vXyl); TFA (trifluoroacetic acid); THF (tetrahydrofuran); μg (microgram(s)); (microliter(s)); μΜ (micromolar); wt% (weight percent). Synthesis
Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the
intermediates, or products at the temperatures at which the reactions are carried out, e.g. , temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in P. G. M. Wuts and T. W. Greene, Protective Groups in Organic Synthesis, 4th Ed., Wiley & Sons, Inc., New York (2006), which is incorporated herein by reference in its entirety. Protecting groups in the synthetic schemes are typically represented by "PG."
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy {e.g., JH or 13C), infrared spectroscopy, spectrophotometry {e.g., UV- visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC). Compounds can be purified by those skilled in the art by a variety of methods, including high performance liquid chromatography (HPLC) {"Preparative LC-MS Purification: Improved Compound Specific Method Optimization" Karl F. Blom, Brian Glass, Richard Sparks, Andrew P. Combs J. Combi. Chem. 2004, 6(6), 874-883, which is incorporated herein by reference in its entirety) and normal phase silica chromatography.
Compounds of Formula I can be formed as shown in Scheme I. The heterocyclic halide
(i) (Hal = CI, Br, or I) can be coupled to M-Het, where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)2, Het-Sn(Bu)4, or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) and a base (e.g., bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)), to give a derivative of Formula I (iii).
Alternatively, heterocyclic halide (i) can be converted to a boronic acid or boronate ester (iv) under standard transmetalation conditions (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)). The heterocyclic boronate (iv) can be coupled to halo substituted heterocycles (v), (e.g., Hal-Het, where Hal = CI, Br, or I), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) and a base (e.g., bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) to give a compound of Formula I (iii).
Scheme I
Figure imgf000044_0001
3. Optional
alkylation Synthesis of heterocyclic intermediates useful in the preparation of compounds of Formula I can be formed as shown in Scheme II. The heterocycle (i) can be alkylated (e.g., Z- Hal, where Hal = Br, CI, or I) with a base (e.g., triethylamine, NaH or Na2C03) or under Mitsunobu conditions to afford the heterocycle (ii). Alternatively, heterocycle (i) can be arylated either under Evans' conditions with an aryl-boronic acid (e.g., Z-B(OR)2, in the presence of a palladium(O) catalyst) or Ullman conditions with an aryl halide (e.g., Z-Hal, in the presence of palladium(O)) to afford the heterocycle (ii). Halogenation of heterocycle (ii) under standard conditions (Br2, AcOH or N-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide) can give halide (iii) where Hal = CI, Br or I.
Scheme II
Figure imgf000045_0001
Z-Hal, Cu Synthesis of heterocyclic intermediates useful in the preparation of compounds of
Formula I can be formed as shown in Scheme III. Halogenation of heterocycle (i) under standard conditions (e.g., Br2, AcOH or N-chlorosuccinamide, N-bromosuccinamide or N- iodosuccinamide) can give halide (ii) where Hal = CI, Br or I. The heterocycle (ii) can be alkylated (e.g., Z-Hal, where Hal = Br, CI, or I) with a base, (e.g. triethylamine, NaH or Na2C03) or under Mitsunobu conditions to afford the heterocycle (iii). Alternatively, heterocycle (ii) can be arylated either under Evans' conditions with an aryl-boronic acid (e.g., Z-B(OR)2, in the presence of a palladium(O) catalyst) or Ullmann conditions with an aryl halide (e.g., Z-Hal, in the presence of copper) to afford the heterocycle (iii). Scheme III
Figure imgf000046_0001
Compounds of Formula I can be formed as shown in Scheme IV. The heterocyclic fluoride (i) can be coupled to Het-M (ii), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)2, Het-B(OR)2, Het-Sn(Bu)4, or Zn- Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)), to give a compound of formula (iii).
Alternatively, heterocyclic halide (i) can be converted to a boronic acid or boronate acid (iv) under standard transmetalation conditions (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)). The heterocyclic boronate (iv) can be coupled to halo substituted heterocycle (v) (e.g.,Hal-Het, where Hal is a halide (e.g., Hal = CI, Br, or I)), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) to give the compounds of formula (iii). Thiols, amines, and alcohols of formula H-L-Z can displace the fluoro group of compounds (iii) using standard conditions (e.g., CS2CO3/DMSO) to give thioethers, arylamines, and ethers of Formula I (vi) after deprotection of the nitrogen protecting group and optional alkylation with Hal-R2. Scheme IV
Figure imgf000047_0001
Synthesis of heterocyclic intermediates useful in the preparation of compounds of Formula I can be formed as shown in Scheme V. Conversion of Hal derivative (i) wherein Hal = Br, CI, or I, with l,l-dimethoxy-N,N-dimethylmethanamine in the absence or presence of a base can provide enamines (ii). Catalytic hydrogenation of (ii) in the presence of a catalyst (e.g., Raney-Nickel under hydrogen atmosphere) can provide amines that cyclize to form a
heterocycle. Protection of the heterocyclic nitrogen atom with a protecting group such as, but not limited to, benzyl, tosyl, and (trimethylsilyl)ethoxy)methyl group can provide heterocycle (iii). Hydrolysis of the methoxy substituent with an acid such as, but not limited to, hydrochloric acid or hydrobromic acid to provides heterocycles (iv). Compound (iv) can be alkylated (e.g., R2-Hal and a base (e.g., triethylamine, NaH or Na2C03) or under Mitsunobu conditions) to afford the heterocycle (v). The conversion of halide (v) to the boronate (vi) or boronic acid (vi) can be performed under standard conditions (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)). Scheme V
Figure imgf000048_0001
Synthesis of heterocyclic intermediates useful in the preparation of compounds of Formula I can be formed as shown in Scheme VI. Conversion of halo heterocycle (i) with ammonium hydroxide can afford amines (ii). Iodination of amine (ii) with N-iodosuccinimide can afford iodo derivatives (iii). Coupling with (E)-2-(2-ethoxyvinyl)-4,4,S,S-tetramethyl-l,3,2- dioxaborolane utilizing Suzuki coupling reaction conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) can provide heterocycles (iv). Cyclization of (iv) in the presence of an acid such as, but not limited to, acetic acid or hydrochloric acid, followed by protection of the nitrogen atom can afford heterocycles (v). The conversion of halide (v) to the boronate ester (vi) or boronic acid (vi) can be performed under standard conditions (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)). Scheme VI
Figure imgf000049_0001
Synthesis of heterocyclic intermediates useful in the preparation of compounds of Formula I can be formed as shown in Scheme VII. Conversion of iodo derivative (i) to heterocyclic acid (ii) can be performed by reacting with pyruvic acid in the presence of a palladium catalyst (e.g., palladium(II)acetate, and a base such as DBU). Esterification of the acid (ii) can be performed by standard reaction conditions such as treatment with an alcohol under acidic condition. Protection of the nitrogen of the heterocycle (iii) can be performed under standard conditions to give N-protected heterocycle (iv). Hydrolysis of the ester to the acid and formation of the amide (v) can be performed under standard peptide coupling conditions, (e.g., amine HNR in the presence of a coupling reagent, such as, Ι,Γ-carbonyldiimidazole (CDI) or Ν,Ν,Ν',Ν' -tetramethyluronium hexafluorophosphate (HATU)). The conversion of halide (v) to the boronate ester (vi) or boronic acid (vi) can be performed under standard condition (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as
tetrakis(triphenylphosphine)palladium(0)). Scheme VII
Figure imgf000050_0001
Synthesis of heterocyclic intermediates useful in the preparation of compounds of Formula I can be formed as shown in Scheme VIII. Reaction of heterocycle (i) with an oxalate ester in the presence of a base (e.g., potassium ethoxide) and reduction followed by cyclization of the resulting ester (ii) upon heating and protection of the heterocyclic nitrogen can afford heterocycle (iii). Cleavage of the methyl ether under acidic conditions can afford heterocycle (iv). Compounds of formula (iv) can be alkylated (e.g., R2-Hal, where Hal = Br, CI, or I) with a base, such as triethylamine, NaH or Na2C03 or under Mitsunobu conditions to afford the heterocycle (v). The conversion of halide (v) to the boronate ester (vi) or boronic acid (vi) can be performed under standard condition (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)).
Scheme VIII
Figure imgf000051_0001
(iv)
Synthesis of heterocyclic intermediates useful in the preparation of compounds of Formula I can be formed as shown in Scheme IX. Heterocycle (i) can be alkylated with R2-Hal (Hal = CI, Br, I, or other leaving group, e.g., Mel) and a suitable base (e.g., NaH) to give compound (ii). Selective reduction of the nitro heterocycle (ii) (e.g., Hal = CI, Br or I using iron with AcOH or HCl) can give the amine (iii). Cyclization of (iii) to (iv) can be accomplished by isoamylnitrite. Protection of the nitrogen of (iv) can be accomplished using standard conditions (e.g., tosylchloride and NaH) to give (v). The conversion of halide (v) to the boronate ester (vi) or boronic acid (vi) can be performed under standard condition (e.g., pinacol boronate, in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)).
heme IX
Figure imgf000052_0001
Synthesis of compounds of Formula I can be formed as shown in Scheme X. Thiols, amines, and alcohols of formula H-L-Z can displace the fluoro group of compounds (i) using standard conditions (e.g., CS2CO3/DMSO) to give thioethers, arylamines, and ethers of formula (ii) where L = S, NR, and O, respectively. Selective reduction of the nitro benzene (ii) (when Hal = CI, Br or I) using iron/AcOH can give the bis-aniline (iii). Conversion of bis-aniline to urea can occur under standard conditions (e.g., carbonyl diimidazole or triphosgene) to give (iv). The heterocyclic halide (iv) can be coupled to Het-M (v), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)2, Het-B(OR)2, Het-
Sn(Bu)4, or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) and a base (e.g., bicarbonate or carbonate base) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) to give compounds (vi). Deprotection of (vi) can give compounds of Formula I (vii). Scheme X
Figure imgf000053_0001
Compounds of Formula I can be formed as shown in Scheme XI. Aniline (i) (from
Scheme X) can be converted to the trifluoroacetamide using standard conditions (e.g., trifluoroacetic anhydride) and then alkylated with RB-Hal (e.g., Hal = CI, Br, I, or other leaving group, e.g., Mel) and a suitable base (e.g., NaH) to give compound (ii). Removal of the trifluoroacetamide followed by selective reduction of the nitro (when Hal = CI, Br or I) using iron/AcOH can give the bis-aniline (iii). Conversion of bis-aniline to urea can occur under standard conditions (e.g., carbonyl diimidazole or triphosgene) to give (iv). The heterocyclic halide (iv) can be coupled to Het-M (v), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)2, Het-B(OR)2, Het-Sn(Bu)4, or Zn- Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) to give compounds (vi). Deprotection of (vi) can give compounds of the invention (vii). heme XI
Figure imgf000054_0001
Compounds of Formula I can be formed as shown in Scheme XII. The aniline (i) can be coupled to Het-M (ii), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)2, Het-B(OR)2, Het-Sn(Bu)4, or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as
tetrakis(triphenylphosphine)palladium(0)) to give compounds (iii). The nitro group of (iii) can be reduced to give the bis-aniline which can be converted to the urea under standard conditions (e.g., carbonyl diimidazole or triphosgene) to give (vii). Deprotection of (vii) can give compounds of the invention (vi).
Alternatively, the aniline of compound (iii) can be converted to the trifluoroacetamide using standard conditions (e.g., trifluoroacetic anhydride) and then alkylated with RB-Hal (Hal = CI, Br, I, or other leaving group, eg. Mel) and a suitable base (e.g., NaH) to give compound (iv). Removal of the trifluoroacetamide followed by reduction of the nitro under standard conditions (e.g., hydrogenation with palladium, iron/AcOH, or zinc) can give the bis-aniline which can be converted to the urea under standard conditions (e.g., carbonyl diimidazole or triphosgene) to give (v). Finally deprotection of (v) can give compounds of the invention (vi).
Scheme XII
Figure imgf000055_0001
Compounds of Formula I can be formed as shown in Scheme XIII. Selective reduction of the nitro benzene (i) (when Hal = CI, Br or I) using iron/AcOH can give the bis-aniline which can be converted under standard conditions (e.g., (EtO)3CRB with /?-TsOH, RBCHO with
TMSCl or peroxide/HCL or copper catalyzed, or RBC02H with borane) to give benzimidazole (ii). The benzimidazole (ii) can be coupled to Het-M (iii), where M is a boronic acid, boronate ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)2, Het-B(OR)2, Het- Sn(Bu)4, or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) to give compounds (iv). Finally deprotection of (iv) can give compounds of the invention (v).
Alternatively, aniline (i) can be converted to the trifluoroacetamide using standard conditions (e.g., trifluoroacetic anhydride) and then alkylated with RB-Hal (Hal = CI, Br, I, or other leaving group, eg. Mel) and a suitable base (e.g., NaH) to give compound (vi). Removal of the trifluoroacetamide followed by selective reduction of the nitro (when Hal = CI, Br or I) using iron/AcOH can give the bis-aniline which can be converted under standard conditions (e.g., (EtO)3CRB with /?-TsOH, RBCHO with TMSC1 or peroxide/HCL or copper catalyzed, or
RBC02H with borane) to give benzimidazole (vii). The benzimidazole (vii) can be coupled to Het-M (iii), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)2, Het-B(OR)2, Het-Sn(Bu)4, or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as
tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as
tetrakis(triphenylphosphine)palladium(0)) to give compounds of the invention (v) after deprotection and optional alkylation.
heme XIII
Figure imgf000057_0001
Compounds of Formula I can be formed as shown in Scheme XIV. Selective reduction of the nitro benzene (i) (when Hal = CI, Br or I) using iron/AcOH can give the bis-aniline which can be converted (e.g., sodium nitrite/acetic acid) to benzotriazole (ii). The benzotriazole (ii) can be coupled to Het-M (iii), where M is a boronic acid, boronate ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)2, Het-B(OR)2, Het-Sn(Bu , or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) to give compounds (iv). Finally deprotection of (iv) can give compounds of the invention (v).
Alternatively, aniline (i) can be converted to the trifluoroacetamide using standard conditions (e.g., trifluoroacetic anhydride) and then alkylated with RB-Hal (Hal = CI, Br, I, or other leaving group, eg. Mel) and a suitable base (e.g., NaH) to give compound (vi). Removal of the trifluoroacetamide followed by selective reduction of the nitro (when Hal = CI, Br or I) using iron/AcOH can give the bis-aniline which can be converted (e.g., sodium nitrite with acetic acid) to benzotriazole (vii). The benzotriazole (vii) can be coupled to Het-M (iii), where M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., Het-M is Het-B(OH)2, Het-B(OR)2, Het-Sn(Bu)4, or Zn-Het), under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as
tetrakis(triphenylphosphine)palladium(0) and a base (e.g., bicarbonate or carbonate base)) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as
tetrakis(triphenylphosphine)palladium(0)) to give compounds of the invention (v) after deprotection and optional alkylation.
Scheme XIV
Figure imgf000058_0001
Methods of Use
Compounds of the invention are BET protein inhibitors and, thus, are useful in treating diseases and disorders associated with activity of BET proteins. For the uses described herein, any of the compounds of the invention, including any of the embodiments thereof, may be used.
The compounds of the invention can inhibit one or more of BET proteins BRD2, BRD3, BRD4, and BRD-t. In some embodiments, the BET protein is BRD2. In some embodiments, the BET protein is BRD3. In some embodiments, the BET protein is BRD4. In some embodiments, the BET protein is BRD-t. In some embodiments, the compounds of the invention selectively inhibit one or more BET proteins over another. "Selective" means that the compound binds to or inhibits a BET protein with greater affinity or potency, respectively, compared to a reference, such as another BET protein. For example, the compounds can be selective for BRD2 over BRD3, BRD4 and BRD-t, selective for BRD3 over BRD2, BRD4 and BRD-t, selective for BRD4 over BRD2, BRD3 and BRD-t, or selective for BRD-t over BRD2, BRD3 and BRD4. In some embodiments, the compounds inhibit two or more of the BET proteins, or all of the BET proteins. In general, selectivity can be at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500- fold or at least about 1000-fold.
In some embodiments, the present invention is directed to a method of inhibiting BRD2 comprising contacting a compound of the invention with BRD2. In some embodiments, the present invention is directed to a method of inhibiting BRD3 comprising contacting a compound of the invention with BRD3. In some embodiments, the present invention is directed to a method of inhibiting BRD4 comprising contacting a compound of the invention with BRD4. In some embodiments, the present invention is directed to a method of inhibiting BRD-t comprising contacting a compound of the invention with BRD-t.
The compounds of the invention are therefore useful for treating BET protein mediated disorders. The term "BET-mediated" refers to any disease or condition in which one or more of the BET proteins, such as BRD2, BRD3, BRD4 and/or BRD-t, or a mutant thereof, plays a role, or where the disease or condition is associated with expression or activity of one or more of the BET proteins. The compounds of the invention can therefore be used to treat or lessen the severity of diseases and conditions where BET proteins, such as BRD2, BRD3, BRD4, and/or BRD-t, or a mutant thereof, are known to play a role.
Diseases and conditions treatable using the compounds of the invention include, but are not limited to, cancer and other proliferative disorders, autoimmune disease, chronic
inflammatory diseases, acute inflammatory diseases, sepsis, and viral infection. The diseases can be treated by administering to an individual (e.g., a patient) in need of the treatment a therapeutically effective amount or dose of a compound of the invention, or any of the embodiments thereof, or a pharmaceutical composition thereof. The present disclosure also provides a compound of the invention, or any of the embodiments thereof, or a pharmaceutical composition thereof, for use in treating a BET-mediated disease or disorder. Also provided is the use of a compound of the invention, or any of the embodiments thereof, or a pharmaceutical composition thereof, in the manufacture of a medicament for treating a BET-mediated disease or disorder.
Diseases that can be treated with the compounds of the invention include cancers. The cancers can include, but are not limited to, adrenal cancer, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm, adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia,
AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoid tumor, B- cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor, Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear-cell sarcoma of the kidney,
craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, endocrine gland neoplasm, endodermal sinus tumor, enteropathy-associated T-cell lymphoma, esophageal cancer, fetus in fetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, gynandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer,
hemangiopericytoma, hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary carcinoma of the breast, medullary thyroid cancer, meduUoblastoma, melanoma, meningioma, merkel cell cancer, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor, mucinous tumor, multiple myeloma, muscle tissue neoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma, pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryoma, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, primary peritoneal cancer, prostate cancer, pancreatic cancer, pharyngeal cancer, pseudomyxoma peritonei, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter's transformation, rectal cancer, sarcoma, Schwannomatosis, seminoma, Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumors, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary' s disease, small intestine cancer, squamous carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, and Wilms' tumor. In some embodiments, the cancer can be adenocarcinoma, adult T-cell leukemia/lymphoma, bladder cancer, blastoma, bone cancer, breast cancer, brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colorectal cancer, esophageal cancer,
gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladder cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, intestinal cancer, kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, ocular cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, stomach cancer, T-cell lymphoma, testicular cancer, thyroid cancer, throat cancer, urogenital cancer, urothelial carcinoma, uterine cancer, vaginal cancer, or Wilms' tumor.
The diseases treatable using the compounds of the invention also include MYC dependent cancers wherein the cancer is associated with at least one of myc R A expression or MYC protein expression. A patient can be identified for such treatment by determining myc RNA expression or MYC protein expression in the cancerous tissue or cells.
Diseases that can be treated with compounds of the invention also include non-cancerous proliferative disorders. Examples of proliferative disorders that can be treated include, but are not limited to, benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granuloma, lipoma, meningioma, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma, pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroid nodules, cystic neoplasms of the pancreas, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman disease, chronic pilonidal disease, dermatofibroma, pilar cyst, pyogenic granuloma, and juvenile polyposis syndrome.
The diseases and conditions that can be treated with the compounds of the invention also include chronic autoimmune and inflammatory conditions. Examples of autoimmune and inflammatory conditions that can be treated include acute, hyperacute or chronic rejection of transplanted organs, acute gout, acute inflammatory responses (such as acute respiratory distress syndrome and ischemia/reperfusion injury), Addison's disease, agammaglobulinemia, allergic rhinitis, allergy, alopecia, Alzheimer's disease, appendicitis, atherosclerosis, asthma,
osteoarthritis, , juvenile arthritis, psoriatic arthritis, rheumatoid arthriti, satopic dermatitis, autoimmune alopecia, autoimmune hemolytic and thrombocytopenic states, autoimmune hypopituitarism, autoimmune polyglandular disease, Behcet's disease, bullous skin diseases, cholecystitis, chronic idiopathic thrombocytopenic purpura, chronic obstructive pulmonary disease (COPD), cirrhosis, degenerative joint disease, depression, dermatitis, dermatomyositis, eczema, enteritis, encephalitis, gastritis glomerulonephritis, giant cell arteritis, Goodpasture's syndrome, Guillain-Barre syndrome, gingivitis, Graves' disease, Hashimoto's thyroiditis, hepatitis, hypophysitis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), inflammatory pelvic disease, irritable bowel syndrome, Kawasaki disease, LPS-induced endotoxic shock, meningitis, multiple sclerosis, myocarditis, myasthenia gravis, mycosis fungoides, myositis, nephritis, osteomyelitis, pancreatitis, Parkinson's disease, pericarditis, pernicious anemia, pneumonitis, primary biliary sclerosing cholangitis, polyarteritis nodosa, psoriasis, retinitis, scleritis, scleracierma, scleroderma, sinusitis, Sjogren's disease, sepsis, septic shock, sunburn, systemic lupus erythematosus, tissue graft rejection, thyroiditis, type I diabetes, Takayasu's arteritis, urethritis, uveitis, vasculitis, vasculitis including giant cell arteritis, vasculitis with organ involvement such as glomerulonephritis, vitiligo, Waldenstrom
macroglobulinemia and Wegener's granulomatosis.
The diseases and conditions that can be treated with the compounds of the invention also include diseases and conditions which involve inflammatory responses to infections with bacteria, viruses, fungi, parasites or their toxins, such as sepsis, sepsis syndrome, septic shock, endotoxaemia, systemic inflammatory response syndrome (SIRS), multi-organ dysfunction syndrome, toxic shock syndrome, acute lung injury, ARDS (adult respiratory distress syndrome), acute renal failure, fulminant hepatitis, burns, acute pancreatitis, post-surgical syndromes, sarcoidosis, Herxheimer reactions, encephalitis, myelitis, meningitis, malaria, SIRS associated with viral infections such as influenza, herpes zoster, herpes simplex and coronavirus.
Other diseases that can be treated with the compounds of the invention include viral infections. Examples of viral infections that can be treated include Epstein-Barr virus, hepatitis B virus, hepatitis C virus, herpes virus, human immunodeficiency virus, human papilloma virus, adenovirus, poxvirus and other episome-based DNA viruses. The compounds can therefore be used to treat disease and conditions such as herpes simplex infections and reactivations, cold sores, herpes zoster infections and reactivations, chickenpox, shingles, human papilloma virus, cervical neoplasia, adenovirus infections, including acute respiratory disease, and poxvirus infections such as cowpox and smallpox and African swine fever virus. In one particular embodiment, the compounds of the invention are indicated for the treatment of human papilloma virus infections of skin or cervical epithelia.
The diseases and conditions that can be treated with the compounds of the invention also include conditions that are associated with ischaemia-reperfusion injury. Examples of such conditions include, but are not limited to conditions such as myocardial infarction,
cerebrovascular ischaemia (stroke), acute coronary syndromes, renal reperfusion injury, organ transplantation, coronary artery bypass grafting, cardio-pulmonary bypass procedures and pulmonary, renal, hepatic, gastro-intestinal or peripheral limb embolism.
The compounds of the invention are also useful in the treatment of disorders of lipid metabolism via the regulation of APO-A1 such as hypercholesterolemia, atherosclerosis and Alzheimer's disease.
The compounds of the invention are also useful in the treatment of fibrotic conditions such as idiopathic pulmonary fibrosis, renal fibrosis, post-operative stricture, keloid formation, scleroderma and cardiac fibrosis.
The compounds of the invention can also be used to treat ophthamological indications such as dry eye.
The compounds of the invention can also be used to treat heart disease such as heart failure.
As used herein, the term "contacting" refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, "contacting" a BET protein with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having a BET protein, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the BET protein.
As used herein, the term "individual" or "patient, " used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician.
As used herein, the term "treating" or "treatment" refers to inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e.,, arresting further development of the pathology and/or symptomatology) or ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e.,, reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
As used herein, the term "preventing" or "prevention" refers to preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.
Combination Therapies
The compounds of the invention can be used in combination treatments where the compound of the invention is administered in conjunction with other treatments such as the administration of one or more additional therapeutic agents. The additional therapeutic agents are typically those which are normally used to treat the particular condition to be treated. The additional therapeutic agents can include, e.g., chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, as well as Bcr-Abl, Flt-3, RAF, FAK, and JAK kinase inhibitors for treatment of BET protein-associated diseases, disorders or conditions. The one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially.
In some embodiments, the compounds of the invention can be used in combination with a therapeutic agent that targets an epigenetic regulator. Examples of epigenetic regulators include the histone lysine methyltransferases, histone arginine methyl transferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases. Histone deacetylase inhibitors include, e.g., vorinostat. For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with chemotherapeutic agents, or other anti-proliferative agents. The compounds of the invention can also be used in combination with medical therapy such as surgery or radiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes. Examples of suitable chemotherapeutic agents include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, and zoledronate.
For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with ruxolitinib.
For treating autoimmune or inflammatory conditions, the compound of the invention can be administered in combination with a corticosteroid such as triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone. For treating autoimmune or inflammatory conditions, the compound of the invention can be administered in combination with an immune suppressant such as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol, Alcon), or cyclosporine (Restasis®).
For treating autoimmune or inflammatory conditions, the compound of the invention can be administered in combination with one or more additional agents selected from Dehydrex™ (Holies Labs), Civamide (Opko), sodium hyaluronate (Vismed, Lantibio/TRB Chemedia), cyclosporine (ST-603, Sirion Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine, doxycycline (ALTY-0501, Alacrity), minocycline, iDestrin™
(NP50301, Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin, MOLI1901, Lantibio), CF101 (2S, 3S, 4R, 5R)-3, 4-dihydroxy-5-[6-[(3- iodophenyl)methylamino]purin-9-yl]-N-methyl-oxolane-2-carbamyl, Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences), ARG103 (Agentis), RX- 10045 (synthetic resolvin analog, Resolvyx), DYN15 (Dyanmis Therapeutics), rivoglitazone (DE011, Daiichi Sanko), TB4 (RegeneRx), OPH-01 (Ophtalmis Monaco), PCS 101 (Pericor Science), REV 1-31 (Evolutec), Lacritin (Senju), rebamipide (Otsuka-Novartis), OT-551 (Othera), PAI-2 (University of Pennsylvania and Temple University), pilocarpine, tacrolimus, pimecrolimus (AMS981, Novartis), loteprednol etabonate, rituximab, diquafosol tetrasodium (INS365, Inspire), KLS- 0611 (Kissei Pharmaceuticals), dehydroepiandrosterone, anakinra, efalizumab,
mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267 (TorreyPines Therapeutics), or thalidomide.
In some embodiments, the compound of the invention can be administered in
combination with one or more agents selected from an antibiotic, antiviral, antifungal, anesthetic, anti-inflammatory agents including steroidal and non-steroidal anti-inflammatories, and anti- allergic agents. Examples of suitable medicaments include aminoglycosides such as amikacin, gentamycin, tobramycin, streptomycin, netilmycin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin; paramomycin;
colistimethate; bacitracin; vancomycin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; amphotericins; fluconazole; flucytosine; natamycin; miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen; ketorolac; suprofen;
cromolyn; lodoxamide; levocabastin; naphazoline; antazoline; pheniramine; or azalide antibiotic.
Other examples of agents, one or more of which a provided compound may also be combined with include: a treatment for Alzheimer's Disease such as donepezil and rivastigmine; a treatment for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinirole, pramipexole, bromocriptine, pergolide, trihexyphenidyl, and amantadine; an agent for treating multiple sclerosis (MS) such as beta interferon (e.g., Avonex® and Rebif®), glatiramer acetate, and mitoxantrone; a treatment for asthma such as albuterol and montelukast; an agent for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; an anti-inflammatory agent such as a corticosteroid, such as dexamethasone or prednisone, a TNF blocker, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; an immunomodulatory agent, including immunosuppressive agents, such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, an interferon, a corticosteroid, cyclophosphamide, azathioprine, and sulfasalazine; a neurotrophic factor such as an acetylcholinesterase inhibitor, an MAO inhibitor, an interferon, an anti- convulsant, an ion channel blocker, riluzole, or an anti-Parkinson's agent; an agent for treating cardiovascular disease such as a beta-blocker, an ACE inhibitor, a diuretic, a nitrate, a calcium channel blocker, or a statin; an agent for treating liver disease such as a corticosteroid, cholestyramine, an interferon, and an anti-viral agent; an agent for treating blood disorders such as a corticosteroid, an anti-leukemic agent, or a growth factor; or an agent for treating
immunodeficiency disorders such as gamma globulin.
Formulation, Dosage Forms and Administration
When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
This invention also includes pharmaceutical compositions which contain, as the active ingredient, the compound of the invention or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical administration. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is
substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art, e.g., see International App. No. WO 2002/000196.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
The active compound may be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the active ingredient of the present invention.
The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar
pharmaceutical vehicles.
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
Topical formulations can contain one or more conventional carriers. In some
embodiments, ointments can contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white vaseline, and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, for example, glycerol, hydroxyethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2, or at least about 5 wt % of the compound of the invention. The topical formulations can be suitably packaged in tubes of, for example, 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.
The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
The therapeutic dosage of a compound of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
The compositions of the invention can further include one or more additional
pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant, examples of which are listed hereinabove. The compounds of the invention can be provided with or used in combination with a companion diagnostic. As used herein, the term "companion diagnostic" refers to a diagnostic device useful for determining the safe and effective use of a therapeutic agent. For example, a companion diagnostic may be used to customize dosage of a therapeutic agent for a given subject, identify appropriate subpopulations for treatment, or identify populations who should not receive a particular treatment because of an increased risk of a serious side effect.
In some embodiments, the companion diagnostic is used to monitor treatment response in a patient. In some embodiments, the companion diagnostic is used to identify a subject that is likely to benefit from a given compound or therapeutic agent. In some embodiments, the companion diagnostic is used to identify a subject having an increased risk of adverse side effects from administration of a therapeutic agent, compared to a reference standard. In some embodiments, the companion diagnostic is an in-vitro diagnostic or imaging tool selected from the list of FDA cleared or approved companion diagnostic devices. In some embodiments, the companion diagnostic is selected from the list of tests that have been cleared or approved by the Center for Devices and Radiological Health.
Labeled Compounds and Assay Methods
Another aspect of the present invention relates to labeled compounds of the invention (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating BET proteins in tissue samples, including human, and for identifying BET protein ligands by inhibition binding of a labeled compound. Accordingly, the present invention includes BET protein assays that contain such labeled compounds.
The present invention further includes isotopically-labeled compounds of the invention. An "isotopically" or "radio-labeled" compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 3H (also written as T for tritium), nC, 13C, 14C, 13N, 15N, 150, 170, 180, 18F, 35S, 36C1, 82Br, 75Br, 76Br, 77Br, 1231, 1241, 125I and 131I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro BET protein labeling and competition assays, compounds that incorporate 3H, 14C, 82Br, 1251 , 131I, or 35S will generally be most useful. For radio-imaging applications UC, 18F, 125I, 123I, 124I, 131I, 75Br, 76Br or 77Br will generally be most useful.
It is to be understood that a "radio-labeled " or "labeled compound" is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of 3H, 14C, 1251, 35S and 82Br. In some embodiments, the compound incorporates 1, 2, or 3 deuterium atoms.
The present invention can further include synthetic methods for incorporating radio- isotopes into compounds of the invention. Synthetic methods for incorporating radio-isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of invention.
A labeled compound of the invention can be used in a screening assay to
identify/evaluate compounds. For example, a newly synthesized or identified compound {i.e., test compound) which is labeled can be evaluated for its ability to bind a BET protein by monitoring its concentration variation when contacting with the BET protein, through tracking of the labeling. For example, a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a BET protein {i.e., standard
compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the BET protein directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of one or more BET proteins as described below. EXAMPLES
Experimental procedures for compounds of the invention are provided below.
Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g. "Two- Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi.
Chem., 5, 670 (2003); and "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity check under the following conditions: Instrument; Agilent 1 100 series, LC/MSD, Column: Waters Sunfire™ Cis 5 μιη, 2.1 x 5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: 0.025% TFA in acetonitrile; gradient 2% to 80% of B in 3 minutes with flow rate 1.5 mL/minute.
Some of the compounds prepared were also separated on a preparative scale by reverse- phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse-phase high performance liquid chromatography (RP-HPLC) column conditions are as follows:
pH = 2 purifications: Waters Sunfire™ Cis 5 μιη, 19 x 100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: 0.1% TFA in acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method
Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem. , 6, 874-883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 mL/minute.
pH = 10 purifications: Waters XBridge Cis 5 μιη, 19 x 100 mm column, eluting with mobile phase A: 0.15% NFLtOH in water and mobile phase B: 0.15% NFLtOH in acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with 30 x 100 mm column was 60 mL/minute. Example 1. 4-(2,4-Difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c] pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000076_0001
Step 1. 4-Bromo-3-(2,4-difluorophenox -2-nitroaniline
Figure imgf000076_0002
A solution of 4-bromo-3-fluoro-2-nitroaniline (0.100 g, 0.426 mmol) [Combi-Blocks,
AN-2785] and cesium carbonate (0.167 g, 0.511 mmol) in dimethyl sulfoxide (0.47 mL) was treated with 2,4-difluorophenol (0.083 mL, 0.512 mmol) and stirred at 20 °C for 30 min and heated at 110 °C for 30 min. The reaction mixture was diluted with ethyl acetate and water. The organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (100% hexanes to 40% EtOAc/hexanes) gave the desired product (140 mg, 95%>) as an orange/brown oil. LCMS calculated for Ci2H8BrF2N203 (M+H)+: m/z = 345.0, 347.0; found: 344.9, 346.9. Step 2. 4- [4-amino-2-(2 ,4-dtfluorophenoxy)-3-nitrophenyl] -6-methyl- 1- [(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000077_0001
A suspension of 6-methyl-l-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (0.17 g, 0.40 mmol), 4-bromo-3- (2,4-difluorophenoxy)-2-nitroaniline (0.14 g, 0.40 mmol), potassium phosphate (0.22 g, 1.0 mmol), tris(dibenzylideneacetone)dipalladium (0) (0.01 g, 0.01 mmol), and 1,3,5,7-tetramethyl- 8-phenyl-2,4,6-trioxa-8-phosphatricyclo[3.3.1.13,7]decane (0.0139 g, 0.0475 mmol) in 1,4- dioxane (4 mL) and water (0.9 mL) was degassed with nitrogen for 5 min and stirred at 80 °C for 2 h. The reaction mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried with magnesium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (100% hexanes to 40%
EtOAc/hexanes) gave the desired product (108 mg, 23%) as a brown oil. LCMS calculated for C27H21F2N4O6S (M+H)+: m/z = 567.1; found: 567.1.
Step 3. 4-[3,4-Diamino-2-(2,4-difluorophenoxy)phenyl] -6-methyl-l -[ (4-methylphenyl)sulfonylJ - 1, 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000077_0002
A solution of 4-[4-amino-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (108 mg, 0.191 mmol) in ethyl acetate (0.46 mL) was treated with methanol (0.46 mL) and saturated aqueous ammonium chloride solution (0.166 mL, 2.48 mmol) and cooled to 0 °C. The reaction mixture was treated with zinc (99.7 mg, 1.52 mmol) and stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate, filtered through a pad of Celite, and the solids were washed with ethyl acetate. The filtrate was washed with saturated sodium bicarbonate solution (40 mL). The aqueous layer was separated and re-extracted with ethyl acetate (40 mL). The combined organic layers were washed with brine, dried with sodium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (40% EtOAc/hexanes to 100% EtOAc) gave the desired product (100 mg, 93%>) as a brown oil. LCMS calculated for
C27H23F2N4O4S (M+H)+: m/z = 537.1; found: 537.1.
Step 4. 4-(2,4-Difluorophenoxy)-5-(6-methyl-7-oxo-6, 7-dihydro- lH-pyrrolo [2,3-c] pyridin-4-yl)- l,3-dihydro-2H-benzimidazol-2-one
A solution of 4-[3,4-diamino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (35.0 mg, 0.065 mmol) in ethyl acetate (0.289 mL) was heated to 50 °C, treated with N,N-carbonyldiimidazole (21 mg, 0.13 mmol), and stirred at 50 °C for 1 h. The reaction mixture was concentrated to give the crude intermediate urea which was used immediately without further purification. The intermediate urea was dissolved in ethanol (1.0 mL), treated with 1.0 M sodium hydroxide in water (326 0.326 mmol), and heated at 60 °C overnight. The reaction mixture was diluted with ethyl acetate and water. The organic layer was separated and washed with brine, dried with sodium sulfate, filtered, and concentrated to give a crude residue. This material was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of methanol/water containing 0.1%) trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (7.3 mg, 19%>) as a white solid. ¾ NMR (300 MHz, DMSO-ώ) δ 11.93 (br s, 1H), 11.01 (s, 1H), 10.91 (s, 1H), 7.23 - 7.11 (m, 2H), 7.11 - 7.03 (m, 2H), 6.98 - 6.92 (m, 1H), 6.76 - 6.64 (m, 1H), 6.52 - 6.37 (m, 1H), 6.14 - 6.05 (m, 1H), 3.43 (s, 3H); LCMS calculated for C21H15F2N4O3 (M+H)+: m/z = 409.1; found: 409.1.
Example 2. 4- [4-(2,4-Difluorophenoxy)- lH-benzimidazol-5-yl] -6-methyl- 1 ,6-dihydro-7H- pyrrolo [2,3-c] pyridin-7-one trifluoroacetate
Figure imgf000079_0001
A solution of 4-[3,4-diamino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (31.0 mg, 0.058 mmol) in tetrahydrofuran (0.50 mL) was treated with ethyl orthoformate (28.8 μί, 0.173 mmol) followed by /?-toluenesulfonic acid monohydrate (1.1 mg, 5.8 μιηοΐ) and stirred at 50 °C for 1 h. The reaction mixture was concentrated to give the intermediate benzimidazole which was used immediately without further purification. The intermediate benzimidazole was dissolved in ethanol (1.0 mL), treated with 1.0 M sodium hydroxide in water (300 μί, 0.90 mmol), and heated at 60 °C overnight. The reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of methanol/water containing 0.1% trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (6 mg, 26%) as a white solid. JH NMR (300 MHz, DMSO-ώ) δ 12.01 (s, 1H), 8.72 (br s, 1H), 7.65 (d, J= 8.4 Hz, 1H), 7.44 (d, J= 8.3 Hz, 1H), 7.32 - 7.15 (m, 3H), 6.80 - 6.65 (m, 1H), 6.63 - 6.48 (m, 1H), 6.20 - 6.03 (m, 1H), 3.48 (s, 3H); LCMS calculated for C21H15F2N4O2 (M+H)+: m/z = 393.1; found: 393.1.
Example 3. 4-[4-(2,4-Difluorophenoxy)-2-methyl-lH-benzimidazol-5-yl]-6-methyl-l,6- dihydr o-7H-pyrrolo [2,3-c] pyridin-7-one trifluoroacetate
Figure imgf000079_0002
This compound was synthesized according to the procedure of Example 2 using triethyl orthoacetate instead of ethyl orthoformate. ¾ NMR (300 MHz, DMSO-ώ) δ 12.01 (s, 1H), 7.68 (d, J= 8.4 Hz, 1H), 7.50 (d, J= 8.4 Hz, 1H), 7.31 - 7.10 (m, 3H), 6.78 - 6.63 (m, 1H), 6.60 - 6.43 (m, 1H), 6.14 - 6.02 (m, 1H), 3.46 (s, 3H), 2.69 (s, 3H); LCMS calculated for C22H17F2N4O2 (M+H)+: m/z = 407.1; found: 407.1.
Example 4. 4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-6-methyl-l,6- dihydr o-7H-pyrrolo [2,3-c] pyridin-7-one trifluoroacetate
Figure imgf000080_0001
Step 1. N-(3-(2,4-Difluorophenoxy)-4-{6-methyl-l-[ (4-methylphenyl)sulfonyl]-7-oxo-6, 7- dihydro- lH-pyrrolo [2 ,3-c] pyridin-4-yl}-2-nitrophenyl)-2 2 ,2-trifluoroacetamide
Figure imgf000080_0002
A solution of 4-[4-amino-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (250 mg, 0.441 mmol) in methylene chloride (2.1 mL) was treated with triethylamine (123 μί, 0.882 mmol), cooled to 0 °C, treated with trifluoroacetic anhydride (125 μί, 0.882 mmol) dropwise, and stirred at ambient temperature for 1.5 h. The above reaction mixture was diluted with dichloromethane (50 mL) and brine (50 mL). The aqueous layer was separated and extracted with dichloromethane (2 x 40 mL). The combined organic layers were washed with brine, dried with sodium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (40% EtOAc/hexanes to 80%> EtOAc/hexanes) gave the desired product (293 mg, quantitative) as a solid. LCMS calculated for C29H20F5N4O7S (M+H)+: m/z = 663.1; found: 663.0. Step 2. 4-[2-(2,4-Difluorophenoxy)-4-(methylamino)-3-nitrophenyl]-6-methyl-l-[(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000081_0001
A solution of N-(3-(2,4-difluorophenoxy)-4-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7- oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl}-2-nitrophenyl)-2,2,2-trifiuoroacetamide (80.0 mg, 0.121 mmol) in N,N-dimethylformamide (1.4 mL) was treated with cesium carbonate (78.7 mg, 0.241 mmol) followed by methyl iodide (37.6 μί, 0.604 mmol) and stirred at 50 °C for 2 h. The reaction mixture was diluted with ethyl acetate (200 mL), washed with water (3 x 50 mL) and brine, dried with magnesium sulfate, filtered, and concentrated to give the desired methylated amide that was used immediately without further purification. The intermediate methyl trifluoroacetamide was dissolved in methanol (1.4 mL, 33.7 mmol) and water (0.27 mL), treated with potassium carbonate (83.4 mg, 0.604 mmol), and stirred at 60 °C for 3 h. The reaction mixture was diluted with ethyl acetate (-100 mL), washed with water & brine, dried with magnesium sulfate, filtered, and concentrated to give the desired product (69 mg, 98%) that was used without further purification. LCMS calculated for C28H23F2N4O6S (M+H)+: m/z = 581.1; found: 581.1.
Step 3. 4-[3-Amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000081_0002
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-[2-(2,4-difluorophenoxy)-4-(methylamino)-3-nitrophenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one instead of 4-[4-amino-2-(2, 4-difluorophenoxy)-3-nitrophenyl]-6-methyl-l-[(4-methylphenyl)sulfonyl]-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one. LCMS calculated for C28H25F2N4O4S (M+H)+: m/z = 551.2; found: 551.2.
Step 4. 4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-6-methyl- pyrrolo[2, 3-cJpyridin- 7 -one trifluoroacetate
This compound was synthesized according to the procedure of Example 2 using 4-[3- amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one instead of 4-[3,4-diamino- 2-(2,4-difluorophenoxy)phenyl]-6-methyl-l-[(4-methylphenyl)sulfonyl]-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one. lU NMR (500 MHz, DMSO-ώ) δ 11.98 (s, 1H), 8.50 (br s, 1H), 7.65 (d, J= 8.4 Hz, 1H), 7.46 (d, J= 8.4 Hz, 1H), 7.31 - 7.12 (m, 3H), 6.78 - 6.66 (m, 1H), 6.63 - 6.53 (m, 1H), 6.10 (dd, J= 2.3, 2.3 Hz, 1H), 3.93 (s, 3H), 3.49 (s, 3H); LCMS calculated for C22H17F2N4O2 (M+H)+: m/z = 407.1; found: 407.1.
Example 5. 4- [4-(2,4-Difluorophenoxy)- 1 ,2-dimethyl- lH-benzimidazol-5-yl] -6-methyl- 1,6- dihydro-7H-pyrrolo[2,3-c]pyridi -7-one trifluoroacetate
Figure imgf000082_0001
This compound was synthesized according to the procedure of Example 2 using 4-[3- amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one instead of 4-[3,4-diamino- 2-(2,4-difluorophenoxy)phenyl]-6-methyl-l-[(4-methylphenyl)sulfonyl]-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one and triethyl orthoacetate instead of ethyl orthoformate. lH NMR (500 MHz, DMSO-</i) 8 11.99 (s, 1H), 7.77 (d, J= 8.3 Hz, 1H), 7.54 (d, J= 8.4 Hz, 1H), 7.27 - 7.15 (m, 3H), 6.75 - 6.64 (m, 1H), 6.55 - 6.47 (m, 1H), 6.07 (dd, J= 2.3, 2.3 Hz, 1H), 3.92 (s, 3H), 3.47 (s, 3H), 2.69 (s, 3H); LCMS calculated for C23H19F2N4O2 (M+H)+: m/z = 421.1; found: 421.1.
Example 6. 4-(2,4-Difluorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo [2,3-c] pyridin-4-yl)- 1 ,3-dih dro-2H-benzimidazol-2-one
Figure imgf000083_0001
Step 1. 4-(2,4-difluorophenoxy)-l-methyl-5-{6-methyl-l-[(4-methylphenyl)sulfonylJ-7- dihydro- lH^yrrolo [2,3-c] pyridin-4-yl}- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000083_0002
A solution of 4-[3-amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l- [(4-methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (98.0 mg, 0.178 mmol) in tetrahydrofuran (1.0 mL) was treated with N,N-carbonyldiimidazole (57.7 mg, 0.356 mmol) and stirred at 50 °C for 1 h. The reaction mixture was purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (77 mg, 75%). LCMS calculated for C29H23F2N4O5S (M+H)+: m/z = 577.1; found: 577.1. Step 2. 4-(2,4-Difluorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3- c] pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000084_0001
A solution of 4-(2,4-difluorophenoxy)-l-methyl-5-{6-methyl-l-[(4- methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl}-l,3-dihydro-2H- benzimidazol-2-one (20.0 mg, 0.0347 mmol) in ethanol (2.0 mL) was treated with 3.0 M Sodium hydroxide in water (116
Figure imgf000084_0002
0.347 mmol) and stirred at RT overnight. The reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of
acetonitrile/water containing 0.1% trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (14.5 mg, 99%). ¾ NMR (400 MHz, DMSO-ώ) δ 11.94 (s, 1H), 11.25 (s,
1H), 7.25 - 7.06 (m, 5H), 6.74 - 6.62 (m, 1H), 6.51 - 6.38 (m, 1H), 6.14 - 6.05 (m, 1H), 3.44 (s, 3H), 3.34 (s, 3H); LCMS calculated for C22H17F2N4O3 (M+H)+: m/z = 423.1; found: 423.1.
Example 7. 4-(2,4-Difluorophenoxy)-l,3-dimethyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo [2,3-c] pyridin-4-yl)- 1 ,3-dih dro-2H-benzimidazol-2-one
Figure imgf000084_0003
A solution of 4-(2,4-difluorophenoxy)-l-methyl-5-{6-methyl-l-[(4- methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl}-l,3-dihydro-2H- benzimidazol-2-one (30.0 mg, 0.0520 mmol) in N,N-dimethylformamide (0.25 mL) was treated with sodium hydride (4.2 mg, 0.104 mmol) and stirred at RT for 30 min. The reaction mixture was treated with methyl iodide (4.9 μί, 0.0780 mmol) and stirred at RT for 1 h. Analytical LCMS indicated the reaction was complete. The reaction mixture was diluted with ethanol (3.0 mL), treated with 3.0 M sodium hydroxide in water (0.175 mL, 0.525 mmol), and stirred at RT overnight. The reaction was quenched with acetic acid (0.044 mL, 0.780 mmol) and purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water containing 0.1% trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (14.5 mg, 64%). 'H NMR (400 MHz, DMSO-ώ) δ 11.93 (s, 1H), 7.25 - 7.10 (m, 5H), 6.74 - 6.62 (m, 1H), 6.56 - 6.42 (m, 1H), 6.16 - 6.05 (m, 1H), 3.44 (s, 3H), 3.39 (s, 3H), 3.32 (s, 3H); LCMS calculated for C23H19F2N4O3 (M+H)+: m/z = 437.1; found: 437.1.
Example 8. 4- [4-(2,4-Difluorophenoxy)- 1H- 1 ,2,3-benzotriazol-5-yl] -6-methyl- 1 ,6-dihydro- 7H-pyr rolo [2,3-c] pyridin-7-one
Figure imgf000085_0001
Step 1. 4-f4-(2,4-Difluorophenoxy)-lH-l,2,3-benzotriazol-5-ylJ-6-methyl-l-f(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H- rrolo[2, 3-cJpyridin- 7 -one
Figure imgf000085_0002
A solution of 4-[3,4-diamino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (0.040 g, 0.074 mmol) in acetic acid (0.1 mL, 3 mmol) was treated with water (0.37 mL, 21 mmol) followed by sodium nitrite (0.026 g, 0.37 mmol) and stirred at 20 °C for 30 min. The reaction mixture was diluted with ethyl acetate and water. The organic layer was washed with saturated sodium bicarbonate (2x) and brine, dried with magnesium sulfate, filtered, and concentrated to give the desired product (32 mg, 78%) as a crude brown residue that was used immediately without further purification. LCMS calculated for C27H20F2N5O4S (M+H)+: m z = 548.1; found: 548.1. Step 2. 4-f4-(2,4-Difluorophenoxy)-lH-l,2,3-benzotriazol-5-ylJ-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one
Figure imgf000086_0001
A solution of 4-[4-(2,4-difluorophenoxy)-lH-l,2,3-benzotriazol-5-yl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (32 mg, 0.058 mmol) in ethanol (3.4 mL) was treated with 3.0 M sodium hydroxide in water (195
Figure imgf000086_0002
0.584 mmol) and stirred at 20 °C for 15 h. The reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (13 mg, 56%). ¾ NMR (400 MHz, DMSO-ώ) δ 12.05 (s, 1H), 7.77 (br s, 1H), 7.53 (d, J= 8.5 Hz, 1H), 7.37 - 7.19 (m, 3H), 6.77 (br s, 2H), 6.23 - 6.07 (m, 1H), 3.50 (s, 3H); LCMS calculated for C20H14F2N5O2 (M+H)+: m/z = 394.1; found: 394.0.
Example 9. 4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-l,2,3-benzotriazol-5-yl]-6-methyl-l,6- dihydr o-7H-pyrrolo [2,3-c] pyridin-7-one
Figure imgf000086_0003
This compound was synthesized according to the procedure of Example 8 using 4-[3- amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. lH NMR (400 MHz, DMSO-ώ) δ 12.08 (s, 1H), 7.77 (d, J= 8.6 Hz, 1H), 7.64 (d, J= 8.5 Hz, 1H), 7.37 - 7.21 (m, 3H), 6.91 - 6.77 (m, 2H), 6.13 (s, 1H), 4.33 (s, 3H), 3.52 (s, 3H); LCMS calculated for C21H16F2N5O2 (M+H)+: m/z = 408.1; found: 408.1.
Example 10. 4- [4-(2,4-Difluorophenoxy)- 1H- 1 ,2,3-benzotriazol-5-yl] -6-methyl- 1,6- dihydro-7H-pyrazolo[3,4-c]pyridin-7-one
Figure imgf000087_0001
Step 1. 5-Bromo- 1 ,4-dimethyl-3-nitropyridin-2 ( lH)-one
Figure imgf000087_0002
A solution of 5-bromo-4-methyl-3-nitropyridin-2-ol (15.00 g, 64.37 mmol) [Combi- Blocks, AN- 1086] in N,N-dimethylformamide (250 mL) was treated with sodium hydride (3.09 g, 77.3 mmol) (60% dispersion on mineral oil) slowly and portionwise, and stirred at RT for 30 min. The reaction mixture was treated with methyl iodide (4.81 mL, 77.2 mmol) dropwise and stirred at RT for 3 h. LCMS indicated a clean peak for methylated product. The reaction mixture was poured over water/ice (-400 mL) and allowed to stir while the ice melted. The aqueous mixture was extracted with ethyl acetate. The organic layer was washed with water (3x) and brine, dried with magnesium sulfate, filtered, and concentrated to give the desired product (14.9 g, 93%)) that was used without further purification. LCMS calculated for
Figure imgf000087_0003
(M+H)+: m/z = 247.0, 249.0; found: 247.0, 248.9.
Step 2. 4-Bromo-6-methyl-l , 6-dihydro- 7H-pyrazolo[ 3, 4-cJpyridin
Figure imgf000088_0001
A solution of 3-amino-5-bromo-l,4-dimethylpyridin-2(lH)-one (12.1 g, 55.9 mmol) in toluene (300 mL) was treated with acetic anhydride (15.8 mL, 168 mmol) followed by potassium acetate (6.58 g, 67.1 mmol) and stirred at RT overnight. The reaction mixture was treated with amyl nitrite (11.3 mL, 83.8 mmol) and heated at 80 °C overnight. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with magnesium sulfate, filtered, and concentrated to give a mixture of the desired product along with the acetylated desired product. This mixture was diluted with methanol (490 mL) and treated with 1.0 M sodium hydroxide in water (280 mL) and stirred at RT for 1 h. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with magnesium sulfate, filtered, and concentrated to give crude product. Purification by flash column chromatography (100% hexanes to 100% EtOAc) gave the desired product (8.4 g, 66%>). LCMS calculated for
CvHvBrNsO (M+H)+: m/z = 228.0, 230.0; found: 227.9, 229.9. Step 3. 4-Bromo-6-methyl-l-{[2-(trimethylsilyl)ethoxyJmethyl}-l,6-dihydro-7H-py
cJpyridin-7-one and 4-bromo-6-methyl-2-{[2-(trimethylsilyl)ethoxy]methyl}-2,6-dihydro-7H- pyrazolof 3, 4-c] pyridin- 7 -one
Figure imgf000088_0002
A solution of 4-bromo-6-methyl-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one (5.40 g, 23.7 mmol) in N,N-dimethylformamide (170 mL) at 0 °C was treated with sodium hydride (1.42 g, 35.5 mmol) and stirred at 0 °C for 30 min. The reaction mixture was treated with [β- (trimethylsilyl)ethoxy]methyl chloride (7.90 g, 47.4 mmol) and stirred at 0 °C for 1 h. The reaction mixture was poured into ethyl acetate (200 mL) and washed with saturated sodium bicarbonate solution. The aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water (3x) and brine, dried with magnesium sulfate, filtered, and concentrated to give the crude product. Purification by flash column chromatography (100% hexanes to 100% EtOAc) gave a major product and a minor product (8.5 g total yield, quantitative) as an ~4: 1 mixture of SEM-protected isomers. ¾ NMR analysis of the individual products revealed the major isomer was consistent with the SEM group at the 1- position and the minor isomer was consistent with the SEM group at the 2-position. In practice, the isomers were not separated at this step and used as a mixture of isomers in the next step. LCMS calculated for CisftiBrNsC Si (M+H)+: m/z = 358.1, 360.1; found: 358.0, 360.0.
Step 4. 6-Methyl-4-(4, 4, 5, 5-tetramethyl-l, 3,2-dioxaborolan-2-yl)-l-{[ 2-
( trimethylsilyl)ethoxy] methyl}- 1, 6-dihydro- 7H-pyrazolo[ 3, 4-c] pyridin- 7 -one and 6-methyl-4-(4, 4, 5 ', 5-tetramethyl-l , 3,2-dioxaborolan-2-yl)-2-{[2-(trimethylsilyl)ethoxy]methyl}-2, 6-dihydro- 7H- pyrazolof 3, 4-c] pyridin- 7 -one
Figure imgf000089_0001
A suspension of 4-bromo-6-methyl-l-{[2-(trimethylsilyl)ethoxy]methyl}-l,6-dihydro- 7H-pyrazolo[3,4-c]pyridin-7-one and 4-bromo-6-methyl-2-{[2-(trimethylsilyl)ethoxy]methyl}-2, 6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one (8.50 g, 23.7 mmol) (-4: 1 mixture of isomers), 4,4, 5,5,4',4',5',5'-cctamethyl-[2,2']bi[[l,3,2]dioxaborolanyl] (12.0 g, 47.5 mmol), dicyclohexyl(2',4', 6'-triisopropylbiphenyl-2-yl)phosphine (1.23 g, 2.58 mmol), potassium acetate (5.12 g, 52.2 mmol), and tris(dibenzylideneacetone)dipalladium(0) (543 mg, 0.592 mmol) in 1,4-dioxane (120 mL) was degassed with nitrogen for 10 min and stirred at 80 °C for 3 h. The reaction mixture was diluted with ethyl acetate (100 mL) and saturated sodium bicarbonate solution (100 mL), filtered over Celite, and washed with ethyl acetate. The aqueous layer was separated and re- extracted with ethyl acetate (100 mL). The combined organic layers were washed with brine, dried with magnesium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (100% hexanes to 60% EtOAc/hexanes) gave the individual isomers of the desired product (major isomer: 5.23 g, 54%>; minor isomer: 1.28 g, 13%). Major isomer (SEM at 1-position): LCMS calculated for CigtfcBNsCMSi (M+H)+: m/z = 406.2; found: 406.2; minor isomer (SEM at 2-position): LCMS calculated for C19H33BN3O4S1 (M+H)+: m/z = 406.2; found: 406.2.
Step 5. 4-[4-Amino-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-2-{[2- ( trimethylsilyl)ethoxy] methyl} -2, 6-dih dro- 7H-pyrazolo[ 3, 4-cJpyridin- 7 -one
Figure imgf000090_0001
A solution of 4-(di-tert-butylphosphino)-N,N-dimethylaniline - dichloropalladium (2: 1) (22.3 mg, 0.0314 mmol), cesium fluoride (1.11 g, 7.34 mmol), 4-bromo-3-(2,4- difluorophenoxy)-2-nitroaniline (724 mg, 2.10 mmol), and 6-methyl-4-(4,4,5,5-tetramethyl-l,3, 2-dioxaborolan-2-yl)-2-{[2-(trimethylsilyl)ethoxy]methyl}-2,6-dihydro-7H-pyrazolo[3,4- c]pyridin-7-one (850 mg, 2.097 mmol) in 1-butanol (9.5 mL) and water (2.2 mL) was degassed with nitrogen for 5 min and heated at 100 °C for 2 h. The reaction mixture was diluted with ethyl acetate and water. The organic layer was separated and washed with brine, dried with magnesium sulfate, filtered, and concentrated to give the crude product. Purification by flash column chromatography (50% EtOAc/hexanes to 100%) EtOAc) gave the desired product (0.57 g, 50%). LCMS calculated for C25H28F2N505Si (M+H)+: m/z = 544.2; found: 544.1.
Step 6. 4-f 3, 4-Diamino-2-(2, 4-difluorophenoxy)phenyl]-6-methyl-2-{[ 2- ( trimethylsilyl)ethoxy] methyl} -2, 6-dihydro- 7H-pyrazolo[ 3, 4-cJpyridin- 7 -one
Figure imgf000090_0002
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-[4-amino-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-2-{[2- (trimethylsilyl)ethoxy]methyl}-2,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material. LCMS calculated for C25H30F2N5O3S1 (M+H)+: m/z = 514.2; found: 514.2.
Step 7. 4-f 4- ( 2, 4-Difluorophenoxy)-lH-l , 2, 3-benzotriazol-5-yl]-6-methyl-l, 6-dihydro- 7H- pyrazolo[3,4-c]pyridin-7-one
A solution of 4-[3,4-diamino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-2-{[2- (trimethylsilyl)ethoxy]methyl}-2,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one (103 mg, 0.200 mmol) in acetic acid (0.40 mL) was treated with water (1.0 mL) followed by sodium nitrite (69.0 mg, 1.00 mmol) and stirred at 20 °C for 30 min. The reaction mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with saturated sodium bicarbonate (2x) and brine, dried with magnesium sulfate, filtered, and concentrated to give the SEM- protected intermediate which was used without further purification. The crude intermediate was diluted with methylene chloride (4.00 mL) and trifluoroacetic acid (4.00 mL) and stirred at 40 °C for 3 h. The reaction mixture was concentrated, diluted with acetonitrile, adjusted to pH ~7 with 1 M NaOH, and purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (16 mg, 20%). lU NMR (500 MHz, DMSO-ώ) δ 14.05 (br s, 1H), 7.86 - 7.72 (m, 2H), 7.57 (d, J= 8.4 Hz, 1H), 7.35 (s, 1H), 7.31 - 7.22 (m, 1H), 6.85 - 6.73 (m, 2H), 3.53 (s, 3H); LCMS calculated for C19H13F2N6O2 (M+H)+: m/z = 395.1; found: 395.1.
Example 11. 4-(Cyclopropylmethoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c] pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000091_0001
Step 1. 4-Bromo-3-(cyclopropylmethoxy)-2-nitroaniline
Figure imgf000092_0001
A solution of cyclopropyl carbinol (0.269 mL, 3.40 mmol) in tetrahydrofuran (6.9 mL) at 0 °C was treated with sodium hydride (0.0860 g, 3.40 mmol) and stirred at RT for 30 min. The reaction mixture was cooled to 0 °C, treated with 4-bromo-3-fluoro-2-nitroaniline (0.400 g, 1.70 mmol) [Combi-B locks, AN-2785] and stirred at RT for 15 h. The reaction mixture was cooled to 0 °C and quenched with saturated ammonium chloride solution. The reaction mixture was diluted with ethyl acetate (50 mL) and water (40 mL). The organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated to give crude oil. Purification by flash column chromatography (100% hexanes to 40% EtOAc/hexanes) gave the desired product (0.365 g, 75%). LCMS calculated for CioHi2BrN203 (M+H)+: m/z = 287.1 ; found: 286.8.
Step 2. 4-(4-Amino-2-(cyclopropylmethoxy)-3-nitrophenyl)-6-methyl-l-tosyl-lH-pyrrolo[2,3- cjpyridin- 7( 6H)-one
Figure imgf000092_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using 4-bromo-3-(cyclopropylmethoxy)-2-nitroaniline and 6-methyl-l-[(4- methylphenyl)sulfonyl]-4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C25H25N406S (M+H)+: m/z = 509.1 ; found: 509.1.
Step 3. 4-[3,4-Diamino-2-(cyclopropylmethoxy)phenyl]-6-methyl-l-[ (4-methylphenyl)sulfonylJ- 1, 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000093_0001
A suspension of 4-[4-amino-2-(cyclopropylmethoxy)-3-nitrophenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (0.119 g, 0.234 mmol) in ethyl acetate (1.2 mL) and methanol (1.2 mL) was treated with saturated aqueous ammonium chloride solution (0.274 mL, 4.09 mmol). The mixture was cooled to 0 °C, treated with zinc
(0.122 g, 1.87 mmol) in two portions over 5 min, stirred at RT for 30 min and heated at 55 °C for 1 h. The reaction mixture was diluted with dichloromethane, filtered through a Celite pad, and the solids were washed with dichloromethane. The filtrate was concentrated to give
a residue. The residue was dissolved in dichloromethane (30 mL), washed with saturated sodium bicarbonate solution (20 mL), dried with sodium sulfate, filtered, and concentrated to give the desired product that was used without further purification. LCMS calculated for C25H27N4O4S (M+H)+: m/z = 479.2; found: 479.1.
Step 4. 4-(Cyclopropylmethoxy)-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin l,3-dihydro-2H-benzimidazol-2-one
Figure imgf000093_0002
This compound was synthesized according to the procedure of Example 1, Step 4, using 4-[3,4-diamino-2-(cyclopropylmethoxy)phenyl]-6-methyl-l-[(4-methylphenyl)sulfonyl]-l,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. JH NMR (400 MHz, DMSO- de) δ 11.98 (s, 1H), 10.84 (s, 1H), 10.69 (s, 1H), 7.24 (dd, J= 2.7, 2.7 Hz, 1H), 7.20 (s, 1H), 6.93 (d, J= 8.0 Hz, 1H), 6.74 (d, J= 8.0 Hz, 1H), 6.13 (dd, J= 2.3, 2.3 Hz, 1H), 3.55 (s, 3H), 3.45 (d, J= 7.0 Hz, 2H), 0.98 - 0.83 (m, 1H), 0.30 - 0.20 (m, 2H), -0.06 - -0.14 (m, 2H); LCMS calculated for C19H19N4O3 (M+H)+: m/z = 351.1; found: 351.1.
Example 12. 4-[4-(Cyclopropylmethoxy)-lH-benzimidazol-5-yl]-6-methyl-l,6-dihyd] pyrrolo [2,3-c] pyridin-7-one
Figure imgf000094_0001
This compound was synthesized according to the procedure of Example 2 using 4-[3,4- diamino-2-(cyclopropylmethoxy)phenyl]-6-methyl- 1 -[(4-methylphenyl)sulfonyl]- 1 ,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. ¾ NMR (400 MHz, DMSO-ώ) δ 12.64 (s, 0.25H), 12.50 (s, 0.75H), 12.01 (s, 0.25H), 11.95 (s, 0.75H), 8.21 (s, 0.25H), 8.16 (s, 0.75H), 7.49 - 7.38 (m, 0.25H), 7.31 - 7.08 (m, 3.75H), 6.13 (s, 0.25H), 6.08 (s, 0.75H), 4.43 (d, J= 6.8 Hz, 2H), 3.56 (s, 3H), 1.09 - 0.90 (m, 1H), 0.40 - 0.32 (m, 1.5H), 0.31 - 0.22 (m, 0.5H), 0.16 - 0.08 (m, 1.5H), -0.01 - -0.12 (m, 0.5H); LCMS calculated for C19H19N4O2 (M+H)+: m/z = 335.1: found: 335.1.
Example 13. 4-[4-(Cyclopropylmethoxy)-2-methyl-lH-benzimidazol-5-yl]-6-methyl-l,6- dihydr o-7H-pyrrolo [2,3-c] pyridin- -one
Figure imgf000094_0002
This compound was synthesized according to the procedure of Example 2 using 4- [3, 4- diamino-2-(cyclopropylmethoxy)phenyl]-6-methyl- 1 -[(4-methylphenyl)sulfonyl]- 1 ,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one as the starting material and triethyl orthoacetate instead of ethyl orthoformate. ¾ NMR (300 MHz, DMSO-ώ) δ 12.23 (s, 1H), 11.99 (s, 0.3H), 11.93 (s, 0.7H), 7.33 - 7.19 (m, 1.2H), 7.18 - 7.00 (m, 2.8H), 6.17 - 6.10 (m, 0.3H), 6.10 - 6.02 (m, 0.7H), 4.37 (d, J= 6.8 Hz, 2H), 3.62 - 3.51 (m, 3H), 1.09 - 0.89 (m, 1H), 0.41 - 0.25 (m, 2H), 0.17 - 0.06 (m, 1.4H), -0.01 - -0.12 (m, 0.6H); LCMS calculated for C20H21N4O2 (M+H)+: m/z = 349.2; found: 349.1.
Example 14. 4-[4-(2,4-Difluorophenoxy)-lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrazolo [3 ,4-c] py ridin-7-one
Figure imgf000095_0001
A solution of 4-[3,4-diamino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-2-{[2-
(trimethylsilyl)ethoxy]methyl}-2,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one (50.0 mg, 0.0973 mmol) in tetrahydrofuran (0.842 mL) was treated with ethyl orthoformate (48.6 μί, 0.292 mmol) followed by p-toluenesulfonic acid monohydrate (1.85 mg, 0.00973 mmol) and stirred at 50 °C for 1 h. The reaction mixture was diluted with methylene chloride (4.0 mL), treated with trifluoroacetic acid (4.0 mL), and heated at 40 °C for 2 h. The reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (23 mg, 60%). JH NMR (500 MHz, DMSO-ώ) δ 14.02 (s, 1H), 12.79 (br s, 1H), 8.22 (s, 1H), 7.72 (s, 1H), 7.56 (d, J= 8.2 Hz, 1H), 7.35 (d, J= 8.3 Hz, 1H), 7.30 - 7.14 (m, 2H), 6.73 (dd, J= 8.0, 8.0 Hz, 1H), 6.66 - 6.49 (m, 1H), 3.52 (s, 3H); LCMS calculated for C20H14F2N5O2 (M+H)+: m/z = 394.1; found: 394.1.
Example 15. 4-[4-(2,4-Difluorophenoxy)-2-methyl-lH-benzimidazol-5-yl]-6-methyl-l,6- dihydro-7H-pyrazolo[3,4-c]pyridin-7-one
Figure imgf000096_0001
This compound was synthesized according to the procedure of Example 14 using triethyl orthoacetate instead of ethyl orthoformate. ¾ NMR (500 MHz, DMSO-ώ) δ 14.00 (s, 1H), 12.59 (br s, 1H), 7.69 (s, 1H), 7.46 (d, J= 8.2, 8.2 Hz, 1H), 7.31 - 7.14 (m, 3H), 6.71 (dd, J = 8.1, 8.1 Hz, 1H), 6.56 - 6.40 (m, 1H), 3.50 (s, 3H), 2.46 (s, 3H); LCMS calculated for
C21H16F2N5O2 (M+H)+: m/z = 408.1; found: 408.1.
Example 16. 4-[4-(2,4-Difluorophenoxy)-2-oxo-2,3-dihydro-lH-benzimidazol-5-yl]-6- methyl- 1 ,6-dihydro-7H-pyr azolo [3,4-c] pyridin-7-one
Figure imgf000096_0002
Step 1. 4- [4-Amino-2-(2 ,4-difluorophenoxy)-3-nitrophenyl] -6-methyl- 1-{ [2- ( trimethylsilyl)ethoxyJ methyl}- 1, 6-dihydro- 7H-pyrazolo[ 3, 4-c] pyridin- 7 -one
Figure imgf000096_0003
This compound was synthesized according to the procedure of Example 10, Step 5, using 6-methyl-4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 - { [2-(trimethylsilyl)ethoxy]methyl} - l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one instead of 4-bromo-6-methyl-2-{[2- (trimethylsilyl)ethoxy]methyl}-2,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one. LCMS calculated for C25H28F2N5O5S1 (M+H)+: m/z = 544.2; found: 544.1.
Step 2. 4-f 3, 4-Diamino-2-(2, 4-difluorophenoxy)phenyl]-6-methyl-l-{[ 2- ( trimethylsilyl)ethoxyJ methyl}- 1, 6-dihydro- 7H-pyrazolo[ 3, 4-c] pyridin- 7 -one
Figure imgf000097_0001
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-[4-amino-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-l-{[2-
(trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material.
Step 3. 4-[4-(2,4-Difluorophenoxy)-2-oxo-2,3-dihydro-lH-benzimidazol-5-yl]-6-methyl-l,6- dihydro- 7H-pyrazolo[ 3, 4-c] pyridin- 7 -one
Figure imgf000097_0002
A solution of 4-[3,4-diamino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one (80.0 mg, 0.156 mmol) in tetrahydrofuran (3.0 mL) was treated with N,N-carbonyldiimidazole (50.0 mg, 0.31 mmol) and stirred at 50 °C for 1 h. The reaction mixture was diluted with ethyl acetate and water. The organic layer was separated and washed with water and brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the SEM-protected intermediate which was used without further purification. The crude intermediate was diluted with methylene chloride (4.0 mL) and trifluoroacetic acid (4.0 mL) and stirred at 40 °C for 2 h. The reaction mixture was concentrated, diluted with acetonitrile, adjusted to pH ~7 with 1 M NaOH, and purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (16 mg, 20%). lH NMR (500 MHz, DMSO-ώ) δ 13.96 (br s, 1H), 11.03 (br s, 1H), 10.91 (br s, 1H), 7.68 (br s, 1H), 7.22 - 7.05 (m, 3H), 6.97 (d, J= 8.0 Hz, 1H), 6.70 (dd, J= 8.6, 8.6 Hz, 1H), 6.53 - 6.39 (m, 1H), 3.46 (s, 3H); LCMS calculated for C20H14F2N5O3 (M+H)+: m/z = 410.1; found: 410.1.
Example 17. 4-[4-(2,4-Difluorophenoxy)-l-(2-morpholin-4-ylethyl)-lH-benzimidazol-5-yl]- 6-methyl- 1 ,6-dihydro-7H-pyrazolo 3,4-c] pyridin-7-one
Figure imgf000098_0001
Step 1. N-[3-(2,4-Difluorophenoxy)-4-(6-methyl-7-oxo-l-{[2-(trimethylsilyl)ethoxyJmethyl}-6, 7- dihydro- lH-pyrazolo [3 ' ,4-c] pyridin-4-yl)-2-nitrophenyl] '-2 2 ,2-trifluoroacetamide
Figure imgf000098_0002
This compound was synthesized according to the procedure of Example 4, Step 1, using 4-[4-amino-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-l-{[2-
(trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material. LCMS calculated for C27H26F5N506SiNa (M+Na)+: m/z = 662.2; found: 662.0. Step 2. 4-{2-(2,4-Difluorophenoxy)-4-f (2-morpholin-4-ylethyl)amino]-3-nitrophenyl}-6-methyl- l-{[2-(trimethylsilyl)ethoxy) 'meth - 1 ,6-dihydro-7H-pyrazolo [3 ,4-cJpyridin-7-one
Figure imgf000099_0001
A solution of 4-morpholineethanol (43.0 μί, 0.352 mmol) and triphenylphosphine (92.3 mg, 0.352 mmol) in tetrahydrofuran (1.9 mL) was treated with diisopropyl azodicarboxylate (73.9 μί, 0.375 mmol) and stirred at 20 °C for 5 min. The reaction mixture was treated with a solution of N-[3-(2,4-difluorophenoxy)-4-(6-methyl-7-oxo-l-{[2-(trimethylsilyl)ethoxy]methyl}- 6,7-dihydro-lH-pyrazolo[3,4-c]pyridin-4-yl)-2-nitrophenyl]-2,2,2-trifluoroacetamide (150 mg, 0.235 mmol) in THF and stirred overnight at RT. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with water and brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude trifluoroacetamide which was used without further purification. The crude intermediate was diluted with methylene chloride (2.0 mL) and ammonium hydroxide (1.0 mL) and stirred at RT for 30 min. The reaction mixture was diluted with methanol and purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (44 mg, 29%). LCMS calculated for C3iH39F2N606Si (M+H)+: m/z = 657.3; found: 657.3.
Step 3. 4-{3-Amino-2-(2,4-difluorophenoxy)-4-f (2-morpholin-4-ylethyl)amino]phenyl}-6- methyl-l-{[2-(trimethylsilyl)ethoxy]methyl}-l ,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one
Figure imgf000100_0001
This compound was synthesized according to the procedure of Example 1, Step 3, using 4- {2-(2,4-difluorophenoxy)-4-[(2-morpholin-4-ylethyl)amino]-3-nitrophenyl} -6-methyl- 1 - {[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material. LCMS calculated for C31H41F2N6O4S1 (M+H)+: m/z = 627.3; found: 627.3.
Step 4. 4-[4-(2,4-Difluorophenoxy)-l-(2-morpholin-4-ylethyl)-lH-benzimidazo
1, 6-dihydro- 7H-pyrazolo[ 3, 4-c] pyridin- 7 -one
Figure imgf000100_0002
This compound was synthesized according to the procedure of Example 14 using 4-{3- amino-2-(2,4-difluorophenoxy)-4-[(2-morpholin-4-ylethyl)amino]phenyl} -6-methyl- 1 - { [2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material. ¾ NMR (500 MHz, DMSO-ώ) δ 14.02 (br s, 1H), 8.19 (s, 1H), 7.73 (s, 1H), 7.62 (d, J= 8.4 Hz, 1H), 7.39 (d, J= 8.3 Hz, 1H), 7.25 (s, 1H), 7.21 (ddd, J= 11.6, 8.8, 3.0 Hz, 1H), 6.80 - 6.71 (m, 1H), 6.64 (ddd, J= 9.3, 9.3, 5.5 Hz, 1H), 4.39 (t, J= 6.2 Hz, 2H), 3.61 - 3.45 (m, 6H), 2.72 (t, J= 6.2 Hz, 2H), 2.47 - 2.38 (m, 4H); LCMS calculated for C26H25F2N6O3 (M+H)+: m/z = 507.2; found: 507.1. Example 18. 4- [4-(2,4-Difluorophenoxy)- 1-methyl- lH-benzimidazol-5-yl] -6-methyl- 1 ,6- dihydr o-7H-pyrazolo [3 ,4-c] pyridin- -one.
Figure imgf000101_0001
Step 1. 4-[2-(2, 4-Difluorophenoxy)-4-(methylamino)-3-nitrophenyl]-6-methyl-l-{[2- ( trimethylsilyl)ethoxy] methyl}- 1, 6-dihydro- 7H-pyrazolo[ 3, 4-c] pyridin- 7 -one
Figure imgf000101_0002
This compound was synthesized according to the procedure of Example 4, Step 2, using N-[3-(2,4-difluorophenoxy)-4-(6-methyl-7-oxo-l-{[2-(trimethylsilyl)ethoxy]methyl}-6,7- dihydro-lH-pyrazolo[3,4-c]pyridin-4-yl)-2-nitrophenyl]-2,2,2-trifluoroacetamide as the starting material. LCMS calculated for C26H30F2N5O5S1 (M+H)+: m/z = 558.2; found: 558.2.
Step 2. 4-f3-Amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenylJ-6-methyl-l-{[2- ( trimethylsilyl)ethoxyJ methyl}- 1, 6-dihydro- 7H-pyrazolof 3, 4-c] pyridin- 7 -one
Figure imgf000101_0003
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-[2-(2,4-difluorophenoxy)-4-(methylamino)-3-nitrophenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material. LCMS calculated for C26H32F2N5O3S1 (M+H)+: m/z = 528.2; found: 528.2. Step 3. 4-f4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-ylJ-6-methyl-l,6-dihydro-7H- pyrazolof 3, 4-cJpyridin- 7 -one
This compound was synthesized according to the procedure of Example 14 using 4-[3- amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl- 1 - { [2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material. ¾ NMR (400 MHz, DMSO-ώ) δ 8.15 (s, 1H), 7.71 (br s, 1H), 7.64 - 7.50 (m, 1H), 7.49 - 7.34 (m, 1H), 7.33 - 7.13 (m, 2H), 6.87 - 6.69 (m, 1H), 6.69 - 6.51 (m, 1H), 3.88 (s, 3H), 3.53 (s, 3H); LCMS calculated for C21H16F2N5O2 (M+H)+: m/z = 408.1; found: 408.1.
Example 19. 4-[4-(2,4-Difluorophenoxy)-l,2-dimethyl-lH-benzimidazol-5-yl]-6-methyl-l,6- dihydro-7H-pyrazolo[3,4-c]pyridin- -one
Figure imgf000102_0001
This compound was synthesized according to the procedure of Example 18 using triethyl orthoacetate instead of ethyl orthoformate. ¾ NMR (400 MHz, DMSO-ώ) δ 7.70 (s, 1H), 7.51 (d, J= 8.3 Hz, 1H), 7.34 (d, J= 8.3 Hz, 1H), 7.29 - 7.14 (m, 2H), 6.79 - 6.67 (m, 1H), 6.55 - 6.44 (m, 1H), 3.77 (s, 3H), 3.51 (s, 3H), 2.48 (s, 3H); LCMS calculated for C22H18F2N5O2 (M+H)+: m/z = 422.1; found: 422.1.
Example 20. 4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-l,2,3-benzotriazol-5-yl]-6-methyl- l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one
Figure imgf000103_0001
This compound was synthesized according to the procedure of Example 10, Step 7, using 4-[3-amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material. ¾ NMR (400 MHz, DMSO-ώ) δ 7.80 (d, J= 8.6 Hz, 1H), 7.75 (br s, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.39 (br s, 1H), 7.36 - 7.24 (m, 1H), 6.99 - 6.77 (m, 2H), 4.33 (s, 3H), 3.56 (s, 3H); LCMS calculated for C20H15F2N6O2 (M+H)+: m/z = 409.1; found: 409.1.
Example 21. 4-[4-(2,4-Difluorophenoxy)-l-methyl-2-oxo-2,3-dihydro-lH-benzimidazol-5- yl] -6-methyl- 1 ,6-dihydro-7H-pyrazolo 3,4-c] pyridin-7-one
Figure imgf000103_0002
This compound was synthesized according to the procedure of Example 16, Step 3, using 4-[3-amino-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material. ¾ NMR (400 MHz, DMSO-d6) δ 11.31 (br s, 1H), 7.69 (s, 1H), 7.26 - 7.07 (m, 4H), 6.76 - 6.63 (m, 1H), 6.53 - 6.38 (m, 1H), 3.47 (s, 3H), 3.35 (s, 3H); LCMS calculated for C21H16F2N5O3 (M+H)+: m/z = 424.1; found: 424.1.
The examples in Table 1 were synthesized according to procedure of Examples 1 or 11 using the appropriate phenols or alcohols Table 1
Figure imgf000104_0001
Figure imgf000104_0002
Table la. XH NMR data for examples 22-26
Figure imgf000104_0003
Ex. No. XH NMR
(400 MHz, DMSO-ώ) δ 11.95 (br s, 1H), 10.96 (br s, 2H), 7.23 (d, J= 2.7
25 Hz, 1H), 7.18 - 7.05 (m, 3H), 6.95 (d, J= 8.0 Hz, 1H), 6.72 - 6.64 (m, 1H),
6.46 - 6.37 (m, 2H), 6.17 (d, J= 2.7 Hz, 1H), 3.42 (s, 3H)
(400 MHz, DMSO-ώ) δ 11.99 (br s, 1H), 10.73 (br s, 2H), 7.25 (dd, J= 2.6, 2.6 Hz, 1H), 7.21 (s, 1H), 6.94 (d, J= 8.0 Hz, 1H), 6.76 (d, J= 8.0 Hz, 1H),
26 6.18 - 6.09 (m, 1H), 3.66 - 3.57 (m, 1H), 3.55 (s, 3H), 3.49 - 3.39 (m, 1H),
3.20 - 3.07 (m, 2H), 1.67 - 1.59 (m, 1H), 1.56 - 1.46 (m, 1H), 1.45 - 1.36 (m, 1H), 1.20 - 1.04 (m, 1H), 0.91 - 0.79 (m, 1H)
Example 27. 4-(Benzyloxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c] pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000105_0001
Step 1. 3-(Benzyloxy)-4-bromo-2-nitroaniline
Figure imgf000105_0002
This compound was synthesized according to the procedure of Example 11, Step 1, using benzyl alcohol instead of cyclopropyl carbinol. LCMS calculated for Ci3Hi2BrN2C)3 (M+H)+: m/z = 323.0, 325.0; found: 323.0, 325.0.
Step 2. 4-[4-Amino-2-(benzyloxy)-3-nitrophenyl]-6-methyl-l-[ (4-methylphenyl)sulfonylJ -1 ,6- dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000106_0001
This compound was synthesized according to the procedure of Example 10, Step 5, using 3-(benzyloxy)-4-bromo-2-nitroaniline and 6-methyl-l-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C28H25N4O6S (M+H)+: m/z = 545.1; found: 545.2.
Step 3. N-(3-(Benzyloxy)-4-{6-methyl-l-f(4-methylphenyl)sulfonylJ-7-oxo-6, 7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl}-2-nitro henyl)-2,2,2-trifluoroacetamide
Figure imgf000106_0002
This compound was synthesized according to the procedure of Example 4, Step 1, using 4-[4-amino-2-(benzyloxy)-3-nitrophenyl]-6-methyl- 1 -[(4-methylphenyl)sulfonyl]- 1 ,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for C30H24F3N4O7S (M+H)+: m/z = 641.1; found: 641.2.
Step 4. 4- [2-(Benzyloxy)-4-(methylamino)-3-nitrophenyl] -6-methyl- 1- [(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000107_0001
This compound was synthesized according to the procedure of Example 4, Step 2, using N-(3-(benzyloxy)-4-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl}-2-nitrophenyl)-2,2,2-trifluoroacetamide as the starting material. LCMS calculated for C29H27N4O6S (M+H)+: m/z = 559.2; found: 559.1.
Step 5. 4-[3-Amino-2-(benzyloxy)-4-(methylamino)phenyl]-6-methyl-l-[ (4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000107_0002
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-[2-(benzyloxy)-4-(methylamino)-3-nitrophenyl]-6-methyl- 1 -[(4-methylphenyl)sulfonyl]- 1 ,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for
C29H29N4O4S (M+H)+: m/z = 529.2; found: 529.2.
Step 6. 4-(Benzyloxy)-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- l,3-dihydro-2H-benzimidazol-2-one This compound was synthesized according to the procedure of Example 1, Step 4, using 4-[3-amino-2-(benzyloxy)-4-(methylamino)phenyl]-6-methyl- 1 -[(4-methylphenyl)sulfonyl]- 1 ,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for
C23H21N4O3 (M+H)+: m/z = 401.2; found: 401.1.
The examples in Table 2 were synthesized according to procedure of examples 6, 27, or 88 using the appropriate phenols or alcohols.
Table 2
Figure imgf000108_0001
Figure imgf000108_0002
Figure imgf000109_0001
Table 2a. XH NMR data for examples 28, 29 ,37-41, 74 ,89-93
Figure imgf000109_0002
Figure imgf000110_0001
Examples 30 and 31. 4-[7-(2,4-Difluorophenoxy)-l-(2-morpholin-4-yl-2-oxoethyl)-lH- benzimidazol-6-yl]-6-methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one and
4-[4-(2,4-difluorophenoxy)-l-(2-morpholin-4-yl-2-oxoethyl)-lH-benzimidazol-5-yl]-6- methyl- 1 ,6-dihydr o-7H-pyrrolo [2,3-c] py ridin-7-one
Figure imgf000111_0001
Step 1. 4-Bromo-6-methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin
Figure imgf000111_0002
A solution of 4-bromo-6-methyl-l-[(4-methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2, 3-c]pyridin-7-one (5.81 g, 15.2 mmol) in ethanol (100 mL) was treated with 3.0 M sodium hydroxide in water (50.8 mL, 152 mmol) and stirred at 20 °C for 16 h. The reaction mixture was concentrated in vacuo to remove most of the ethanol. The remaining aqueous layer was neutralized with concentrated HC1 to pH ~ 7 and extracted with ethyl acetate (2x). The combined organic layers were dried with magnesium sulfate, filtered, and concentrated to give the desired product (3.74 g, quantitative) which was used without further purification. LCMS calculated for CsHsBr^O (M+H)+: m/z = 227.0, 229.0; found: 227.0, 228.9.
Step 2. 4-Bromo-6-methyl-l-{[2-(trimethylsilyl)ethoxyJmethyl}-l,6-dihydro-7H-pyrrolo[2,3- cjpyridin- 7 -one
Figure imgf000111_0003
A solution of 4-bromo-6-methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (0.967 g, 4.26 mmol) in N,N-dimethylformamide (30.6 mL) at 0 °C was treated with sodium hydride (0.255 g, 6.38 mmol) and stirred at 0 °C for 30 min. After this time the reaction mixture was treated with [P-(trimethylsilyl)ethoxy]methyl chloride (1.13 mL, 6.39 mmol) and subsequently stirred at 20 °C for 1 h. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with water (3x), dried with magnesium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (100% hexanes to 30%> EtOAc/hexanes) gave the desired product (1.03 g, 68%>) as a white solid. LCMS calculated for Ci4H22BrN202Si (M+H)+: m/z = 357.1, 359.1; found: 357.0, 359.0.
Step 3. 6-Methyl-4-(4, 4, 5, 5-tetramethyl-l, 3,2-dioxaborolan-2-yl)-l-{[ 2- (trimethylsilyl)ethoxy] methyl}- l,6-dihyd -7H-pyrrolo [2, 3-c]pyridin-7-one
Figure imgf000112_0001
This compound was synthesized according to the procedure of Example 10, Step 4, using 4-bromo-6-methyl- 1 - {[2-(trimethylsilyl)ethoxy]methyl} - 1 ,6-dihydro-7H-pyrrolo[2,3-c]pyridin- 7-one as the starting material. LCMS calculated for C2oH34BN204Si (M+H)+: m/z = 405.2; found: 405.2. Step 4. 4-[4-Amino-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy) 'methyl}- 1 ,6-dih dro-7H-pyrrolo [2, 3-c]pyridin-7 -one
Figure imgf000112_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using 4-bromo-3-(2,4-difluorophenoxy)-2-nitroaniline and 6-methyl-4-(4,4,5,5-tetramethyl-l ,3,2- dioxaborolan-2-yl)-l-{[2-(trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin- 7-one as the starting materials. LCMS calculated for C26H29F2N4O5S1 (M+H)+: m/z = 543.2; found: 543.2.
Step 5. 4-[ 3, 4-Diamino-2-(2, 4-dtfluorophenoxy)phenyl]-6-methyl-l-{[ 2- (trimethylsilyl)ethoxyJmethyl}-l,6-dih dro-7H-pyrrolo[2,3-cJpyridin-7-one
Figure imgf000113_0001
This compound was synthesized according to the procedure of Example 1, Step 3, using
4-[4-amino-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for C26H3iF2N403Si (M+H)+: m/z = 513.2; found: 513.2. Step 6. 4-[4-(2,4-Difluorophenoxy)-lH-benzimidazol-5-yl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy) 'methyl}- 1 ,6-dihydro-7H-pyrrolo [2, 3-c]pyridin-7-one
Figure imgf000113_0002
A solution of 4-[3,4-diamino-2-(2,4-difluorophenoxy)phenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (460 mg, 0.897 mmol) in tetrahydrofuran (7.76 mL) was treated with ethyl orthoformate (448 μί, 2.69 mmol) followed by addition of /?-toluenesulfonic acid monohydrate (17.1 mg, 0.0897 mmol). The resultant reaction mixture was stirred at 50 °C for 1 h, after which time the reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude product. Purification by gradient flash column chromatography (50% EtOAc/hexanes to 100% EtOAc) gave the desired product (0.378 g, 81%). LCMS calculated for C27H29F2N403Si (M+H)+: m/z = 523.2; found: 523.2.
Step 7. Ethyl [4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-l-{[2-(trimethylsilyl)ethoxy]methyl}- 6, 7-dihydro-lH-pyrrolo[2 ,3-c] pyridin-4-yl)- lH-benzimidazol- 1-yl] 'acetate and ethyl [7-(2,4- difluorophenoxy)-6-(6-methyl-7-oxo-l-{[2-(trimethylsilyl)ethoxy]methyl}-6, 7-dihydro-lH- pyrrolo[2, 3-c]pyridin-4- l)-lH-benzimidazol-l-yl] acetate
Figure imgf000114_0001
A solution of 4-[4-(2,4-difluorophenoxy)-lH-benzimidazol-5-yl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (150 mg, 0.287 mmol) in N,N-dimethylformamide (2.84 mL) was treated with cesium carbonate (280 mg, 0.861 mmol) and ethyl bromoacetate (63.6
Figure imgf000114_0002
0.574 mmol) and the resultant reaction mixture was stirred at 60 °C overnight, after which time the reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated to give the crude product as a mixture of isomers (~3 : 1) which was used without further purification. LCMS calculated for C3iH35F2N40sSi (M+H)+: m/z = 609.2; found: 609.1.
Step 8. [4-(2,4-Difluorophenoxy)-5-(6-methyl-7-oxo-l-{[2-(trimethylsilyl)ethoxy]methyl}-6, 7- dihydro-lH-pyrrolo[2,3-cJpyridin-4-yl)-lH-benzimidazol-l-ylJacetic acid and [7-(2,4- difluorophenoxy)-6-(6-methyl-7-oxo-l-{[2-(trimethylsilyl)ethoxy]methyl}-6, 7-dihydro-lH- pyrrolo[2, 3-c]pyridin-4-yl)-lH-benzimidazol-l-yl] acetic acid
Figure imgf000115_0001
A solution of ethyl [4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-l-{[2- (trimethylsilyl)ethoxy]methyl} -6,7-dihydro- 1 H-pyrrolo[2,3-c]pyridin-4-yl)- 1 H-benzimidazol- 1 - yljacetate and ethyl [7-(2,4-difluorophenoxy)-6-(6-methyl-7-oxo-l-{[2- (trimethylsilyl)ethoxy]methyl} -6,7-dihydro- 1 H-pyrrolo[2,3-c]pyridin-4-yl)- 1 H-benzimidazol- 1 - yljacetate (169.0 mg, 0.2776 mmol, mixture of isomers) in methanol (1.42 mL) and
tetrahydrofuran (2.84 mL) was treated with 4.0 M lithium hydroxide in water (350 μί, 1.40 mmol) and stirred at RT for 2 h. The reaction mixture was quenched with acetic acid to pH~6, filtered, and purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (105 mg, 65%) as a mixture of isomers. LCMS calculated for C29H31F2N4O5S1 (M+H)+: m/z = 581.2; found: 581.2.
Step 9. 4-f7-(2,4-Difluorophenoxy)-l-(2-morpholin-4-yl-2-oxoethyl)-lH-benzimidazol-6-ylJ-6- methyl-1 ,6-dihydro-7H-pyrrolo[2 ',3-cJpyridin-'/ 7-one and 4-[4-(2,4-difluorophenoxy)-l-(2- morpholin-4-yl-2-oxoethyl)-lH-benzimidazol-5-yl]-6-methyl-l, 6-dihydro- 7H-pyrrolo[ 2, 3- cjpyridin- 7-one
A solution of [4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-l-{[2- (trimethylsilyl)ethoxy]methyl} -6,7-dihydro- 1 H-pyrrolo[2,3-c]pyridin-4-yl)- 1 H-benzimidazol- 1 - yljacetic acid (30.0 mg, 0.0517 mmol, mixture of isomers) in N,N-dimethylformamide (1.01 mL) was treated with morpholine (11.3 μί, 0.129 mmol) followed by N,N-diisopropylethylamine (45.0 μί, 0.258 mmol). The reaction mixture was stirred for several minutes and treated with benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophosphate (34.3 mg, 0.0775 mmol) and the reasultant mixture was stirred at RT for 1 h, after which time the reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated to give the crude intermediate amide as a mixture of isomers which was used without further purification. The crude mixture of intermediate amides was diluted with methylene chloride (2.00 mL) and trifluoroacetic acid (1.00 mL) and stirred at RT for 2 h, after which time the reaction mixture was concentrated in vacuo and the resultant residue was reconcentrated from toluene. This crude residue was diluted with methanol (2.00 mL), treated with ethylenediamine (27.6 μί, 0.413 mmol), and stirred at RT overnight. The reaction mixture was concentrated in vacuo and purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of
acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product 4-[7-(2,4-Difluorophenoxy)-l-(2-morpholin-4-yl-2-oxoethyl)-lH-benzimidazol-6-yl]-6- methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (Example 30) as peak 1 (5 mg, 19%>) and the desired product 4-[4-(2,4-difluorophenoxy)-l-(2-morpholin-4-yl-2-oxoethyl)-lH- benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (Example 31) as peak 2 (12 mg, 45%). Example 30: ¾ NMR (500 MHz, DMSO-ώ) δ 11.84 (br s, 1H), 8.15 (s, 1H), 7.65 (d, J= 8.3 Hz, 1H), 7.28 (d, J= 8.3 Hz, 1H), 7.24 - 7.11 (m, 2H), 7.08 (s, 1H), 6.59 - 6.48 (m, 1H), 6.40 - 6.27 (m, 1H), 6.09 (d, J= 2.8 Hz, 1H), 5.26 (s, 2H), 3.49 - 3.39 (m, 5H), 3.39 - 3.32 (m, 2H), 3.26 - 3.19 (m, 2H), 3.06 - 2.98 (m, 2H); LCMS calculated for C27H24F2N5O4 (M+H)+: m/z = 520.2; found: 520.3. Example 31 : lU NMR (500 MHz, DMSO-ώ) δ 11.97 (s, 1H), 8.05 (s, 1H), 7.48 (d, J= 8.4 Hz, 1H), 7.35 (d, J= 8.3 Hz, 1H), 7.29 - 7.15 (m, 3H), 6.81 - 6.71 (m, 1H), 6.69 - 6.58 (m, 1H), 6.14 (d, J= 2.8 Hz, 1H), 5.34 (s, 2H), 3.76 - 3.67 (m, 2H), 3.66 - 3.55 (m, 4H), 3.54 - 3.42 (m, 5H); LCMS calculated for C27H24F2N5O4 (M+H)+: m/z = 520.2; found: 520.3
Example 32. 4-Methoxy-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo [2,3- c] pyridin-4-yl)- 1 ,3-dihydr o-2H-benzimidazol-2-one
Figure imgf000117_0001
Step 1. N-( 4-Bromo-3-fluoro-2-nitrophen l)-2, 2, 2-trifluoroacetamide
Figure imgf000117_0002
A solution of 4-bromo-3-fluoro-2-nitroaniline (0.955 g, 4.06 mmol) and triethylamine (1.13 mL, 8.13 mmol) in methylene chloride (21.0 mL) was cooled to 0 °C, followed by dropwise addition of trifluoroacetic anhydride (1.15 mL, 8.13 mmol). The reaction mixture was stirred at 0 °C for 30 min, then warmed to 20 °C and stirred at that temperature for 1 h. The reaction mixture was diluted with brine. Layers were separated and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give a crude oil. Purification by flash column chromatography (100% hexanes to 30% EtOAc/hexanes) gave the desired product (1.27 g, 94%) as a yellow solid.
Step 2. 4-Bromo-3-methoxy-N-methyl-2-nitroaniline
Figure imgf000117_0003
A solution of N-(4-bromo-3-fluoro-2-nitrophenyl)-2,2,2-trifluoroacetamide (1.27 g, 3.84 mmol) in N,N-dimethylformamide (43.4 mL) was treated with cesium carbonate (2.50 g, 7.67 mmol) followed by the addition of methyl iodide (1.19 mL, 19.2 mmol). The reaction mixture was stirred at 20 °C for 1 h, then warmed to 50 °C and stirred at that temperature for 16 h, after which time additional methyl iodide (0.5 eq) was added to the reaction mixture and the reaction mixture was heated at 50 °C for 4 h. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with water (3x) and brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude methylated amide which was used without further purification. The crude intermediate methylated amide was dissolved in methanol (43.4 mL) and water (8.68 mL, 482 mmol), treated with potassium carbonate (2.65 g, 19.2 mmol), and the resultant mixture was stirred at 60 °C for 15 h, after which time the reaction mixture was concentrated to remove most of the methanol and the aqueous residue was extracted with ethyl acetate (2x). The combined organic layers
were washed with brine, dried with magnesium sulfate, filtered, and concentrated to give the desired product (906 mg, 90%) as a yellow solid. LCMS calculated for
Figure imgf000118_0001
(M+H)+: m/z = 261.0, 263.0; found: 260.9, 262.8.
Step 3. 4-[2-Methoxy-4-(methylamino)-3-nitrophenyl]-6-methyl-l-[ (4-methylphenyl)sulfonyl) '- 1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000118_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using 4-bromo-3-methoxy-N-methyl-2-nitroaniline and 6-methyl-l-[(4-methylphenyl)sulfonyl]- 4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)-l ,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C23H23N4O6S (M+H)+: m/z = 483.1 ; found: 483.1.
Step 4. 4-[3-Amino-2-methoxy-4-(methylamino)phenyl]-6-methyl-l-[(4-m
1, 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000119_0001
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-[2-methoxy-4-(methylamino)-3-nitrophenyl]-6-methyl-l-[(4-methylphenyl)sulfonyl]-l,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for
C23H25N4O4S (M+H)+: m/z = 453.2; found: 453.1.
Step 5. 4-Methoxy-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro- lH-pyrrolo [2 ,3-c] pyridin-4-yl)- 1 ,3- dihydro-2H-benzimidazol-2-one
Figure imgf000119_0002
This compound was synthesized according to the procedure of Example 1, Step 4, using
4-[3-amino-2-methoxy-4-(methylamino)phenyl]-6-methyl- 1 -[(4-methylphenyl)sulfonyl]- 1 ,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. JH NMR (300 MHz, DMSO- d6) h 12.01 (br s, 1H), 11.11 (br s, 1H), 7.29 - 7.21 (m, 1H), 7.17 (s, 1H), 6.99 (d, J= 8.0 Hz, 1H), 6.91 (d, J= 8.0 Hz, 1H), 6.08 (s, 1H), 3.55 (s, 3H), 3.52 (s, 3H), 3.29 (s, 3H); LCMS calculated for C17H17N4O3 (M+H)+: m/z = 325.1; found: 325.2.
Examples 33 and 34. 2-[7-(2,4-Difluorophenoxy)-6-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl)-lH-benzimidazol-l-yl]-N,N-dimethylacetamide and 2-[4-(2,4- difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-lH- benzimidazol-l-yl]-N,N-dimethylacetamide
Figure imgf000120_0001
These compounds were synthesized according to the procedure of Examples 30 and 31 , Step 9, using dimethylamine instead of morpholine. 2-[7-(2,4-Difluorophenoxy)-6-(6-methyl-7- oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-lH-benzimidazol-l-yl]-N,N-dimethylacetamide (Example 33): ¾ NMR (300 MHz, DMSO-ώ) δ 1 1.90 (br s, 1H), 8.15 (s, 1H), 7.66 (d, J= 8.3 Hz, 1H), 7.29 (d, J= 8.3 Hz, 1H), 7.24 - 7.04 (m, 3H), 6.67 - 6.48 (m, 1H), 6.37 - 6.24 (m, 1H), 6.13 (d, J= 2.7 Hz, 1H), 5.21 (s, 2H), 3.43 (s, 3H), 2.85 (s, 3H), 2.39 (s, 3H); LCMS calculated for C25H22F2N5O3 (M+H)+: m/z = 478.2; found: 478.3. 2-[4-(2,4-difluorophenoxy)-5-(6-methyl- 7-0X0-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-lH-benzimidazol-l-yl]-N,N- dimethylacetamide (Example 34): ¾ NMR (300 MHz, DMSO-d6) δ 1 1.99 (br s, 1H), 8.04 (s, 1H), 7.47 (d, J= 8.4 Hz, 1H), 7.33 (d, J= 8.3 Hz, 1H), 7.30 - 7.12 (m, 3H), 6.84 - 6.71 (m, 1H), 6.69 - 6.55 (m, 1H), 6.14 (d, J= 2.7 Hz, 1H), 5.30 (s, 2H), 3.49 (s, 3H), 3.12 (s, 3H), 2.88 (s, 3H); LCMS calculated for C25H22F2N5O3 (M+H)+: m/z = 478.2; found: 478.2. Examples 35 and 36. 2-[7-(2,4-Difluorophenoxy)-6-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl)-lH-benzimidazol-l-yl]- V-methylacetamide and
2-[4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- lH-benzimidazol-l-yl]- -methylacetamide
Figure imgf000120_0002
These compounds were synthesized according to the procedure of Examples 30 and 31, Step 9, using methylamine instead of morpholine. 2-[7-(2,4-Difluorophenoxy)-6-(6-methyl-7- oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-lH-benzimidazol-l-yl]-N-methylacetamide (Example 35): ¾ NMR (300 MHz, DMSO-ώ) δ 11.91 (s, 1H), 8.55 (s, 1H), 8.06 - 7.91 (m, 1H), 7.70 (d, J= 8.4 Hz, 1H), 7.37 (d, J= 8.3 Hz, 1H), 7.22 - 7.16 (m, 1H), 7.16 - 7.02 (m, 2H), 6.62 - 6.48 (m, 1H), 6.40 - 6.26 (m, 1H), 6.06 (s, 1H), 5.00 (s, 2H), 3.43 (s, 3H), 2.23 (d, J= 4.4 Hz, 3H); LCMS calculated for C24H20F2N5O3 (M+H)+: m/z = 464.2; found: 464.2. 2-[4-(2,4- difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-lH- benzimidazol-l-yl]-N-methylacetamide (Example 36): ¾ NMR (300 MHz, DMSO-ώ) δ 12.00 (br s, 1H), 8.36 - 8.20 (m, 1H), 8.12 (s, 1H), 7.43 (d, J= 8.4 Hz, 1H), 7.35 (d, J= 8.3 Hz, 1H), 7.29 - 7.13 (m, 3H), 6.84 - 6.70 (m, 1H), 6.70 - 6.55 (m, 1H), 6.13 (d, J= 2.7 Hz, 1H), 4.95 (s, 2H), 3.49 (s, 3H), 2.65 (d, J= 4.5 Hz, 3H); LCMS calculated for C24H20F2N5O3 (M+H)+: m/z = 464.2; found: 464.2. Examples 42 and 43. 6-Methyl-4-[l-(2-morpholin-4-ylethyl)-7-phenoxy-lH-benzimidazol- 6-yl] - 1 ,6-dihydr o-7H-pyrrolo [2,3-c] py ridin-7-one and 6-methyl-4- [ l-(2-morpholin-4- ylethyl)-4-phenoxy-lH-benzimidazol-5- l]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Figure imgf000121_0001
A solution of 6-methyl-4-(4-phenoxy-lH-benzimidazol-5-yl)-l-{[2-
(trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (50.0 mg, 0.103 mmol) in N,N-dimethylformamide (1.02 mL) was treated with cesium carbonate (167 mg, 0.514 mmol) followed by the addition of 4-(2-bromoethyl)morpholine hydrochloride (59.2 mg, 0.257 mmol). The resultant reaction mixture was warmed to 60 °C and stirred at that temrerature for for 1 h. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated to give the crude intermediate amides as a mixture of isomers which was used without further purification. The crude mixture of intermediate amides was diluted with methylene chloride (1.0 mL) and trifluoroacetic acid (0.5 mL) and stirred at RT for 30 min. The reaction mixture was concentrated in vacuo and the resultant residue was reconcentrated from toluene. This crude residue was diluted with methanol (1.0 mL), treated with ethylenediamine (0.25 mL), and stirred at RT for 2 h. The reaction mixture was concentrated and purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired compound 6-Methyl-4-[l- (2-morpholin-4-ylethyl)-7-phenoxy-lH-benzimidazol-6-yl]-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one (Example 42) as peak 1 (6 mg, 12%) and the desired compound 6-methyl-4-[l- (2-morpholin-4-ylethyl)-4-phenoxy-lH-benzimidazol-5-yl]-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one (Example 43) as peak 2 (18 mg, 37%). Example 42: ¾ NMR (300 MHz, DMSC ¾) 5 11.98 (br s, 1H), 8.17 (s, 1H), 7.61 (d, J= 8.4 Hz, 1H), 7.37 (d, J= 8.4 Hz, 1H), 7.24 (d, J= 2.8 Hz, 1H), 7.21 - 7.03 (m, 2H), 6.84 (dd, J= 7.3, 7.3 Hz, 1H), 6.72 - 6.56 (m, 2H), 6.17 (d, J= 2.8 Hz, 1H), 4.39 (dd, J= 6.2, 6.2 Hz, 2H), 3.62 - 3.50 (m, 4H), 3.33 (s, 3H), 2.72 (dd, J= 6.2, 6.2 Hz, 2H), 2.47 - 2.41 (m, 4H); LCMS calculated for C27H28N5O3 (M+H)+: m/z = 470.2; found: 470.2. Example 43: lU NMR (300 MHz, DMSO-ώ) δ 11.93 (br s, 1H), 8.21 (s, 1H), 7.65 (d, J= 8.3 Hz, 1H), 7.32 (d, J= 8.3 Hz, 1H), 7.25 (dd, J= 2.7, 2.7 Hz, 1H), 7.15 (s, 1H), 7.13 - 7.04 (m, 2H), 6.83 (dd, J= 7.3, 7.3 Hz, 1H), 6.55 (d, J= 7.8 Hz, 2H), 6.32 - 6.14 (m, 1H), 4.21 (dd, J= 6.2, 6.2 Hz, 2H), 3.50 - 3.43 (m, 4H), 3.33 (s, 3H), 2.53 (d, J= 6.2 Hz, 2H), 2.30 - 2.19 (m, 4H); LCMS calculated for C27H28N5O3 (M+H)+: m/z = 470.2; found: 470.2.
Example 44. 3-Benzyl-4-methoxy-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo [2,3- c] pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000122_0001
Step 1. 5-Bromo-4-methoxy-l -methyl- l,3-dihydro-2H-benzimidazol-2-one
Figure imgf000123_0001
A 1.0 M solution of hydrogen chloride in water (2.3 mL, 2.3 mmol) was added to a suspension of iron (1.28 g, 23.0 mmol) (<10 μιη) in ethanol (25.1 mL) and the resultant suspension was stirred at 60 °C for 2 h. The reaction mixture was then cooled to 55-60 °C and treated with a 5.0 M solution of ammonium chloride in water (3950
Figure imgf000123_0002
19.8 mmol), followed by the addition of 4-bromo-3-methoxy-N-methyl-2-nitroaniline (1.20 g, 4.60 mmol) as a solid. The flask containing 4-bromo-3-methoxy-N-methyl-2-nitroaniline was rinsed with ethanol (3.75 mL) and the solution was added to the reaction mixture. The resultant reaction mixture was stirred at 60-65 °C for 2 h, after which time the reaction mixture was diluted with ethyl acetate (100 mL), treated with anhydrous magnesium sulfate, stirred for 10 min and then filtered through a pad of Celite. The filtrate was concentrated to dryness in vacuo and the resulting solid was used immediately without further purification. The crude bis-aniline was dissolved in tetrahydrofuran (32.0 mL), treated with N,N-carbonyldiimidazole (1.86 g, 11.5 mmol) and stirred at RT overnight. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude product. Purification by flash column chromatography (100% hexanes to 30% EtOAc/hexanes to 100% EtOAc) gave the desired product (1.05 g, 89%) as a solid. LCMS calculated for C9HioBrN202 (M+H)+: m/z = 257.0, 259.0; found: 257.1, 259.1.
Step 2. 3-Benzyl-5-bromo-4-methoxy-l -methyl- 1, 3-dihydro-2H-benzimidazol-2-one
Figure imgf000123_0003
A solution of 5-bromo-4-methoxy-l-methyl-l,3-dihydro-2H-benzimidazol-2-one (60.0 mg, 0.233 mmol) in N,N-dimethylformamide (2.31 mL) was treated with cesium carbonate (380 mg, 1.17 mmol) and benzyl bromide (99.8 mg, 0.583 mmol) and stirred at 60 °C for 30 min. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude product. Purification by flash column chromatography (15% EtOAc/hexanes to 40% EtOAc/hexanes) gave the desired product (73 mg, 90%). LCMS calculated for
Ci6Hi6BrN202 (M+H)+: m/z = 347.1, 349.1; found: 347.0, 349.0.
Step 3. 3-Benzyl-4-methoxy-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin- 4-yl)-l,3-dihydro-2H-benzimidazol-2-
Figure imgf000124_0001
A solution of 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2: 1) (2.20 mg, 0.00311 mmol), cesium fluoride (110 mg, 0.726 mmol), 3-benzyl-5-bromo-4- methoxy-1 -methyl- 1, 3 -dihydro-2H-benzimidazol-2-one (72.0 mg, 0.207 mmol), 6-methyl-l-[(4- methylphenyl)sulfonyl]-4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one (88.8 mg, 0.207 mmol) in 1-butanol (0.944 mL) and water (0.22 mL) was degassed with nitrogen for 5 minutes and the resultant reaction mixture was stirred at 100 °C for 1 h. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated to give the crude intermediate urea which was used without further purification. The intermediate urea was dissolved in methanol (1.0 mL), treated with 3.0 M sodium hydroxide in water (0.5 mL, 1.5 mmol), and heated at 60 °C for 3 h. The reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water containing 0.1%) trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (40 mg, 47%). 'H NMR (300 MHz, DMSO-ώ) δ 12.02 (br s, 1H), 7.38 - 7.28 (m, 2H), 7.28 - 7.15 (m, 5H),
7.04 (s, 2H), 6.07 - 5.97 (m, 1H), 5.20 (s, 2H), 3.53 (s, 3H), 3.39 (s, 3H), 3.04 (s, 3H); LCMS calculated for C24H23N403 (M+H)+: m/z = 415.2; found: 415.1. The examples in Table 3 were synthesized according to procedure of Examples 42 and 43 using the appropriate electrophiles.
Table 3
Figure imgf000125_0001
Figure imgf000125_0002
Table 3a. XH NMR data for examples 45-48, 51, 52, 55, 113
Figure imgf000126_0001
The examples in Table 4 were synthesized according to procedure of Example 44 using the appropriate electrophiles.
Table 4
Figure imgf000126_0002
Figure imgf000127_0001
- y ro- H- enzm azo- -y propanentr e
Table 4a. NMR data for examples 49, 50, 53, 54
Figure imgf000127_0002
The examples in Table 5 were synthesized according to procedure of example 4 using the appropriate phenols.
Figure imgf000128_0001
rroo , -c r n- -one
Figure imgf000128_0002
Figure imgf000129_0001
Example 60. 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo [2,3-c] pyridin-4-yl)-3-(2-mor holin-4-ylethyl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000129_0002
Step 1. 4-Bromo-3-fluoro-N-methyl-2-nitroaniline
Figure imgf000129_0003
A solution of N-(4-bromo-3-fluoro-2-nitrophenyl)-2,2,2-trifluoroacetamide (3.42 g, 10.3 mmol) and triphenylphosphine (3.79 g, 14.4 mmol) in tetrahydrofuran (31.0 mL) at 0 °C was treated with methanol (1.67 mL, 41.3 mmol) followed by dropwise addition of diisopropyl azodicarboxylate (2.84 mL, 14.4 mmol), and the resultant reaction mixture was stirred at RT for 2 h. The reaction mixture was quenched with water (10 mL), concentrated in vacuo to remove most of the THF. Water (200 mL) was added and the resultant mixture was
extracted with ethyl acetate (200 mL). Layers were separated and the organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated to give the crude product.
Purification by flash column chromatography (100% hexanes to 80% dichloromethane/hexanes) gave the desired product (2.46 g, 96%>) as an orange solid. LCMS calculated for C7H7BrFN202 (M+H)+: m/z = 249.0, 251.0; found: 248.9, 250.9. Step 2. 4-Bromo-3-(cyclobutylmethoxy)-N-methyl-2-nitroaniline
Figure imgf000130_0001
This compound was synthesized according to the procedure of Example 1 1 , Step 1 , using 4-bromo-3-fluoro-N-methyl-2-nitroaniline and cyclobutylmethanol as the starting materials. LCMS calculated for Ci2Hi6BrN203 (M+H)+: m/z = 315.0, 317.0; found: 315.0, 317.0.
Step 3. 4-Bromo-3-(cyclobutylmethoxy)-N1 -methylbenzene-1 ,2-diamine
Figure imgf000130_0002
This compound was synthesized according to the procedure of Example 1 , Step 3, using 4-bromo-3-(cyclobutylmethoxy)-N-methyl-2-nitroaniline as the starting material. LCMS calculated for Ci2HisBrN20 (M+H)+: m/z = 285.1 , 287.1 ; found: 285.1 , 287.1.
Step 4. 5-Bromo-4-(cyclobutylmethoxy)-l-meth l-l,3-dihydro-2H-benzimidazol-2-one
Figure imgf000130_0003
This compound was synthesized according to the procedure of Example 6, Step 1 , using 4-bromo-3-(cyclobutylmethoxy)-N1-methylbenzene-l ,2-diamine as the starting material. LCMS calculated for Ci3HieBrN202 (M+H)+: m/z = 31 1.0, 313.0; found: 31 1.0, 313.0.
Step 5. 5-Bromo-4-(cyclobutylmethoxy)-l-methyl-3-(2-morpholin-4-ylethyl)-l,3-dihydro-2H- benzimidazol-2-one
Figure imgf000131_0001
This compound was synthesized according to the procedure of Example 44, Step 2, using 5-bromo-4-(cyclobutylmethoxy)- 1 -methyl- 1 ,3-dihydro-2H-benzimidazol-2-one and 4-(2- bromoethyl)morpholine hydrochloride as the starting materials. LCMS calculated for
CwftvBrNsOs (M+H)+: m/z = 424.1, 426.1; found: 424.3, 426.3.
Step 6. 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-3-(2-morpholin-4-ylethyl)-l,3-dihydro-2H-benzimidazo
This compound was synthesized according to the procedure of Example 44, Step 3, using 5-bromo-4-(cyclobutylmethoxy)- 1 -methyl-3-(2-morpholin-4-ylethyl)- 1 ,3-dihydro-2H- benzimidazol-2-one as the starting material. JH NMR (300 MHz, DMSO-ώ) δ 12.01 (br s, 1H), 7.30 - 7.26 (m, 1H), 7.23 (s, 1H), 7.05 (d, J= 8.0 Hz, 1H), 6.99 (d, J= 8.0 Hz, 1H), 6.10 (s, 1H), 4.07 (dd, J= 6.4, 6.4 Hz, 2H), 3.56 (s, 3H), 3.55 - 3.41 (m, 6H), 3.33 (s, 3H), 2.63 (dd, J= 6.5, 6.5 Hz, 2H), 2.46 - 2.32 (m, 5H), 1.84 - 1.60 (m, 3H), 1.60 - 1.44 (m, 1H), 1.44 - 1.16 (m, 2H); LCMS calculated for C27H34N5O4 (M+H)+: m/z = 492.3; found: 492.2. The examples in Table 6 were synthesized according to procedure of Example 60 using the appropriate electrophiles.
Table 6
Figure imgf000131_0002
Figure imgf000132_0001
Table 6a. XH NMR data for examples 61-64
Figure imgf000132_0002
Example 65. 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo [2,3-c] pyridin-4-yl)-3-(2-piperidin-4-ylethyl)- 1 ,3-dihydro-2H-benzimidazol-2-
Figure imgf000133_0001
Step 1. tert-Butyl 4-{2- [6-bromo-7-(cyclobutylmethoxy)-3-methyl-2-oxo-2 ,3-dihydro- 1H- benzimidazol-l -ylj ethyljpiperidine-l -carbox late
Figure imgf000133_0002
This compound was synthesized according to the procedure of Example 44, Step 2, using 5-bromo-4-(cyclobutylmethoxy)-l -methyl- l,3-dihydro-2H-benzimidazol-2-one and tert-butyl 4- (2-bromoethyl)piperidine-l -carboxylate as the starting materials. LCMS calculated for
C2oH29BrN302 ([M-Boc+H]+H)+: m/z = 422.2, 424.2; found: 422.0, 424.0.
Step 2. 4-(Cyclobutylmethoxy)-l-methyl-5-{6-methyl-l-[ (4-methylphenyl) sulfonyl] -7 -oxo-6, 7- dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl}-3-(2-piperidin-4-yletk^
2-one trifluoroacetate
Figure imgf000133_0003
A solution of 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2: 1) (1.46 mg, 0.00206 mmol), cesium fluoride (72.8 mg, 0.480 mmol), tert-butyl 4-{2-[6-bromo-7- (cyclobutylmethoxy)-3 -methyl-2-oxo-2,3 -dihydro- 1 H-benzimidazol- 1 -yl] ethyl} piperidine- 1 - carboxylate (71.6 mg, 0.137 mmol), 6-methyl-l-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (58.7 mg, 0.137 mmol) in 1-butanol (0.624 mL) and water (0.15 mL) was degassed with nitrogen for 5 min and the resultant reaction mixture was stirred at 100 °C for 1 h. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude intermediate which was used without further purification. The crude intermediate was dissolved in a mixture of methylene chloride (2.0 mL) and trifluoroacetic acid (1.0 mL) and the resultant solution was stirred at RT for 3 h, after which time the reaction mixture was purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1%
trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (37 mg, 42%). LCMS calculated for C35H42N5O5S (M+H)+: m/z = 644.3; found: 644.3.
Step 3. 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6, 7 -dihydro- lH-pyrrolo [2,3- c]pyridin-4-yl)-3-(2-piperidin-4-ylethyl)-l, 3-dihydro-2H-benzimidazol-2-one
A 3.0 M solution of sodium hydroxide in water (0.40 L) was added to the solution of 4- (cyclobutylmethoxy)-l-methyl-5-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro- lH-pyrrolo[2,3-c]pyridin-4-yl}-3-(2-piperidin-4-ylethyl)-l,3-dihydro-2H-benzimidazol-2-one (20.0 mg, 0.031 mmol) in methanol (1.0 mL), and the resultant reaction mixture was stirred at 60 °C for 1 h. The reaction mixture was purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (1.1 mg, 7%). LCMS calculated for C28H36N5O3 (M+H)+: m/z = 490.3; found: 490.3.
Example 66. 3-(2-(4-Acetylpiperazin-l-yl)ethyl)-4-(cyclobutylmethoxy)-l-methyl-5-(6- methyl- 7-oxo-6,7-dihydro-lH-pyrrolo [2,3-c] pyridin-4-yl)-lH-benzo [d] imidazol-2(3H)-one
Figure imgf000135_0001
Step 1. 5-Bromo-4-(cyclobutylmethoxy)-l-methyl-3-(2-piperazin-l-ylethyl)-l,3-dihydro benzimidazol-2-one
Figure imgf000135_0002
A solution of 5 -bromo-4-(cyclobutylmethoxy)- 1 -methyl- 1 ,3 -dihydro-2H-benzimidazol-2- one (250 mg, 0.803 mmol) in N,N-dimethylformamide (7.96 mL) was treated with cesium carbonate (1.31 g, 4.02 mmol) followed by the addition of tert-butyl 4-(2-bromoethyl)piperazine- 1-carboxylate (471 mg, 1.61 mmol), and the resultant reaction mixture was stirred at 60 °C overnight, after which time the LCMS analysis of the reaction mixture indicated complete conversion of the starting materials. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude intermediate tert-butyl carboxylate, which was used in further step without purification. The crude intermediate tert- butyl carboxylate was dissolved in the mixture of methylene chloride (4.0 mL) and
trifluoroacetic acid (3.0 mL) and the resultant reaction mixture was stirred at RT for 2 h.
Solvents were removed in vacuo and the resulting residue was diluted with ethyl acetate and saturated sodium bicarbonate solution. Layers were separated and the organic layer was washed with water and brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the desired product (289 mg, 85%) that was used in further step without purification. LCMS calculated for CwftsBr^C (M+H)+: m/z = 423.1, 425.1; found: 423.1, 425.1. Step 2. 3- [2-(4-Acetylpiperazin- l-yl)ethyl] -5-bromo-4-(cyclobutylmethoxy)- 1-methyl- 1 ,3- dihydro-2H-benzimidazol-2-one
Figure imgf000136_0001
A solution of 5-bromo-4-(cyclobutylmethoxy)-l-methyl-3-(2-piperazin-l-ylethyl)-l,3- dihydro-2H-benzimidazol-2-one (40.0 mg, 0.0945 mmol) in methylene chloride (2.0 mL) was treated with N,N-diisopropylethylamine (49.4
Figure imgf000136_0002
0.283 mmol) followed by the addition of acetyl chloride (10.1
Figure imgf000136_0003
0.142 mmol), and the resultant reaction mixture was stirred at RT for 1 h. Purification by flash column chromatography (5% MeOH/EtOAc) gave the desired product (46 mg, 94%). LCMS calculated for C2iH30BrN4O3 (M+H)+: m/z = 465.1, 467.1; found: 465.1, 467.1.
Step 3. 3-(2-(4-Acetylpiperazin-l-yl)ethyl)-4-(cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo- 6 -dihydro-lH-pyrrolo[2,3-c]pyridin-4- l)-lH-benzo[d]imidazol-2(3H)-one
Figure imgf000136_0004
This compound was synthesized according to the procedure of Example 44, Step 3, using 3 - [2-(4-acetylpiperazin- 1 -yl)ethyl] -5 -bromo-4-(cyclobutylmethoxy)- 1 -methyl- 1 ,3 -dihydro-2H- benzimidazol-2-one as the starting material. JH NMR (300 MHz, DMSO-ώ) δ 7.27 (d, J = 2.7 Hz, 1H), 7.24 (s, 1H), 7.06 (d, J = 8.0 Hz, 1H), 6.99 (d, J = 8.1 Hz, 1H), 6.10 (d, J = 2.7 Hz, 1H), 4.08 (dd, J = 6.2, 6.2 Hz, 2H), 3.56 (s, 3H), 3.51 (d, J = 6.6 Hz, 2H), 2.65 (dd, J = 6.4, 6.4 Hz, 2H), 2.46 - 2.40 (m, 2H), 2.40 - 2.30 (m, 2H), 1.96 (s, 3H), 1.82 - 1.63 (m, 3H), 1.63 - 1.45 (m, 1H), 1.42 - 1.29 (m, 2H); LCMS calculated for C^ftvNeCM (M+H)+: m/z = 533.3; found: 533.3. Example 67. 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl)-3-{2-[4-(methylsulfonyl)piperazin-l-yl]ethyl}-l,3-dihyd] benzimidazol-2-one
Figure imgf000137_0001
This compound was synthesized according to the procedure of Example 66 using methanesulfonyl chloride instead of acetyl chloride. ¾ NMR (300 MHz, DMSO-ώ) δ 12.02 (br s, 1H), 7.28 (d, J= 2.7 Hz, 1H), 7.24 (s, 1H), 7.06 (d, J= 8.0 Hz, 1H), 6.99 (d, J= 8.0 Hz, 1H), 6.11 (d, J= 2.7 Hz, 1H), 4.07 (dd, J= 6.1, 6.1 Hz, 2H), 3.56 (s, 3H), 3.51 (d, J= 6.6 Hz, 2H), 3.17 - 2.95 (m, 4H), 2.70 (dd, J= 6.2, 6.2 Hz, 2H), 2.57 - 2.51 (m, 2H), 2.44 - 2.31 (m, 2H), 1.83 - 1.60 (m, 3H), 1.60 - 1.44 (m, 1H), 1.44 - 1.24 (m, 2H); LCMS calculated for
C28H37N6O5S (M+H)+: m/z = 569.3; found: 569.2.
Example 68. 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl)-3-[2-(4-methylpiperazin-l-yl)ethyl]-l,3-dihydro-2H- benzimidazol-2-one
Figure imgf000137_0002
Step 1. 5-Bromo-4-(cyclobutylmethoxy)-l-methyl-3-[2-(4-methylpiperazin-l-yl)ethyl]-l,3- dihydro-2H-benzimidazol-2-one
Figure imgf000138_0001
A solution of 5-bromo-4-(cyclobutylmethoxy)-l-methyl-3-(2-piperazin-l-ylethyl)-l,3- dihydro-2H-benzimidazol-2-one (40.0 mg, 0.0945 mmol) in tetrahydrofuran (2.0 mL) was treated with a 1.23M solution of formaldehyde in water (384 μΐ^, 0.474 mmol). The resultant reaction mixture was stirred at RT for 30 min, followed by the addition of sodium
cyanoborohydride (17.8 mg, 0.284 mmol). After stirring at RT for 2 h, the reaction mixture was quenched with acetic acid (0.5 mL) and concentrated in vacuo to give the crude product.
Purification via preparative LCMS (XBridge CI 8 column, eluting with a gradient of
acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) gave the desired product (38 mg, 92%). LCMS calculated for C2oH3oBrN402 (M+H)+: m/z = 437.2, 439.2; found: 437.1, 439.1.
Step 2. 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-3-[2-(4-methylpiperazin-l-yl)ethyl]-l,3-dihydro-2H-benzM
This compound was synthesized according to the procedure of Example 44, step 3, using 5 -bromo-4-(cyclobutylmethoxy)- 1 -methyl-3 - [2-(4-methylpiperazin- 1 -yl)ethyl] - 1 ,3 -dihydro-2H- benzimidazol-2-one as the starting material. LCMS calculated for Q8H37N6O3 (M+H)+: m/z = 505.3; found: 505.3.
Example 69. 5-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-l-(2- morpholin-4-ylethyl)-4-phenoxy-l -dihydro-2H-benzimidazol-2-one trifluoroacetate
Figure imgf000138_0002
Step 1. l-Bromo-4-fluoro-3-nitro-2-phenoxybenzene
Figure imgf000139_0001
A solution of l-bromo-2,4-difluoro-3-nitrobenzene (0.128 g, 0.538 mmol) [Combi- Blocks, AN-3334] and cesium carbonate (0.211 g, 0.646 mmol) in dimethyl sulfoxide (0.59 mL) was treated with phenol (0.0609 g, 0.647 mmol) and stirred at 20 °C for 3 h, after which time the reaction mixture was diluted with water and ethyl acetate. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated to give a crude oil. Purification by preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water containing 0.1% trifluoroacetic acid, at flow rate of 60 mL/min) gave the desired product (57 mg, 34%) as a yellow solid.
Step 2. 4-Bromo-N-(2-morpholin- -ylethyl)-2-nitro-3-phenoxyaniline
Figure imgf000139_0002
A solution of l-bromo-4-fluoro-3-nitro-2-phenoxybenzene (0.057 g, 0.18 mmol) and cesium carbonate (0.0715 g, 0.220 mmol) in dimethyl sulfoxide (0.20 mL, 2.8 mmol) was treated with N-(2-aminoethyl)morpholine (0.0289 mL, 0.220 mmol) and stirred at 20 °C for 24 h, after which time the reaction mixture was diluted with water and ethyl acetate. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude product. Purification by flash column chromatography (100% hexanes to 100% EtOAc) gave the desired product (60 mg, 78%) a brown oil. LCMS calculated for CisftiBrNsCM (M+H)+: m/z = 422.1 , 424.1 ; found: 422.1 , 424.1.
Step 3. 4-Bromo-Nl-(2-morpholin-4-ylethyl)-3-phenoxybenzene-l,2-diamine
Figure imgf000140_0001
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-bromo-N-(2-morpholin-4-ylethyl)-2-nitro-3-phenoxyaniline as the starting material. LCMS calculated for CisffeBrNsC (M+H)+: m/z = 392.1, 394.1; found: 392.1, 394.0. Step 4. 5-Bromo-l-(2-morpholin-4-ylethyl)-4^henoxy-l,3-dihydro-2H-benzimidazol-2-one
Figure imgf000140_0002
This compound was synthesized according to the procedure of Example 6, Step 1, using 4-bromo-N1-(2-morpholin-4-ylethyl)-3-phenoxybenzene-l,2-diamine as the starting material. LCMS calculated for CwftiBrNsOs (M+H)+: m/z = 418.1, 420.1; found: 418.0, 420.1.
Step 5. 5-{6-Methyl-l-f(4-methylphenyl)sulfonylJ-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin- 4-yl}-l-(2-morpholin-4-ylethyl)- -phenoxy-l,3-dihydro-2H-benzimidazol-2-one trifluoroacetate
Figure imgf000140_0003
This compound was synthesized according to the procedure of Example 10, Step 5, using 5-bromo-l-(2-morpholin-4-ylethyl)-4-phenoxy-l,3-dihydro-2H-benzimidazol-2-one as the starting material. Purification by preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% trifluoroacetic acid, at flow rate of 60 mL/min) gave the desired product as a TFA salt. LCMS calculated for C34H34N5O6S (M+H)+: m/z = 640.2; found: 640.3. Step 6. 5-(6-Methyl-7-oxo-6 -dihydro-lH^yrrolo[2,3-c]pyridin-4-yl)-l-(2-morpholin-4- ylethyl)-4-phenoxy-l,3-dihydro-2H-benzimidazol-2-one trifluoroacetate
This compound was synthesized according to the procedure of Example 6, Step 2, using 5- {6-methyl- 1 -[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl} - 1 - (2-morpholin-4-ylethyl)-4-phenoxy-l,3-dihydro-2H-benzimidazol-2-one trifluoroacetate as the starting material. Purification by preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.1% trifluoroacetic acid, at flow rate of 60 mL/min) gave the desired product as a TFA salt. lU NMR (400 MHz, DMSO-ώ) δ 11.97 (br s, 1H), 11.43 (br s, 1H), 7.33 - 7.23 (m, 2H), 7.20 (d, J= 8.1 Hz, 1H), 7.14 - 7.02 (m, 3H), 6.84 (dd, J = 7.3, 7.3 Hz, 1H), 6.58 (d, J= 7.8 Hz, 2H), 6.24 - 6.11 (m, 1H), 4.36 - 4.20 (m, 2H), 4.14 - 3.94 (m, 2H), 3.83 - 3.50 (m, 6H), 3.41 (s, 3H), 3.29 - 3.08 (m, 2H); LCMS calculated for
C27H28N5O4 (M+H)+: m/z = 486.2; found: 486.2.
Example 70. l-{2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]ethyl}-5-(6-methyl-7-oxo-6,7- dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-l,3-dihydro-2H-benzimidazol-2-one trifluoroacetate
Figure imgf000141_0001
This compound was synthesized according to the procedure of Example 69 using 2-[(2R, 6S)-2,6-dimethylmorpholin-4-yl]ethanamine instead of N-(2-aminoethyl)morpholine in step 2. 'H NMR (400 MHz, DMSO-ώ) δ 11.96 (br s, 1H), 11.41 (s, 1H), 7.35 - 7.27 (m, 1H), 7.26 - 7.22 (m, 1H), 7.20 (d, J= 8.1 Hz, 1H), 7.13 - 7.01 (m, 3H), 6.84 (dd, J= 7.3, 7.3 Hz, 1H), 6.58 (d, J= 7.8 Hz, 2H), 6.17 (dd, J= 2.4, 2.4 Hz, 1H), 4.41 - 4.15 (m, 2H), 3.90 - 3.74 (m, 2H), 3.74 - 3.64 (m, 2H), 3.41 (s, 3H), 2.85 - 2.65 (m, 2H), 1.14 (d, J= 6.3 Hz, 6H); LCMS calculated for C29H32N5O4 (M+H)+: m/z = 514.2; found: 514.2.
Example 71. 4-(2-(Benzylamino)-l-{2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethyl}-4- phenoxy-lH-benzimidazol-5-yl)-6-methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one trifluoroacetate
Figure imgf000142_0001
A solution of l-{2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethyl}-5-{6-methyl-l-[(4- methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl}-4-phenoxy-l,3- dihydro-2H-benzimidazol-2-one (74.5 mg, 0.112 mmol) (from example 70) in phosphoryl chloride (2.079 mL, 22.31 mmol) was heated at 60 °C overnight, after which time the reaction mixture was concentrated in vacuo and the resultant residue was dissolved in toluene and reconcentrated to give the crude chloride which was used in further step without purification. The solution of crude chloride in N-methylpyrrolidinone (1.0 mL) was treated with benzylamine (122 μί, 1.12 mmol) and heated in the microwave reactor at 150 °C for 20 min. The reaction mixture was then treated with methanol (1.0 mL) and 2.0 M solution of sodium hydroxide in water (200 μί, 0.400 mmol) and stirred at 60 °C for 30 min. The reaction mixture was purified by preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water containing 0.1% trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (5 mg, 7%). ¾ NMR (400 MHz, DMSO-ώ) δ 12.08 (br s, 1H), 11.51 (br s, 1H), 8.26 (dd, J= 6.2, 6.2 Hz, 1H), 7.78 (dd, J= 2.8, 2.8 Hz, 1H), 7.67 (s, 1H), 7.42 - 7.26 (m, 6H), 7.19 (d, J= 8.1 Hz, 1H), 7.05 (dd, J= 7.8, 7.8 Hz, 2H), 6.84 (dd, J= 7.4, 7.4 Hz, 1H), 6.51 (d, J= 8.6 Hz, 2H), 6.42 (s, 1H), 5.75 (s, 2H), 5.02 (d, J= 6.1 Hz, 2H), 4.39 - 4.16 (m, 2H), 3.88 (s, 3H), 3.86 - 3.73 (m, 2H), 2.86 - 2.63 (m, 2H), 1.14 (d, J= 6.1 Hz, 6H); LCMS calculated for CseHsgNeOs (M+H)+: m/z = 603.3; found: 603.3.
Example 72. 4-(2-[(Cyclopropylmethyl)amino]-l-{2-[(2R,6S)-2,6-dimethylmorpholin-4- yl]ethyl}-4-phenoxy-lH-benzimidazol-5-yl)-6-methyl-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one trifluoroacetate
Figure imgf000143_0001
This compound was synthesized according to the procedure of Example 71 using cyclopropylmethylamine instead of benzylamine. ¾ NMR (400 MHz, DMSO-ώ) δ 12.16 (br s, 1H), 11.51 (br s, 1H), 7.81 (dd, J = 3.0, 3.0 Hz, 1H), 7.73 (dd, J= 5.7, 5.7 Hz, 1H), 7.61 (s, 1H), 7.34 (d, J= 8.2 Hz, 1H), 7.20 (d, J= 8.1 Hz, 1H), 7.11 - 7.03 (m, 2H), 6.83 (dd, J= 7.3, 7.3 Hz, 1H), 6.53 (dd, J= 8.7, 1.0 Hz, 2H), 6.45 (dd, J= 2.8, 1.6 Hz, 1H), 5.75 (s, 1H), 4.39 - 4.17 (m, 2H), 3.82 (s, 3H), 3.67 - 3.59 (m, 2H), 2.95 - 2.61 (m, 2H), 1.22 - 1.13 (m, 6H), 1.13 - 1.06 (m, 1H), 0.56 - 0.43 (m, 2H), 0.38 - 0.27 (m, 2H); LCMS calculated for C33H39N6O3 (M+H)+: m/z = 567.3; found: 567.3.
Example 73. 4-(7-Ethoxy-2,5-dimethylpyrazolo[l,5-a]pyrimidin-6-yl)-6-methyl-l,6- dihydr o-7H-pyrrolo [2,3-c] pyridin-7-one
Figure imgf000144_0001
Step 1. Ethyl 2-bromo-3-oxobutanoate
Figure imgf000144_0002
3-Oxobutanoic acid ethyl ester (1.26 mL, 10.0 mmol) was added dropwise to a suspension of N-bromosuccinimide (1.78 g, 10.0 mmol) and /?-toluenesulfonic acid (10.0 mg, 0.0581 mmol) in methylene chloride (30.0 mL) at 0 °C, and the resultant reaction mixture was stirred at 0°C for 3 h, then warmed to RT and stirred at that temperature for 1 h. The reaction mixture was concentrated in vacuo and the resultant oily solid was treated with hexanes and the resultant suspension was filtered. The solid was washed with additional hexanes and the filtrate was concentrated in vacuo to give a crude oil. Purification by flash column chromatography (100% hexanes to 30% Et20/hexanes) gave the desired product (1.20 g, 57%) as an oil.
Step 2. 6-Bromo-2, 5-dimethylpyrazolof 1, 5 -a Jpyrimidin- 7-ol
Figure imgf000144_0003
A mixture of 3 -methyl- lH-pyrazol-5 -amine (0.186 g, 1.92 mmol) and acetic acid (3.71 mL, 65.2 mmol) was slightly heated until complete dissolution and and the resultant solution was cooled to RT and mixed with ethyl 2-bromo-3-oxobutanoate (1.20 g, 5.74 mmol). The resultant reaction mixture was stirred at RT for 16 h, after which time the reaction mixture was diluted with diethyl ether, cooled to 0 °C and stirred at that temperature for 30 min. The white solid precipitate was separated by filtration and washed with cold diethyl ether and dried to give the desired product (363 mg, 78%) as a white solid. LCMS calculated for CsHgBrNsO (M+H)+: m/z = 242.0, 244.0; found: 241.9, 244.0.
Step 3. 6-Bromo- 7-chloro-2, 5-dimethylpyrazolo[ 1, 5-aJpyrimidine
Figure imgf000145_0001
Pyridine (0.179 mL, 2.22 mmol) was added dropwise to a solution of 6-bromo-2,5- dimethylpyrazolo[l,5-a]pyrimidin-7(4H)-one (0.179 g, 0.739 mmol) in phosphoryl chloride (1.85 mL, 19.8 mmol) and 1 ,2-dichloroethane (1.85 mL). The resultant reaction mixture was stirred at RT for 15 min, then warmed to 80 °C and stirred at that temperature for 15 h. The reaction mixture was concentrated in vacuo to yield a crude residue which was diluted with dichloromethane and the resultant solution was added dropwise to a saturated solution of sodium bicarbonate (40 mL) at 0 °C. Additional dichloromethane (50 mL) was added, layers were separated and the organic layer was dried with sodium sulfate, filtered, and concentrated in vacuo to give a crude residue. Purification by flash column chromatography (100% hexanes to 30%) EtOAc/hexanes) gave the desired product (171 mg, 89%>) as a white solid. LCMS calculated for CsHsBrClNs (M+H)+: m/z = 260.0, 262.0; found: 259.9, 261.9.
Step 4. 6-Bromo- 7- ( 2, 4-dtfluorophenoxy)-2, 5-dimethylpyrazolo[ 1, 5-a Jpyrimidine
Figure imgf000145_0002
A solution of 2,4-difluorophenol (0.156 mL, 0.960 mmol) in tetrahydrofuran (3.0 mL) was treated with sodium hydride (0.0242 g, 0.960 mmol) at 0 °C. The resultant reaction mixture was warmed to RT and stirred at that temperature for 30 min. The reaction mixture was then cooled to 0 °C, treated with 6-bromo-7-chloro-2,5-dimethylpyrazolo[l,5-a]pyrimidine (0.125 g, 0.480 mmol), warmed to RT and stirred at RT for 14 h. The reaction mixture was cooled to 0 °C, quenched with saturated ammonium chloride solution, and diluted with ethyl acetate. Layers were separated and the organic layer was washed with water and brine, dried with sodium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (100% hexanes to 30% Et20/hexanes) gave the desired product (162 mg, 95%>) as a white solid. LCMS calculated for Ci4HnBrF2N30 (M+H)+: m/z = 354.0, 356.0; found: 353.9, 356.0.
Step 5. 4-f7-(2,4-Difluorophenoxy)-2,5-dimethylpyrazolofl,5-aJpyrimidin-6-ylJ-6-methy methylphenyl)sulfonylJ -1 , 6-dihydro- -pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000146_0001
This compound was synthesized according to the procedure of Example 10, Step 5, using 6-bromo-7-(2,4-difluorophenoxy)-2,5-dimethylpyrazolo[l,5-a]pyrimidine and 6-methyl-l-[(4- methylphenyl)sulfonyl]-4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for
Figure imgf000146_0002
(M+H)+: m/z = 576.1; found: 576.1. Step 6. 4-(7-Ethoxy-2, 5-dimethylpyrazolof 1, 5-a]pyrimidin-6-yl)-6-methyl-l, 6-dihydro- 7H- pyrrolo[2,3-c]pyridin-7-one
A suspension of 4-[7-(2,4-difluorophenoxy)-2,5-dimethylpyrazolo[l,5-a]pyrimidin-6-yl]-
6-methyl- 1 -[(4-methylphenyl)sulfonyl]- 1 ,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (29.1 mg,
50.6 μιηοΐ) in ethanol (1.0 mL) was treated with a 3.0 M solution of sodium hydroxide in water (0.254 mL, 0.762 mmol), then warmed to 55 °C and stirred at that temperature for 30 min. The reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (6 mg, 14%). lU NMR (300 MHz, DMSO-ώ) δ 12.15 (br s, 1H), 7.28 (d, J = 2.8 Hz, 1H), 7.24 (s, 1H), 6.39 (s, 1H), 6.03 (d, J= 2.7 Hz, 1H), 4.45 (q, J= 7.0 Hz, 2H), 3.55 (s, 3H), 2.42 (s, 3H), 2.24 (s, 3H), 1.07 (t, J= 7.1 Hz, 3H); LCMS calculated for C18H20N5O2 (M+H)+: m/z = 338.2; found: 338.1.
Example 75. 8-(2,4-Difluorophenoxy)-7-(6-methyl-7-oxo-6,7-dihydro-lH-pyrazolo[3,4- c]pyridin-4-yl)quinoxalin-2(lH)-one
Figure imgf000147_0001
Step 1. N-f4-Bromo-3-(2,4-difluorophenoxy)-2-nitrophenylJ-2,2,2-trifluoroacetamide
Figure imgf000147_0002
This compound was synthesized according to the procedure of Example 4, Step 1, using 4-bromo-3-(2,4-difluorophenoxy)-2-nitroaniline as the starting material.
Step 2. Methyl { [4-bromo-3-(2 ,4-dtfluorophenoxy)-2-nitrophenyl] 'amino} acetate
Figure imgf000147_0003
A solution of 2- hydroxyacetic acid methyl ester (0.0742 mL, 0.961 mmol) in
tetrahydrofuran (2.42 mL) was treated with triphenylphosphine (0.176 g, 0.673 mmol), cooled to 0 °C, followed by dropwise addition of with diisopropyl azodicarboxylate (0.142 mL, 0.721 mmol). The reaction mixture was stirred at 0 °C for 15 min, treated with N-[4-bromo-3-(2,4- difluorophenoxy)-2-nitrophenyl]-2,2,2-trifluoroacetamide (0.212 g, 0.481 mmol), warmed to RT and stirred at RT for 16 h. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the aqueous layer was re-extracted with ethyl acetate. The combined organic layers were washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give the intermediate trifluoroacetamide. This crude intermediate trifluoroacetamide was dissolved in methanol (2.42 mL), the the resultant solution was treated with ammonium hydroxide (0.187 mL, 4.81 mmol) and then stirred at RT for 15 min. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (2 x 50 mL). The combined organic layers were washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give the crude product. Purification by flash column chromatography (100% hexanes to 20%) CEbCk/hexanes) gave the desired product (123 mg, 61%>) as a yellow solid. LCMS calculated for
Figure imgf000148_0001
(M+H)+: m/z = 417.0, 419.0; found: 416.9, 418.9.
Step 3. Methyl {[3-(2,4-difluorophenoxy)-4-(6-methyl-7-oxo-l-{[2- ( trimethylsilyl)ethoxyJmethyl}-6, 7-dihydro-lH-pyrazolof 3, 4-cJpyridin
nitrophenyl] amino} acetate
Figure imgf000148_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using methyl {[4-bromo-3-(2,4-difluorophenoxy)-2-nitrophenyl]amino}acetate and 6-methyl-4-(4,4,5, 5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 - { [2-(trimethylsilyl)ethoxy]methyl} - 1 ,6-dihydro-7H- pyrazolo[3,4-c]pyridin-7-one as the starting materials. LCMS calculated for C28H32F2N5O7S1 (M+H)+: m/z = 616.2; found: 616.2.
Step 4. 8-(2,4-Difluorophenoxy)-7-(6-methyl-7-oxo-l-{f2-(trimethylsilyl)ethoxyJmethyl}-6, 7- dihydro-lH^yrazolo[3,4-cJpyridin-4- l)-3,4-dihydroquinoxalin-2(lH)-one
Figure imgf000149_0001
A suspension of methyl {[3-(2,4-difluorophenoxy)-4-(6-methyl-7-oxo-l-{[2-
(trimethylsilyl)ethoxy]methyl}-6,7-dihydro-lH-pyrazolo[3,4-c]pyridin-4-yl)-2- nitrophenyl] amino} acetate (0.048 g, 0.078 mmol) in ethyl acetate (0.452 mL) and methanol (0.452 mL) was cooled to 0 °C and then treated with saturated ammonium chloride solution (0.0679 mL, 1.01 mmol) at that temperature. Zinc (0.0408 g, 0.624 mmol) was added to the reaction mixture in two portions over 5 min and the reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with dichloromethane and filtered through a pad of Celite. The solids were washed with additional dichloromethane and the filtrate was concentrated in vacuo to yield a crude residue. The residue was dissolved in dichloromethane and the organic phase was washed with saturated sodium bicarbonate solution, dried with sodium sulfate, filtered, and concentrated oin vacuo to give the crude product. Purification via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) gave the desired product (10.5 mg, 24%) along with a small amount of the oxidized product, 8-(2,4-difluorophenoxy)-7-(6-methyl-7-oxo-l-{[2- (trimethylsilyl)ethoxy]methyl}-6,7-dihydro-lH-pyrazolo[3,4-c]pyridin-4-yl)quinoxalin-2(lH)- one. This mixture was used in the next step without separation. LCMS calculated for
C27H3oF2N504Si (M+H)+: m/z = 554.2; found: 554.1. Step 5. 8-(2,4-Difluorophenoxy)-7-(6-methyl-7-oxo-6, 7-dihydro- lH-pyrazolo [3 ,4-c] pyridin-4- yl)quinoxalin-2(lH)-one
Trifluoroacetic acid (0.40 mL, 5.19 mmol) was added dropwise at RT to a solution of 8- (2,4-difluorophenoxy)-7-(6-methyl-7-oxo- 1 - { [2-(trimethylsilyl)ethoxy]methyl} -6, 7-dihydro- 1 H- pyrazolo[3,4-c]pyridine-4-yl)-3,4-dihydroquinoxalin-2(lH)-one (10.5 mg, 0.0190 mmol, mixture of oxidized (quinoxalin) and reduced (dihydroquinoxalin) forms from previous step) in methylene chloride (0.40 mL), and the reaction mixture was stirred at RT for 1 h. The reaction mixture was purified via preparative LCMS (XBridge C 18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (4 mg, 50%). lU NMR (500 MHz, DMSO-ώ) δ 14.05 (br s, 1H), 12.50 (br s, 1H), 8.19 (s, 1H), 7.79 (d, J= 8.4 Hz, 2H), 7.42 (d, J= 8.3 Hz, 1H), 7.35 (s, 1H), 7.16 - 6.99 (m, 1H), 6.70 - 6.56 (m, 1H), 6.55 - 6.34 (m, 1H), 3.48 (s, 3H); LCMS calculated for C21H14F2N5O3 (M+H)+: m/z = 422.1; found: 422.0.
Example 76. 4-[4-(Cyclopropylmethoxy)-l-methyl-lH-indazol-5-yl]-6-methyl-l,6-dihydro- 7H-pyr rolo [2,3-c] pyridin-7-one
Figure imgf000150_0001
Step 1. 3-Bromo-6-fluoro-2-methoxybenzaldehyde
Figure imgf000150_0002
1.6 M Solution of n-butyllithium in hexanes (3.35 mL, 5.36 mmol) was added dropwise to a solution of N,N-diisopropylamine (0.960 mL, 6.85 mmol) in tetrahydrofuran (10 mL) at -78 °C and the resultant reaction mixture was stirred at -78 °C for 10 min. A solution of l-bromo-4- fluoro-2-methoxybenzene (1.0 g, 4.9 mmol) in tetrahydrofuran (2 mL) was added to the reaction mixture dropwise at -78 °C and the reaction mixture was stirred at -78 °C for 1 h. N,N- dimethylformamide (0.412 mL, 5.32 mmol) was added to the reaction mixture dropwise at -78 °C and the reaction mixture was stirred at -78 °C for 1 h. Reaction mixture was quenched with saturated ammonium chloride, warmed to 20 °C, and diluted with ether and 1M aqueous solution of HC1. Layers were separated and the aqueous layer was and re-extracted with ether. The combined organic layers were washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give a crude residue. Purification by flash column chromatography (100% hexanes to 30% EtOAc/hexanes) gave the desired product (727 mg, 64%>) as a yellow solid. LCMS calculated for CsHvBrFC (M+H)+: m/z = 233.0, 235.0; found: 233.0, 234.8.
Step 2. 5-Bromo-4-methoxy-lH-indazole
Figure imgf000151_0001
A solution of 3-bromo-6-fluoro-2-methoxybenzaldehyde (0.727 g, 3.12 mmol) and methoxylamine hydrochloride (0.260 g, 3.12 mmol) in 1 ,2-dimethoxyethane (4 mL) was treated with potassium carbonate (0.472 g, 3.42 mmol) and stirred at 20 °C for 5 h. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give a residue. This residue was dissolved in 1 ,2-dimethoxyethane (4 mL), the resultant solution was treated with hydrazine (4 mL), warmed to 100 °C and stirred at that temperature for 15 h. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was separated, washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give a crude residue. This residue was triturated with ether to give the desired product (185 mg, 26%>) as a gray solid. LCMS calculated for CsHsBr^O (M+H)+: m/z = 227.0, 229.0; found: 226.9, 229.0.
Step 3. 5-Bromo-4-methoxy-l-methyl-lH-indazole
Figure imgf000151_0002
A solution of 5-bromo-4-methoxy-lH-indazole (0.125 g, 0.550 mmol) in N,N- dimethylformamide (2.20 mL) was treated with sodium hydride (0.0166 g, 0.659 mmol) at 20 °C and then stirred at 20 °C for 30 min. The resultant reaction mixture was treated with methyl iodide (0.0410 mL, 0.658 mmol) and stirred at 20 °C for 1 h. The reaction mixture was diluted with water and ethyl acetate. Layers were separated and the organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give the crude
product. Purification by flash column chromatography (100% hexanes to 100% EtOAc) gave the desired product (87 mg, 66%) as a white solid. LCMS calculated for CgHioBrlN O (M+H)+: m/z = 241.0, 243.0; found: 240.9, 242.9.
Step 4. 5-Bromo-l-methyl-lH-indazol-4-ol
Figure imgf000152_0001
A solution of 5 -bromo-4-methoxy-l -methyl- lH-indazole (86.1 mg, 0.357 mmol) in methylene chloride (1.74 mL) was treated with boron tribromide (0.0405 mL, 0.428 mmol) at 0 °C. The reaction mixture was warmed to RT and stirred at RT for 16 h, after which time the reaction mixture was cooled to 0 °C, treated with additional boron tribromide (0.0405 mL, 0.428 mmol), warmed to RT and stirred at RT for 1.5 h. The reaction mixture was cooled to 0 °C, treated with more boron tribromide (0.0405 mL, 0.428 mmol), and stirred for 2 h. The reaction mixture was then cooled to 0 °C and quenched carefully with saturated sodium bicarbonate (30 mL) and extracted with dichloromethane (2 x 30 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo to yield a crude mixture. This mixture was re-subjected to the initial reaction conditions. The crude mixture was suspended in 1 ,2-dichloroethane (1.74 mL), cooled to 0 °C, treated with boron tribromide (0.0810 mL, 0.857 mmol), warmed to RT and stirred at RT for 2 h. The reaction mixture was cooled to 0 °C and quenched carefully with saturated solution of sodium bicarbonate (30 mL) and extracted with dichloromethane (2 x 30 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo to give the crude product. This material was diluted with methanol (2.0 mL), treated with ammonium hydroxide (0.278 mL, 7.14 mmol), and stirred for 15 min. The resultant suspension was diluted with saturated ammonium chloride (30 mL) and extracted with dichloromethane (2 x 30 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated to give the desired product (73 mg, 90%) as a yellow solid. LCMS calculated for C8H8BrN20 (M+H)+: m/z = 227.0, 229.0; found: 226.9, 228.9.
Step 5. 5-Bromo-4-(cyclopropylmethox -l-methyl-lH-indazole
Figure imgf000153_0001
A solution of 5-bromo-l-methyl-lH-indazol-4-ol (73.7 mg, 0.324 mmol) and cyclopropyl carbinol (0.0386 mL, 0.489 mmol) in tetrahydrofuran (2.80 mL) was treated with
triphenylphosphine (0.102 g, 0.390 mmol), cooled to 0 °C, followed by dropwise addition of diisopropyl azodicarboxylate (0.0767 mL, 0.390 mmol). Reaction mixture was warmed to RT and stirred at RT for 16 h. The reaction mixture was poured into saturated sodium bicarbonate solution and extracted with ethyl acetate. Layers were separated and the organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo to give the crude product. Purification by flash column chromatography (100% hexanes to 100% CH2CI2) gave the desired product (72 mg, 78%>) as a yellow solid. LCMS calculated for Ci2Hi4BrN20 (M+H)+: m/z = 281.0, 283.0; found: 281.0, 283.0. Step 6. 4-[4-(Cyclopropylmethoxy)-l-methyl-lH-indazol-5-yl]-6-methyl-l-[(4- methylphenyl)sulfonylJ -1 , 6-dihydro- -pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000153_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using 5 -bromo-4-(cyclopropylmethoxy)- 1 -methyl- 1 H-indazole and 6-methyl- 1 - [(4- methylphenyl)sulfonyl]-4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C27H27N4O4S (M+H)+: m/z = 503.2; found: 503.1.
Step 7. 4-[ 4-(Cyclopropylmethoxy)-l-methyl-lH-indazol-5-yl] -6-methyl-l , 6-dihydro- 7H- pyrrolo[2, 3-cJpyridin- 7 -one
This compound was synthesized according to the procedure of Example 8, Step 2, using 4- [4-(cyclopropylmethoxy)- 1 -methyl- 1 H-indazol-5 -yl] -6-methyl- 1 - [(4-methylphenyl)sulfonyl] - l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. lH NMR (500 MHz, DMSO-ώ) δ 11.96 (br s, 1H), 8.19 (s, 1H), 7.41 - 7.28 (m, 2H), 7.28 - 7.17 (m, 2H), 6.09 (d, J = 2.7 Hz, 1H), 4.03 (s, 3H), 3.98 (d, J= 6.8 Hz, 2H), 3.56 (s, 3H), 1.08 - 0.90 (m, 1H), 0.43 - 0.23 (m, 2H), 0.21 - -0.03 (m, 2H); LCMS calculated for C20H21N4O2 (M+H)+: m/z = 349.2; found: 349.1.
Example 77. 4-[4-(Cyclopropylmethoxy)-l-methyl-lH-indazol-5-yl]-6-methyl-l,6-dihydro- 7H-pyrazolo [3,4-c] pyridin-7-one
Figure imgf000154_0001
Step 1. 4-(4-(cyclopropylmethoxy)-l-methyl-lH-indazol-5-yl)-6-methyl-l-( (2- ( trimethylsilyl)ethoxy)methyl)- lH-pyrazolo [ 3, 4-cJpyridin- 7( 6H)-one
Figure imgf000154_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using 5 -bromo-4-(cyclopropylmethoxy)-l -methyl- lH-indazole and 6-methyl-4-(4,4,5,5-tetramethyl-l, 3 ,2-dioxaborolan-2-yl)- 1 - { [2-(trimethylsilyl)ethoxy]methyl} - 1 ,6-dihydro-7H-pyrazolo[3 ,4- c]pyridin-7-one as the starting materials. LCMS calculated for C25H34N5O3S1 (M+H)+: m/z = 480.2; found: 480.1.
Step 2. 4-[ 4-(Cyclopropylmethoxy)-l-methyl-lH-indazol-5-yl] -6-methyl-l , 6-dihydro- 7H- pyrazolof 3, 4-c] pyridin- 7 -one
Figure imgf000155_0001
Trifluoroacetic acid (0.564 mL) was added dropwise to a solution of 4-[4-
(cyclopropylmethoxy)- 1 -methyl- 1 H-indazol-5 -yl] -6-methyl- 1 - { [2-
(trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one (0.0549 g, 0.114 mmol) in methylene chloride (0.564 mL) and the resultant reaction mixture was stirred at RT for 30 min. The reaction mixture was concentrated in vacuo to yield a crude residue. The crude residue was dissolved in methanol (1.00 mL), followed by dropwise addition of 15.0 M solution of ammonium hydroxide in water (0.250 mL, 3.76 mmol). The reasultant reaction mixture was stirred at RT for 30 min. The reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (26.8 mg, 67%). lU NMR (500 MHz, DMSO-ώ) δ 14.00 (br s, 1H), 8.23 (s, 1H), 7.72 (s, 1H), 7.38 (d, J= 8.5 Hz, 1H), 7.33 (d, J= 8.5 Hz, 1H), 7.28 (s, 1H), 4.05 (d, J= 6.8 Hz, 2H), 4.03 (s, 3H), 3.58 (s, 3H), 1.23 - 0.81 (m, 1H), 0.51 - 0.26 (m, 2H), 0.25 - -0.01 (m, 2H); LCMS calculated for C19H20N5O2 (M+H)+: m/z = 350.2; found: 350.1. Example 78. 4-[4-(2,4-Difluorophenoxy)-7-(l-hydroxyethyl)-l-methyl-lH-benzimidazol-5- yl] -6-methyl- 1 ,6-dihydro-7H-pyrazolo [3,4-c] pyridin-7-one
Figure imgf000156_0001
Step 1. 4-[5-Bromo-2-(2,4-difluorophenoxy)-4-(methylamino)-3-nitrophenyl]-6-methyl-l-{[2- ( trimethylsilyl)ethoxy] methyl}- 1, 6-dihydro- 7H-pyrazolo[ 3, 4-cJpyridin- 7 -one
Figure imgf000156_0002
A solution of 4-[2-(2,4-difluorophenoxy)-4-(methylamino)-3-nitrophenyl]-6-methyl-l-
{[2-(trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one (0.433 g, 0.776 mmol) in N,N-dimethylformamide (5.0 mL) was cooled to 0 °C. Two portions of N- bromosuccinimide (0.159 g, 0.893 mmol) were added with a 5 min interval to the above solution at 0 °C, and the resultant reaction mixture was stirred at 0 °C for 30 min, after which time the reaction mixture was diluted with water and ethyl acetate. Layers were separated and the organic layer was washed with saturated sodium bicarbonate, dried with sodium sulfate, filtered, and concentrated to give a crude residue. Purification by flash column chromatography (100% hexanes to 50% EtOAc/hexanes [EtOAc contained 5% MeOH]) gave the desired product (444 mg, 90%) as a yellow solid. LCMS calculated for C26H29BrF2N505Si (M+H)+: m/z = 636.1, 638.1; found: 636.0, 638.1.
Step 2. 4-[3-Amino-5-bromo-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-{[2- ( trimethylsilyl)ethoxy] methyl}- 1, 6-dihydro- 7H-pyrazolo[ 3, 4-cJpyridin- 7 -one
Figure imgf000157_0001
A suspension of 4-[5-bromo-2-(2,4-difluorophenoxy)-4-(methylamino)-3-nitrophenyl]-6- methyl- 1 - { [2-(trimethylsilyl)ethoxy]methyl} - 1 ,6-dihydro-7H-pyrazolo[3 ,4-c]pyridin-7-one (0.209 g, 0.328 mmol) in tetrahydrofuran (1.38 mL) was treated with iron (0.183 g, 3.28 mmol), followed by the addition of acetic acid (1.38 mL, 24.3 mmol). The resultant reaction mixture was warmed to 60 °C and stirred at 60 °C for 1.5 h. The reaction mixture was treated with iron (0.0917 g, 1.64 mmol) and stirred at 60 °C for 14 h, after which time the reaction mixture was filtered through the pad of Celite and washed with ethyl acetate. The filtrate was concentrated in vacuo to give a crude residue. The crude residue was diluted with saturated solution of sodium bicarbonate and ethyl acetate. Layers were separated and the organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give a crude residue. Purification by flash column chromatography (100% hexanes to 40%
EtOAc/hexanes) gave the desired product (104 mg, 52%) as a white solid. LCMS calculated for C26H3iBrF2N503Si (M+H)+: m/z = 606.1, 608.1; found: 606.0, 608.0.
Step 3. 4-[7-Bromo-4-(2,4-difluorophenoxy)-l-methyl-lH-benzimidazol-5-ylJ-6-methyl-l-{[2- ( trimethylsilyl)ethoxy] methyl}- 1, 6-dihydro- 7H-pyrazolo[ 3, 4-cJpyridin- 7 -one
Figure imgf000157_0002
This compound was synthesized according to the procedure of Examples 30 and 31, Step 6, using 4-[3-amino-5-bromo-2-(2,4-difluorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material. LCMS calculated for C27H29BrF2N503Si (M+H)+: m/z = 616.1, 618.1; found: 615.9, 618.0.
Step 4. 4-f4-(2,4-Difluorophenoxy)-l-methyl-7-vinyl-lH-benzimidazol-5-ylJ-6-methyl-l-{[2- ( trimethylsilyl)ethoxy] methyl}- 1, 6-dihydro- 7H-pyrazolo[ 3, 4-cJpyridin- 7 -one
Figure imgf000158_0001
A mixture of 4-[7-bromo-4-(2,4-difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-6- methyl- 1 - { [2-(trimethylsilyl)ethoxy]methyl} - 1 ,6-dihydro-7H-pyrazolo[3 ,4-c]pyridin-7-one (0.0990 g, 0.160 mmol), 4,4,5,5-tetramethyl-2-vinyl-l,3,2-dioxaborolane (0.0408 mL, 0.241 mmol), [1,1 '-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with
dichloromethane (1 : 1) (0.0131 g, 0.0160 mmol) and potassium carbonate (0.0555 g, 0.401 mmol) in 1,4-dioxane (1.0 mL, 12.8 mmol) and water (0.580 mL, 32.2 mmol) was degassed with nitrogen for 10 min, warmed to 80 °C and stirred at 80 °C for 2 h. The reaction mixture was diluted with water and ethyl acetate. Layers were separated and the organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give a crude residue. Purification by flash column chromatography (100% hexanes to 100% EtOAc [EtOAc contained 5%> MeOH]) gave the desired product (77 mg, 85%>) as a white foam. LCMS calculated for C^Hs^NsOsSi (M+H)+: m/z = 564.2; found: 564.1. Step 5. 4-(2,4-Difluorophenoxy)-l-methyl-5-(6-methyl-7-oxo-l-{[2-
( trimethylsilyl)ethoxyJmethyl}-6, 7-dihydro-lH-pyrazolof 3, 4-c] pyridin-4-yl)- lH-benzimidazole- 7-carbaldehyde
Figure imgf000159_0001
A mixture of 4-[4-(2,4-difluorophenoxy)-l-methyl-7-vinyl-lH-benzimidazol-5-yl]-6- methyl- 1 - { [2-(trimethylsilyl)ethoxy]methyl} - 1 ,6-dihydro-7H-pyrazolo[3 ,4-c]pyridin-7-one (0.076 g, 0.13 mmol) and sodium metaperiodate (0.0865 g, 0.404 mmol) in water (0.23 mL) and tetrahydrofuran (3.10 mL) was treated with 0.16M solution of osmium tetraoxide in water (0.172 mL, 0.0270 mmol). The resultant reaction mixture was stirred at 60 °C for 30 min. The reaction mixture was diluted with water and ethyl acetate. Layers were separated and the organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give a crude residue. Purification by flash column chromatography (100% hexanes to 100% EtOAc [EtOAc contained 5% MeOH]) gave the desired product (50.6 mg, 66%). LCMS calculated for C28H3oF2N504Si (M+H)+: m/z = 566.2; found: 566.1.
Step 6. 4-[4-(2,4-Difluorophenoxy)-7-(l-hydroxyethyl)-l-methyl-lH-benzimidazo
methyl- 1-{ [2-(trimethylsilyl)ethoxy]methyl}- 1 ,6-dihydro-7H-pyrazolo [3 ' ,4-c]pyridin-7-one
Figure imgf000159_0002
A 3.0 M solution of methylmagnesium iodide in diethyl ether (21.1
Figure imgf000159_0003
0.0634 mmol) was added to a solution of 4-(2,4-difluorophenoxy)-l-methyl-5-(6-methyl-7-oxo-l-{[2- (trimethylsilyl)ethoxy]methyl} -6,7-dihydro- 1 H-pyrazolo[3 ,4-c]pyridin-4-yl)- 1 H-benzimidazole- 7-carbaldehyde (0.0478 g, 0.0845 mmol) in tetrahydrofuran (0.734 mL) at 0 °C. The resultant reaction mixture was stirred at 0°C for 1 h, after which time an additional amount of 3.0 M solution of methylmagnesium iodide in diethyl ether (42.2
Figure imgf000159_0004
0.127 mmol) was added to the reaction mixture and stirring was continued at 0 °C for 30 min. The reaction mixture was quenched at 0 °C with methanol, diluted with methanol, and purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (25.2 mg, 51%). LCMS calculated for C29H34F2N5O4S1 (M+H)+: m/z = 582.2; found: 582.2.
Step 7. 4-[4-(2,4-Difluorophenoxy)-7-(l-hydroxyethyl)-l-methyl-lH-benzimidazol-5-yl]-6- methyl-1, 6-dihydro- 7H-pyrazolo[ 3, 4-c] pyridin- 7 -one
This compound was synthesized according to the procedure of Example 77, Step 2, using 4- [4-(2,4-difluorophenoxy)-7-( 1 -hydroxy ethyl)- 1 -methyl- 1 H-benzimidazol-5 -yl]-6-methyl- 1 - {[2-(trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one as the starting material. 'H NMR (500 MHz, DMSO-d6) δ 14.04 (br s, 1H), 8.12 (s, 1H), 7.76 (s, 1H), 7.45 (s, 1H), 7.29 - 7.17 (m, 2H), 6.83 - 6.63 (m, 1H), 6.63 - 6.41 (m, 1H), 5.45 (q, J = 6.3 Hz, 1H), 4.11 (s, 3H), 3.53 (s, 3H), 1.56 (d, J = 6.3 Hz, 3H); LCMS calculated for C23H20F2N5O3 (M+H)+: m/z = 452.2; found: 452.1.
Example 79. 4-(2,4-Difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo [2,3- c] pyridin-4-yl)-7- { [(2-morpholin-4-ylethyl)amino] methyl}- 1 ,3-dihydr o-2H-benzimidazol-2-
Figure imgf000160_0001
Step 1. 4-[4-Amino-5-bromo-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-l-[ (4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-c] pyridin- 7 -one
Figure imgf000161_0001
This compound was synthesized according to the procedure of Example 78, sStep 1, using 4-[4-amino-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for C27H2oBrF2N406S (M+H)+: m/z = 645.0, 647.0; found: 644.9, 646.9.
Step 2. 4-[4-Amino-2-(2,4-difluorophenoxy)-3-nitro-5-vinylphenyl]-6-methyl-l-[(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000161_0002
This compound was synthesized according to the procedure of Example 78, Step 4, using 4-[4-amino-5-bromo-2-(2,4-difluorophenoxy)-3-nitrophenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for C29H23F2N40eS (M+H)+: m/z = 593.1; found: 593.0.
Step 3. 4- [3 -Diamino-2-(2,4-difluorophenoxy)-5-vinylphenyl] -6-methyl- 1- [(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000162_0001
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-[4-amino-2-(2,4-difluorophenoxy)-3-nitro-5-vinylphenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for C29H25F2N4O4S (M+H)+: m/z = 563.2; found: 563.1.
Step 4. 4-(2,4-Difluorophenoxy)-5-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6, 7-dihydro- lH^yrrolo[2,3-c]pyridin-4-yl}-7-vin l-l,3-dihydro-2H-benzimidazol-2-one
Figure imgf000162_0002
This compound was synthesized according to the procedure of Example 6, Step 1, using 4-[3,4-diamino-2-(2,4-difluorophenoxy)-5-vinylphenyl]-6-methyl-l-[(4-methylphenyl)sulfonyl]- l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for C30H23F2N4O5S (M+H)+: m/z = 589.1; found: 589.1.
Step 5. 7-(2,4-Difluorophenoxy)-6-{6-methyl-l-f(4-methylphenyl)sulfonylJ-7-oxo-6, 7-dihydro- lH^yrrolo[2,3-c]pyridin-4-yl}-2-oxo-2,3-dihydro-lH-benzimidazole-4-carbaldehyde
Figure imgf000163_0001
This compound was synthesized according to the procedure of Example 78, Step 5, using 4-(2,4-difluorophenoxy)-5-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl}-7-vinyl-l,3-dihydro-2H-benzimidazol-2-one as the starting material. LCMS calculated for C29H21F2N4O6S (M+H)+: m/z = 591.1; found: 591.0.
Step 6. 4-(2,4-Difluorophenoxy)-5-{6-methyl-l-f(4-methylphenyl)sulfonylJ-7-oxo-6, 7-dihydro- lH-pyrrolo[2,3-c]pyridin-4-yl}-'/ 7-{[(2-morpholin-4-ylethyl)amino]methyl}-l,3-dihydro-2H- benzimidazol-2-one
Figure imgf000163_0002
A suspension of 7-(2,4-difluorophenoxy)-6-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7- oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl}-2-oxo-2,3-dihydro-lH-benzimidazole-4- carbaldehyde (25.0 mg, 0.0423 mmol) and N-(2-aminoethyl)morpholine (0.0111 mL, 0.0847 mmol) in methanol (0.40 mL) and methylene chloride (0.40 mL) was heated to 60 °C and stirred at 60 °C for 1 h. The reaction mixture was cooled to 0 °C, treated with sodium cyanoborohydride (0.0106 g, 0.169 mmol), warmed to RT and stirred for at RT 15 h. The reaction mixture was concentrated in vacuo and the residue was dissolved in methanol (0.50 mL), treated with sodium cyanoborohydride (0.00532 g, 0.0847 mmol), and stirred at 60 °C for 3 h. The reaction mixture was diluted with acetonitrile, methanol and a few drops of water and purified via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (11.9 mg, 40%). LCMS calculated for C35H35F2N6O6S (M+H)+: m/z = 705.2; found: 705.2. Step 7. 4-(2,4-Difluorophenoxy)-5-(6-methyl-7-oxo-6, 7-dihydro- IH-pyrrolo [2,3-c] pyridin-4-yl)- 7-{[(2-morpholin-4-ylethyl)amino] methyl}- l,3-dihydro-2H-benzimidazol-2-one
This compound was synthesized according to the procedure of Example 6, Step 2, using 4-(2,4-difluorophenoxy)-5-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl} -7- {[(2-morpholin-4-ylethyl)amino]methyl} - 1 ,3-dihydro-2H- benzimidazol-2-one as the starting material. ¾ NMR (500 MHz, DMSO-ώ) δ 11.90 (br s, 1H), 10.95 (br s, 1H), 7.19 (d, J= 2.3 Hz, 1H), 7.18 - 7.10 (m, 1H), 7.06 (s, 1H), 7.02 (s, 1H), 6.69 (dd, J= 7.9, 7.9 Hz, 1H), 6.49 - 6.33 (m, 1H), 6.11 (d, J= 2.5 Hz, 1H), 3.80 (s, 2H), 3.66 - 3.51 (m, 4H), 3.43 (s, 3H), 2.65 (t, J= 6.1 Hz, 2H), 2.40 (t, J= 6.1 Hz, 2H), 2.37 - 2.21 (m, 4H); LCMS calculated for C28H29F2N6O4 (M+H)+: m/z = 551.2; found: 551.2.
Example 80. 7- [(Benzylamino)methyl] -4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7- dihydro-lH-pyrrolo[2,3-c]pyridin-4- l)-l,3-dihydro-2H-benzimidazol-2-one
Figure imgf000164_0001
This compound was synthesized according to the procedure of Example 79 using benzyl amine in Step 6 instead of N-(2-aminoethyl)morpholine. ¾ NMR (300 MHz, DMSO-ώ) δ
11.91 (br s, 1H), 10.97 (br s, 1H), 7.42 - 7.00 (m, 7H), 6.81 - 6.58 (m, 1H), 6.52 - 6.31 (m, 1H), 6.14 (br s, 1H), 3.82 (s, 2H), 3.73 (s, 2H), 3.43 (s, 3H); LCMS calculated for C29H24F2N5O3 (M+H)+: m/z = 528.2; found: 528.1. Example 81. 7-{[(Cyclopropylmethyl)amino]methyl}-4-(2,4-difluorophenoxy)-5-(6-methyl- 7-oxo-6,7-dihydro- IH-pyrrolo [2,3-c] pyridin-4-yl)- 1 ,3-dihydr o-2H-benzimidazol-2-one
Figure imgf000165_0001
This compound was synthesized according to the procedure of Example 79 using 1- cyclopropylmethanamine hydrochloride in Step 6 instead of N-(2-aminoethyl)morpholine. lH NMR (400 MHz, DMSO-ώ) δ 11.94 (br s, 1H), 11.00 (br s, 1H), 7.24 - 7.11 (m, 2H), 7.08 (d, J = 1.4 Hz, 2H), 6.79 - 6.62 (m, 1H), 6.51 - 6.32 (m, 1H), 6.12 (d, J= 2.4 Hz, 1H), 3.80 (s, 2H), 3.43 (s, 3H), 2.39 (d, J= 6.7 Hz, 2H), 1.01 - 0.76 (m, 1H), 0.50 - 0.28 (m, 2H), 0.24 - -0.10 (m, 2H); LCMS calculated for C26H24F2N5O3 (M+H)+: m/z = 492.2; found: 492.1.
Example 82. 4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one
Figure imgf000165_0002
Step 1. N- [4-Bromo-3-(2 ,4-dtfluoro henoxy)-2-nitrophenyl) -2 ',2 ,2-trifluoroacetamide
Figure imgf000165_0003
This compound was synthesized according to the procedure of Example 32, Step 1, using 4-bromo-3-(2,4-difluorophenoxy)-2-nitroaniline as the starting material.
Step 2. 4-Bromo-3-(2,4-difluorophenoxy)-N-methyl-2-nitroaniline
Figure imgf000166_0001
This compound was synthesized according to the procedure of Example 4, Step 2, using N-[4-bromo-3-(2,4-difluorophenoxy)-2-nitrophenyl]-2,2,2-trifluoroacetamide as the starting material. LCMS calculated for Ci3HioBrF2N203 (M+H)+: m/z = 359.0, 361.0; found: 359.0, 361.0.
Step 3. 4-Bromo-3-(2,4-difluorophenoxy)-N-methyl-2-nitroaniline
Figure imgf000166_0002
This compound was synthesized according to the procedure of Example 1 , Step 3, using 4-bromo-3-(2,4-difluorophenoxy)-N-methyl-2-nitroaniline as the starting material. LCMS calculated for Ci3Hi2BrF2N20 (M+H)+: m/z = 329.0, 331.0; found: 329.0, 330.9.
Step 4. 4-Bromo-3-(2,4-difluorophenoxy)-N-methyl-2-nitroaniline
Figure imgf000166_0003
This compound was synthesized according to the procedure of Examples 30 and 31 , Step
6, using 4-bromo-3-(2,4-difluorophenoxy)-N1-methylbenzene-l ,2-diamine as the starting material. LCMS calculated for Ci4HioBrF2N20 (M+H)+: m/z = 339.0, 341.0; found: 338.9, 340.9. Step 5. 4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-l-[(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000167_0001
A suspension of 5-bromo-4-(2,4-difluorophenoxy)-l-methyl-lH-benzimidazole (0.300 g, 0.885 mmol) and potassium acetate (0.260 g, 2.65 mmol) in ethanol (6.63 mL) was degassed with nitrogen for 5 min, treated with tetrahydroxydiborane (0.238 g, 2.65 mmol),
dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (0.0056 g, 0.012 mmol), and dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine - (2'-aminobiphenyl-2- yl)(chloro)palladium (1 : 1) (0.0035 g, 0.0044 mmol). The resultant reaction mixture was degassed with nitrogen for another 5 min, warmed to 80 °C and stirred at that temperature for 17 h, after which time the reaction mixture was cooled to RT, degassed with nitrogen for 5 min, treated with previously degassed 1.8M solution of potassium carbonate in water (1.47 mL, 2.65 mmol), followed by addition of 4-bromo-l-[(4-methylphenyl)sulfonyl]-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one (0.108 g, 0.295 mmol) and dicyclohexyl(2',4',6'- triisopropylbiphenyl-2-yl)phosphine - (2'-aminobiphenyl-2-yl)(chloro)palladium (1 : 1) (0.0046 g, 0.0059 mmol). The resultant reaction mixture was degassed with nitrogen for another 5 min, and heated at 90 °C for 2 h. The reaction mixture was diluted with saturated sodium bicarbonate solution and ethyl acetate. The precipitate was collected by filtration, layers of filtrate were separated and the organic layer was dried with sodium sulfate, filtered, and concentrated to give a crude residue. This crude residue was combined with the previously collected solid precipitate and purified by flash column chromatography (100% CH2CI2 to 12% MeOH/CffcCk) gave the desired product (84.8 mg, 53%) as a yellow solid. LCMS calculated for C28H21F2N4O4S (M+H)+: m/z = 547.1; found: 547.0.
Step 6. 4-f4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-ylJ-l,6-dihydro-7H-pyrrolof2,
3- cJpyridin- 7 -one
This compound was synthesized according to the procedure of Example 8, Step 2, using
4- [4-(2,4-difluorophenoxy)- 1 -methyl- lH-benzimidazol-5-yl]- 1 -[(4-methylphenyl)sulfonyl]-l ,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. JH NMR (400 MHz, DMSO- de) δ 12.01 (br s, 1H), 10.97 (d, J= 5.7 Hz, 1H), 8.12 (s, 1H), 7.55 (d, J= 8.4 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.34 - 7.17 (m, 2H), 6.82 (d, J= 5.7 Hz, 1H), 6.80 - 6.66 (m, 1H), 6.66 - 6.47 (m, 1H), 6.15 (s, 1H), 3.87 (s, 3H); LCMS calculated for C21H15F2N4O2 (M+H)+: m/z = 393.1; found: 393.1.
Example 83. 4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-6-ethyl-l,6- dihydr o-7H-pyrrolo [2,3-c] pyridin-7-one
Figure imgf000168_0001
Step 1. 4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-ylJ-6-ethyl-l-[(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000168_0002
A suspension of 4-[4-(2,4-difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (33.2 mg, 0.0607 mmol) in tetrahydrofuran (1.0 mL) at 0 °C was treated with 1.0 M solution of potassium tert- butoxide in THF (0.0850 mL, 0.0850 mmol) and the resultant reaction mixture was stirred at 0 °C for 30 min, after which time the reaction mixture was treated with iodoethane (0.00680 mL, 0.0850 mmol), warmed to RT and stirred at RT for 19 h. The reaction mixture was quenched with saturated ammonium chloride solution, diluted with water, and extracted with ethyl acetate. Layers were separated and the organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give a crude residue. Purification via preparative LCMS (XBridge C18 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) gave the desired product (15.4 mg, 44%). LCMS calculated for C30H25F2N4O4S (M+H)+: m/z = 575.2; found: 575.1. Step 2. 4-f4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-ylJ-6-ethyl-l,6-dihydro-7H- pyrrolo[2, 3-cJpyridin- 7 -one
This compound was synthesized according to the procedure of Example 8, Step 2, using 4-[4-(2,4-difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-6-ethyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. XH NMR (400 MHz, DMSO-ώ) δ 11.99 (br s, 1H), 8.14 (s, 1H), 7.56 (d, J= 8.4 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.31 - 7.19 (m, 2H), 7.15 (s, 1H), 6.80 - 6.68 (m, 1H), 6.65 - 6.47 (m, 1H), 6.12 (d, J= 2.8 Hz, 1H), 3.96 (q, J= 7.1 Hz, 2H), 3.88 (s, 3H), 1.16 (t, J = 7.1 Hz, 3H); LCMS calculated for C23H19F2N4O2 (M+H)+: m/z = 421.1; found: 421.0.
Example 84. 6-Benzyl-4-[4-(2,4-difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-l,6- dihydr o-7H-pyrrolo [2,3-c] pyrid -7-one trifluoroacetate
Figure imgf000169_0001
This compound was synthesized according to the procedure of Example 83 using benzyl bromide in Step 1 instead of iodoethane. ¾ NMR (500 MHz, DMSO-ώ) δ 12.04 (s, 1H), 8.51 (br s, 1H), 7.67 (d, J= 8.4 Hz, 1H), 7.47 (d, J= 8.4 Hz, 1H), 7.34 - 7.03 (m, 8H), 6.78 - 6.58 (m, 1H), 6.59 - 6.40 (m, 1H), 6.32 - 5.92 (m, 1H), 5.16 (s, 2H), 3.93 (s, 3H); LCMS calculated for C28H21F2N4O2 (M+H)+: m z = 483.2; found: 483.1.
Example 85. {4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-7- dihydr o-6H-pyrrolo [2,3-c] pyridin-6-yl} acetonitrile trifluoroacetate
Figure imgf000170_0001
Step 1. {4-Bromo-l-[ (4-methylphenyl)sulfonyl] -7-oxo- 1 , 7-dihydro-6H-pyrrolo [2 ,3-c] pyridin-6- yljacetonitrile
Figure imgf000170_0002
This compound was synthesized according to the procedure of Example 83, Step 1, using
4-bromo-l-[(4-methylphenyl)sulfonyl]-lH-pyrrolo[2,3-c]pyridin-7-ol and bromoacetonitrile as the starting materials. LCMS calculated for CieHisBrNsOsS (M+H)+: m/z = 406.0, 408.0; found: 405.9, 407.9. Step 2. {4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-l-[(4- methylphenyl)sulfonylJ- 7-oxo- 1, 7-dihydro-6H-pyrrolo[ 2, 3-c] pyridin-6-yl}acetonitrile
Figure imgf000170_0003
This compound was synthesized according to the procedure of Example 82, Step 5, using {4-bromo- 1 -[(4-methylphenyl)sulfonyl]-7-oxo- 1 ,7-dihydro-6H-pyrrolo[2,3-c]pyridin-6- yl}acetonitrile instead of 4-bromo-l-[(4-methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one. LCMS calculated for C30H22F2N5O4S (M+H)+: m/z = 586.1; found: 586.0.
Step 3. {4-[4-(2,4-Difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-7-oxo-l, 7-dihydro-6H- pyrrolo[2, 3-c] pyridin-6-yl}acetonitrile trifluoroacetate
A 1.0 M solution of tetra-n-butylammonium fluoride in THF (0.330 mL, 0.330 mmol) was added dropwise to a solution of {4-[4-(2,4-difluorophenoxy)-l-methyl-lH-benzimidazol-5- yl]-l -[(4-methylphenyl)sulfonyl]-7-oxo- 1 ,7-dihydro-6H-pyrrolo[2,3-c]pyridine-6-yl} acetonitrile (38.6 mg, 0.0659 mmol) in tetrahydrofuran (1.00 mL), and the resultant reaction mixture was stirred at RT for 30 min. The reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water containing 0.1% trifluoroacetic acid, at flow rate of 60 mL/min) to give the desired product (13.8 mg, 38%) as a white solid. ¾ NMR (400 MHz, DMSO-ώ) δ 12.28 (s, 1H), 8.51 (br s, 1H), 7.67 (d, J= 8.4 Hz, 1H), 7.45 (d, J= 8.4 Hz, 1H), 7.39 - 7.27 (m, 2H), 7.26 - 7.11 (m, 1H), 6.82 - 6.67 (m, 1H), 6.67 - 6.49 (m, 1H), 6.19 - 6.06 (m, 1H), 5.10 (s, 2H), 3.94 (s, 3H); LCMS calculated for C23H16F2N5O2 (M+H)+: m/z = 432.0; found: 432.0. Example 86. 4-(4-Chlorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2, 3-c]pyridin-4-yl)-l,3-dihydro-2H-benzimidazol-2-one
Figure imgf000171_0001
Step 1. 4-[2-Fluoro-4-(methylamino)-3-nitrophenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H^yrrolo[2,3-c]pyridin-7-one
Figure imgf000172_0001
This compound was synthesized according to the procedure of Example 10, Step 5, using 4-bromo-3-fluoro-N-methyl-2-nitroaniline and 6-methyl-4-(4,4,5,5-tetramethyl-l ,3,2- dioxaborolan-2-yl)-l-{[2-(trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin- 7-one as the starting materials. LCMS calculated for C21H28FN4O4S1 (M+H)+: m/z = 447.2; found: 447.1.
Step 2. 4- [2-(4-Chlorophenoxy)-4-(methylamino)-3-nitrophenyl] -6-methyl- 1-{ [2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Figure imgf000172_0002
This compound was synthesized according to the procedure of Example 1, Step 1, using 4- [2-fluoro-4-(methylamino)-3 -nitrophenyl] -6-methyl- 1 - { [2-(trimethylsilyl)ethoxy]methyl} -1,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one and /?-chlorophenol as the starting materials. LCMS calculated for C27H32ClN405Si (M+H)+: m/z = 555.2; found: 555.1.
Step 3. 4- [3-Amino-2-(4-chlorophenoxy)-4-(methylamino)phenyl] -6-methyl- 1-{ [2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one
Figure imgf000173_0001
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-[2-(4-chlorophenoxy)-4-(methylamino)-3-nitrophenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for C27H34CIN4O3S1 (M+H)+: m/z = 525.2; found: 525.1.
Step 4. 4-(4-chlorophenoxy)-l-methyl-5-(6-methyl-7-oxo-l-{[2-(trimethylsilyl)ethoxyJmethyl}-6, 7-dihydro-lH-pyrrolof 2, 3-c]pyridin-4- l)-l, 3-dihydro-2H-benzimidazol-2-one
Figure imgf000173_0002
This compound was synthesized according to the procedure of Example 6, Step 1, using
4-[3-amino-2-(4-chlorophenoxy)-4-(methylamino)phenyl]-6-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for C28H32ClN404Si (M+H)+: m/z = 551.2; found: 551.1. Step 5. 4-(4-Chlorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3- c] pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Trifluoroacetic acid (1.50 mL) was added dropwise to a solution of 4-(4- chlorophenoxy)- 1 -methyl-5 -(6-methyl-7-oxo- 1 - { [2-(trimethylsilyl)ethoxy]methyl} -6,7-dihydro- lH-pyrrolo[2,3-c]pyridin-4-yl)-l,3-dihydro-2H-benzimidazol-2-one (0.057 g, 0.103 mmol) in methylene chloride (0.50 mL), and the resultant reaction mixture was stirred at RT for 3 h, after which time the reaction mixture was concentrated in vacuo to give a residue. This residue was dissolved in methanol (0.50 mL), treated with ethylenediamine (0.131 mL, 1.95 mmol) dropwise, and the resultant solution was stirred at RT for 16 h. The reaction mixture was purified via preparative LCMS (XBridge CI 8 column, eluting with a gradient of acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (24.6 mg, 60%). lH NMR (400 MHz, DMSO-ώ) δ 11.96 (br s, 1H), 11.20 (br s, 1H), 7.23 (dd, J= 2.7, 2.7 Hz, 1H), 7.21 - 6.99 (m, 5H), 6.70 - 6.48 (m, 2H), 6.25 - 6.06 (m, 1H), 3.43 (s, 3H), 3.33 (s, 3H); LCMS calculated for C22H18CIN4O3 (M+H)+: m/z = 421.1; found: 421.1.
Example 87. 4-(3-Chlorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2, 3-c]pyridin-4-yl)-l,3-dihydro-2H-benzimidazol-2-one
Figure imgf000174_0001
This compound was synthesized according to the procedure of Example 86 using 3- chlorophenol in Step 2 instead of/?-chlorophenol. ¾ NMR (400 MHz, DMSO-ώ) δ 11.97 (br s, 1H), 11.24 (s, 1H), 7.24 (dd, J= 2.8, 2.8 Hz, 1H), 7.22 - 7.05 (m, 4H), 6.94 - 6.86 (m, 1H), 6.62 (dd, J= 2.2, 2.2 Hz, 1H), 6.60 - 6.47 (m, 1H), 6.32 - 6.02 (m, 1H), 3.43 (s, 3H), 3.34 (s, 3H); LCMS calculated for C22H18CIN4O3 (M+H)+: m/z = 421.1; found: 421.0.
Example 88. 4-(Cyclohexylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo [2,3-c] pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000175_0001
Step 1. 4-Bromo-3- ( yclohexylmethoxy)-N-methyl-2-nitroaniline
Figure imgf000175_0002
This compound was synthesized according to the procedure of Example 11, Step 1, using 4-bromo-3-fluoro-N-methyl-2-nitroaniline and cyclohexanemethanol as the starting materials. LCMS calculated for Ci4H2oBrN203 (M+H)+: m/z = 343.1, 345.1; found: 343.0, 345.1.
Step 2. 4-[2-(Cyclohexylmethoxy)-4-(methylamino)-3-nitrophenyl]-6-methyl-l-[(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[ 2, 3-cJpyridin- 7 -one
Figure imgf000175_0003
This compound was synthesized according to the procedure of Example 10, Step 5, using 6-methyl-l-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one and 4-bromo-3-(cyclohexylmethoxy)-N-methyl-2- nitroaniline as the starting materials. LCMS calculated for C29H33N4O6S (M+H)+: m/z = 565.2; found: 565.1.
Step 4. 4-[3-Amino-2-(cyclohexylmethoxy)-4-(methylamino)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000176_0001
This compound was synthesized according to the procedure of Example 1, Step 3, using 4- [2-(cyclohexylmethoxy)-4-(methylamino)-3 -nitrophenyl] -6-methyl- 1 - [(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for C29H35N4O4S (M+H)+: m/z = 535.2; found: 535.2.
Step 5. 4-(Cyclohexylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3- c] pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000176_0002
This compound was synthesized according to the procedure of Example 1, Step 4, using 4-[3-amino-2-(cyclohexylmethoxy)-4-(methylamino)phenyl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. XH NMR (400 MHz, DMSO-ώ) δ 11.98 (br s, 1H), 11.06 (s, 1H), 7.25 (dd, J= 2.7, 2.7 Hz, 1H), 7.18 (s, 1H), 7.02 (d, J= 8.0 Hz, 1H), 6.91 (d, J= 8.1 Hz, 1H), 6.09 (dd, J= 2.3, 2.3 Hz, 1H), 3.54 (s, 3H), 3.44 (d, J= 5.9 Hz, 2H), 3.29 (s, 3H), 1.56 - 1.33 (m, 6H), 1.12 - 0.80 (m, 3H), 0.75 - 0.49 (m, 2H); LCMS calculated for C23H27N4O3 (M+H)+: m/z = 407.2; found: 407.1.
Example 94. 6-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-5-phenoxy-2H- l,4-benzoxazin-3(4H)-one
Figure imgf000177_0001
Step 1. l-Fluoro-3-methoxy-2-nitrobenze
Figure imgf000177_0002
This compound was synthesized according to the procedure of Example 76, Step 5, using 3-fluoro-2-nitrophenol [Combi-Blocks, OR-7136] and methanol as the starting materials.
Step 2. l-Bromo-2-fluoro-4-methoxy-3-nitrobenzene
Figure imgf000177_0003
Bromine (1.55 mL, 30.1 mmol) was added dropwise to a solution of l-fluoro-3-methoxy- 2-nitrobenzene (1.29 g, 7.53 mmol) in acetic acid (15.1 mL). The reaction mixture was warmed to 55 °C and stirred at 55 °C for 17 h, after which time the reaction mixture was concentrated in vacuo to give a crude solid. The crude solid was diluted with saturated sodium bicarbonate solution and extracted with ethyl acetate. Layers were separated and the organic layer was washed with saturated sodium bicarbonate solution, dried with sodium sulfate, filtered, and concentrated in vacuo to give the desired product (1.87 g, 99%) as a yellow solid that was used in further step without purification.
Step 3. l-Bromo-4-methoxy-3-nitro-2-phenoxybenzene
Figure imgf000178_0001
This compound was synthesized according to the procedure of Example 1, Step 1, using l-bromo-2-fluoro-4-methoxy-3 -nitrobenzene and phenol as the starting materials.
Step 4. l-Bromo-4-methoxy-3-nitro-2-phenoxybenzene
Figure imgf000178_0002
A solution of l-bromo-4-methoxy-3-nitro-2-phenoxybenzene (0.709 g, 2.19 mmol) in methylene chloride (8.76 mL) at -78 °C was treated with 1.0 M solution of boron tribromide in dichloromethane (4.37 mL, 4.37 mmol) and stirred at RT for 30 min, after which time the reaction mixture was quenched with saturated sodium bicarbonate solution and extracted with dichloromethane (2x). The combined organic layers were washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give the desired product (673 mg g, 99%) as a yellow solid that was used in further step without purification.
Step 5. 2-Amino-4-bromo-3-phenoxyphenol
Figure imgf000178_0003
A solution of 4-bromo-2-nitro-3-phenoxyphenol (0.468 g, 1.51 mmol) in ethanol (11.2 mL, 192 mmol) was degassed with nitrogen and treated with a slurry of Raney Nickel 2800 in water (0.468 ml). The reaction mixture was degassed again with nitrogen and hydrogenated with a balloon of hydrogen for 30 min. The reaction suspension was diluted with dichloromethane and methanol and filtered through a pad of Celite. The pad of Celite was washed with ethyl acetate and dichloromethane and the filtrate was concentrated in vacuo to give brown
oil. Purification by flash column chromatography (100% CH2CI2 to 30% CH3CN/CH2CI2
[CH3CN contained 5% MeOH]) gave the desired product (346 mg, 82%) as a tan solid. LCMS calculated for Ci2HnBrN02 (M+H)+: m/z = 280.0, 282.0; found: 280.0, 282.0.
Step 6. 6-Bromo-5-phenoxy-2H-l,4-benzoxazin-3 4H)-one
Figure imgf000179_0001
A solution of 2-amino-4-bromo-3-phenoxyphenol (0.060 g, 0.214 mmol) in acetonitrile (3.88 mL) and water (1.21 mL) was treated with potassium carbonate (0.118 g, 0.857
mmol), followed by the addition of bromoacetyl bromide (0.0279 mL, 0.321 mmol), and the resultant reaction mixture was stirred at RT for 30 min, after which time additional bromoacetyl bromide (0.0186 mL, 0.214 mmol) was added dropwise and the reaction mixture was stirred at RT for 1 h, then warmed to 75 °C and stirred at that temperature for 30 min. The reaction mixture was concentrated and diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo the yield a crude product. Purification by flash column chromatography (100% hexanes to 50%) EtOAc/hexanes) gave the desired product (59.5 mg, 87%) as a white solid. LCMS calculated for CnHnBrNOs (M+H)+: m/z = 320.0, 322.0; found: 319.9, 321.9.
Step 7. 6-{6-Methyl-l-f(4-methylphenyl)sulfonylJ-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin- 4-yl}-5-phenoxy-2H-l,4-benzoxazin-3 4H)-one
Figure imgf000179_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using 6-bromo-5-phenoxy-2H-l,4-benzoxazin-3(4H)-one and 6-methyl-l-[(4- methylphenyl)sulfonyl]-4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C29H24N3O6S (M+H)+: m/z = 542.1 ; found: 542.0.
Step 8. 6-(6-Methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-5-phenoxy-2H-l,4- benzoxazin-3( 4H)-one
This compound was synthesized according to the procedure of Example 8, Step 2, using 6-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl}-5- phenoxy-2H-l,4-benzoxazin-3(4H)-one as the starting material. lH NMR (500 MHz, DMSO-ώ) δ 11.89 (br s, 1H), 10.58 (br s, 1H), 7.23 (d, J= 2.7 Hz, 1H), 7.10 - 7.04 (m, 3H), 7.03 (s, 1H), 6.99 (d, J= 8.4 Hz, 1H), 6.81 (dd, J= 7.3, 7.3 Hz, 1H), 6.68 - 6.49 (m, 2H), 6.17 (d, J= 2.8 Hz, 1H), 4.64 (s, 2H), 3.38 (s, 3H); LCMS calculated for C22H18N3O4 (M+H)+: m/z = 388.1; found: 388.1.
Example 95. 2,2-Dimethyl-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- 5-phenoxy-2H-l,4-benzoxazin-3(4H)-one
Figure imgf000181_0001
This compound was synthesized according to the procedure of Example 94 using 2- bromo-2-methylpropanoyl bromide, in Step 6 instead of bromoacetyl bromide. XH NMR (500 MHz, DMSO-ώ) δ 11.89 (br s, 1H), 10.49 (br s, 1H), 7.23 (d, J= 2.6 Hz, 1H), 7.14 - 7.02 (m, 4H), 6.98 (d, J= 8.4 Hz, 1H), 6.82 (dd, J= 7.3, 7.3 Hz, 1H), 6.55 (d, J= 8.0 Hz, 2H), 6.19 (d, J = 2.6 Hz, 1H), 3.38 (s, 3H), 1.44 (s, 6H); LCMS calculated for C24H22N3O4 (M+H)+: m/z = 416.2; found: 416.1.
Example 96. 6-Methyl-4-(4-phenoxy-l,3-benzoxazol-5-yl)-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one
Figure imgf000181_0002
Step 1. 5-Bromo-4-phenoxy-l,3-benzoxazole
Figure imgf000181_0003
A solution of 2-amino-4-bromo-3-phenoxyphenol (0.075 g, 0.268 mmol) in ethyl orthoformate (0.405 mL, 2.43 mmol) was heated at 100 °C for 2.5 h. after which time the reaction mixture was cooled to RT and concentrated in vacuo to a crude residue. Purification by flash column chromatography (100% hexanes to 50% EtOAc/hexanes) gave the desired product (75.1 mg, 97%) as a white solid. LCMS calculated for CisffeBrNC (M+H)+: m/z = 290.0, 292.0; found: 289.9, 291.9.
Step 2. 6-Methyl-l-f(4-methylphenyl)sulfonylJ-4-(4-phenoxy-l,3-benzoxazol-5-yl)-l,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one
Figure imgf000182_0001
This compound was synthesized according to the procedure of Example 10, Step 5, using 5-bromo-4-phenoxy-l,3-benzoxazole and 6-methyl-l-[(4-methylphenyl)sulfonyl]-4-(4,4,5, 5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C28H22N3O5S (M+H)+: m/z = 512.1; found: 512.0.
Step 3. 6-Methyl-4- ( 4-phenoxy-l, 3-benzoxazol-5-yl)-l , 6-dihydro- 7H-pyrrolo[ 2, 3-cJpyridin- 7- one
This compound was synthesized according to the procedure of Example 85, Step 3, using 6-methyl- 1 -[(4-methylphenyl)sulfonyl]-4-(4-phenoxy-l ,3-benzoxazol-5-yl)- 1 ,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. JH NMR (500 MHz, DMSO-ώ) δ 11.99 (br s, 1H), 8.68 (s, 1H), 7.74 (d, J= 8.4 Hz, 1H), 7.57 (d, J= 8.4 Hz, 1H), 7.24 (dd, J= 2.7, 2.7 Hz, 1H), 7.21 - 7.09 (m, 3H), 6.91 (dd, J= 7.3, 7.3 Hz, 1H), 6.71 (d, J= 8.0 Hz, 2H), 6.17 (dd, J = 2.2, 2.2 Hz, 1H), 3.46 (s, 3H); LCMS calculated for C21H16N3O3 (M+H)+: m z = 358.1; found: 358.1.
Example 97. l-Methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo [2,3-c] pyridin-4-yl)-4- (phenylthio)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000183_0001
Step 1. 4-Bromo-N-methyl-2-nitro-3-(phenylthio)aniline
Figure imgf000183_0002
A solution of 4-bromo-3-fluoro-N-methyl-2-nitroaniline (0.30 g, 1.20 mmol) m N,N- dimethylformamide (2.45 mL) was treated with cesium carbonate (0.472 g, 1.45
mmol) and benzenethiol (0.149 mL, 1.45 mmol). The resultant reaction mixture was warmed to 80 °C and stirred at 80 °C for 30 min, after which time the reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with 10% solution of K2CO3 and brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give the crude product. Purification by flash column chromatography (100% hexanes to 40% EtOAc/hexanes) gave the desired product (396 mg, 97%) as an orange solid. LCMS calculated for Ci3Hi2BrN202S (M+H)+: m/z = 339.0, 341.0; found: 338.9, 340.9.
Step 2. 4-Bromo-Nl-methyl-3-(phenylthio)benzene-l,2-diamine
Figure imgf000183_0003
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-bromo-N-methyl-2-nitro-3-(phenylthio)aniline as the starting material. LCMS calculated for Ci3Hi4BrN2S (M+H)+: m/z = 309.0, 311.0; found: 309.0, 310.9.
Step 3. 5-Bromo-l-methyl-4-(phenylthio)-l, 3-dihydro-2H-benzimidazol-2-one
Figure imgf000184_0001
This compound was synthesized according to the procedure of Example 6, Step 1, using 4-bromo-Nl-methyl-3-(phenylthio)benzene-l,2-diamine as the starting material. LCMS calculated for Ci4Hi2BrN2OS (M+H)+: m/z = 335.0, 337.0; found: 334.9, 336.9.
Step 4. l-Methyl-5-{6-methyl-l-[ (4-methylphenyl)sulfonyl]-7-oxo-6, 7-dihydro-l H-pyrrolo [2 ,3- c] pyridin-4-yl}-4-(phenylthio)- 1 ,3-dih dro-2H-benzimidazol-2-one
Figure imgf000184_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using 5-bromo-l-methyl-4-(phenylthio)-l,3-dihydro-2H-benzimidazol-2-one and 6-methyl-l- [(4-methylphenyl)sulfonyl]-4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C2 H25N404S2 (M+H)+: m/z = 557.1; found: 557.0. Step 5. l-Methyl-5-(6-methyl-7-oxo-6, 7-dihydro- lH-pyrrolo [2 ,3-c] pyridin-4-yl)-4-(phenylthio)- l,3-dihydro-2H-benzimidazol-2-one
This compound was synthesized according to the procedure of Example 8, Step 2, using l-methyl-5-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl}-4-(phenylthio)-l,3-dihydro-2H-benzimidazol-2-one as the starting material. lH NMR (500 MHz, DMSO-ώ) δ 11.95 (br s, 1H), 11.10 (br s, 1H), 7.26 (d, J= 8.0 Hz, 1H), 7.20 (s, 1H), 7.18 - 7.11 (m, 3H), 7.04 (dd, J= 7.4, 7.4 Hz, 1H), 6.88 (s, 1H), 6.82 (d, J= 7.4 Hz, 2H), 5.92 (d, J= 2.3 Hz, 1H), 3.40 (s, 3H), 3.33 (s, 3H); LCMS calculated for C22Hi9N402S (M+H)+: m/z = 403.1 ; found: 403.1.
Example 98. 4-(Ethylthio)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c] pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000185_0001
Step 1. 4-Bromo-3-(ethylthio)-N-methyl- -nitroaniline
Figure imgf000185_0002
This compound was synthesized according to the procedure of Example 1 1 , Step 1 , using 4-bromo-3-fluoro-N-methyl-2-nitroaniline and ethanethiol as the starting materials. LCMS calculated for C9Hi2BrN202S (M+H)+: m/z = 291.0, 293.0; found: 290.9, 292.9.
Step 2. 4-Bromo-3-(ethylthio)-Nl-methylbenzene-l,2-diamine
Figure imgf000185_0003
This compound was synthesized according to the procedure of Example 1 , Step 3, usin 4-bromo-3-(ethylthio)-N-methyl-2-nitroaniline as the starting material. LCMS calculated for C9Hi4BrN2S (M+H)+: m/z = 261.0, 263.9; found: 261.0, 263.9.
Step 3. 5-Bromo-4-(ethylthio)-l-methyl-l,3-dihydro-2H-benzimidazol-2-one
Figure imgf000186_0001
This compound was synthesized according to the procedure of Example 6, Step 1 , using 4-bromo-3-(ethylthio)-Nl-methylbenzene-l ,2-diamine as the starting material. LCMS calculated for CioHi2BrN2OS (M+H)+: m/z = 287.0, 289.0; found: 286.9, 288.9.
Step 4. 4-(Ethylthio)-l-methyl-5-{6-methyl-l-[ (4-methylphenyl)sulfonylJ-7-oxo-6, 7-dihydro-lH- pyrrolo [2,3-c] pyridin-4-yl}- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000186_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using 5-bromo-4-(ethylthio)-l-methyl-l ,3-dihydro-2H-benzimidazol-2-one and 6-methyl-l-[(4- methylphenyl)sulfonyl]-4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C25H25N404S2 (M+H)+: m/z = 509.1 ; found: 509.1. Step 5. 4-(Ethylthio)-l-methyl-5-(6-methyl-7-oxo-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-l,
3- dihydro-2H-benzimidazol-2-one
This compound was synthesized according to the procedure of Example 8, Step 2, using
4- (ethylthio)- 1 -methyl-5- {6-methyl- 1 -[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro- 1 H- pyrrolo[2,3-c]pyridin-4-yl}-l ,3-dihydro-2H-benzimidazol-2-one as the starting material. lH NMR (500 MHz, DMSO-ώ) δ 1 1.96 (br s, 1H), 1 1.03 (br s, 1H), 7.21 (s, 1H), 7.12 (d, J = 8.0
Hz, 1H), 7.09 - 6.97 (m, 2H), 5.96 - 5.80 (m, 1H), 3.54 (s, 3H), 3.31 (s, 3H), 2.52 (q, J = 7.4 Hz, 2H), 0.84 (t, J = 7.3 Hz, 3H); LCMS calculated for Ci8Hi9N402S (M+H)+: m z = 355.1 ; found: 355.1.
Example 99. 4-(Ethylsulfonyl)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c] pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one
Figure imgf000187_0001
A suspension of 4-(ethylthio)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-l,3-dihydro-2H-benzimidazol-2-one (0.0424 g, 0.120 mmol) in methylene chloride (11.4 mL, 178 mmol) at 0 °C was treated with m-chloroperbenzoic acid (0.0938 g, 0.419 mmol) (77% MCPBA) and stirred at room temperature for 17 h. The reaction mixture was concentrated in vacuo and the crude residue was dissolved in ethyl acetate. The resultant solution was washed with 10%> solution of Na2S203, saturated sodium bicarbonate solution, and brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give a crude residue.
Purification by preparative LCMS (XBridge CI 8 column, eluting with a gradient of
acetonitrile/water 0.1% ammonium hydroxide, at flow rate of 60 mL/min) to give the desired product (7.2 mg, 16%) as a white solid. ¾ NMR (300 MHz, DMSO-ώ) δ 12.08 (br s, 1H), 10.50 (br s, 1H), 7.45 (d, J= 8.0 Hz, 1H), 7.23 (d, J= 2.5 Hz, 1H), 7.19 - 6.99 (m, 2H), 5.84 (s, 1H), 3.52 (s, 3H), 3.36 (s, 3H), 3.16 - 2.75 (m, 2H), 0.97 (t, J= 7.3 Hz, 3H); LCMS calculated for C18H19N4O4S (M+H)+: m/z = 387.1; found: 387.1. Example 100. 4-Methyl-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-5- phenoxy-2H- 1 ,4-benzoxazin-3(4H)-one
Figure imgf000188_0001
Step 1. 6-Bromo-4-methyl-5-phenoxy-2H- 1 ,4-benzoxazin-3 (4H)-one
Figure imgf000188_0002
This compound was synthesized according to the procedure of Example 83, Step 1 , using 6-bromo-5-phenoxy-2H-l ,4-benzoxazin-3(4H)-one and methyl iodide as the starting materials. LCMS calculated for CisHisBrNOs (M+H)+: m/z = 334.0, 336.0; found: 333.9, 335.9.
Step 2. 4-Methyl-6-{6-methyl-l-[ (4-methylphenyl)sulfonyl]-7-oxo-6, 7-dihydro-lH-pyrrolo [2 ,3- c] pyridin-4-yl}-5-phenoxy-2H- 1 ,4-benzoxazin-3 4H)-one
Figure imgf000188_0003
This compound was synthesized according to the procedure of Example 10, Step 5, using 6-bromo-4-methyl-5-phenoxy-2H-l ,4-benzoxazin-3(4H)-one and 6-methyl-l-[(4- methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)-l ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C30H26N3O6S (M+H)+: m/z = 556.2; found: 556.0.
Step 3. 4-Methyl-6-(6-methyl-7-oxo-6 -dihydro-lH^yrrolo[2,3-c]pyridin-4-yl)-5^henoxy-2H- l,4-benzoxazin-3(4H)-one This compound was synthesized according to the procedure of Example 8, Step 2, using 4-methyl-6-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl}-5-phenoxy-2H-l,4-benzoxazin-3(4H)-one as the starting material. lH NMR (500 MHz, DMSO-ώ) δ 11.90 (br s, 1H), 7.28 - 7.15 (m, 2H), 7.14 - 7.02 (m, 4H), 6.84 (dd, J= 7.3, 7.3 Hz, 1H), 6.57 (d, J= 7.9 Hz, 2H), 6.22 (d, J= 2.7 Hz, 1H), 4.66 (s, 2H), 3.40 (s, 3H), 3.26 (s, 3H); LCMS calculated for C23H20N3O4 (M+H)+: m/z = 402.1; found: 402.1.
Example 101. 4-Benzyl-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-5- henoxy-2H- 1 ,4-benzoxazin-3(4H)-one
Figure imgf000189_0001
This compound was synthesized according to the procedure of Example 100 using benzyl bromide in step 1 instead of methyl iodide. ¾ NMR (400 MHz, DMSO-ώ) δ 11.87 (br s, 1H), 7.38 - 7.26 (m, 2H), 7.26 - 7.02 (m, 8H), 6.92 (s, 1H), 6.85 (dd, J= 7.3, 7.3 Hz, 1H), 6.58 - 6.40 (m, 2H), 5.72 (d, J= 1.9 Hz, 1H), 5.14 (s, 2H), 4.78 (s, 2H), 3.36 (s, 3H); LCMS calculated for C29H24N3O4 (M+H)+: m/z = 478.2; found: 478.2.
Example 102. 6-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-(2- morpholin-4-ylethyl)-5-phenoxy-2 one trifluoroacetate
Figure imgf000189_0002
This compound was synthesized according to the procedure of Example 100 using 4-(2- bromoethyl)morpholine hydrochloride in step 1 instead of methyl iodide. lH NMR (400 MHz, DMSC ¾) 5 11.96 (br s, 1H), 7.30 - 7.23 (m, 2H), 7.16 (d, J= 8.4 Hz, 1H), 7.10 (dd, J= 8.6, 7.4 Hz, 2H), 7.05 (s, 1H), 6.86 (dd, J= 7.4, 7.4 Hz, 1H), 6.60 (d, J= 7.8 Hz, 2H), 6.30 - 6.18 (m, 1H), 4.74 (s, 2H), 4.33 - 4.13 (m, 4H), 4.13 - 3.82 (m, 4H), 3.81 - 3.54 (m, 2H), 3.39 (s, 3H), 3.18 - 2.90 (m, 2H); LCMS calculated for C28H29N4O5 (M+H)+: m/z = 501.2; found: 501.1.
Example 103. 4- [2-(Aminomethyl)-4-phenoxy- 1 ,3-benzoxazol-5-yl] -6-methyl- 1 ,6-dihydr 0- 7H-pyr rolo [2,3-c] pyridin-7-one
Figure imgf000190_0001
tert-Butyl {2-[(3-bromo-6-hydrox -2-phenoxyphenyl)amino]-2-oxoethyl}carbamate
Figure imgf000190_0002
A solution of N-a-(tert-butoxycarbonyl)glycine (0.172 g, 0.982 mmol) in N,N- dimethylformamide (3.57 mL) was treated with N,N-carbonyldiimidazole (0.174 g, 1.07 mmol), stirred at RT for 30 min, treated with 2-amino-4-bromo-3-phenoxyphenol (0.250 g, 0.892 mmol) and stirred at RT for 1 h and then at 60 °C for 16 h. The reaction mixture was diluted with ethyl acetate and washed with water, 0.1M solution of HCl, saturated sodium bicarbonate solution, and brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give a crude residue. Purification by flash column chromatography (100% hexanes to 30% EtOAc/hexanes) gave the desired product (376 mg, 96%) as a tan foam. LCMS calculated for Ci H2iBrN20sNa (M+Na)+: m/z = 459.1, 461.1; found: 459.0, 461.0.
Step 2. tert-Butyl [ (5-bromo-4-phenoxy-l, 3-benzoxazol-2-yl)methylJ carbamate
Figure imgf000191_0001
A mixture of tert-butyl {2-[(3-bromo-6-hydroxy-2-phenoxyphenyl)amino]-2- oxoethyl} carbamate (0.298 g, 0.681 mmol), triphenylphosphine (0.393 g, 1.50 mmol), and freshly activated 4A molecular sieves (2.72g, 4g / mmol) at 0 °C was treated with
tetrahydrofuran (10.2 mL) and stirred at 0 °C for 1 h, followed by dropwise addition of diisopropyl azodicarboxylate (0.295 mL, 1.50 mmol) at this temperature. The resultant reaction mixture was warmed to RT and stirred at RT for 16 h, after which time the reaction mixture was filtered through a pad of Celite and washed with ethyl acetate. The filtrate was concentrated in vacuo to yield a crude residue that was purified by flash column chromatography (100% hexanes to 40%) EtOAc/hexanes) to give the desired product (207 mg, 72%) as a tan solid. LCMS calculated for Ci9Hi9BrN204Na (M+Na)+: m/z = 441.0, 443.0; found: 441.0, 443.0. tert-Butyl [ (5-bromo-4-phenoxy-l, 3-benzoxazol-2-yl)methyl] carbamate
Figure imgf000191_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using tert-butyl [(5-bromo-4-phenoxy-l,3-benzoxazol-2-yl)methyl]carbamate and 6-methyl-l- [(4-methylphenyl)sulfonyl]-4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C34H33N4O7S (M+H)+: m/z = 641.2; found: 641.1. Step 4. 4- [2-(Aminomethyl)-4-phenoxy- 1 ,3-benzoxazol-5-yl] -6-methyl- 1- [(4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000192_0001
Trifluoroacetic acid (2.20 mL) was added dropwise to a solution of tert-butyl [(5- {6- methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl}-4- phenoxy-1, 3 -benzoxazol-2-yl)methyl] carbamate (0.282 g, 0.440 mmol) in methylene chloride (2.20 mL) and the resultant reaction mixture was stirred at RT for 30 min. The reaction mixture was concentrated in vacuo to a residue that was dissolved in small amount of dichloromethane and added dropwise to a saturated solution of sodium bicarbonate at 0 °C. The aqueous solution was extracted with dichloromethane to give the desired product (231 mg, 97%) which was used immediately without further purification. LCMS calculated for C29H25N4O5S (M+H)+: m/z = 541.2; found: 541.1.
Step 5. 4- [2-(Aminomethyl)-4-phenoxy- 1 ,3-benzoxazol-5-yl] -6-methyl- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one
This compound was synthesized according to the procedure of Example 85, Step 3, using 4-[2-(aminomethyl)-4-phenoxy-l,3-benzoxazol-5-yl]-6-methyl-l-[(4- methylphenyl)sulfonyl]-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. lH NMR (500 MHz, DMSO-ώ) δ 11.97 (br s, 1H), 7.68 (d, J= 8.4 Hz, 1H), 7.49 (d, J= 8.4 Hz, 1H), 7.24 (d, J= 2.7 Hz, 1H), 7.19 - 7.03 (m, 2H), 6.88 (dd, J= 7.3, 7.3 Hz, 1H), 6.65 (d, J= 7.8 Hz, 2H), 6.16 (d, J= 2.7 Hz, 1H), 3.91 (s, 2H), 3.44 (s, 3H); LCMS calculated for C22H19N4O3 (M+H)+: m/z = 387.1; found: 387.1.
Example 104. V-{[5-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4- phenoxy-l,3-benzoxazol-2-yl]methyl}acetamide
Figure imgf000193_0001
Step 1. N-f (5-{6-Methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6, 7-dihydro- lH-pyrrolo [2 ,3- cJpyridin-4-yl}-4-phenoxy-l,3-benzoxazol-2- l meth l acetamide
Figure imgf000193_0002
This compound was synthesized according to the procedure of Example 66, Step 2, using 4-[2-(aminomethyl)-4-phenoxy- 1 ,3-benzoxazol-5-yl]-6-methyl-l -[(4-methylphenyl)sulfonyl]- 1 , 6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. LCMS calculated for C31H27N4O6S (M+H)+: m/z = 583.2; found: 583.2.
Step 2. N-{[ 5-( 6-Methyl- 7 -oxo-6, 7-dihydro-lH-pyrrolof 2, 3-c]pyridin-4-yl)-4-phenoxy-l, 3- benzoxazol-2-ylJmethyl}acetamide
This compound was synthesized according to the procedure of Example 85, Step 3, using N-[(5-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl}-4-phenoxy-l,3-benzoxazol-2-yl)methyl]acetamide as the starting material. ¾ NMR (300 MHz, DMSO-ώ) δ 12.00 (br s, 1H), 8.67 (dd, J= 5.7, 5.7 Hz, 1H), 7.71 (d, J= 8.4 Hz, 1H), 7.51 (d, J= 8.5 Hz, 1H), 7.35 - 7.23 (m, 1H), 7.21 - 7.02 (m, 3H), 6.88 (dd, J= 7.3, 7.3 Hz, 1H), 6.65 (d, J= 7.8 Hz, 2H), 6.16 (s, 1H), 4.50 (d, J= 5.8 Hz, 2H), 3.44 (s, 3H), 1.87 (s, 3H); LCMS calculated for C24H21N4O4 (M+H)+: m/z = 429.2; found: 429.1.
The examples in Table 7 were synthesized according to procedure of Example 104 using the appropriate acid chlorides or sulfonyl chlorides.
Table 7
Figure imgf000194_0001
Figure imgf000194_0002
Figure imgf000194_0003
Figure imgf000195_0001
Example 110. 6-Methyl-4-(5-phenoxy-3-phenyl-3,4-dihydro-2H-l,4-benzoxazin-6-yl)-l,6- dihydr o-7H-pyrrolo [2,3-c] pyridin-7-one
Figure imgf000195_0002
Step 1. 2-(4-Bromo-2-nitro-3-phenoxyphenoxy)-l-phenylethanone
Figure imgf000195_0003
This compound was synthesized according to the procedure of Example 76, Step 5, using 4-bromo-2-nitro-3-phenoxyphenol and 2-hydroxy-l-phenylethanone as the starting materials. LCMS calculated for C2oHi5BrN05 (M+H)+: m/z = 428.0, 430.0; found: 427.9, 429.9.
Step 2. 6-Bromo-5-phenoxy-3-phenyl-2 - 1 ,4-benzoxazine
Figure imgf000196_0001
This compound was synthesized according to the procedure of Example 78, Step 2, using 2-(4-bromo-2-nitro-3-phenoxyphenoxy)-l-phenylethanone as the starting material. LCMS calculated for C20Hi5BrNO2 (M+H)+: m/z = 380.0, 382.0; found: 380.0, 382.0.
Step 3. 6-Bromo-5-phenoxy-3-phenyl-3, -dihydro-2H-l, 4-benzoxazine
Figure imgf000196_0002
A suspension of 6-bromo-5-phenoxy-3-phenyl-2H-l , 4-benzoxazine (0.0692 g, 0.182 mmol) in ethanol (1.20 mL) and water (0.240 mL) was treated with sodium tetrahydroborate (13.8 mg, 0.364 mmol) and stirred at 90 °C for 2 h. The reaction mixture was diluted with water and ethyl acetate. Layers were separated and the organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give the crude product. Purification by flash column chromatography (100% hexanes to 30% EtOAc/hexanes) gave the desired product (67.3 mg, 97%) as a colorless oil. LCMS calculated for C2oHivBrN02 (M+H)+: m/z = 382.0, 384.0; found: 382.0, 384.0.
Step 4. 6-Bromo-5-phenoxy-3-phenyl-3, 4-dihydro-2H-l, 4-benzoxazine
Figure imgf000197_0001
This compound was synthesized according to the procedure of Example 10, Step 5, using 6-bromo-5-phenoxy-3-phenyl-3,4-dihydro-2H-l,4-benzoxazine and 6-methyl-l-[(4- methylphenyl)sulfonyl]-4-(4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for C35H30N3O5S (M+H)+: m/z = 604.2; found: 604.0.
Step 5. 6-Methyl-4- ( 5-phenoxy-3-phenyl-3, 4-dihydro-2H-l, 4-benzoxazin-6-yl)-l , 6-dihydro- 7H- pyrrolo[2, 3-cJpyridin- 7 -one
This compound was synthesized according to the procedure of Example 6, Step 2, using
6-methyl-l-[(4-methylphenyl)sulfonyl]-4-(5-phenoxy-3-phenyl-3,4-dihydro-2H-l,4-benzoxazin- 6-yl)-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting material. lH NMR (500 MHz, DMSO-ώ) δ 11.86 (br s, 1H), 7.38 - 7.18 (m, 6H), 7.10 (dd, J= 7.8, 7.8 Hz, 2H), 7.03 (s, 1H), 6.89 - 6.72 (m, 2H), 6.68 (d, J= 8.2 Hz, 3H), 6.23 (s, 1H), 5.77 (s, 1H), 4.68 - 4.47 (m, 1H), 4.40 - 4.16 (m, 1H), 4.13 - 3.92 (m, 1H), 3.39 (s, 3H); LCMS calculated for C28H24N3O3 (M+H)+: m/z = 450.2; found: 450.2.
Example 111. V-{[l-Methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- 4-phenoxy-lH-benzimidazol-2-yl]methyl}cyclobutanecarboxamide
Figure imgf000198_0001
Step 1. 4-Bromo-N-methyl-2-nitro-3-phenoxyaniline
Figure imgf000198_0002
This compound was synthesized according to the procedure of Example 1, Step 1, using 4-bromo-3-fluoro-N-methyl-2-nitroaniline and phenol as the starting materials. LCMS calculated for Ci3Hi2BrN203 (M+H)+: m/z = 323.0, 325.0; found: 322.9, 325.0.
Step 2. 4-Bromo-Nl -methyl- 3 -phenoxybenzene-1 ,2-diamine
This compound was synthesized according to the procedure of Example 1, Step 3, using 4-bromo-N-methyl-2-nitro-3-phenoxyaniline as the starting material. LCMS calculated for Ci3Hi4BrN20 (M+H)+: m/z = 293.0, 295.0; found: 293.0, 295.0. tert-Butyl [(5-bromo-l-methyl-4-phenoxy-lH-benzimidazol-2-yl)methyl] carbamate
Figure imgf000199_0001
Phosphoryl chloride (0.0864 mL, 0.927 mmol) was added dropwise at -15 °C to a solution of N-a-(tert-butoxycarbonyl)glycine (0.150 g, 0.856 mmol) and 4-bromo-N1-methyl-3- phenoxybenzene-l,2-diamine (0.209 g, 0.713 mmol) in pyridine (2.85 mL). The reaction mixture was warmed to RT and stirred at RT for 1 h, after which time the reaction mixture was concentrated in vacuo to give a crude residue. The residue was dissolved in ethyl acetate and the solution was washed with saturated solution of sodium bicarbonate and brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give a crude residue. This residue was dissolved in acetic acid (5.00 mL) and heated at 70 °C for 30 min. The reaction mixture was concentrated to give a crude residue, which was diluted with saturated sodium bicarbonate solution and ethyl acetate. Layers were separated and the organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to give the crude product. Purification by flash column chromatography (100% hexanes to 80% EtOAc/hexanes [EtOAc contained 5% MeOH]) gave the desired product (149 mg, 48%). LCMS calculated for C2oH23BrN303 (M+H)+: m/z = 432.1, 434.1; found: 432.1, 434.1. tert-Butyl [(5-bromo-l-methyl-4-phenoxy-lH-benzimidazol-2-yl)methyl) 'carbamate
Figure imgf000199_0002
This compound was synthesized according to the procedure of Example 10, Step 5, using tert-butyl [(5-bromo-l-methyl-4-phenoxy-lH-benzimidazol-2-yl)methyl]carbamate and 6- methyl-l-[(4-methylphenyl)sulfonyl]-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,6- dihydro-7H-pyrrolo[2,3-c]pyridin-7-one as the starting materials. LCMS calculated for
CssHseNsOeS (M+H)+: m/z = 654.2; found: 654.3.
Step 5. 4-f2-(Aminomethyl)-l-methyl-4-phenoxy-lH-benzimidazol-5-ylJ-6-methyl-l-f (4- methylphenyl)sulfonylJ -1 , 6-dihydro- 7H-pyrrolo[2, 3-cJpyridin- 7 -one
Figure imgf000200_0001
This compound was synthesized according to the procedure of Example 103, Step 4, using tert-butyl [(l-methyl-5-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl}-4-phenoxy-lH-benzimidazol-2-yl)methyl]carbamate as the starting material. LCMS calculated for C30H28N5O4S (M+H)+: m/z = 554.2; found: 554.2.
Step 6. N-f (l-Methyl-5-{6-methyl-l-[ (4-methylphenyl)sulfonylJ-7-oxo-6, 7-dihydro-lH- pyrrolo[2,3-cJpyridin-4-yl}-4-phenoxy-lH-benzimidazol-2-yl)methylJcyclobutanecarboxam
Figure imgf000200_0002
This compound was synthesized according to the procedure of Example 66, Step 2, using 4-[2-(aminomethyl)-l -methyl-4-phenoxy-l H-benzimidazol-5-yl]-6-methyl- 1 -[(4- methylphenyl)sulfonyl]- 1 ,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one and cyclobutanecarboxylic acid chloride as the starting materials. LCMS calculated for C35H34N5O5S (M+H)+: m/z = 636.2; found: 636.2. Step 7. N-{[1 -Methyl- 5-(6-methyl-7 -oxo-6, 7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy- lH-benzimidazol-2-yl]methyl}cyclobutanecarboxamide
This compound was synthesized according to the procedure of Example 6, Step 2, using N-[(l-methyl-5-{6-methyl-l-[(4-methylphenyl)sulfonyl]-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl}-4-phenoxy-lH-benzimidazol-2-yl)methyl]cyclobutanecarboxamide as the starting material. lU NMR (500 MHz, DMSO-ώ) δ 11.92 (br s, 1H), 8.29 (dd, J= 5.6, 5.6 Hz, 1H), 7.52 (d, J= 8.4 Hz, 1H), 7.37 (d, J= 8.3 Hz, 1H), 7.23 (dd, J= 2.8, 2.8 Hz, 1H), 7.18 - 7.03 (m, 3H), 6.82 (dd, J= 7.3, 7.3 Hz, 1H), 6.59 (dd, J= 8.7, 1.0 Hz, 2H), 6.29 - 6.08 (m, 1H), 4.48 (d, J= 5.7 Hz, 2H), 3.81 (s, 3H), 3.42 (s, 3H), 3.15 - 2.88 (m, 1H), 2.17 - 2.04 (m, 2H), 2.03 - 1.92 (m, 2H), 1.91 - 1.78 (m, 1H), 1.78 - 1.66 (m, 1H); LCMS calculated for C28H28N5O3 (M+H)+: m/z = 482.2; found: 482.2.
Example 112. V-{[l-Methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- 4-phenoxy-lH-benzimidazol-2-yl]methyl}cyclopropanecarboxamide
Figure imgf000201_0001
This compound was synthesized according to the procedure of Example 111 using cyclopropanecarbonyl chloride in step 6 instead of cyclobutanecarboxylic acid chloride. lH NMR (500 MHz, DMSO-ώ) δ 11.92 (br s, 1H), 8.71 (dd, J= 5.6, 5.6 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 7.37 (d, J= 8.3 Hz, 1H), 7.23 (dd, J= 2.7, 2.7 Hz, 1H), 7.18 - 7.02 (m, 3H), 6.82 (dd, J = 7.3, 7.3 Hz, 1H), 6.60 (dd, J= 8.7, 0.9 Hz, 2H), 6.26 - 6.11 (m, 1H), 4.52 (d, J= 5.7 Hz, 2H), 3.82 (s, 3H), 3.42 (s, 3H), 1.72 - 1.45 (m, 1H), 0.84 - 0.45 (m, 4H); LCMS calculated for C27H26N5O3 (M+H)+: m/z = 468.2; found: 468.2.
Example Al: BRD4 AlphaScreen™ Assay
BRD4-BD1 and BRD4-BD2 assays were conducted in white 384-well polystyrene plate in a final volume of 20 for BD1 and 40 for BD2. Inhibitors were first serially diluted in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 1.25% (BD1) and 0.83% (BD2). The assays were carried out at room temperature for 75 min. in the assay buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 0.05% CHAPS, 0.01 % BSA), containing 50 nM Biotin-labeled tetra-acetylated histone H4 peptide (H4Ac4), 3.8 nM (BRD4-BD1, BPS Bioscience #31040) or 20 nM (BRD4-BD2, BPS Bioscience # 31041). The reaction followed by the addition of 20 of assay buffer
supplemented with Streptavidin donor beads (PerkinElmer 6760002) and GSH Acceptor beads (PerkinElmer-AL109C) at 4 μg/mL under reduced light. After plate sealing, the plate was incubated in the dark at room temperature for 75 min. before reading on a PHERAstar FS plate reader (BMG Labtech). IC50 determination was performed by fitting the curve of percent control activity versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
IC50 data for the Examples is presented in Table 8 as determined by Assay Al .
Table 8
Figure imgf000202_0001
Figure imgf000203_0001
Figure imgf000204_0001
Figure imgf000205_0001
* column symbols:
+ refers to < 100 nM
++ refers to > 100 nM to 1000 nM
+++ refers to >1000 nM to 10000 nM
NT = not tested
Example Bl: KMS.12.BM Cell Viability Assay
KMS.12.BM cell line (human myeloma) was purchased from JCRB (Osaka, Japan) and maintained in RPMI with 10% FBS culture medium. To measure the cytotoxic activity of the compounds through ATP quantitation, the KMS.12.BM cells are plated in the RPMI culture medium at 5000 cells / well/ per 100 μΐ, into a 96-well polystyrene clear black tissue culture plate (Greiner-bio-one through VWR, NJ), in the presence or absence of a concentration range of test compounds. After 3 days, 100 mL Cell Titer-GLO Luminescent (Promega, Madison, WI) cell culture agent is added to each well for 10 minutes at room temperature to stabilize the luminescent signal. This determines the number of viable cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells. Luminescence is measured with the Top Count 384 (Packard Bioscience through Perkin Elmer, Boston, MA). Compound inhibition is determined relative to cells cultured with no drug and the ICso is reported as the compound concentration required for 50% cell death. ICso data for the Examples is presented in Table 9 as determined by Assay B 1. Table 9
Figure imgf000206_0001
Example # KMS cellular IC50 (nM)*
43 +
44 +
45 +
46 +
47 +
48 +
49 +
50 NT
51 +
52 +
53 +
54 +
55 +
56 +
57 +
58 +
59 +
60 +
61 +
62 +
63 +
64 +
65 ++
66 +
67 +
68 +
69 +
70 +
71 NT
72 ++
73 NT
74 +
75 +
76 +
77 +
78 +
79 ++
80 +
81 +
82 NT
83 +
84 NT
85 NT
86 + Example # KMS cellular IC50 (nM)*
87 +
88 +
89 +
90 +
91 +
92 +
93 +
94 +
95 +
96 +
97 +
98 +
99 NT
100 +
101 NT
102 NT
103 +
104 +
105 +
106 +
107 +
108 +
109 +
110 NT
111 +
112 +
113 +
* column symbols:
+ refers to < 1000 nM
++ refers to >1000 nM to 10000 nM
NT = not tested
Example CI: KMS.12.BM C-myc ELISA Assay
KMS.12.BM cell line (human myeloma) was purchased from JCRB (Osaka, Japan) and maintained in RPMI with 10% FBS culture medium. To measure the C-myc inhibitory activity of the compounds, the KMS.12.BM cells are plated in the RPMI culture medium at 75000 cells / well/ per 200 μΐ, into a 96-well flat bottom polystyrene tissue culture plate (Corning through VWR, NJ), in the presence or absence of a concentration range of test compounds. After 2 hours, cell are pelleted and lysed with Cell Extraction Buffer (BioSource, Carlsbad, CA) in the presence of protease inhibitors (Life Technologies, Grand Island, NY and Sigma, St Louis, MO). Clarified lyses are tested in a C-myc commercial ELISA (Life Technologies, Grand Island, NY). Compound inhibition is determined relative to cells cultured with no drug and the IC50 is reported as the compound concentration required for 50% C-myc inhibition. IC50 data for the Examples is presented in Table 10 as determined by Assay C 1.
Table 10
Figure imgf000209_0001
Example # KMS C-myc IC50 (nM)*
35 NT
36 +
37 +
38 +
39 +
40 +
41 +
42 +
43 +
44 NT
45 +
46 +
47 +
48 +
49 NT
50 NT
51 +
52 +
53 +
54 +
55 +
56 +
57 +
58 +
59 +
60 +
61 +
62 +
63 NT
64 +
65 NT
66 +
67 NT
68 +
69 +
70 +
71 NT
72 NT
73 NT
74 +
75 +
76 +
77 + Example # KMS C-myc IC50 (nM)*
78 +
79 NT
80 NT
81 NT
82 NT
83 NT
84 NT
85 NT
86 +
87 +
88 +
89 +
90 +
91 +
92 +
93 +
94 +
95 NT
96 +
97 NT
98 NT
99 NT
100 NT
101 NT
102 NT
103 +
104 +
105 +
106 ++
107 +
108 +
109 ++
1 10 NT
1 1 1 NT
1 12 NT
1 13 +
* column symbols:
+ refers to < 1000 nM
++ refers to >1000 nM to 10000 nM NT = not tested Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.

Claims

What is claimed is:
1. A compound of Formula I :
Figure imgf000213_0001
or a pharmaceutically acceptable salt thereof, wherein:
represents a single or double bond;
Ring B is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, Cs-cycloalkyl, Ce- cycloalkyl, 5-membered heterocycloalkyl, or 6-membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 RB;
L is absent, -(CRaRb)P-, -(CRaRb)n-0-(CRaRb)m-, -(CRaRb)n-S-(CRaRb)m-,
Figure imgf000213_0002
b)n-NRc-(CRaRb)m-, -
Figure imgf000213_0003
-(CRaRb)n-NRcC(=0)NRd-(CRaRb)m-;
Al is CR3orN;
A2is CR4orN;
A3 is C or N;
A4 is C or N;
wherein when one of A3 and A4 is N, then the other of A3 and A4 is C;
Wis CR5orN;
Xis CR6orN;
Yis CR7orN; Z is Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, or 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 Rz;
R1 is H or C 1-4 alkyl;
R2 is H, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, Ci-4 cyanoalkyl, or C6-io aryl-Ci-6 alkyl;
R3 and R4 are each independently selected from H, halo, CN, NO2, Ci-6 alkyl, Ci-6 haloalkyl, C 1-6 hydroxyalkyl, Ci-6 aminoalkyl, Ci-6 alkylamino-Ci-6 alkyl, di-Ci-6-alkylamino-Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said Ci-6 alkylamino-Ci-6 alkyl, di-Ci-6-alkylamino- C1-6 alkyl, are each optionally substituted with 1 or 2 substituents independently selected from C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl;
R5 is H, halo, Ci-6 alkyl, or Ci-6 haloalkyl;
R6 is H, Ci-6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)Rbl, C(0)NRclRdl, C(0)ORal, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, or S(0)2NRclRdl, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, ORal, SRal, C(0)Rbl, C(0)NRclRdl, C(0)ORal, OC(0)Rbl, OC(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)ORal,
NRclC(0)NRclRdl, C(=NRel)Rbl, C(=NRel)NRclRdl, NRclC(=NRel)NRclRdl, NRclS(0)Rbl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, and S(0)2NRclRdl;
R7 is H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, or S(0)2NRc2Rd2, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, OC(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)ORa2,
NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2;
each RB is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, CN, NO2, ORa3, SR33, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3,
OC(0)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3, C(=NRe3)Rb3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3,
NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and
S(0)2NRc3Rd3, and wherein said phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each independently substituted by 1, 2, or 3 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and
S(0)2NRc3Rd3;
each Rz is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4,
OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, C(=NRe4)Rb4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4S(0)Rb4, NRc4S(0)2Rb4, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2Rb4, and S(0)2NRc4Rd4; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4,
NRc4S(0)Rb4, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2Rb4, and
S(0)2NRc4Rd4;
each Ra and Rb is independently selected from H, halo, OH, methyl, and ethyl;
each Rc and Rd is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, and cyclopropyl; each Ral, Rbl, Rcl, Rdl, Ra2, Rb2, Rc2, Rd2, R33, Rb3, Rc3, Rd3, Ra4, Rb4, Rc4, and Rd4 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3- 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-6 alkyl, C3-10 cycloalky-Ci-6 alkyl, (5-10 membered heteroaryl)-Ci-6 alkyl, and (4-10 membered heterocycloalkyl)-Ci-6 alkyl, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-6 alkyl, C3- 10 cycloalky-Ci-6 alkyl, (5-10 membered heteroaryl)-Ci-6 alkyl, and (4-10 membered
heterocycloalkyl)-Ci-6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents
independently selected from Ci-4 alkyl, C 1-4 haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rcl and Rdl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rc2 and Rd2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rc4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
each Rel, Re2, Re3, and Re4 is independently selected from H, CM alkyl, CN, ORa5, SRb5, S(0)2Rb5, C(0)Rb5, S(0)2NRc5Rd5, and C(0)NRc5Rd5; each R , R , R , and R is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein said Ci-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, C1-4 haloalkyl, and Ci-4 haloalkoxy;
each Re5 is independently selected from H, Ci-4 alkyl, and CN;
n is 0, 1, or 2;
m is 0, 1, or 2; and
p is 1, 2, 3, or 4;
wherein any aforementioned heterocycloalkyl group, including the heterocycloalkyl group of Ring B, is optionally substituted by 1 or 2 oxo groups.
2. A compound of Formula I :
Figure imgf000218_0001
or a pharmaceutically acceptable salt thereof, wherein:
represents a single or double bond;
Ring B is phenyl, 5-membered heteroaryl, 6-membered heteroaryl, Cs-cycloalkyl, C6- cycloalkyl, 5-membered heterocycloalkyl, or 6-membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 RB;
L is absent, -(CRaRb)P-, -(CRaRb)n-0-(CRaRb)m-, -(CRaRb)n-S-(CRaRb)m-,
Figure imgf000218_0002
Figure imgf000218_0003
-(CRaRb)n-NRc-(CRaRb)m-,
Figure imgf000219_0001
-(CRaRb)n-NRcC(=0)NRd-(CRaRb)m-;
Al is CR3 or N;
A2 is CR4 or N;
A3 is C or N;
A4 is C or N;
wherein when one of A3 and A4 is N, then the other of A3 and A4 is C;
W is CR5 or N;
X is CR6 or N;
Y is CR7 or N;
Z is C6-io aryl, C3-10 cycloalkyl, or 5-10 membered heteroaryl, or 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 Rz;
R1 is H or Ci-4 alkyl;
R2 is Ci-4 alkyl, Ci-4 haloalkyl, or Ci-4 hydroxyalkyl;
R3 and R4 are each independently selected from H, halo, CN, NO2, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
R5 is H, halo, Ci-6 alkyl, or Ci-6 haloalkyl;
R6 is H, Ci-6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)Rbl, C(0)NRclRdl, C(0)ORal, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, or S(0)2NRclRdl, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, ORal, SRal, C(0)Rbl, C(0)NRclRdl, C(0)ORal, OC(0)Rbl, OC(0)NRclRdl, NRclRdl, NRclC(0)Rbl, NRclC(0)ORal,
NRclC(0)NRclRdl, C(=NRel)Rbl, C(=NRel)NRclRdl, NRclC(=NRel)NRclRdl, NRclS(0)Rbl, NRclS(0)2Rbl, NRclS(0)2NRclRdl, S(0)Rbl, S(0)NRclRdl, S(0)2Rbl, and S(0)2NRclRdl;
R7 is H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, or S(0)2NRc2Rd2, wherein said Ci-e alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo, CM haloalkyl, CN, NO2, ORa2, SRa2, C(0)Rb2, C(0)NRc2Rd2, C(0)ORa2, OC(0)Rb2, OC(0)NRc2Rd2, NRc2Rd2, NRc2C(0)Rb2, NRc2C(0)ORa2,
NRc2C(0)NRc2Rd2, C(=NRe2)Rb2, C(=NRe2)NRc2Rd2, NRc2C(=NRe2)NRc2Rd2, NRc2S(0)Rb2, NRc2S(0)2Rb2, NRc2S(0)2NRc2Rd2, S(0)Rb2, S(0)NRc2Rd2, S(0)2Rb2, and S(0)2NRc2Rd2; each R is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, CN, NO2, ORa3, SR33, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3,
OC(0)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3, C(=NRe3)Rb3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3,
NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and
S(0)2NRc3Rd3;
each Rz is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4,
OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, C(=NRe4)Rb4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4S(0)Rb4, NRc4S(0)2Rb4, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2Rb4, and S(0)2NRc4Rd4; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4,
NRc4S(0)Rb4, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)Rb4, S(0)NRc4Rd4, S(0)2Rb4, and
S(0)2NRc4Rd4;
each Ra and Rb is independently selected from H, halo, OH, methyl, and ethyl;
each Rc and Rd is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, Ci-4 hydroxyalkyl, and cyclopropyl;
each Ral, Rbl, Rcl, Rdl, Ra2, Rb2, Rc2, Rd2, R33, Rb3, Rc3, Rd3, Ra4, Rb4, Rc4, and Rd4 is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3- 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-6 alkyl, C3-10 cycloalky-Ci-6 alkyl, (5-10 membered heteroaryl)-Ci-6 alkyl, and (4-10 membered heterocycloalkyl)-Ci-6 alkyl, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-io aryl-Ci-6 alkyl, C3- 10 cycloalky-Ci-6 alkyl, (5-10 membered heteroaryl)-Ci-6 alkyl, and (4-10 membered
heterocycloalkyl)-Ci-6 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents
independently selected from Ci-4 alkyl, Ci-4 haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rcl and Rdl together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rc2 and Rd2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, M R , NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
or any Rc4 and Rd4 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-e haloalkyl, halo, CN, ORa5, SRa5, C(0)Rb5, C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5, NRc5C(0)NRc5Rd5,
NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4- 7 membered heterocycloalkyl, C6-io aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa5, SRa5, C(0)Rb5,
C(0)NRc5Rd5, C(0)ORa5, OC(0)Rb5, OC(0)NRc5Rd5, NRc5Rd5, NRc5C(0)Rb5,
NRc5C(0)NRc5Rd5, NRc5C(0)ORa5, C(=NRe5)NRc5Rd5, NRc5C(=NRe5)NRc5Rd5, S(0)Rb5, S(0)NRc5Rd5, S(0)2Rb5, NRc5S(0)2Rb5, NRc5S(0)2NRc5Rd5, and S(0)2NRc5Rd5;
each Rel, Re2, Re3, and Re4 is independently selected from H, CM alkyl, CN, ORa5, SRb5, S(0)2Rb5, C(0)Rb5, S(0)2NRc5Rd5, and C(0)NRc5Rd5;
each Ra5, Rb5, Rc5, and Rd5 is independently selected from H, Ci-4 alkyl, Ci-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein said Ci-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, C1-4 haloalkyl, and Ci-4 haloalkoxy;
each Re5 is independently selected from H, Ci-4 alkyl, and CN;
n is 0, 1, or 2;
m is 0, 1, or 2; and
p is 1, 2, 3, or 4;
wherein any aforementioned heterocycloalkyl group, including the heterocycloalkyl group of Ring B, is optionally substituted by 1 or 2 oxo groups.
3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R1 is H.
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is Ci-4 alkyl, Ci-4 cyanoalkyl, or C6-io aryl-Ci-6 alkyl.
5. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R2 is C 1-4 alkyl.
6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl, cyanomethyl, or benzyl.
7. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl.
8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein W is CR5.
9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein X is CR6.
10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein Y is CR7.
11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein Y is N.
12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein L is -(CRaRb)P-, -(CRaRb)n-0-(CRaRb)m-, -(CRaRb)n-S-(CRaRb)m-, or -(CRaRb)n-S(=0)2- (CRaRb)m-.
13. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein L is -(CRaRb)n-0-(CRaRb)m-.
14. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein L is -CH2-0-.
15. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein L is O, S, or S(=0)2.
16. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein L is O.
17. The compound of any one of claims 1 and 3-16, or a pharmaceutically acceptable salt thereof, wherein Z is Ci-4 alkyl, C6-io aryl, C3-10 cycloalkyl, or 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 Rz.
18. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein Z is C6-io aryl or C3-10 cycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 Rz.
19. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein Z is phenyl optionally substituted by 1, 2, 3, 4, or 5 Rz.
20. The compound of any one of claims 1 and 3-16, or a pharmaceutically acceptable salt thereof, wherein Z is C1-4 alkyl.
21. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein Z is C3-7 cycloalkyl optionally substituted by 1, 2, 3, 4, or 5 Rz.
22. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein Z is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 Rz.
23. The compound of any one of claims 1 and 3-16, or a pharmaceutically acceptable salt thereof, wherein Z is 4-10 membered heterocycloalkyl optionally substituted by 1, 2, 3, 4, or 5 Rz.
24. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein Z is tetrahydropyranyl.
25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt thereof, wherein each Rz is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, NO2, ORa4, SRa4, C(0)Rb4, C(0)NRc4Rd4, C(0)ORa4, OC(0)Rb4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)Rb4, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, C(=NRe4)Rb4, C(=NRe4)NRc4Rd4, NRc4C(=NRe4)NRc4Rd4, NRc4S(0)Rb4, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)Rb4,
S(0)NRc4Rd4, S(0)2RM, and S(0)2NRc4Rd4.
26. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt thereof, wherein each Rz is independently selected from F, CI, and Br.
27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt thereof, wherein Al is CR3.
28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein A2 is CR4.
29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein A2 is N.
30. The compound of any one of claims 1 and 3-29, or a pharmaceutically acceptable salt thereof, wherein R4 is H, Ci-6 hydroxyalkyl, or Ci-6 alkylamino-Ci-6 alkyl, wherein said Ci-6 alkylamino-Ci-6 alkyl is optionally substituted with 1 or 2 substituents independently selected from C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl.
31. The compound of any one of claims 1 and 3-29, or a pharmaceutically acceptable salt thereof, wherein R4 is H.
32. The compound of any one of claims 1 and 3-29, or a pharmaceutically acceptable salt thereof, wherein R4 is 1 -hydroxy ethyl.
33. The compound of any one of claims 1 and 3-29, or a pharmaceutically acceptable salt thereof, wherein R4 is Ci-6 alkylamino-Ci-6 alkyl substituted with 2-(morpholin-N-yl)ethyl, benzyl, or cyclopropylmethyl.
34. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein A3 is C.
35. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein A4 is C.
36. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein A4 is N.
37. The compound of any one o a II:
Figure imgf000227_0001
II
or a pharmaceutically acceptable salt thereof, wherein:
the 5-membered ring formed by A3, A4, Bl, B2, and B3 is (1) 5-membered heteroaryl wherein Bl, B2, and B3 are each independently selected from CH, N, NH, O, and S, (2) Cs- cycloalkyl wherein Bl, B2, and B3 are each independently selected from CH, CH2, and C(O), or (3) 5-membered heterocycloalkyl wherein Bl, B2, and B3 are each independently selected from CH, CH2, C(O), N, NH, O, S, S(O), and S(0)2; and
q is 0, 1, 2 or 3.
38. The compound of claim 37, or a pharmaceutically acceptable salt thereof, wherein Bl, B2, and B3 are each independently selected from CH, C(O), N, O, and NH.
39. The compound of claim 37, or a pharmaceutically acceptable salt thereof, wherein Bl, B2, and B3 are each independently selected from CH, C(O), N, and NH.
40. The compound of any one of claims 37-39, or a pharmaceutically acceptable salt thereof, wherein Bl is N, NH, CH, or O.
41. The compound of any one of claims 37-39, or a pharmaceutically acceptable salt thereof, wherein Bl is NH.
42. The compound of any one of claims 37-39, or a pharmaceutically acceptable salt thereof, wherein B2 is N, C(O), C or CH.
43. The compound of any one of claims 37-39, or a pharmaceutically acceptable salt thereof, wherein B2 is N, C(O), or CH.
44. The compound of any one of claims 37-39, or a pharmaceutically acceptable salt thereof, wherein B3 is N, NH, or CH.
45. The compound of any one of claims 37-39, or a pharmaceutically acceptable salt thereof, wherein B3 is N or NH.
The compound of any one of claims 37-45 having Formula Ila:
Figure imgf000228_0001
Ila
or a pharmaceutically acceptable salt thereof.
The compound of any one of claims 37-45 having Formula lib
Figure imgf000229_0001
or a pharmaceutically acceptable salt thereof.
48. The compound of any one of claims 37-45 having Formula lie:
Figure imgf000229_0002
lie
or a pharmaceutically acceptable salt thereof, wherein r is 0, 1, 2, 3, 4, or 5. The compound of any one of claims 37-48 having Formula lid, He, Ilf, or IIf-1
Figure imgf000230_0001
Figure imgf000230_0002
Ilf IIf-1 or a pharmaceutically acceptable salt thereof, wherein:
r is 0, 1, 2, 3, 4, or 5; and
each RB is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, CN, NO2, ORa3, SR*3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3, C(=NRe3)Rb3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3; wherein said Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3,
NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and
S(0)2NRc3Rd3, and wherein said phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each independently substituted by 1, 2, or 3 substituents independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, CN, NO2, ORa3, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, OC(0)Rb3, OC(0)NRc3Rd3, C(=NRe3)NRc3Rd3, NRc3C(=NRe3)NRc3Rd3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)ORa3, NRc3C(0)NRc3Rd3,
NRc3S(0)Rb3, NRc3S(0)2Rb3, NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and
S(0)2NRc3Rd3.
50. The compound of any one of claims 37-48 having Formula lid, He, or Ilf:
Figure imgf000231_0001
lid He
Figure imgf000232_0001
or a pharmaceutically acceptable salt thereof, wherein:
r is 0, 1, 2, 3, 4, or 5; and
R8, R9, and R10 are each independently selected from H, Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein said Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, Ci-e alkyl, Ci-e haloalkyl, CN, NO2, OR33, SRa3, C(0)Rb3, C(0)NRc3Rd3, C(0)ORa3, NRc3Rd3, NRc3C(0)Rb3, NRc3C(0)NRc3Rd3, NRc3S(0)Rb3, NRc3S(0)2Rb3,
NRc3S(0)2NRc3Rd3, S(0)Rb3, S(0)NRc3Rd3, S(0)2Rb3, and S(0)2NRc3Rd3.
51. The compound of any one of claims 48-50, or a pharmaceutically acceptable salt thereof, wherein r is 0, 1, 2, or 3.
52. The compound of any one of claims 1-20 having Formula III:
Figure imgf000233_0001
or a pharmaceutically acceptable salt thereof, wherein:
the 6-membered ring formed by A3, A4, B4, B5, B6, and B7 is (1) phenyl, (2) 6- membered heteroaryl wherein B4, B5, B6, and B7 are each independently selected from CH and N, (3) C6-cycloalkyl wherein B4, B5, B6, and B7 are each independently selected from CH, CH2, and C(O), or (4) 6-membered heterocycloalkyl wherein B4, B5, B6, and B7 are each
independently selected from CH, CH2, C(O), N, NH, O, S, S(O), and S(0)2; and
s is 0, 1, 2, 3, or 4.
53. The compound of claim 52, or a pharmaceutically acceptable salt thereof, wherein the 6- membered ring formed by A3, A4, B4, B5, B6, and B7 is 6-membered heterocycloalkyl wherein B4, B5, B6, and B7 are each independently selected from CH, CH2, C(O), N, NH, O, S, S(O), and S(0)2.
54. The compound of claim 52 or 53, or a pharmaceutically acceptable salt thereof, wherein B4 is selected from O or N.
55. The compound of any one of claims 52-54, or a pharmaceutically acceptable salt thereof, wherein B5 is selected from C, CH, or CH2.
56. The compound of any one of claims 52-55, or a pharmaceutically acceptable salt thereof, wherein B6 is selected from CH or C(=0).
57. The compound of any one of claims 52-56, or a pharmaceutically acceptable salt thereof, wherein B7 is selected from N or NH.
58. The compound of any one of claims 52-57 havin Formula Ilia:
Figure imgf000234_0001
Ilia
or a pharmaceutically acceptable salt thereof.
59. The compound of claim 1 selected from:
4-(2,4-Difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- l,3-dihydro-2H-benzimidazol-2-one;
4-[4-(2,4-Difluorophenoxy)-lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one; and
4-[4-(2,4-Difluorophenoxy)-2-methyl-lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
4-[4-(2,4-Difluorophenoxy)-l -methyl- lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
4-[4-(2,4-Difluorophenoxy)-l,2-dimethyl-lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one; 4-(2,4-Difluorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-(2,4-Difluorophenoxy)-l,3-dimethyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-[4-(2,4-Difluorophenoxy)-lH-l,2,3-benzotriazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
4-[4-(2,4-Difluorophenoxy)-l -methyl- lH-l,2,3-benzotriazol-5-yl]-6-methyl-l,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one;
4-[4-(2,4-Difluorophenoxy)-lH-l,2,3-benzotriazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrazolo[3,4-c]pyridin-7-one;
4-(Cyclopropylmethoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- l,3-dihydro-2H-benzimidazol-2-one;
4-[4-(Cyclopropylmethoxy)-lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one; and
4-[4-(Cyclopropylmethoxy)-2-methyl-lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one,
or a pharmaceutically acceptable salt of any of the aforementioned.
60. The compound of claim 1 selected from:
4-[4-(2,4-Difluorophenoxy)-lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrazolo[3,4-c]pyridin-7-one;
4-[4-(2,4-Difluorophenoxy)-2-methyl-lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrazolo[3,4-c]pyridin-7-one;
4-[4-(2,4-Difluorophenoxy)-2-oxo-2,3-dihydro-lH-benzimidazol-5-yl]-6-methyl-l,6- dihydro-7H-pyrazolo[3,4-c]pyridin-7-one;
4-[4-(2,4-Difluorophenoxy)-l-(2-morpholin-4-ylethyl)-lH-benzimidazol-5-yl]-6-methyl- l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one;
4-[4-(2,4-Difluorophenoxy)-l -methyl- lH-benzimidazol-5-yl]-6-methyl-l, 6-dihydro-7H- pyrazolo[3,4-c]pyridin-7-one;
4-[4-(2,4-Difluorophenoxy)-l,2-dimethyl-lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro- 7H-pyrazolo[3,4-c]pyridin-7-one; 4-[4-(2,4-Difluorophenoxy)-l -methyl- lH-1, 2,3-benzotriazol-5-yl]-6-methyl- 1, 6-dihydro- 7H-pyrazolo[3,4-c]pyridin-7-one;
4- [4-(2,4-Difluorophenoxy)-l-methyl-2-oxo-2,3-dihydro-lH-benzimidazol-5-yl]-6- methyl-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one;
5- (6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-l,3-dihydro- 2H-benzimidazol-2-one;
4-[(4,4-Difluorocyclohexyl)oxy]-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-(4-Fluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-l,3- dihydro-2H-benzimidazol-2-one;
4- (3-Fluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-l,3- dihydro-2H-benzimidazol-2-one;
5- (6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-(tetrahydro-2H-pyran- 3-yloxy)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-(Benzyloxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- l,3-dihydro-2H-benzimidazol-2-one;
4-[(2,4-Difluorobenzyl)oxy]-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
1- Methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-(tetrahydro- 2H-pyran-4-yloxy)-l,3-dihydro-2H-benzimidazol-2-one;
4-[7-(2,4-Difluorophenoxy)-l-(2-morpholin-4-yl-2-oxoethyl)-lH-benzimidazol-6-yl]-6- methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
4-[4-(2,4-difluorophenoxy)-l-(2-morpholin-4-yl-2-oxoethyl)-lH-benzimidazol-5-yl]-6- methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
4-Methoxy-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-l,3- dihydro-2H-benzimidazol-2-one;
2- [7-(2,4-Difluorophenoxy)-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4- yl)- 1 H-benzimidazol- 1 -yl] -N,N-dimethylacetamide;
2-[4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4- yl)- 1 H-benzimidazol- 1 -yl] -N,N-dimethylacetamide; 2-[7-(2,4-Difluorophenoxy)-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4- yl)- 1 H-benzimidazol- 1 -yl]-N-methylacetamide;
2- [4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4- yl)- 1 H-benzimidazol- 1 -yl]-N-methylacetamide;
4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
l-Methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-l,3- dihydro-2H-benzimidazol-2-one;
4-(2-Fluorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin- 4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-(3-Fluorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin- 4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-(4-Fluorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin- 4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
6-Methyl-4- [ 1 -(2-morpholin-4-ylethyl)-7-phenoxy- 1 H-benzimidazol-6-yl]- 1 ,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one;
6-methyl-4-[l-(2-morpholin-4-ylethyl)-4-phenoxy-lH-benzimidazol-5-yl]-l,6-dihydro- 7H-pyrrolo[2,3-c]pyridin-7-one;
3- Benzyl-4-methoxy-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin- 4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4- (l-Benzyl-7-phenoxy-lH-benzimidazol-6-yl)-6-methyl-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one;
4-(l-Benzyl-4-phenoxy-lH-benzimidazol-5-yl)-6-methyl-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one;
6-Methyl-4-[7-phenoxy- 1 -(2-phenylethyl)- 1 H-benzimidazol-6-yl]- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
6-Methyl-4-[4-phenoxy-l-(2-phenylethyl)-lH-benzimidazol-5-yl]-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
4-Methoxy-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-3- (2-phenylethyl)- 1 ,3-dihydro-2H-benzimidazol-2-one; 4-Methoxy-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-3- (2-morpholin-4-ylethyl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-[6-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-7-phenoxy-lH- benzimidazol- 1 -yljbutanenitrile;
4-[5-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-lH- benzimidazol- 1 -yljbutanenitrile;
4-[7-Methoxy-3-methyl-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- 2-0X0-2, 3-dihydro- 1 H-benzimidazol- 1 -yljbutanenitrile;
3-[7-Methoxy-3-methyl-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- 2-0X0-2, 3-dihydro- 1 H-benzimidazol- 1 -yljpropanenitrile;
3- [6-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-7-phenoxy-lH- benzimidazol- 1 -yljpropanenitrile;
6-Methyl-4-(l-methyl-4-phenoxy-lH-benzimidazol-5-yl)-l,6-dihydro-7H-pyrrolo[2,3- c]pyridin-7-one;
4- [4-(2-Fluorophenoxy)-l -methyl- lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
4-[4-(3-Fluorophenoxy)-l -methyl- lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
4-[4-(4-Fluorophenoxy)-l -methyl- lH-benzimidazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-3-(2-morpholin-4-ylethyl)-l,3-dihydro-2H-benzimidazol-2-one;
4-[7-(Cyclobutylmethoxy)-3-methyl-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-2-oxo-2, 3-dihydro- 1 H-benzimidazol- 1 -yljbutanenitrile;
3- [7-(Cyclobutylmethoxy)-3-methyl-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-2-oxo-2, 3-dihydro- 1 H-benzimidazol- 1 -yljpropanenitrile;
4- (Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-3-(2-phenylethyl)-l,3-dihydro-2H-benzimidazol-2-one;
3-Benzyl-4-(cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one; 4-(Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-3-(2-piperidin-4-ylethyl)-l,3-dihydro-2H-benzimidazol-2-one;
3 - (2-(4-Acetylpiperazin- 1 -yl)ethyl)-4-(cyclobutylmethoxy)- 1 -methyl-5 -(6-methyl-7-oxo- 6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-lH-benzo[d]imidazol-2(3H)-one;
4- (Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-3- {2-[4-(methylsulfonyl)piperazin- 1 -yljethyl} - 1 ,3-dihydro-2H-benzimidazol-2- one;
4- (Cyclobutylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)-3-[2-(4-methylpiperazm^
5- (6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-l-(2-morpholin-4- ylethyl)-4-phenoxy- 1 ,3-dihydro-2H-benzimidazol-2-one;
l-{2 (2R,6S)-2,6-Dimethylmorpholin-4-yl]ethyl}-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-l,3-dihydro-2H-benzimidazol-2-one;
4-(2-(Benzylamino)-l-{2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethyl}-4-phenoxy-lH- benzimidazol-5-yl)-6-methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
4-(2-[(Cyclopropylmethyl)amino]- 1 - {2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethyl} -4- phenoxy-lH-benzimidazol-5-yl)-6-methyl-l,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;
4-(Cyclopropylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
8-(2,4-Difluorophenoxy)-7-(6-methyl-7-oxo-6,7-dihydro-lH-pyrazolo[3,4-c]pyridin-4- yl)quinoxalin-2( 1 H)-one;
4- [4-(Cyclopropylmethoxy)-l -methyl- lH-indazol-5 -yl]-6-methyl-l, 6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
4- [4-(Cyclopropylmethoxy)-l -methyl- lH-indazol-5 -yl]-6-methyl-l, 6-dihy dro-7H- pyrazolo[3,4-c]pyridin-7-one;
4- [4-(2,4-Difluorophenoxy)-7-(l -hydroxy ethyl)- 1 -methyl- lH-benzimidazol-5-yl] -6- methyl-l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-one;
4-(2,4-Difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)- 7-{[(2-morpholin-4-ylethyl)amino]methyl}-l,3-dihydro-2H-benzimidazol-2-one;
7-[(Benzylamino)methyl]-4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7-dihydro-lH- pyrrolo[2,3-c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one; 7-{[(Cyclopropylmethyl)amino]methyl}-4-(2,4-difluorophenoxy)-5-(6-methyl-7-oxo-6,7- dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-l,3-dihydro-2H-benzimidazol-2-one;
4-[4-(2,4-Difluorophenoxy)-l -methyl- lH-benzimidazol-5-yl]-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
4-[4-(2,4-Difluorophenoxy)- 1 -methyl- lH-benzimidazol-5-yl]-6-ethyl- 1 ,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
6-Benzyl-4-[4-(2,4-difluorophenoxy)-l-methyl-lH-benzimidazol-5-yl]-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
{4-[4-(2,4-Difluorophenoxy)-l -methyl- lH-benzimidazol-5-yl]-7-oxo-l, 7-dihydro-6H- pyrrolo[2,3-c]pyridin-6-yl}acetonitrile;
4-(4-Chlorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-(3-Chlorophenoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-(Cyclohexylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-(Cyclobutyloxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4- yl)-l,3-dihydro-2H-benzimidazol-2-one;
4-(Cyclohexyloxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4- yl)-l,3-dihydro-2H-benzimidazol-2-one;
l-Methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-(tetrahydro- 2H-pyran-3-yloxy)-l,3-dihydro-2H-benzimidazol-2-one;
4-(Cyclopentylmethoxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3- c]pyridin-4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
4-(Cyclopentyloxy)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin- 4-yl)- 1 ,3-dihydro-2H-benzimidazol-2-one;
6-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-5-phenoxy-2H-l,4- benzoxazin-3(4H)-one;
2,2-Dimethyl-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-5-phenoxy- 2H- 1 ,4-benzoxazin-3(4H)-one; 6-Methyl-4-(4-phenoxy- 1 ,3-benzoxazol-5-yl)- 1 ,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7- one;
1- Methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-(phenylthio l,3-dihydro-2H-benzimidazol-2-one;
4-(Ethylthio)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-y^
1.3- dihydro-2H-benzimidazol-2-one;
4-(Ethylsulfonyl)-l-methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4- yl)-l,3-dihydro-2H-benzimidazol-2-one;
4-Methyl-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-5-phenoxy-2H-
1.4- benzoxazin-3(4H)-one;
4-Benzyl-6-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-5-phenoxy-2H- 1 ,4-benzoxazin-3(4H)-one;
6-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-(2-morpholin-4- ylethyl)-5-phenoxy-2H-l,4-benzoxazin-3(4H)-one;
4-[2-(Aminomethyl)-4-phenoxy-l,3-benzoxazol-5-yl]-6-methyl-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one;
N-{[5-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-l,3- benzoxazol-2-yl]methyl}acetamide;
N-{[5-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-l,3- benzoxazol-2-yl]methyl}methanesulfonamide'
N-{[5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-l,3- benzoxazol-2-yl]methyl}benzamide;
N-{[5-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-l,3- benzoxazol-2-yl]methyl}-2-phenylacetamide;
N-{[5-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-l,3- benzoxazol-2-yl]methyl}cyclopropanecarboxamide;
2- Cyclopentyl-N-{[5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4- phenoxy- 1 ,3-benzoxazol-2-yl]methyl} acetamide;
6-Methyl-4-(5-phenoxy-3-phenyl-3,4-dihydro-2H-l,4-benzoxazin-6-yl)-l,6-dihydro-7H- pyrrolo[2,3-c]pyridin-7-one; N-{[l-Methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4- phenoxy- 1 H-benzimidazol-2-yl]methyl} cyclobutanecarboxamide;
N-{[l-Methyl-5-(6-methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4- phenoxy- 1 H-benzimidazol-2-yl]methyl} cyclopropanecarboxamide; and
3-[5-(6-Methyl-7-oxo-6,7-dihydro-lH-pyrrolo[2,3-c]pyridin-4-yl)-4-phenoxy-lH- benzimidazol- 1 -yljpropanenitrile,
or a pharmaceutically acceptable salt of any of the aforementioned.
61. A pharmaceutical composition comprising a compound of any one of claims 1-60, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
62. A method of inhibiting a BET protein comprising contacting a compound of any one of claims 1-60, or a pharmaceutically acceptable salt thereof, with said BET protein.
63. A method of treating a BET-mediated disease or condition comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of any one of claims 1-60, or a pharmaceutically acceptable salt thereof.
64. A method of treating a proliferative disorder comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of any one of claims 1- 60, or a pharmaceutically acceptable salt thereof.
65. The method of claim 64, wherein the proliferative disorder is cancer.
66. The method of claim 65, wherein the cancer is adenocarcinoma, adult T-cell
leukemia/lymphoma, bladder cancer, blastoma, bone cancer, breast cancer, brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colorectal cancer, esophageal cancer,
gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladder cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, intestinal cancer, kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, ocular cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, stomach cancer, T-cell lymphoma, testicular cancer, thyroid cancer, throat cancer, urogenital cancer, urothelial carcinoma, uterine cancer, vaginal cancer, or Wilms' tumor.
67. The method of claim 64, wherein the proliferative disorder is a non-cancerous proliferative disorder.
68. A method of treating an autoimmune or inflammatory disease comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of any one of claims 1-60, or a pharmaceutically acceptable salt thereof.
69. The method of claim 68, wherein the autoimmune or inflammatory disease is selected from allergy, allergic rhinitis, arthritis, asthma, chronic obstructive pulmonary disease, degenerative joint disease, dermatitis, organ rejection, eczema, hepatitis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, psoriasis, sepsis, sepsis syndrome, septic shock, systemic lupus erythematosus, tissue graft rejection, and type I diabetes.
70. A method of treating a viral infection comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of any one of claims 1-60, or a pharmaceutically acceptable salt thereof.
71. The method of claim 70, wherein the viral infection is infection with adenovirus, Epstein- Barr virus, hepatitis B virus, hepatitis C virus, a herpes virus, human immunodeficiency virus, human papilloma virus or a pox virus.
72. A method of treating heart disease comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of any one of claims 1-60, or a pharmaceutically acceptable salt thereof.
PCT/US2014/067629 2013-11-26 2014-11-26 Bicyclic heterocycles as bet protein inhibitors WO2015081203A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908968P 2013-11-26 2013-11-26
US61/908,968 2013-11-26

Publications (1)

Publication Number Publication Date
WO2015081203A1 true WO2015081203A1 (en) 2015-06-04

Family

ID=52021472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/067629 WO2015081203A1 (en) 2013-11-26 2014-11-26 Bicyclic heterocycles as bet protein inhibitors

Country Status (2)

Country Link
US (2) US9399640B2 (en)
WO (1) WO2015081203A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077378A1 (en) * 2014-11-10 2016-05-19 Genentech, Inc. Substituted pyrrolopyrdines as inhibitors of bromodomain
WO2016077380A1 (en) * 2014-11-10 2016-05-19 Genentech, Inc. Substituted pyrrolopyridines as inhibitors of bromodomain
US9399640B2 (en) * 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2016139361A1 (en) * 2015-03-05 2016-09-09 Boehringer Ingelheim International Gmbh New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9533997B2 (en) 2013-07-08 2017-01-03 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
US9540368B2 (en) 2014-04-23 2017-01-10 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US9624241B2 (en) 2013-03-15 2017-04-18 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9737516B2 (en) 2013-11-26 2017-08-22 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9777003B2 (en) 2013-12-19 2017-10-03 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US10189832B2 (en) 2016-06-20 2019-01-29 Incyte Corporation Crystalline solid forms of a BET inhibitor
US10202378B2 (en) 2015-01-29 2019-02-12 Genentech, Inc. Therapeutic compounds and uses thereof
US10258603B2 (en) 2014-11-10 2019-04-16 Genentech, Inc. Therapeutic compounds and uses thereof
US10329305B2 (en) 2015-10-29 2019-06-25 Incyte Corporation Amorphous solid form of a BET protein inhibitor
WO2019120234A3 (en) * 2017-12-20 2019-08-29 贝达药业股份有限公司 Compound functioning as bromodomain protein inhibitor, and composition
WO2020020308A1 (en) * 2018-07-27 2020-01-30 成都海创药业有限公司 Brd4 inhibitor, preparation method and use thereof
US10633379B2 (en) 2016-04-15 2020-04-28 Abbvie Inc. Bromodomain inhibitors
WO2020132004A1 (en) * 2018-12-20 2020-06-25 Saint Louis University Bet inhibitors for modulating dux4 expression in fshd
CN112625036A (en) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 Compound with BRD4 inhibitory activity, preparation method and application thereof
WO2021233371A1 (en) * 2020-05-21 2021-11-25 贝达药业股份有限公司 Compound functioning as bromodomain protein inhibitor, and composition
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
RU2818456C1 (en) * 2017-12-20 2024-05-02 Бетта Фармасьютикалз Ко., Лтд Compound used as inhibitor of bromo-domain-containing proteins, and composition

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
EP4414369A3 (en) 2015-03-18 2024-10-16 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
EP3331906A1 (en) 2015-08-06 2018-06-13 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
EP3334717B1 (en) 2015-08-11 2020-07-01 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
US10703740B2 (en) 2015-08-12 2020-07-07 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
EP3436006A1 (en) 2016-03-30 2019-02-06 Wisconsin Alumni Research Foundation Methods and compositions for modulating frataxin expression
CN109641874A (en) 2016-05-10 2019-04-16 C4医药公司 C for target protein degradation3The glutarimide degron body of carbon connection
CN109562107A (en) 2016-05-10 2019-04-02 C4医药公司 Heterocycle degron body for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3580212A4 (en) 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
WO2018183679A1 (en) 2017-03-29 2018-10-04 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
WO2019199816A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN113453679A (en) 2018-12-20 2021-09-28 C4医药公司 Targeted protein degradation
JP2023504623A (en) * 2019-12-04 2023-02-06 アーカス バイオサイエンシーズ，インコーポレーテッド Inhibitor of HIF-2 alpha
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2021240068A1 (en) 2020-03-19 2022-09-08 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281398A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0314566A (en) 1989-06-09 1991-01-23 Sankyo Co Ltd Benzimidazole derivative
US5244912A (en) 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof
FR2710915B1 (en) 1993-10-04 1995-11-24 Synthelabo Piperidine derivatives, their preparation and their therapeutic use.
FR2731708B1 (en) 1995-03-13 1997-04-30 Synthelabo PIPERIDINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
FR2747678B1 (en) 1996-04-22 1998-05-22 Synthelabo COMPOUNDS DERIVED FROM IMIDAZOBENZOXAZINE, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES
CN1554343A (en) 2000-04-21 2004-12-15 �������Ŷ���Լ��������˾ Compounds for treating fibromyalgia and chronic fatigue syndrome
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
US6919334B2 (en) 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
AU2003293006A1 (en) 2002-11-22 2004-06-18 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
EP1462103A1 (en) 2003-03-25 2004-09-29 Faust Pharmaceuticals NO donors, combination products and uses as modulators of neurotransmitter release
JPWO2005080334A1 (en) 2004-02-23 2007-08-02 大日本住友製薬株式会社 New heterocyclic compounds
EP1732541A4 (en) 2004-04-07 2008-03-05 Takeda Pharmaceutical Cyclic compounds
DE102005011058A1 (en) 2005-03-10 2006-09-14 Merck Patent Gmbh Substituted tetrahydro-pyrrolo-quinoline derivatives
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
JP2009503069A (en) 2005-08-05 2009-01-29 アストラゼネカ アクチボラグ Tricyclic benzimidazoles and their use as modulators of metabolic glutamate receptors
EP2147310A4 (en) 2007-04-27 2010-09-08 Univ Rochester Compositions and methods for inhibiting g protein signaling
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009020559A2 (en) 2007-08-03 2009-02-12 The J. David Gladstone Institutes Agents that inhibit p-tefb interactions and methods of use thereof
CN101910182B (en) 2007-12-28 2013-07-17 田边三菱制药株式会社 Antitumor agent
DE102008052618A1 (en) 2008-10-21 2010-04-22 Henkel Ag & Co. Kgaa Tricyclic aldehydes and C, H-acidic compounds
US8669249B2 (en) 2009-03-27 2014-03-11 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
TW201105681A (en) 2009-06-10 2011-02-16 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
TW201103941A (en) 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
WO2011024987A1 (en) 2009-08-31 2011-03-03 塩野義製薬株式会社 Aromatic fused heterocyclic derivative and pharmaceutical composition containing same
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
RS53179B (en) 2009-11-05 2014-06-30 Glaxosmithkline Llc Benzodiazepine bromodamain inhibitor
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
JP5702396B2 (en) 2009-11-05 2015-04-15 グラクソスミスクライン エルエルシー Benzodiazepine bromodomain inhibitor
EP2496945B1 (en) 2009-11-05 2015-04-01 GlaxoSmithKline LLC Novel process
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102939088A (en) 2010-04-23 2013-02-20 奇尼塔公司 Anti-viral compounds
JP5935030B2 (en) 2010-05-14 2016-06-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Compositions and methods for treating leukemia
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
US20130252331A1 (en) 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (en) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc BROMODOMINIUM INHIBITORS AND USES OF THE SAME
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
BR112013020329A2 (en) 2011-02-09 2016-08-02 Hoffmann La Roche heterocyclic compounds as pi3 kinase inhibitors
CN103547152A (en) 2011-02-23 2014-01-29 西奈山伊坎医学院 Inhibitors of bromodomains as modulators of gene expression
GB201106799D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106743D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012178208A2 (en) 2011-06-24 2012-12-27 The Trustees Of The Stevens Institute Of Technology Selective inhibitors of histone deacetylase isoform 6 and methods thereof
JP2013010719A (en) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd Benzimidazolone and oxindole derivative, and pharmaceutical application of them
JP2014524409A (en) 2011-07-29 2014-09-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Compositions and methods for the treatment of HIV
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
WO2013033269A1 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
CN105712976A (en) 2011-08-31 2016-06-29 大塚制药株式会社 Quinolone compound
DE102011082013A1 (en) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepines
WO2013043553A1 (en) * 2011-09-22 2013-03-28 Glaxosmithkline Llc Pyrrolopyridinone compounds and methods for treating hiv
WO2013044511A1 (en) 2011-09-30 2013-04-04 沈阳蓝桑医药生物技术研发有限公司 Pharmaceutical composition containing riligustilide and use thereof
RS58911B1 (en) 2011-11-01 2019-08-30 Resverlogix Corp Oral immediate release formulations for substituted quinazolinones
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2830629A4 (en) 2012-03-28 2016-01-20 Icahn School Of Medicine Mount Sinai Compositions and methods for reactivating latent immunodeficiency virus
US20130281396A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
EP2838881B1 (en) 2012-04-20 2018-08-08 AbbVie Inc. Isoindolone derivatives
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (en) 2012-06-06 2017-10-21 星宿藥物公司 Bromodomain inhibitors and uses thereof
EP2858982A4 (en) 2012-06-12 2015-11-11 Abbvie Inc Pyridinone and pyridazinone derivatives
AU2013283378B2 (en) 2012-06-25 2017-07-13 Oncoethix Gmbh Method of treating lymphoma using thienotriazolodiazepine compounds
US9610332B2 (en) 2012-07-18 2017-04-04 Massachusetts Institute Of Technology Compositions and methods for modulating BRD4 bioactivity
KR20150042231A (en) 2012-08-16 2015-04-20 글락소스미스클라인 엘엘씨 Benzodiazepines for treating small cell lung cancer
ES2628005T3 (en) 2012-08-16 2017-08-01 Bayer Pharma Aktiengesellschaft 2,3-Benzodiazepines
CN104781259B (en) 2012-09-28 2018-06-01 拜耳制药股份公司 Inhibit the 5- aryl triazoles and azepine * of BET albumen
EP2900221B1 (en) 2012-09-28 2019-03-06 Oncoethix GmbH Pharmaceutical formulation containing thienotriazolodiazepine compounds
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9663533B2 (en) 2012-11-14 2017-05-30 Glaxosmithkline Llc Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US20160193206A1 (en) 2012-12-20 2016-07-07 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydropyridopyrazinones
WO2014095775A1 (en) 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydroquinoxalinones
KR20150096794A (en) 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 Novel heterocyclic compounds as bromodomain inhibitors
WO2014128655A1 (en) 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CN105189488B (en) 2013-02-27 2018-07-24 百时美施贵宝公司 Carbazole compound as bromodomain inhibitor
US8980879B2 (en) 2013-03-11 2015-03-17 Abbvie Inc. Bromodomain inhibitors
MX2015012005A (en) 2013-03-11 2016-04-04 Abbvie Inc Bromodomain inhibitors.
WO2014164596A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
BR112015022643A2 (en) 2013-03-12 2017-07-18 Abbvie Inc dihydropyrrolpyridinone inhibitors
WO2014165127A1 (en) 2013-03-12 2014-10-09 Abbvie Inc. Pyrrole amide inhibitors
AU2014231563A1 (en) 2013-03-12 2015-09-17 Abbvie Inc. Tetracyclic bromodomain inhibitors
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
EP3511323B1 (en) 2013-03-14 2022-03-02 GlaxoSmithKline Intellectual Property (No.2) Limited 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
EA201591746A1 (en) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи METHODS AND COMPOSITIONS FOR INHIBITING BRODOMODEN-CONTAINING PROTEINS
WO2014140077A1 (en) 2013-03-14 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Furopyridines as bromodomain inhibitors
EP2970265B1 (en) 2013-03-15 2018-08-08 Plexxikon Inc. Heterocyclic compounds and uses thereof
KR102216288B1 (en) 2013-03-15 2021-02-18 인사이트 홀딩스 코포레이션 Tricyclic heterocycles as bet protein inhibitors
CA2904364A1 (en) 2013-03-15 2014-09-25 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
JP6370368B2 (en) 2013-03-27 2018-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Indolinone analogs as BRD4 inhibitors
EP2978758B1 (en) 2013-03-27 2017-02-08 Boehringer Ingelheim International GmbH Dihydroquinazolinone analogues as brd4 inhibitors
TWI530499B (en) 2013-03-28 2016-04-21 吉李德科學股份有限公司 Benzimidazolone derivatives as bromodomain inhibitors
WO2014170350A1 (en) 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
BR112015027130A2 (en) 2013-04-26 2018-07-24 Beigene Ltd Substituted 5- (3,5-dimethylisoxazol-4-yl) indolin-2-one
TWI527811B (en) 2013-05-09 2016-04-01 吉李德科學股份有限公司 Benzimidazole derivatives as bromodomain inhibitors
CA2913697A1 (en) 2013-05-27 2014-12-04 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CN105246896B (en) 2013-05-28 2017-09-08 诺华股份有限公司 The ketone derivatives of pyrazoles pyrrolizine 4 and its purposes in treatment disease
EP3004108B1 (en) 2013-05-28 2017-10-18 Novartis AG Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
CA2915419A1 (en) 2013-06-17 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted phenyl-2,3-benzodiazepines
ES2806135T3 (en) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd New bicyclic bromodomain inhibitors
JP6461118B2 (en) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． Novel substituted bicyclic compounds as bromodomain inhibitors
AR096758A1 (en) 2013-06-28 2016-02-03 Abbvie Inc BROMODOMINIUM CRYSTAL INHIBITORS
EP3013828A4 (en) 2013-06-28 2016-11-23 Abbvie Inc Bromodomain inhibitors
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
KR101672096B1 (en) 2013-09-30 2016-11-02 주식회사 엘지화학 Heterocyclic compound and organic light emitting device comprising the same
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081246A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
JP2016539970A (en) 2013-12-09 2016-12-22 アッヴィ・インコーポレイテッド Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
CA2946731C (en) 2014-04-23 2022-06-07 Incyte Corporation 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
CN106687117A (en) 2014-05-02 2017-05-17 翁科埃斯克斯有限公司 Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or ALK+ non-small cell lung cancer using thienotriazolodiazepine compounds
WO2015168621A1 (en) 2014-05-02 2015-11-05 Oncoethix Sa Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
WO2015169953A1 (en) 2014-05-08 2015-11-12 Oncoethix Gmbh Method of treating glioma using thienotriazolodiazepine compounds
EP3139959A1 (en) 2014-05-08 2017-03-15 Oncoethix GmbH Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
EP3148543B1 (en) 2014-05-30 2020-04-08 Icahn School of Medicine at Mount Sinai Small molecule transcription modulators of bromodomains
TWI712603B (en) 2014-09-15 2020-12-11 美商英塞特公司 Tricyclic heterocycles as bet protein inhibitors
WO2016186453A1 (en) 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors
TWI700284B (en) 2015-05-29 2020-08-01 日商塩野義製藥股份有限公司 Nitrogen-containing tricyclic derivertives having hiv reprication inhibitory activity
AR106520A1 (en) 2015-10-29 2018-01-24 Incyte Corp SOLID FORM AMORFA OF A BET PROTEIN INHIBITOR
US20170127985A1 (en) 2015-11-11 2017-05-11 Medtronic Minimed, Inc. Sensor set
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
JP2019508494A (en) 2016-02-05 2019-03-28 チーア タイ ティエンチン ファーマシューティカル グループ カンパニー，リミティド Tricyclic compounds of bromo domain protein inhibitors and their preparation, pharmaceutical compositions and uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281398A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624241B2 (en) 2013-03-15 2017-04-18 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US10919912B2 (en) 2013-03-15 2021-02-16 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
US10464947B2 (en) 2013-03-15 2019-11-05 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
US11498926B2 (en) 2013-03-15 2022-11-15 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9938294B2 (en) 2013-03-15 2018-04-10 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9533997B2 (en) 2013-07-08 2017-01-03 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
US9850257B2 (en) 2013-07-08 2017-12-26 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9737516B2 (en) 2013-11-26 2017-08-22 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) * 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9918990B2 (en) 2013-11-26 2018-03-20 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US10442803B2 (en) 2013-12-19 2019-10-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US9777003B2 (en) 2013-12-19 2017-10-03 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US11091484B2 (en) 2013-12-19 2021-08-17 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9957268B2 (en) 2014-04-23 2018-05-01 Incyte Corporation 1H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US10781209B2 (en) 2014-04-23 2020-09-22 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US11059821B2 (en) 2014-04-23 2021-07-13 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US11702416B2 (en) 2014-04-23 2023-07-18 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US9540368B2 (en) 2014-04-23 2017-01-10 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US10472358B2 (en) 2014-04-23 2019-11-12 Incyte Corporation 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US10227359B2 (en) 2014-09-15 2019-03-12 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US10618910B2 (en) 2014-09-15 2020-04-14 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US9834565B2 (en) 2014-09-15 2017-12-05 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US10258603B2 (en) 2014-11-10 2019-04-16 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016077378A1 (en) * 2014-11-10 2016-05-19 Genentech, Inc. Substituted pyrrolopyrdines as inhibitors of bromodomain
US10183009B2 (en) 2014-11-10 2019-01-22 Genentech, Inc. Therapeutic compounds and uses thereof
US10150767B2 (en) 2014-11-10 2018-12-11 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016077380A1 (en) * 2014-11-10 2016-05-19 Genentech, Inc. Substituted pyrrolopyridines as inhibitors of bromodomain
US10202378B2 (en) 2015-01-29 2019-02-12 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016139361A1 (en) * 2015-03-05 2016-09-09 Boehringer Ingelheim International Gmbh New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
US11319318B2 (en) 2015-03-05 2022-05-03 Boehringer Ingelheim International Gmbh Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9
US10329305B2 (en) 2015-10-29 2019-06-25 Incyte Corporation Amorphous solid form of a BET protein inhibitor
US10858372B2 (en) 2015-10-29 2020-12-08 Incyte Corporation Amorphous solid form of a BET protein inhibitor
US10633379B2 (en) 2016-04-15 2020-04-28 Abbvie Inc. Bromodomain inhibitors
US10626114B2 (en) 2016-06-20 2020-04-21 Incyte Corporation Crystalline solid forms of a BET inhibitor
US10189832B2 (en) 2016-06-20 2019-01-29 Incyte Corporation Crystalline solid forms of a BET inhibitor
US12030882B2 (en) 2016-06-20 2024-07-09 Incyte Corporation Crystalline solid forms of a bet inhibitor
US11091480B2 (en) 2016-06-20 2021-08-17 Incyte Corporation Crystalline solid forms of a BET inhibitor
US11377446B2 (en) 2016-06-20 2022-07-05 Incyte Corporation Crystalline solid forms of a BET inhibitor
JP2021506903A (en) * 2017-12-20 2021-02-22 貝達薬業股▲ふん▼有限公司Ｂｅｔｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．，Ｌｔｄ Compounds and compositions that are bromodomain protein inhibitors
IL275478B1 (en) * 2017-12-20 2024-02-01 Betta Pharmaceuticals Co Ltd Compound functioning as bromodomain protein inhibitor, and composition
WO2019120234A3 (en) * 2017-12-20 2019-08-29 贝达药业股份有限公司 Compound functioning as bromodomain protein inhibitor, and composition
IL275478B2 (en) * 2017-12-20 2024-06-01 Betta Pharmaceuticals Co Ltd Compound functioning as bromodomain protein inhibitor, and composition
US11845762B2 (en) 2017-12-20 2023-12-19 Betta Pharmaceuticals Co., Ltd. Compound functioning as bromodomain protein inhibitor, and composition
RU2818456C1 (en) * 2017-12-20 2024-05-02 Бетта Фармасьютикалз Ко., Лтд Compound used as inhibitor of bromo-domain-containing proteins, and composition
CN111712496A (en) * 2017-12-20 2020-09-25 贝达药业股份有限公司 Compounds and compositions as bromodomain protein inhibitors
US11466034B2 (en) 2017-12-20 2022-10-11 Betta Pharmaceuticals Co., Ltd. Compound functioning as bromodomain protein inhibitor, and composition
JP2021532151A (en) * 2018-07-27 2021-11-25 ヒノバ ファーマシューティカルズ インコーポレイテッド BRD4 inhibitor and its manufacturing method and use
WO2020020308A1 (en) * 2018-07-27 2020-01-30 成都海创药业有限公司 Brd4 inhibitor, preparation method and use thereof
JP7531479B2 (en) 2018-07-27 2024-08-09 ヒノバ ファーマシューティカルズ インコーポレイテッド BRD4 inhibitors and their preparation and use
WO2020132004A1 (en) * 2018-12-20 2020-06-25 Saint Louis University Bet inhibitors for modulating dux4 expression in fshd
JP2022551299A (en) * 2019-10-08 2022-12-08 ハイヘ バイオファーマ カンパニー、リミテッド COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION AND USE THEREOF
EP4043462A4 (en) * 2019-10-08 2023-11-01 Haihe Biopharma Co., Ltd. Compound having brd4 inhibitory activity, preparation method therefor and use thereof
JP7405468B2 (en) 2019-10-08 2023-12-26 ハイヘ バイオファーマ カンパニー、リミテッド Compounds with BRD4 inhibitory activity, preparation methods and uses thereof
AU2020362763B2 (en) * 2019-10-08 2024-02-15 Haihe Biopharma Co., Ltd. Compound having BRD4 inhibitory activity, preparation method therefor and use thereof
CN114401964A (en) * 2019-10-08 2022-04-26 上海海和药物研究开发股份有限公司 Compound with BRD4 inhibitory activity, preparation method and application thereof
WO2021068755A1 (en) * 2019-10-08 2021-04-15 上海海和药物研究开发股份有限公司 Compound having brd4 inhibitory activity, preparation method therefor and use thereof
CN112625036A (en) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 Compound with BRD4 inhibitory activity, preparation method and application thereof
CN114401964B (en) * 2019-10-08 2024-10-01 上海海和药物研究开发股份有限公司 Compound with BRD4 inhibitory activity, preparation method and application thereof
CN115667254A (en) * 2020-05-21 2023-01-31 贝达药业股份有限公司 Compounds and compositions as bromodomain protein inhibitors
WO2021233371A1 (en) * 2020-05-21 2021-11-25 贝达药业股份有限公司 Compound functioning as bromodomain protein inhibitor, and composition
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Also Published As

Publication number Publication date
US20170014418A1 (en) 2017-01-19
US9918990B2 (en) 2018-03-20
US9399640B2 (en) 2016-07-26
US20150148342A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
US9918990B2 (en) Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9737516B2 (en) Bicyclic heterocycles as bet protein inhibitors
US10781209B2 (en) 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
ES2909778T3 (en) Tricyclic heterocycles as BET protein inhibitors for use in the treatment of proliferative disease in combination with a Janus kinase inhibitor
EP3019502B1 (en) Tricyclic heterocycles as bet protein inhibitors
US11091484B2 (en) Tricyclic heterocycles as BET protein inhibitors
WO2015081246A1 (en) Bicyclic heterocycles as bet protein inhibitors
EP3194406A1 (en) Tricyclic heterocycles for use as bet protein inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14810107

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14810107

Country of ref document: EP

Kind code of ref document: A1